name;identifier;SMILES;inchikey;MW;LogP;pubchem;drugbank;pdb;chEMBL;membrane;method;temperature;charge;note;X_min;X_min_acc;G_pen;G_pen_acc;G_wat;G_wat_acc;LogK;LogK_acc;LogPerm;LogPerm_acc;theta;theta_acc;abs_wl;abs_wl_acc;fluo_wl;fluo_wl_acc;QY;QY_acc;lt;lt_acc;primary_reference;secondary_reference
4-(dimethylamino)-1,5-dimethyl-2-phenylpyrazol-3-one;MM00331;Cc1c(N(C)C)c(=O)n(-c2ccccc2)n1C;RMMXTBMQSGEXHJ-UHFFFAOYSA-N;231.299;1.55;6009;DB01424;;CHEMBL288470;CACO;ECACO;37;0;;;;;;;;;;-4.44;;;;;;;;;;;;"Yazdanian M., Glynn S.L., Wright  J.L., Hawi A.: Correlating partitioning and Caco-2 cell permeability of structurally diverse small molecular weight compounds. Pharm Res., 15(9):1490-1494, 1998.";"Yazdanian M., Glynn S.L., Wright  J.L., Hawi A.: Correlating partitioning and Caco-2 cell permeability of structurally diverse small molecular weight compounds. Pharm Res., 15(9):1490-1494, 1998."
4-hydroxy-2-methyl-1,1-dioxo-N-pyridin-2-yl-1lambda6,2-benzothiazine-3-carboxamide;MM00682;CN1C(C(=O)Nc2ccccn2)=C(O)c2ccccc2S1(=O)=O;QYSPLQLAKJAUJT-UHFFFAOYSA-N;331.346;1.58;54676228;DB00554;;CHEMBL527;CACO;ECACO;37;-1;;;;;;;;;;-4.45;;;;;;;;;;;;"Yazdanian M., Glynn S.L., Wright  J.L., Hawi A.: Correlating partitioning and Caco-2 cell permeability of structurally diverse small molecular weight compounds. Pharm Res., 15(9):1490-1494, 1998.";"Yazdanian M., Glynn S.L., Wright  J.L., Hawi A.: Correlating partitioning and Caco-2 cell permeability of structurally diverse small molecular weight compounds. Pharm Res., 15(9):1490-1494, 1998."
7-chloro-1-methyl-5-phenyl-3H-1,4-benzodiazepin-2-one;MM00094;CN1C(=O)CN=C(c2ccccc2)c2cc(Cl)ccc21;AAOVKJBEBIDNHE-UHFFFAOYSA-N;284.743;3.15;3016;DB00829;DZP;CHEMBL12;CACO;ECACO;37;0;;;;;;;;;;-4.48;;;;;;;;;;;;"Yazdanian M., Glynn S.L., Wright  J.L., Hawi A.: Correlating partitioning and Caco-2 cell permeability of structurally diverse small molecular weight compounds. Pharm Res., 15(9):1490-1494, 1998.";"Yazdanian M., Glynn S.L., Wright  J.L., Hawi A.: Correlating partitioning and Caco-2 cell permeability of structurally diverse small molecular weight compounds. Pharm Res., 15(9):1490-1494, 1998."
Caffeine;MM00040;Cn1c(=O)c2c(ncn2C)n(C)c1=O;RYYVLZVUVIJVGH-UHFFFAOYSA-N;194.194;-1.03;2519;DB00201;CFF;CHEMBL113;CACO;ECACO;37;0;;;;;;;;;;-4.51;;;;;;;;;;;;"Yazdanian M., Glynn S.L., Wright  J.L., Hawi A.: Correlating partitioning and Caco-2 cell permeability of structurally diverse small molecular weight compounds. Pharm Res., 15(9):1490-1494, 1998.";"Yazdanian M., Glynn S.L., Wright  J.L., Hawi A.: Correlating partitioning and Caco-2 cell permeability of structurally diverse small molecular weight compounds. Pharm Res., 15(9):1490-1494, 1998."
Nevirapine;MM01034;Cc1ccnc2c1NC(=O)c1cccnc1N2C1CC1;NQDJXKOVJZTUJA-UHFFFAOYSA-N;266.304;2.65;4463;DB00238;NVP;CHEMBL57;CACO;ECACO;37;0;;;;;;;;;;-4.52;;;;;;;;;;;;"Yazdanian M., Glynn S.L., Wright  J.L., Hawi A.: Correlating partitioning and Caco-2 cell permeability of structurally diverse small molecular weight compounds. Pharm Res., 15(9):1490-1494, 1998.";"Yazdanian M., Glynn S.L., Wright  J.L., Hawi A.: Correlating partitioning and Caco-2 cell permeability of structurally diverse small molecular weight compounds. Pharm Res., 15(9):1490-1494, 1998."
5,5-diphenylimidazolidine-2,4-dione;MM00406;O=C1N=C(O)NC1(c1ccccc1)c1ccccc1;CXOFVDLJLONNDW-UHFFFAOYSA-N;252.273;1.97;1775;DB00252;;CHEMBL16;CACO;ECACO;37;1;;;;;;;;;;-4.57;;;;;;;;;;;;"Yazdanian M., Glynn S.L., Wright  J.L., Hawi A.: Correlating partitioning and Caco-2 cell permeability of structurally diverse small molecular weight compounds. Pharm Res., 15(9):1490-1494, 1998.";"Yazdanian M., Glynn S.L., Wright  J.L., Hawi A.: Correlating partitioning and Caco-2 cell permeability of structurally diverse small molecular weight compounds. Pharm Res., 15(9):1490-1494, 1998."
1-(propan-2-ylamino)-3-(2-prop-2-enylphenoxy)propan-2-ol;MM00440;C=CCc1ccccc1OC[C@H](O)CNC(C)C;PAZJSJFMUHDSTF-UHFFFAOYSA-N;249.354;2.15;2119;DB00866;;CHEMBL266195;CACO;ECACO;37;1;;;;;;;;;;-4.6;;;;;;;;;;;;"Yazdanian M., Glynn S.L., Wright  J.L., Hawi A.: Correlating partitioning and Caco-2 cell permeability of structurally diverse small molecular weight compounds. Pharm Res., 15(9):1490-1494, 1998.";"Yazdanian M., Glynn S.L., Wright  J.L., Hawi A.: Correlating partitioning and Caco-2 cell permeability of structurally diverse small molecular weight compounds. Pharm Res., 15(9):1490-1494, 1998."
Testosterone;MM00423;CC12CCC(=O)C=C1CCC1C2CCC2(C)C(O)CCC12;MUMGGOZAMZWBJJ-UHFFFAOYSA-N;288.431;3.88;6013;DB00624;TES;CHEMBL386630;CACO;ECACO;37;0;;;;;;;;;;-4.6;;;;;;;;;;;;"Yazdanian M., Glynn S.L., Wright  J.L., Hawi A.: Correlating partitioning and Caco-2 cell permeability of structurally diverse small molecular weight compounds. Pharm Res., 15(9):1490-1494, 1998.";"Yazdanian M., Glynn S.L., Wright  J.L., Hawi A.: Correlating partitioning and Caco-2 cell permeability of structurally diverse small molecular weight compounds. Pharm Res., 15(9):1490-1494, 1998."
1-(1-phenylcyclohexyl)piperidine;MM01035;c1ccc(C2(N3CCCCC3)CCCCC2)cc1;JTJMJGYZQZDUJJ-UHFFFAOYSA-N;243.394;4.33;6468;DB03575;1PC;CHEMBL275528;CACO;ECACO;37;1;;;;;;;;;;-4.61;;;;;;;;;;;;"Yazdanian M., Glynn S.L., Wright  J.L., Hawi A.: Correlating partitioning and Caco-2 cell permeability of structurally diverse small molecular weight compounds. Pharm Res., 15(9):1490-1494, 1998.";"Yazdanian M., Glynn S.L., Wright  J.L., Hawi A.: Correlating partitioning and Caco-2 cell permeability of structurally diverse small molecular weight compounds. Pharm Res., 15(9):1490-1494, 1998."
3-(5,6-dihydrobenzo[b][1]benzazepin-11-yl)-N-methylpropan-1-amine;MM00474;CNCCCN1c2ccccc2CCc2ccccc21;HCYAFALTSJYZDH-UHFFFAOYSA-N;266.388;3.53;2995;DB01151;DSM;CHEMBL72;CACO;ECACO;37;1;;;;;;;;;;-4.61;;;;;;;;;;;;"Yazdanian M., Glynn S.L., Wright  J.L., Hawi A.: Correlating partitioning and Caco-2 cell permeability of structurally diverse small molecular weight compounds. Pharm Res., 15(9):1490-1494, 1998.";"Yazdanian M., Glynn S.L., Wright  J.L., Hawi A.: Correlating partitioning and Caco-2 cell permeability of structurally diverse small molecular weight compounds. Pharm Res., 15(9):1490-1494, 1998."
1-[4-(2-methoxyethyl)phenoxy]-3-(propan-2-ylamino)propan-2-ol;MM00275;COCCc1ccc(OCC(O)CNC(C)C)cc1;IUBSYMUCCVWXPE-UHFFFAOYSA-N;267.369;1.61;4171;DB00264;;CHEMBL13;CACO;ECACO;37;1;;;;;;;;;;-4.63;;;;;;;;;;;;"Yazdanian M., Glynn S.L., Wright  J.L., Hawi A.: Correlating partitioning and Caco-2 cell permeability of structurally diverse small molecular weight compounds. Pharm Res., 15(9):1490-1494, 1998.";"Yazdanian M., Glynn S.L., Wright  J.L., Hawi A.: Correlating partitioning and Caco-2 cell permeability of structurally diverse small molecular weight compounds. Pharm Res., 15(9):1490-1494, 1998."
Progesterone;MM00198;CC(=O)C1CCC2C3CCC4=CC(=O)CCC4(C)C3CCC12C;RJKFOVLPORLFTN-UHFFFAOYSA-N;314.469;4.72;5994;DB00396;STR;CHEMBL103;CACO;ECACO;37;0;;;;;;;;;;-4.63;;;;;;;;;;;;"Yazdanian M., Glynn S.L., Wright  J.L., Hawi A.: Correlating partitioning and Caco-2 cell permeability of structurally diverse small molecular weight compounds. Pharm Res., 15(9):1490-1494, 1998.";"Yazdanian M., Glynn S.L., Wright  J.L., Hawi A.: Correlating partitioning and Caco-2 cell permeability of structurally diverse small molecular weight compounds. Pharm Res., 15(9):1490-1494, 1998."
"Salicylic Acid";MM00093;O=C(O)c1ccccc1O;YGSDEFSMJLZEOE-UHFFFAOYSA-N;138.123;1.09;338;DB00936;SAL;CHEMBL424;CACO;ECACO;37;-1;;;;;;;;;;-4.66;;;;;;;;;;;;"Yazdanian M., Glynn S.L., Wright  J.L., Hawi A.: Correlating partitioning and Caco-2 cell permeability of structurally diverse small molecular weight compounds. Pharm Res., 15(9):1490-1494, 1998.";"Yazdanian M., Glynn S.L., Wright  J.L., Hawi A.: Correlating partitioning and Caco-2 cell permeability of structurally diverse small molecular weight compounds. Pharm Res., 15(9):1490-1494, 1998."
N-(2,6-dichlorophenyl)-4,5-dihydro-1H-imidazol-2-amine;MM00344;Clc1cccc(Cl)c1N=C1NCCN1;GJSURZIOUXUGAL-UHFFFAOYSA-N;230.09;2.17;2803;DB00575;CLU;CHEMBL134;CACO;ECACO;37;1;;;;;;;;;;-4.66;;;;;;;;;;;;"Yazdanian M., Glynn S.L., Wright  J.L., Hawi A.: Correlating partitioning and Caco-2 cell permeability of structurally diverse small molecular weight compounds. Pharm Res., 15(9):1490-1494, 1998.";"Yazdanian M., Glynn S.L., Wright  J.L., Hawi A.: Correlating partitioning and Caco-2 cell permeability of structurally diverse small molecular weight compounds. Pharm Res., 15(9):1490-1494, 1998."
1-naphthalen-1-yloxy-3-(propan-2-ylamino)propan-2-ol;MM00085;CC(C)NCC(O)COc1cccc2ccccc12;AQHHHDLHHXJYJD-UHFFFAOYSA-N;259.349;2.58;4946;DB00571;;CHEMBL27;CACO;ECACO;37;1;;;;;;;;;;-4.66;;;;;;;;;;;;"Yazdanian M., Glynn S.L., Wright  J.L., Hawi A.: Correlating partitioning and Caco-2 cell permeability of structurally diverse small molecular weight compounds. Pharm Res., 15(9):1490-1494, 1998.";"Yazdanian M., Glynn S.L., Wright  J.L., Hawi A.: Correlating partitioning and Caco-2 cell permeability of structurally diverse small molecular weight compounds. Pharm Res., 15(9):1490-1494, 1998."
Corticosterone;MM00346;CC12CCC(=O)C=C1CCC1C2C(O)CC2(C)C(C(=O)CO)CCC12;OMFXVFTZEKFJBZ-UHFFFAOYSA-N;346.467;2.67;5753;DB04652;C0R;CHEMBL110739;CACO;ECACO;37;0;;;;;;;;;;-4.67;;;;;;;;;;;;"Yazdanian M., Glynn S.L., Wright  J.L., Hawi A.: Correlating partitioning and Caco-2 cell permeability of structurally diverse small molecular weight compounds. Pharm Res., 15(9):1490-1494, 1998.";"Yazdanian M., Glynn S.L., Wright  J.L., Hawi A.: Correlating partitioning and Caco-2 cell permeability of structurally diverse small molecular weight compounds. Pharm Res., 15(9):1490-1494, 1998."
4-hydroxy-3-(3-oxo-1-phenylbutyl)chromen-2-one;MM00095;CC(=O)CC(c1ccccc1)c1c(O)c2ccccc2oc1=O;PJVWKTKQMONHTI-UHFFFAOYSA-N;308.333;3.61;54678486;DB00682;;CHEMBL1464;CACO;ECACO;37;-1;;;;;;;;;;-4.68;;;;;;;;;;;;"Yazdanian M., Glynn S.L., Wright  J.L., Hawi A.: Correlating partitioning and Caco-2 cell permeability of structurally diverse small molecular weight compounds. Pharm Res., 15(9):1490-1494, 1998.";"Yazdanian M., Glynn S.L., Wright  J.L., Hawi A.: Correlating partitioning and Caco-2 cell permeability of structurally diverse small molecular weight compounds. Pharm Res., 15(9):1490-1494, 1998."
"2-[1-(4-chlorobenzoyl)-5-methoxy-2-methylindol-3-yl]acetic acid";MM00656;COc1ccc2c(c1)c(CC(=O)O)c(C)n2C(=O)c1ccc(Cl)cc1;CGIGDMFJXJATDK-UHFFFAOYSA-N;357.79;3.93;3715;DB00328;IMN;CHEMBL6;CACO;ECACO;37;-1;;;;;;;;;;-4.69;;;;;;;;;;;;"Yazdanian M., Glynn S.L., Wright  J.L., Hawi A.: Correlating partitioning and Caco-2 cell permeability of structurally diverse small molecular weight compounds. Pharm Res., 15(9):1490-1494, 1998.";"Yazdanian M., Glynn S.L., Wright  J.L., Hawi A.: Correlating partitioning and Caco-2 cell permeability of structurally diverse small molecular weight compounds. Pharm Res., 15(9):1490-1494, 1998."
3-(2-chlorophenothiazin-10-yl)-N,N-dimethylpropan-1-amine;MM00461;CN(C)CCCN1c2ccccc2Sc2ccc(Cl)cc21;ZPEIMTDSQAKGNT-UHFFFAOYSA-N;318.863;4.89;2726;DB00477;Z80;CHEMBL71;CACO;ECACO;37;1;;;;;;;;;;-4.7;;;;;;;;;;;;"Yazdanian M., Glynn S.L., Wright  J.L., Hawi A.: Correlating partitioning and Caco-2 cell permeability of structurally diverse small molecular weight compounds. Pharm Res., 15(9):1490-1494, 1998.";"Yazdanian M., Glynn S.L., Wright  J.L., Hawi A.: Correlating partitioning and Caco-2 cell permeability of structurally diverse small molecular weight compounds. Pharm Res., 15(9):1490-1494, 1998."
Meloxicam;MM00668;Cc1cnc(NC(=O)C2=C(O)c3ccccc3S(=O)(=O)N2C)s1;ZRVUJXDFFKFLMG-UHFFFAOYSA-N;351.395;1.95;54677470;DB00814;MXM;CHEMBL599;CACO;ECACO;37;-1;;;;;;;;;;-4.71;;;;;;;;;;;;"Yazdanian M., Glynn S.L., Wright  J.L., Hawi A.: Correlating partitioning and Caco-2 cell permeability of structurally diverse small molecular weight compounds. Pharm Res., 15(9):1490-1494, 1998.";"Yazdanian M., Glynn S.L., Wright  J.L., Hawi A.: Correlating partitioning and Caco-2 cell permeability of structurally diverse small molecular weight compounds. Pharm Res., 15(9):1490-1494, 1998."
3-[(2S)-1-methylpyrrolidin-2-yl]pyridine;MM00529;CN1CCCC1c1cccnc1;SNICXCGAKADSCV-UHFFFAOYSA-N;162.236;1.85;89594;DB00184;NCT;CHEMBL3;CACO;ECACO;37;1;;;;;;;;;;-4.71;;;;;;;;;;;;"Yazdanian M., Glynn S.L., Wright  J.L., Hawi A.: Correlating partitioning and Caco-2 cell permeability of structurally diverse small molecular weight compounds. Pharm Res., 15(9):1490-1494, 1998.";"Yazdanian M., Glynn S.L., Wright  J.L., Hawi A.: Correlating partitioning and Caco-2 cell permeability of structurally diverse small molecular weight compounds. Pharm Res., 15(9):1490-1494, 1998."
Estradiol;MM00197;CC12CCC3c4ccc(O)cc4CCC3C1CCC2O;VOXZDWNPVJITMN-UHFFFAOYSA-N;272.388;3.61;5757;DB00783;EST;CHEMBL135;CACO;ECACO;37;0;;;;;;;;;;-4.77;;;;;;;;;;;;"Yazdanian M., Glynn S.L., Wright  J.L., Hawi A.: Correlating partitioning and Caco-2 cell permeability of structurally diverse small molecular weight compounds. Pharm Res., 15(9):1490-1494, 1998.";"Yazdanian M., Glynn S.L., Wright  J.L., Hawi A.: Correlating partitioning and Caco-2 cell permeability of structurally diverse small molecular weight compounds. Pharm Res., 15(9):1490-1494, 1998."
1-(1H-indol-4-yloxy)-3-(propan-2-ylamino)propan-2-ol;MM00542;CC(C)NCC(O)COc1cccc2[nH]ccc12;JZQKKSLKJUAGIC-UHFFFAOYSA-N;248.326;1.91;4828;DB00960;;CHEMBL500;CACO;ECACO;37;1;;;;;;;;;;-4.78;;;;;;;;;;;;"Yazdanian M., Glynn S.L., Wright  J.L., Hawi A.: Correlating partitioning and Caco-2 cell permeability of structurally diverse small molecular weight compounds. Pharm Res., 15(9):1490-1494, 1998.";"Yazdanian M., Glynn S.L., Wright  J.L., Hawi A.: Correlating partitioning and Caco-2 cell permeability of structurally diverse small molecular weight compounds. Pharm Res., 15(9):1490-1494, 1998."
Telmisartan;MM01037;CCCc1nc2c(C)cc(-c3nc4ccccc4n3C)cc2n1Cc1ccc(-c2ccccc2C(=O)O)cc1;RMMXLENWKUUMAY-UHFFFAOYSA-N;514.629;7.26;65999;DB00966;TLS;CHEMBL1017;CACO;ECACO;37;-1;;;;;;;;;;-4.82;;;;;;;;;;;;"Yazdanian M., Glynn S.L., Wright  J.L., Hawi A.: Correlating partitioning and Caco-2 cell permeability of structurally diverse small molecular weight compounds. Pharm Res., 15(9):1490-1494, 1998.";"Yazdanian M., Glynn S.L., Wright  J.L., Hawi A.: Correlating partitioning and Caco-2 cell permeability of structurally diverse small molecular weight compounds. Pharm Res., 15(9):1490-1494, 1998."
Hydrocortisone;MM00044;CC12CCC(=O)C=C1CCC1C2C(O)CC2(C)C1CCC2(O)C(=O)CO;JYGXADMDTFJGBT-UHFFFAOYSA-N;362.466;1.78;5754;DB00741;HCY;CHEMBL389621;CACO;ECACO;37;0;;;;;;;;;;-4.85;;;;;;;;;;;;"Yazdanian M., Glynn S.L., Wright  J.L., Hawi A.: Correlating partitioning and Caco-2 cell permeability of structurally diverse small molecular weight compounds. Pharm Res., 15(9):1490-1494, 1998.";"Yazdanian M., Glynn S.L., Wright  J.L., Hawi A.: Correlating partitioning and Caco-2 cell permeability of structurally diverse small molecular weight compounds. Pharm Res., 15(9):1490-1494, 1998."
(2S)-1-(tert-butylamino)-3-[(4-morpholin-4-yl-1,2,5-thiadiazol-3-yl)oxy]propan-2-ol;MM00573;CC(C)(C)NCC(O)COc1nsnc1N1CCOCC1;BLJRIMJGRPQVNF-UHFFFAOYSA-N;316.42;0.5;33624;DB00373;TIM;CHEMBL499;CACO;ECACO;37;1;;;;;;;;;;-4.89;;;;;;;;;;;;"Yazdanian M., Glynn S.L., Wright  J.L., Hawi A.: Correlating partitioning and Caco-2 cell permeability of structurally diverse small molecular weight compounds. Pharm Res., 15(9):1490-1494, 1998.";"Yazdanian M., Glynn S.L., Wright  J.L., Hawi A.: Correlating partitioning and Caco-2 cell permeability of structurally diverse small molecular weight compounds. Pharm Res., 15(9):1490-1494, 1998."
Dexamethasone;MM00355;C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO;UREBDLICKHMUKA-CXSFZGCWSA-N;392.467;1.9;5743;DB01234;DEX;CHEMBL384467;CACO;ECACO;37;0;;;;;;;;;;-4.91;;;;;;;;;;;;"Yazdanian M., Glynn S.L., Wright  J.L., Hawi A.: Correlating partitioning and Caco-2 cell permeability of structurally diverse small molecular weight compounds. Pharm Res., 15(9):1490-1494, 1998.";"Yazdanian M., Glynn S.L., Wright  J.L., Hawi A.: Correlating partitioning and Caco-2 cell permeability of structurally diverse small molecular weight compounds. Pharm Res., 15(9):1490-1494, 1998."
Scopolamine;MM00564;CN1[C@H]2CC(OC(=O)[C@H](CO)c3ccccc3)C[C@@H]1[C@H]1O[C@@H]21;STECJAGHUSJQJN-USLFZFAMSA-N;303.358;0.92;3000322;DB00747;;CHEMBL569713;CACO;ECACO;37;1;;;;;;;;;;-4.93;;;;;;;;;;;;"Yazdanian M., Glynn S.L., Wright  J.L., Hawi A.: Correlating partitioning and Caco-2 cell permeability of structurally diverse small molecular weight compounds. Pharm Res., 15(9):1490-1494, 1998.";"Yazdanian M., Glynn S.L., Wright  J.L., Hawi A.: Correlating partitioning and Caco-2 cell permeability of structurally diverse small molecular weight compounds. Pharm Res., 15(9):1490-1494, 1998."
4-(2-aminoethyl)benzene-1,2-diol;MM00483;NCCc1ccc(O)c(O)c1;VYFYYTLLBUKUHU-UHFFFAOYSA-N;153.181;0.6;681;DB00988;LDP;CHEMBL59;CACO;ECACO;37;1;;;;;;;;;;-5.03;;;;;;;;;;;;"Yazdanian M., Glynn S.L., Wright  J.L., Hawi A.: Correlating partitioning and Caco-2 cell permeability of structurally diverse small molecular weight compounds. Pharm Res., 15(9):1490-1494, 1998.";"Yazdanian M., Glynn S.L., Wright  J.L., Hawi A.: Correlating partitioning and Caco-2 cell permeability of structurally diverse small molecular weight compounds. Pharm Res., 15(9):1490-1494, 1998."
2-hydroxy-5-[1-hydroxy-2-(4-phenylbutan-2-ylamino)ethyl]benzamide;MM00507;CC(CCc1ccccc1)NCC(O)c1ccc(O)c(C(N)=O)c1;SGUAFYQXFOLMHL-UHFFFAOYSA-N;328.412;2.14;3869;DB00598;;CHEMBL429;CACO;ECACO;37;1;;;;;;;;;;-5.03;;;;;;;;;;;;"Yazdanian M., Glynn S.L., Wright  J.L., Hawi A.: Correlating partitioning and Caco-2 cell permeability of structurally diverse small molecular weight compounds. Pharm Res., 15(9):1490-1494, 1998.";"Yazdanian M., Glynn S.L., Wright  J.L., Hawi A.: Correlating partitioning and Caco-2 cell permeability of structurally diverse small molecular weight compounds. Pharm Res., 15(9):1490-1494, 1998."
"Acetylsalicylic acid";MM00080;CC(=O)Oc1ccccc1C(=O)O;BSYNRYMUTXBXSQ-UHFFFAOYSA-N;180.159;1.31;2244;DB00945;AIN;CHEMBL25;CACO;ECACO;37;-1;;;;;;;;;;-5.04;;;;;;;;;;;;"Yazdanian M., Glynn S.L., Wright  J.L., Hawi A.: Correlating partitioning and Caco-2 cell permeability of structurally diverse small molecular weight compounds. Pharm Res., 15(9):1490-1494, 1998.";"Yazdanian M., Glynn S.L., Wright  J.L., Hawi A.: Correlating partitioning and Caco-2 cell permeability of structurally diverse small molecular weight compounds. Pharm Res., 15(9):1490-1494, 1998."
Bremazocine;MM00452;CC[C@]12CCN(CC3(O)CC3)[C@H](Cc3ccc(O)cc31)C2(C)C;ZDXGFIXMPOUDFF-XLIONFOSSA-N;315.457;3.22;443406;;;;CACO;ECACO;37;0;;;;;;;;;;-5.1;;;;;;;;;;;;"Yazdanian M., Glynn S.L., Wright  J.L., Hawi A.: Correlating partitioning and Caco-2 cell permeability of structurally diverse small molecular weight compounds. Pharm Res., 15(9):1490-1494, 1998.";"Yazdanian M., Glynn S.L., Wright  J.L., Hawi A.: Correlating partitioning and Caco-2 cell permeability of structurally diverse small molecular weight compounds. Pharm Res., 15(9):1490-1494, 1998."
1-[(2R,4S,5S)-4-azido-5-(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione;MM00077;Cc1cn(C2CC(N=[N+]=[N-])C(CO)O2)c(=O)[nH]c1=O;HBOMLICNUCNMMY-UHFFFAOYSA-N;267.245;-0.2;35370;DB00495;AZZ;CHEMBL129;CACO;ECACO;37;0;;;;;;;;;;-5.16;;;;;;;;;;;;"Yazdanian M., Glynn S.L., Wright  J.L., Hawi A.: Correlating partitioning and Caco-2 cell permeability of structurally diverse small molecular weight compounds. Pharm Res., 15(9):1490-1494, 1998.";"Yazdanian M., Glynn S.L., Wright  J.L., Hawi A.: Correlating partitioning and Caco-2 cell permeability of structurally diverse small molecular weight compounds. Pharm Res., 15(9):1490-1494, 1998."
Urea;MM00065;NC(N)=O;XSQUKJJJFZCRTK-UHFFFAOYSA-N;60.056;-0.98;1176;DB03904;URE;CHEMBL985;CACO;ECACO;37;1;;;;;;;;;;-5.34;;;;;;;;;;;;"Yazdanian M., Glynn S.L., Wright  J.L., Hawi A.: Correlating partitioning and Caco-2 cell permeability of structurally diverse small molecular weight compounds. Pharm Res., 15(9):1490-1494, 1998.";"Yazdanian M., Glynn S.L., Wright  J.L., Hawi A.: Correlating partitioning and Caco-2 cell permeability of structurally diverse small molecular weight compounds. Pharm Res., 15(9):1490-1494, 1998."
1H-pyrimidine-2,4-dione;MM01039;O=c1cc[nH]c(=O)[nH]1;ISAKRJDGNUQOIC-UHFFFAOYSA-N;112.088;-0.94;1174;DB03419;URA;CHEMBL566;CACO;ECACO;37;1;;;;;;;;;;-5.37;;;;;;;;;;;;"Yazdanian M., Glynn S.L., Wright  J.L., Hawi A.: Correlating partitioning and Caco-2 cell permeability of structurally diverse small molecular weight compounds. Pharm Res., 15(9):1490-1494, 1998.";"Yazdanian M., Glynn S.L., Wright  J.L., Hawi A.: Correlating partitioning and Caco-2 cell permeability of structurally diverse small molecular weight compounds. Pharm Res., 15(9):1490-1494, 1998."
(2R,3S)-5-[3-(tert-butylamino)-2-hydroxypropoxy]-1,2,3,4-tetrahydronaphthalene-2,3-diol;MM00525;CC(C)(C)NCC(O)COc1cccc2c1CC(O)C(O)C2;VWPOSFSPZNDTMJ-UHFFFAOYSA-N;309.406;0.63;39147;DB01203;;CHEMBL649;CACO;ECACO;37;1;;;;;;;;;;-5.41;;;;;;;;;;;;"Yazdanian M., Glynn S.L., Wright  J.L., Hawi A.: Correlating partitioning and Caco-2 cell permeability of structurally diverse small molecular weight compounds. Pharm Res., 15(9):1490-1494, 1998.";"Yazdanian M., Glynn S.L., Wright  J.L., Hawi A.: Correlating partitioning and Caco-2 cell permeability of structurally diverse small molecular weight compounds. Pharm Res., 15(9):1490-1494, 1998."
Sucrose;MM00421;OC[C@H]1O[C@H](O[C@]2(CO)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@H](O)[C@@H](O)[C@@H]1O;CZMRCDWAGMRECN-UGDNZRGBSA-N;342.297;-5.4;5988;DB02772;SUC;CHEMBL253582;CACO;ECACO;37;0;;;;;;;;;;-5.77;;;;;;;;;;;;"Yazdanian M., Glynn S.L., Wright  J.L., Hawi A.: Correlating partitioning and Caco-2 cell permeability of structurally diverse small molecular weight compounds. Pharm Res., 15(9):1490-1494, 1998.";"Yazdanian M., Glynn S.L., Wright  J.L., Hawi A.: Correlating partitioning and Caco-2 cell permeability of structurally diverse small molecular weight compounds. Pharm Res., 15(9):1490-1494, 1998."
1-cyano-2-methyl-3-[2-[(5-methyl-1H-imidazol-4-yl)methylsulfanyl]ethyl]guanidine;MM00463;CNC(=NCCSCc1nc[nH]c1C)NC#N;AQIXAKUUQRKLND-UHFFFAOYSA-N;252.34;0.6;2756;DB00501;;CHEMBL30;CACO;ECACO;37;1;;;;;;;;;;-5.86;;;;;;;;;;;;"Yazdanian M., Glynn S.L., Wright  J.L., Hawi A.: Correlating partitioning and Caco-2 cell permeability of structurally diverse small molecular weight compounds. Pharm Res., 15(9):1490-1494, 1998.";"Yazdanian M., Glynn S.L., Wright  J.L., Hawi A.: Correlating partitioning and Caco-2 cell permeability of structurally diverse small molecular weight compounds. Pharm Res., 15(9):1490-1494, 1998."
Methylscopolamine;MM01040;C[N+]1(C)[C@H]2CC(OC(=O)[C@H](CO)c3ccccc3)C[C@@H]1[C@H]1O[C@@H]21;LZCOQTDXKCNBEE-XJMZPCNVSA-N;318.393;1.06;71183;DB00462;;;CACO;ECACO;37;1;;;;;;;;;;-6.16;;;;;;;;;;;;"Yazdanian M., Glynn S.L., Wright  J.L., Hawi A.: Correlating partitioning and Caco-2 cell permeability of structurally diverse small molecular weight compounds. Pharm Res., 15(9):1490-1494, 1998.";"Yazdanian M., Glynn S.L., Wright  J.L., Hawi A.: Correlating partitioning and Caco-2 cell permeability of structurally diverse small molecular weight compounds. Pharm Res., 15(9):1490-1494, 1998."
6-chloro-1,1-dioxo-3,4-dihydro-2H-1lambda6,2,4-benzothiadiazine-7-sulfonamide;MM00373;NS(=O)(=O)c1cc2c(cc1Cl)NCNS2(=O)=O;JZUFKLXOESDKRF-UHFFFAOYSA-N;297.728;-0.35;3639;DB00999;HCZ;CHEMBL435;CACO;ECACO;37;1;;;;;;;;;;-6.29;;;;;;;;;;;;"Yazdanian M., Glynn S.L., Wright  J.L., Hawi A.: Correlating partitioning and Caco-2 cell permeability of structurally diverse small molecular weight compounds. Pharm Res., 15(9):1490-1494, 1998.";"Yazdanian M., Glynn S.L., Wright  J.L., Hawi A.: Correlating partitioning and Caco-2 cell permeability of structurally diverse small molecular weight compounds. Pharm Res., 15(9):1490-1494, 1998."
2-[4-[2-hydroxy-3-(propan-2-ylamino)propoxy]phenyl]acetamide;MM00078;CC(C)NC[C@@H](O)COc1ccc(CC(N)=O)cc1;METKIMKYRPQLGS-UHFFFAOYSA-N;266.341;0.45;2249;DB00335;;CHEMBL24;CACO;ECACO;37;1;;;;;;;;;;-6.28;;;;;;;;;;;;"Yazdanian M., Glynn S.L., Wright  J.L., Hawi A.: Correlating partitioning and Caco-2 cell permeability of structurally diverse small molecular weight compounds. Pharm Res., 15(9):1490-1494, 1998.";"Yazdanian M., Glynn S.L., Wright  J.L., Hawi A.: Correlating partitioning and Caco-2 cell permeability of structurally diverse small molecular weight compounds. Pharm Res., 15(9):1490-1494, 1998."
N-[3-acetyl-4-[2-hydroxy-3-(propan-2-ylamino)propoxy]phenyl]butanamide;MM00437;CCCC(=O)Nc1ccc(OC[C@H](O)CNC(C)C)c(C(C)=O)c1;GOEMGAFJFRBGGG-UHFFFAOYSA-N;336.432;2.37;1978;DB01193;;CHEMBL642;CACO;ECACO;37;1;;;;;;;;;;-6.29;;;;;;;;;;;;"Yazdanian M., Glynn S.L., Wright  J.L., Hawi A.: Correlating partitioning and Caco-2 cell permeability of structurally diverse small molecular weight compounds. Pharm Res., 15(9):1490-1494, 1998.";"Yazdanian M., Glynn S.L., Wright  J.L., Hawi A.: Correlating partitioning and Caco-2 cell permeability of structurally diverse small molecular weight compounds. Pharm Res., 15(9):1490-1494, 1998."
5-[2-(tert-butylamino)-1-hydroxyethyl]benzene-1,3-diol;MM00306;CC(C)(C)NCC(O)c1cc(O)cc(O)c1;XWTYSIMOBUGWOL-UHFFFAOYSA-N;225.288;1.52;5403;DB00871;;CHEMBL1760;CACO;ECACO;37;1;;;;;;;;;;-6.33;;;;;;;;;;;;"Yazdanian M., Glynn S.L., Wright  J.L., Hawi A.: Correlating partitioning and Caco-2 cell permeability of structurally diverse small molecular weight compounds. Pharm Res., 15(9):1490-1494, 1998.";"Yazdanian M., Glynn S.L., Wright  J.L., Hawi A.: Correlating partitioning and Caco-2 cell permeability of structurally diverse small molecular weight compounds. Pharm Res., 15(9):1490-1494, 1998."
Ranitidine;MM01053;CNC(=C[N+](=O)[O-])NCCSCc1ccc(CN(C)C)o1;VMXUWOKSQNHOCA-UHFFFAOYSA-N;314.404;1.46;5039;DB00863;;CHEMBL1790041;CACO;ECACO;37;1;;;;;;;;;;-6.31;;;;;;;;;;;;"Yazdanian M., Glynn S.L., Wright  J.L., Hawi A.: Correlating partitioning and Caco-2 cell permeability of structurally diverse small molecular weight compounds. Pharm Res., 15(9):1490-1494, 1998.";"Yazdanian M., Glynn S.L., Wright  J.L., Hawi A.: Correlating partitioning and Caco-2 cell permeability of structurally diverse small molecular weight compounds. Pharm Res., 15(9):1490-1494, 1998."
11-[2-(4-methylpiperazin-1-yl)acetyl]-5H-pyrido[2,3-b][1,4]benzodiazepin-6-one;MM00543;CN1CCN(CC(=O)N2c3ccccc3C(=O)Nc3cccnc32)CC1;RMHMFHUVIITRHF-UHFFFAOYSA-N;351.41;1.56;4848;DB00670;;CHEMBL9967;CACO;ECACO;37;1;;;;;;;;;;-6.36;;;;;;;;;;;;"Yazdanian M., Glynn S.L., Wright  J.L., Hawi A.: Correlating partitioning and Caco-2 cell permeability of structurally diverse small molecular weight compounds. Pharm Res., 15(9):1490-1494, 1998.";"Yazdanian M., Glynn S.L., Wright  J.L., Hawi A.: Correlating partitioning and Caco-2 cell permeability of structurally diverse small molecular weight compounds. Pharm Res., 15(9):1490-1494, 1998."
(2R,3R,4R,5R)-hexane-1,2,3,4,5,6-hexol;MM00386;OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO;FBPFZTCFMRRESA-KVTDHHQDSA-N;182.172;-3.59;6251;DB00742;MTL;CHEMBL689;CACO;ECACO;37;0;;;;;;;;;;-6.42;;;;;;;;;;;;"Yazdanian M., Glynn S.L., Wright  J.L., Hawi A.: Correlating partitioning and Caco-2 cell permeability of structurally diverse small molecular weight compounds. Pharm Res., 15(9):1490-1494, 1998.";"Yazdanian M., Glynn S.L., Wright  J.L., Hawi A.: Correlating partitioning and Caco-2 cell permeability of structurally diverse small molecular weight compounds. Pharm Res., 15(9):1490-1494, 1998."
2-amino-9-(1,3-dihydroxypropan-2-yloxymethyl)-3H-purin-6-one;MM00367;Nc1nc(O)c2ncn(COC(CO)CO)c2n1;IRSCQMHQWWYFCW-UHFFFAOYSA-N;255.234;-1.56;3454;DB01004;GA2;CHEMBL182;CACO;ECACO;37;0;;;;;;;;;;-6.42;;;;;;;;;;;;"Yazdanian M., Glynn S.L., Wright  J.L., Hawi A.: Correlating partitioning and Caco-2 cell permeability of structurally diverse small molecular weight compounds. Pharm Res., 15(9):1490-1494, 1998.";"Yazdanian M., Glynn S.L., Wright  J.L., Hawi A.: Correlating partitioning and Caco-2 cell permeability of structurally diverse small molecular weight compounds. Pharm Res., 15(9):1490-1494, 1998."
Sulfasalazine;MM00690;O=C(O)c1cc(N=Nc2ccc(S(=O)(=O)Nc3ccccn3)cc2)ccc1O;NCEXYHBECQHGNR-UHFFFAOYSA-N;398.393;3.7;5359476;DB00795;SAS;CHEMBL421;CACO;ECACO;37;-1;;;;;;;;;;-6.52;;;;;;;;;;;;"Yazdanian M., Glynn S.L., Wright  J.L., Hawi A.: Correlating partitioning and Caco-2 cell permeability of structurally diverse small molecular weight compounds. Pharm Res., 15(9):1490-1494, 1998.";"Yazdanian M., Glynn S.L., Wright  J.L., Hawi A.: Correlating partitioning and Caco-2 cell permeability of structurally diverse small molecular weight compounds. Pharm Res., 15(9):1490-1494, 1998."
2-amino-9-(2-hydroxyethoxymethyl)-3H-purin-6-one;MM00074;Nc1nc(=O)c2ncn(COCCO)c2[nH]1;MKUXAQIIEYXACX-UHFFFAOYSA-N;225.208;-0.92;2022;DB00787;AC2;CHEMBL184;CACO;ECACO;37;0;;;;;;;;;;-6.6;;;;;;;;;;;;"Yazdanian M., Glynn S.L., Wright  J.L., Hawi A.: Correlating partitioning and Caco-2 cell permeability of structurally diverse small molecular weight compounds. Pharm Res., 15(9):1490-1494, 1998.";"Yazdanian M., Glynn S.L., Wright  J.L., Hawi A.: Correlating partitioning and Caco-2 cell permeability of structurally diverse small molecular weight compounds. Pharm Res., 15(9):1490-1494, 1998."
6-chloro-1,1-dioxo-4H-1lambda6,2,4-benzothiadiazine-7-sulfonamide;MM00641;NS(=O)(=O)c1cc2c(cc1Cl)NC=NS2(=O)=O;JBMKAUGHUNFTOL-UHFFFAOYSA-N;295.712;0.13;2720;DB00880;;CHEMBL842;CACO;ECACO;37;1;;;;;;;;;;-6.72;;;;;;;;;;;;"Yazdanian M., Glynn S.L., Wright  J.L., Hawi A.: Correlating partitioning and Caco-2 cell permeability of structurally diverse small molecular weight compounds. Pharm Res., 15(9):1490-1494, 1998.";"Yazdanian M., Glynn S.L., Wright  J.L., Hawi A.: Correlating partitioning and Caco-2 cell permeability of structurally diverse small molecular weight compounds. Pharm Res., 15(9):1490-1494, 1998."
2-amino-9-(2-hydroxyethoxymethyl)-3H-purin-6-one;MM00074;Nc1nc(=O)c2ncn(COCCO)c2[nH]1;MKUXAQIIEYXACX-UHFFFAOYSA-N;225.208;-0.92;2022;DB00787;AC2;CHEMBL184;CACO;EPAM;25;0;;;;;;;;;;-6.1;;;;;;;;;;;;"Tam KY, Avdeef A, Tsinman O, Sun N.: The permeation of amphoteric drugs through artificial membranes--an in combo absorption model based on paracellular and transmembrane permeability. J Med Chem, Volume 53 (1), 392-401, 2010";"Tam KY, Avdeef A, Tsinman O, Sun N.: The permeation of amphoteric drugs through artificial membranes--an in combo absorption model based on paracellular and transmembrane permeability. J Med Chem, Volume 53 (1), 392-401, 2010"
Amdinocillin;MM01269;CC1(C)SC2C(N=CN3CCCCCC3)C(=O)N2C1C(=O)O;BWWVAEOLVKTZFQ-UHFFFAOYSA-N;325.427;1.41;36273;DB01163;;;CACO;EPAM;25;+1-1;;;;;;;;;;-6.05;;;;;;;;;;;;"Tam KY, Avdeef A, Tsinman O, Sun N.: The permeation of amphoteric drugs through artificial membranes--an in combo absorption model based on paracellular and transmembrane permeability. J Med Chem, Volume 53 (1), 392-401, 2010";"Tam KY, Avdeef A, Tsinman O, Sun N.: The permeation of amphoteric drugs through artificial membranes--an in combo absorption model based on paracellular and transmembrane permeability. J Med Chem, Volume 53 (1), 392-401, 2010"
Benazepril;MM00629;CCOC(=O)[C@H](CCc1ccccc1)N[C@H]1CCc2ccccc2N(CC(=O)O)C1=O;XPCFTKFZXHTYIP-PMACEKPBSA-N;424.497;2.57;5362124;DB00542;;CHEMBL838;CACO;EPAM;25;-1;;;;;;;;;;-4.77;;;;;;;;;;;;"Tam KY, Avdeef A, Tsinman O, Sun N.: The permeation of amphoteric drugs through artificial membranes--an in combo absorption model based on paracellular and transmembrane permeability. J Med Chem, Volume 53 (1), 392-401, 2010";"Tam KY, Avdeef A, Tsinman O, Sun N.: The permeation of amphoteric drugs through artificial membranes--an in combo absorption model based on paracellular and transmembrane permeability. J Med Chem, Volume 53 (1), 392-401, 2010"
Ceftazidime;MM01270;CC(C)(ON=C(C(=O)NC1C(=O)N2C(C(=O)[O-])=C(C[n+]3ccccc3)CSC12)c1csc(N)n1)C(=O)O;ORFOPKXBNMVMKC-UHFFFAOYSA-N;546.573;-1.3;5481173;DB00438;;;CACO;EPAM;25;+1-1;;;;;;;;;;-6.7;;;;;;;;;;;;"Tam KY, Avdeef A, Tsinman O, Sun N.: The permeation of amphoteric drugs through artificial membranes--an in combo absorption model based on paracellular and transmembrane permeability. J Med Chem, Volume 53 (1), 392-401, 2010";"Tam KY, Avdeef A, Tsinman O, Sun N.: The permeation of amphoteric drugs through artificial membranes--an in combo absorption model based on paracellular and transmembrane permeability. J Med Chem, Volume 53 (1), 392-401, 2010"
Cerivastatin;MM00639;COCc1c(C(C)C)nc(C(C)C)c(C=CC(O)CC(O)CC(=O)O)c1-c1ccc(F)cc1;SEERZIQQUAZTOL-UHFFFAOYSA-N;459.558;4.88;446156;DB00439;116;CHEMBL1477;CACO;EPAM;25;-1;;;;;;;;;;-4.82;;;;;;;;;;;;"Tam KY, Avdeef A, Tsinman O, Sun N.: The permeation of amphoteric drugs through artificial membranes--an in combo absorption model based on paracellular and transmembrane permeability. J Med Chem, Volume 53 (1), 392-401, 2010";"Tam KY, Avdeef A, Tsinman O, Sun N.: The permeation of amphoteric drugs through artificial membranes--an in combo absorption model based on paracellular and transmembrane permeability. J Med Chem, Volume 53 (1), 392-401, 2010"
"2-[2-[4-[(4-chlorophenyl)-phenylmethyl]piperazin-1-yl]ethoxy]acetic acid";MM00724;O=C(O)COCCN1CCN(C(c2ccccc2)c2ccc(Cl)cc2)CC1;ZKLPARSLTMPFCP-UHFFFAOYSA-N;388.892;3.15;2678;DB00341;;CHEMBL1000;CACO;EPAM;25;+1-1;;;;;;;;;;-4.38;;;;;;;;;;;;"Tam KY, Avdeef A, Tsinman O, Sun N.: The permeation of amphoteric drugs through artificial membranes--an in combo absorption model based on paracellular and transmembrane permeability. J Med Chem, Volume 53 (1), 392-401, 2010";"Tam KY, Avdeef A, Tsinman O, Sun N.: The permeation of amphoteric drugs through artificial membranes--an in combo absorption model based on paracellular and transmembrane permeability. J Med Chem, Volume 53 (1), 392-401, 2010"
"1-cyclopropyl-6-fluoro-4-oxo-7-piperazin-1-ylquinoline-3-carboxylic acid";MM00726;O=C(O)c1cn(C2CC2)c2cc(N3CCNCC3)c(F)cc2c1=O;MYSWGUAQZAJSOK-UHFFFAOYSA-N;331.347;1.58;2764;DB00537;CPF;CHEMBL8;CACO;EPAM;25;"+1-1, 1";;;;;;;;;;-5.55;;;;;;;;;;;;"Tam KY, Avdeef A, Tsinman O, Sun N.: The permeation of amphoteric drugs through artificial membranes--an in combo absorption model based on paracellular and transmembrane permeability. J Med Chem, Volume 53 (1), 392-401, 2010";"Tam KY, Avdeef A, Tsinman O, Sun N.: The permeation of amphoteric drugs through artificial membranes--an in combo absorption model based on paracellular and transmembrane permeability. J Med Chem, Volume 53 (1), 392-401, 2010"
Daunorubicin;MM00473;COc1cccc2c1C(=O)c1c(O)c3c(c(O)c1C2=O)CC(O)(C(C)=O)CC3OC1CC(N)C(O)C(C)O1;STQGQHZAVUOBTE-UHFFFAOYSA-N;527.526;1.03;30323;DB00694;DM1;CHEMBL178;CACO;EPAM;25;1;;;;;;;;;;-6.52;;;;;;;;;;;;"Tam KY, Avdeef A, Tsinman O, Sun N.: The permeation of amphoteric drugs through artificial membranes--an in combo absorption model based on paracellular and transmembrane permeability. J Med Chem, Volume 53 (1), 392-401, 2010";"Tam KY, Avdeef A, Tsinman O, Sun N.: The permeation of amphoteric drugs through artificial membranes--an in combo absorption model based on paracellular and transmembrane permeability. J Med Chem, Volume 53 (1), 392-401, 2010"
Demeclocycline;MM01271;CN(C)C1C(=O)C(C(N)=O)=C(O)C2(O)C(=O)C3=C(O)c4c(O)ccc(Cl)c4C(O)C3CC12;GUXHBMASAHGULD-UHFFFAOYSA-N;464.855;0.11;54680690;DB00618;;;CACO;EPAM;25;"+1-1, -1";;;;;;;;;;-5.42;;;;;;;;;;;;"Tam KY, Avdeef A, Tsinman O, Sun N.: The permeation of amphoteric drugs through artificial membranes--an in combo absorption model based on paracellular and transmembrane permeability. J Med Chem, Volume 53 (1), 392-401, 2010";"Tam KY, Avdeef A, Tsinman O, Sun N.: The permeation of amphoteric drugs through artificial membranes--an in combo absorption model based on paracellular and transmembrane permeability. J Med Chem, Volume 53 (1), 392-401, 2010"
Doxycycline;MM01272;CC1c2cccc(O)c2C(O)=C2C(=O)C3(O)C(O)=C(C(N)=O)C(=O)C(N(C)C)C3C(O)C21;SGKRLCUYIXIAHR-UHFFFAOYSA-N;444.44;-0.5;54671203;DB00254;;CHEMBL3559889;CACO;EPAM;25;+1-1;;;;;;;;;;-4.7;;;;;;;;;;;;"Tam KY, Avdeef A, Tsinman O, Sun N.: The permeation of amphoteric drugs through artificial membranes--an in combo absorption model based on paracellular and transmembrane permeability. J Med Chem, Volume 53 (1), 392-401, 2010";"Tam KY, Avdeef A, Tsinman O, Sun N.: The permeation of amphoteric drugs through artificial membranes--an in combo absorption model based on paracellular and transmembrane permeability. J Med Chem, Volume 53 (1), 392-401, 2010"
"1-ethyl-6-fluoro-4-oxo-7-piperazin-1-yl-1,8-naphthyridine-3-carboxylic acid";MM00733;CCn1cc(C(=O)O)c(=O)c2cc(F)c(N3CCNCC3)nc21;IDYZIJYBMGIQMJ-UHFFFAOYSA-N;320.324;0.66;3229;DB00467;;CHEMBL826;CACO;EPAM;25;"+1-1, 1";;;;;;;;;;-5.11;;;;;;;;;;;;"Tam KY, Avdeef A, Tsinman O, Sun N.: The permeation of amphoteric drugs through artificial membranes--an in combo absorption model based on paracellular and transmembrane permeability. J Med Chem, Volume 53 (1), 392-401, 2010";"Tam KY, Avdeef A, Tsinman O, Sun N.: The permeation of amphoteric drugs through artificial membranes--an in combo absorption model based on paracellular and transmembrane permeability. J Med Chem, Volume 53 (1), 392-401, 2010"
Famotidine;MM00079;NC(N)=Nc1nc(CSCCC(N)=NS(N)(=O)=O)cs1;XUFQPHANEAPEMJ-UHFFFAOYSA-N;337.435;-0.77;3325;DB00927;;CHEMBL902;CACO;EPAM;25;"1, 0";;;;;;;;;;-6.22;;;;;;;;;;;;"Tam KY, Avdeef A, Tsinman O, Sun N.: The permeation of amphoteric drugs through artificial membranes--an in combo absorption model based on paracellular and transmembrane permeability. J Med Chem, Volume 53 (1), 392-401, 2010";"Tam KY, Avdeef A, Tsinman O, Sun N.: The permeation of amphoteric drugs through artificial membranes--an in combo absorption model based on paracellular and transmembrane permeability. J Med Chem, Volume 53 (1), 392-401, 2010"
Fexofenadine;MM00735;CC(C)(C(=O)O)c1ccc(C(O)CCCN2CCC(C(O)(c3ccccc3)c3ccccc3)CC2)cc1;RWTNPBWLLIMQHL-UHFFFAOYSA-N;501.667;5.51;3348;DB00950;;CHEMBL914;CACO;EPAM;25;+1-1;;;;;;;;;;-5.55;;;;;;;;;;;;"Tam KY, Avdeef A, Tsinman O, Sun N.: The permeation of amphoteric drugs through artificial membranes--an in combo absorption model based on paracellular and transmembrane permeability. J Med Chem, Volume 53 (1), 392-401, 2010";"Tam KY, Avdeef A, Tsinman O, Sun N.: The permeation of amphoteric drugs through artificial membranes--an in combo absorption model based on paracellular and transmembrane permeability. J Med Chem, Volume 53 (1), 392-401, 2010"
2-amino-9-(1,3-dihydroxypropan-2-yloxymethyl)-3H-purin-6-one;MM00367;Nc1nc(O)c2ncn(COC(CO)CO)c2n1;IRSCQMHQWWYFCW-UHFFFAOYSA-N;255.234;-1.56;3454;DB01004;GA2;CHEMBL182;CACO;EPAM;25;0;;;;;;;;;;-6.15;;;;;;;;;;;;"Tam KY, Avdeef A, Tsinman O, Sun N.: The permeation of amphoteric drugs through artificial membranes--an in combo absorption model based on paracellular and transmembrane permeability. J Med Chem, Volume 53 (1), 392-401, 2010";"Tam KY, Avdeef A, Tsinman O, Sun N.: The permeation of amphoteric drugs through artificial membranes--an in combo absorption model based on paracellular and transmembrane permeability. J Med Chem, Volume 53 (1), 392-401, 2010"
Gatifloxacin;MM00738;COc1c(N2CCNC(C)C2)c(F)cc2c(=O)c(C(=O)O)cn(C3CC3)c12;XUBOMFCQGDBHNK-UHFFFAOYSA-N;375.4;1.98;5379;DB01044;;CHEMBL31;CACO;EPAM;25;"+1-1, 1";;;;;;;;;;-4.7;;;;;;;;;;;;"Tam KY, Avdeef A, Tsinman O, Sun N.: The permeation of amphoteric drugs through artificial membranes--an in combo absorption model based on paracellular and transmembrane permeability. J Med Chem, Volume 53 (1), 392-401, 2010";"Tam KY, Avdeef A, Tsinman O, Sun N.: The permeation of amphoteric drugs through artificial membranes--an in combo absorption model based on paracellular and transmembrane permeability. J Med Chem, Volume 53 (1), 392-401, 2010"
Chlortetracycline;MM00725;CN(C)[C@@H]1C(=O)C(C(N)=O)=C(O)[C@@]2(O)C(=O)C3=C(O)c4c(O)ccc(Cl)c4[C@@](C)(O)[C@H]3C[C@@H]12;DHPRQBPJLMKORJ-XRNKAMNCSA-N;478.882;0.28;54675777;DB09093;CTC;CHEMBL404520;CACO;EPAM;25;"+1-1, -1";;;;;;;;;;-5.43;;;;;;;;;;;;"Tam KY, Avdeef A, Tsinman O, Sun N.: The permeation of amphoteric drugs through artificial membranes--an in combo absorption model based on paracellular and transmembrane permeability. J Med Chem, Volume 53 (1), 392-401, 2010";"Tam KY, Avdeef A, Tsinman O, Sun N.: The permeation of amphoteric drugs through artificial membranes--an in combo absorption model based on paracellular and transmembrane permeability. J Med Chem, Volume 53 (1), 392-401, 2010"
Levocarnitine;MM01273;C[N+](C)(C)CC(O)CC(=O)[O-];PHIQHXFUZVPYII-UHFFFAOYSA-N;161.201;-1.81;10917;DB00583;;;CACO;EPAM;25;+1-1;;;;;;;;;;-5.89;;;;;;;;;;;;"Tam KY, Avdeef A, Tsinman O, Sun N.: The permeation of amphoteric drugs through artificial membranes--an in combo absorption model based on paracellular and transmembrane permeability. J Med Chem, Volume 53 (1), 392-401, 2010";"Tam KY, Avdeef A, Tsinman O, Sun N.: The permeation of amphoteric drugs through artificial membranes--an in combo absorption model based on paracellular and transmembrane permeability. J Med Chem, Volume 53 (1), 392-401, 2010"
Lisinopril;MM00763;NCCCCC(NC(CCc1ccccc1)C(=O)O)C(=O)N1CCCC1C(=O)O;RLAWWYSOJDYHDC-UHFFFAOYSA-N;405.495;1.24;5362119;DB00722;LPR;CHEMBL1237;CACO;EPAM;25;"+1-1, -1";;;;;;;;;;-6.22;;;;;;;;;;;;"Tam KY, Avdeef A, Tsinman O, Sun N.: The permeation of amphoteric drugs through artificial membranes--an in combo absorption model based on paracellular and transmembrane permeability. J Med Chem, Volume 53 (1), 392-401, 2010";"Tam KY, Avdeef A, Tsinman O, Sun N.: The permeation of amphoteric drugs through artificial membranes--an in combo absorption model based on paracellular and transmembrane permeability. J Med Chem, Volume 53 (1), 392-401, 2010"
"1-ethyl-6,8-difluoro-7-(3-methylpiperazin-1-yl)-4-oxoquinoline-3-carboxylic acid";MM00764;CCn1cc(C(=O)O)c(=O)c2cc(F)c(N3CCNC(C)C3)c(F)c21;ZEKZLJVOYLTDKK-UHFFFAOYSA-N;351.354;1.8;3948;DB00978;;CHEMBL561;CACO;EPAM;25;+1-1;;;;;;;;;;-4.82;;;;;;;;;;;;"Tam KY, Avdeef A, Tsinman O, Sun N.: The permeation of amphoteric drugs through artificial membranes--an in combo absorption model based on paracellular and transmembrane permeability. J Med Chem, Volume 53 (1), 392-401, 2010";"Tam KY, Avdeef A, Tsinman O, Sun N.: The permeation of amphoteric drugs through artificial membranes--an in combo absorption model based on paracellular and transmembrane permeability. J Med Chem, Volume 53 (1), 392-401, 2010"
Meloxicam;MM00668;Cc1cnc(NC(=O)C2=C(O)c3ccccc3S(=O)(=O)N2C)s1;ZRVUJXDFFKFLMG-UHFFFAOYSA-N;351.395;1.95;54677470;DB00814;MXM;CHEMBL599;CACO;EPAM;25;-1;;;;;;;;;;-4.89;;;;;;;;;;;;"Tam KY, Avdeef A, Tsinman O, Sun N.: The permeation of amphoteric drugs through artificial membranes--an in combo absorption model based on paracellular and transmembrane permeability. J Med Chem, Volume 53 (1), 392-401, 2010";"Tam KY, Avdeef A, Tsinman O, Sun N.: The permeation of amphoteric drugs through artificial membranes--an in combo absorption model based on paracellular and transmembrane permeability. J Med Chem, Volume 53 (1), 392-401, 2010"
"(2S)-2-amino-3-[4-[bis(2-chloroethyl)amino]phenyl]propanoic acid";MM00766;NC(Cc1ccc(N(CCCl)CCCl)cc1)C(=O)O;SGDBTWWWUNNDEQ-UHFFFAOYSA-N;305.199;1.93;460612;DB01042;;CHEMBL852;CACO;EPAM;25;+1-1;;;;;;;;;;-4.08;;;;;;;;;;;;"Tam KY, Avdeef A, Tsinman O, Sun N.: The permeation of amphoteric drugs through artificial membranes--an in combo absorption model based on paracellular and transmembrane permeability. J Med Chem, Volume 53 (1), 392-401, 2010";"Tam KY, Avdeef A, Tsinman O, Sun N.: The permeation of amphoteric drugs through artificial membranes--an in combo absorption model based on paracellular and transmembrane permeability. J Med Chem, Volume 53 (1), 392-401, 2010"
"5-amino-2-hydroxybenzoic acid";MM01274;Nc1ccc(O)c(C(=O)O)c1;KBOPZPXVLCULAV-UHFFFAOYSA-N;153.137;0.67;4075;DB00244;;CHEMBL704;CACO;EPAM;25;"-1, 0";;;;;;;;;;-6.05;;;;;;;;;;;;"Tam KY, Avdeef A, Tsinman O, Sun N.: The permeation of amphoteric drugs through artificial membranes--an in combo absorption model based on paracellular and transmembrane permeability. J Med Chem, Volume 53 (1), 392-401, 2010";"Tam KY, Avdeef A, Tsinman O, Sun N.: The permeation of amphoteric drugs through artificial membranes--an in combo absorption model based on paracellular and transmembrane permeability. J Med Chem, Volume 53 (1), 392-401, 2010"
Minocycline;MM01275;CN(C)c1ccc(O)c2c1CC1CC3C(N(C)C)C(=O)C(C(N)=O)=C(O)C3(O)C(=O)C1=C2O;FFTVPQUHLQBXQZ-UHFFFAOYSA-N;457.483;0.03;54675783;DB01017;;;CACO;EPAM;25;+1-1;;;;;;;;;;-4.3;;;;;;;;;;;;"Tam KY, Avdeef A, Tsinman O, Sun N.: The permeation of amphoteric drugs through artificial membranes--an in combo absorption model based on paracellular and transmembrane permeability. J Med Chem, Volume 53 (1), 392-401, 2010";"Tam KY, Avdeef A, Tsinman O, Sun N.: The permeation of amphoteric drugs through artificial membranes--an in combo absorption model based on paracellular and transmembrane permeability. J Med Chem, Volume 53 (1), 392-401, 2010"
"1-ethyl-6-fluoro-4-oxo-7-piperazin-1-ylquinoline-3-carboxylic acid";MM00768;CCn1cc(C(=O)O)c(=O)c2cc(F)c(N3CCNCC3)cc21;OGJPXUAPXNRGGI-UHFFFAOYSA-N;319.336;1.27;4539;DB01059;;CHEMBL9;CACO;EPAM;25;"+1-1, 1";;;;;;;;;;-6;;;;;;;;;;;;"Tam KY, Avdeef A, Tsinman O, Sun N.: The permeation of amphoteric drugs through artificial membranes--an in combo absorption model based on paracellular and transmembrane permeability. J Med Chem, Volume 53 (1), 392-401, 2010";"Tam KY, Avdeef A, Tsinman O, Sun N.: The permeation of amphoteric drugs through artificial membranes--an in combo absorption model based on paracellular and transmembrane permeability. J Med Chem, Volume 53 (1), 392-401, 2010"
Ofloxacin;MM00769;CC1COc2c(N3CCN(C)CC3)c(F)cc3c(=O)c(C(=O)O)cn1c23;GSDSWSVVBLHKDQ-UHFFFAOYSA-N;361.373;1.54;4583;DB01165;;CHEMBL4;CACO;EPAM;25;"+1-1, 1";;;;;;;;;;-5.33;;;;;;;;;;;;"Tam KY, Avdeef A, Tsinman O, Sun N.: The permeation of amphoteric drugs through artificial membranes--an in combo absorption model based on paracellular and transmembrane permeability. J Med Chem, Volume 53 (1), 392-401, 2010";"Tam KY, Avdeef A, Tsinman O, Sun N.: The permeation of amphoteric drugs through artificial membranes--an in combo absorption model based on paracellular and transmembrane permeability. J Med Chem, Volume 53 (1), 392-401, 2010"
"1-ethyl-6-fluoro-7-(4-methylpiperazin-1-yl)-4-oxoquinoline-3-carboxylic acid";MM00770;CCn1cc(C(=O)O)c(=O)c2cc(F)c(N3CCN(C)CC3)cc21;FHFYDNQZQSQIAI-UHFFFAOYSA-N;333.363;1.61;51081;DB00487;;CHEMBL267648;CACO;EPAM;25;"+1-1, 1";;;;;;;;;;-4.64;;;;;;;;;;;;"Tam KY, Avdeef A, Tsinman O, Sun N.: The permeation of amphoteric drugs through artificial membranes--an in combo absorption model based on paracellular and transmembrane permeability. J Med Chem, Volume 53 (1), 392-401, 2010";"Tam KY, Avdeef A, Tsinman O, Sun N.: The permeation of amphoteric drugs through artificial membranes--an in combo absorption model based on paracellular and transmembrane permeability. J Med Chem, Volume 53 (1), 392-401, 2010"
4-hydroxy-2-methyl-1,1-dioxo-N-pyridin-2-yl-1lambda6,2-benzothiazine-3-carboxamide;MM00682;CN1C(C(=O)Nc2ccccn2)=C(O)c2ccccc2S1(=O)=O;QYSPLQLAKJAUJT-UHFFFAOYSA-N;331.346;1.58;54676228;DB00554;;CHEMBL527;CACO;EPAM;25;-1;;;;;;;;;;-4.7;;;;;;;;;;;;"Tam KY, Avdeef A, Tsinman O, Sun N.: The permeation of amphoteric drugs through artificial membranes--an in combo absorption model based on paracellular and transmembrane permeability. J Med Chem, Volume 53 (1), 392-401, 2010";"Tam KY, Avdeef A, Tsinman O, Sun N.: The permeation of amphoteric drugs through artificial membranes--an in combo absorption model based on paracellular and transmembrane permeability. J Med Chem, Volume 53 (1), 392-401, 2010"
Sparfloxacin;MM00772;CC1CN(c2c(F)c(N)c3c(=O)c(C(=O)O)cn(C4CC4)c3c2F)CC(C)N1;DZZWHBIBMUVIIW-UHFFFAOYSA-N;392.407;2.08;60464;DB01208;;CHEMBL850;CACO;EPAM;25;"+1-1, 1";;;;;;;;;;-4.38;;;;;;;;;;;;"Tam KY, Avdeef A, Tsinman O, Sun N.: The permeation of amphoteric drugs through artificial membranes--an in combo absorption model based on paracellular and transmembrane permeability. J Med Chem, Volume 53 (1), 392-401, 2010";"Tam KY, Avdeef A, Tsinman O, Sun N.: The permeation of amphoteric drugs through artificial membranes--an in combo absorption model based on paracellular and transmembrane permeability. J Med Chem, Volume 53 (1), 392-401, 2010"
4-amino-N-pyrimidin-2-ylbenzenesulfonamide;MM01276;Nc1ccc(S(=O)(=O)Nc2ncccn2)cc1;SEEPANYCNGTZFQ-UHFFFAOYSA-N;250.276;0.86;5215;DB00359;;CHEMBL439;CACO;EPAM;25;"-1, 0";;;;;;;;;;-5.92;;;;;;;;;;;;"Tam KY, Avdeef A, Tsinman O, Sun N.: The permeation of amphoteric drugs through artificial membranes--an in combo absorption model based on paracellular and transmembrane permeability. J Med Chem, Volume 53 (1), 392-401, 2010";"Tam KY, Avdeef A, Tsinman O, Sun N.: The permeation of amphoteric drugs through artificial membranes--an in combo absorption model based on paracellular and transmembrane permeability. J Med Chem, Volume 53 (1), 392-401, 2010"
5-[2-(tert-butylamino)-1-hydroxyethyl]benzene-1,3-diol;MM00306;CC(C)(C)NCC(O)c1cc(O)cc(O)c1;XWTYSIMOBUGWOL-UHFFFAOYSA-N;225.288;1.52;5403;DB00871;;CHEMBL1760;CACO;EPAM;25;1;;;;;;;;;;-5.85;;;;;;;;;;;;"Tam KY, Avdeef A, Tsinman O, Sun N.: The permeation of amphoteric drugs through artificial membranes--an in combo absorption model based on paracellular and transmembrane permeability. J Med Chem, Volume 53 (1), 392-401, 2010";"Tam KY, Avdeef A, Tsinman O, Sun N.: The permeation of amphoteric drugs through artificial membranes--an in combo absorption model based on paracellular and transmembrane permeability. J Med Chem, Volume 53 (1), 392-401, 2010"
Tetracycline;MM01277;CN(C)C1C(O)=C(C(N)=O)C(=O)C2(O)C(O)=C3C(=O)c4c(O)cccc4C(C)(O)C3CC12;OFVLGDICTFRJMM-UHFFFAOYSA-N;444.44;-0.21;54675776;DB00759;;CHEMBL1970834;CACO;EPAM;25;+1-1;;;;;;;;;;-5.42;;;;;;;;;;;;"Tam KY, Avdeef A, Tsinman O, Sun N.: The permeation of amphoteric drugs through artificial membranes--an in combo absorption model based on paracellular and transmembrane permeability. J Med Chem, Volume 53 (1), 392-401, 2010";"Tam KY, Avdeef A, Tsinman O, Sun N.: The permeation of amphoteric drugs through artificial membranes--an in combo absorption model based on paracellular and transmembrane permeability. J Med Chem, Volume 53 (1), 392-401, 2010"
1-[4-(3-methylanilino)pyridin-3-yl]sulfonyl-3-propan-2-ylurea;MM00709;Cc1cccc(Nc2ccncc2S(=O)(=O)NC(=O)NC(C)C)c1;NGBFQHCMQULJNZ-UHFFFAOYSA-N;348.421;2.53;41781;DB00214;;CHEMBL1148;CACO;EPAM;25;"0, -1";;;;;;;;;;-4.66;;;;;;;;;;;;"Tam KY, Avdeef A, Tsinman O, Sun N.: The permeation of amphoteric drugs through artificial membranes--an in combo absorption model based on paracellular and transmembrane permeability. J Med Chem, Volume 53 (1), 392-401, 2010";"Tam KY, Avdeef A, Tsinman O, Sun N.: The permeation of amphoteric drugs through artificial membranes--an in combo absorption model based on paracellular and transmembrane permeability. J Med Chem, Volume 53 (1), 392-401, 2010"
Trovafloxacin;MM00774;NC1[C@@H]2CN(c3nc4c(cc3F)c(=O)c(C(=O)O)cn4-c3ccc(F)cc3F)C[C@H]12;WVPSKSLAZQPAKQ-SOSAQKQKSA-N;416.36;1.89;62959;DB00685;TR6;CHEMBL428;CACO;EPAM;25;"+1-1, 1";;;;;;;;;;-4.24;;;;;;;;;;;;"Tam KY, Avdeef A, Tsinman O, Sun N.: The permeation of amphoteric drugs through artificial membranes--an in combo absorption model based on paracellular and transmembrane permeability. J Med Chem, Volume 53 (1), 392-401, 2010";"Tam KY, Avdeef A, Tsinman O, Sun N.: The permeation of amphoteric drugs through artificial membranes--an in combo absorption model based on paracellular and transmembrane permeability. J Med Chem, Volume 53 (1), 392-401, 2010"
2-amino-9-(2-hydroxyethoxymethyl)-3H-purin-6-one;MM00074;Nc1nc(=O)c2ncn(COCCO)c2[nH]1;MKUXAQIIEYXACX-UHFFFAOYSA-N;225.208;-0.92;2022;DB00787;AC2;CHEMBL184;CACO;ECACO;37;0;;;;;;;;;;-6.92;;;;;;;;;;;;"Bergstrom C. A. S., Strafford M., Lazarova L., Avdeef A., Luthman  K., Artursson P.: Absorption Classification of Oral Drugs Based on Molecular Surface Properties. J. Med. Chem., 46(4), 558-570, 2003.";"Bergstrom C. A. S., Strafford M., Lazarova L., Avdeef A., Luthman  K., Artursson P.: Absorption Classification of Oral Drugs Based on Molecular Surface Properties. J. Med. Chem., 46(4), 558-570, 2003."
3,5-diamino-6-chloro-N-(diaminomethylidene)pyrazine-2-carboxamide;MM00267;N=C(N)NC(=O)c1nc(Cl)c(N)nc1N;XSDQTOBWRPYKKA-UHFFFAOYSA-N;229.628;-1.08;16231;DB00594;AMR;CHEMBL945;CACO;ECACO;37;"0, 1";;;;;;;;;;-6.49;;;;;;;;;;;;"Bergstrom C. A. S., Strafford M., Lazarova L., Avdeef A., Luthman  K., Artursson P.: Absorption Classification of Oral Drugs Based on Molecular Surface Properties. J. Med. Chem., 46(4), 558-570, 2003.";"Bergstrom C. A. S., Strafford M., Lazarova L., Avdeef A., Luthman  K., Artursson P.: Absorption Classification of Oral Drugs Based on Molecular Surface Properties. J. Med. Chem., 46(4), 558-570, 2003."
Amitriptyline;MM00444;CN(C)CCC=C1c2ccccc2CCc2ccccc21;KRMDCWKBEZIMAB-UHFFFAOYSA-N;277.411;4.17;2160;DB00321;TP0;CHEMBL629;CACO;ECACO;37;1;;;;;;;;;;-3.9;;;;;;;;;;;;"Bergstrom C. A. S., Strafford M., Lazarova L., Avdeef A., Luthman  K., Artursson P.: Absorption Classification of Oral Drugs Based on Molecular Surface Properties. J. Med. Chem., 46(4), 558-570, 2003.";"Bergstrom C. A. S., Strafford M., Lazarova L., Avdeef A., Luthman  K., Artursson P.: Absorption Classification of Oral Drugs Based on Molecular Surface Properties. J. Med. Chem., 46(4), 558-570, 2003."
Amoxicillin;MM00716;CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccc(O)cc3)C(=O)N2[C@H]1C(=O)O;LSQZJLSUYDQPKJ-UHFFFAOYSA-N;365.404;0.02;33613;DB01060;;CHEMBL1082;CACO;ECACO;37;"+1-1, -1";;;;;;;;;;-6.74;;;;;;;;;;;;"Bergstrom C. A. S., Strafford M., Lazarova L., Avdeef A., Luthman  K., Artursson P.: Absorption Classification of Oral Drugs Based on Molecular Surface Properties. J. Med. Chem., 46(4), 558-570, 2003.";"Bergstrom C. A. S., Strafford M., Lazarova L., Avdeef A., Luthman  K., Artursson P.: Absorption Classification of Oral Drugs Based on Molecular Surface Properties. J. Med. Chem., 46(4), 558-570, 2003."
"[(1S,5R)-8-methyl-8-azabicyclo[3.2.1]octan-3-yl] 3-hydroxy-2-phenylpropanoate";MM00779;CN1C2CCC1CC(OC(=O)C(CO)c1ccccc1)C2;RKUNBYITZUJHSG-UHFFFAOYSA-N;289.375;1.93;174174;DB00572;OIN;CHEMBL517712;CACO;ECACO;37;1;;;;;;;;;;-4.7;;;;;;;;;;;;"Bergstrom C. A. S., Strafford M., Lazarova L., Avdeef A., Luthman  K., Artursson P.: Absorption Classification of Oral Drugs Based on Molecular Surface Properties. J. Med. Chem., 46(4), 558-570, 2003.";"Bergstrom C. A. S., Strafford M., Lazarova L., Avdeef A., Luthman  K., Artursson P.: Absorption Classification of Oral Drugs Based on Molecular Surface Properties. J. Med. Chem., 46(4), 558-570, 2003."
3-(2-chlorophenothiazin-10-yl)-N,N-dimethylpropan-1-amine;MM00461;CN(C)CCCN1c2ccccc2Sc2ccc(Cl)cc21;ZPEIMTDSQAKGNT-UHFFFAOYSA-N;318.863;4.89;2726;DB00477;Z80;CHEMBL71;CACO;ECACO;37;1;;;;;;;;;;-4.14;;;;;;;;;;;;"Bergstrom C. A. S., Strafford M., Lazarova L., Avdeef A., Luthman  K., Artursson P.: Absorption Classification of Oral Drugs Based on Molecular Surface Properties. J. Med. Chem., 46(4), 558-570, 2003.";"Bergstrom C. A. S., Strafford M., Lazarova L., Avdeef A., Luthman  K., Artursson P.: Absorption Classification of Oral Drugs Based on Molecular Surface Properties. J. Med. Chem., 46(4), 558-570, 2003."
"1-cyclopropyl-6-fluoro-4-oxo-7-piperazin-1-ylquinoline-3-carboxylic acid";MM00726;O=C(O)c1cn(C2CC2)c2cc(N3CCNCC3)c(F)cc2c1=O;MYSWGUAQZAJSOK-UHFFFAOYSA-N;331.347;1.58;2764;DB00537;CPF;CHEMBL8;CACO;ECACO;37;+1-1;;;;;;;;;;-5.11;;;;;;;;;;;;"Bergstrom C. A. S., Strafford M., Lazarova L., Avdeef A., Luthman  K., Artursson P.: Absorption Classification of Oral Drugs Based on Molecular Surface Properties. J. Med. Chem., 46(4), 558-570, 2003.";"Bergstrom C. A. S., Strafford M., Lazarova L., Avdeef A., Luthman  K., Artursson P.: Absorption Classification of Oral Drugs Based on Molecular Surface Properties. J. Med. Chem., 46(4), 558-570, 2003."
3-(5,6-dihydrobenzo[b][1]benzazepin-11-yl)-N-methylpropan-1-amine;MM00474;CNCCCN1c2ccccc2CCc2ccccc21;HCYAFALTSJYZDH-UHFFFAOYSA-N;266.388;3.53;2995;DB01151;DSM;CHEMBL72;CACO;ECACO;37;1;;;;;;;;;;-3.99;;;;;;;;;;;;"Bergstrom C. A. S., Strafford M., Lazarova L., Avdeef A., Luthman  K., Artursson P.: Absorption Classification of Oral Drugs Based on Molecular Surface Properties. J. Med. Chem., 46(4), 558-570, 2003.";"Bergstrom C. A. S., Strafford M., Lazarova L., Avdeef A., Luthman  K., Artursson P.: Absorption Classification of Oral Drugs Based on Molecular Surface Properties. J. Med. Chem., 46(4), 558-570, 2003."
Doxycycline;MM01272;CC1c2cccc(O)c2C(O)=C2C(=O)C3(O)C(O)=C(C(N)=O)C(=O)C(N(C)C)C3C(O)C21;SGKRLCUYIXIAHR-UHFFFAOYSA-N;444.44;-0.5;54671203;DB00254;;CHEMBL3559889;CACO;ECACO;37;+1-1;;;;;;;;;;-5.65;;;;;;;;;;;;"Bergstrom C. A. S., Strafford M., Lazarova L., Avdeef A., Luthman  K., Artursson P.: Absorption Classification of Oral Drugs Based on Molecular Surface Properties. J. Med. Chem., 46(4), 558-570, 2003.";"Bergstrom C. A. S., Strafford M., Lazarova L., Avdeef A., Luthman  K., Artursson P.: Absorption Classification of Oral Drugs Based on Molecular Surface Properties. J. Med. Chem., 46(4), 558-570, 2003."
Ergonovine;MM00487;CC(CO)NC(=O)C1C=C2c3cccc4[nH]cc(c34)CC2N(C)C1;WVVSZNPYNCNODU-UHFFFAOYSA-N;325.412;1.53;443884;DB01253;;CHEMBL119443;CACO;ECACO;37;1;;;;;;;;;;-5.17;;;;;;;;;;;;"Bergstrom C. A. S., Strafford M., Lazarova L., Avdeef A., Luthman  K., Artursson P.: Absorption Classification of Oral Drugs Based on Molecular Surface Properties. J. Med. Chem., 46(4), 558-570, 2003.";"Bergstrom C. A. S., Strafford M., Lazarova L., Avdeef A., Luthman  K., Artursson P.: Absorption Classification of Oral Drugs Based on Molecular Surface Properties. J. Med. Chem., 46(4), 558-570, 2003."
Erythromycin;MM00489;CCC1OC(=O)C(C)C(OC2CC(C)(OC)C(O)C(C)O2)C(C)C(OC2OC(C)CC(N(C)C)C2O)C(C)(O)CC(C)C(=O)C(C)C(O)C1(C)O;ULGZDMOVFRHVEP-UHFFFAOYSA-N;733.937;1.79;12560;DB00199;ERY;CHEMBL532;CACO;ECACO;37;1;;;;;;;;;;-5.95;;;;;;;;;;;;"Bergstrom C. A. S., Strafford M., Lazarova L., Avdeef A., Luthman  K., Artursson P.: Absorption Classification of Oral Drugs Based on Molecular Surface Properties. J. Med. Chem., 46(4), 558-570, 2003.";"Bergstrom C. A. S., Strafford M., Lazarova L., Avdeef A., Luthman  K., Artursson P.: Absorption Classification of Oral Drugs Based on Molecular Surface Properties. J. Med. Chem., 46(4), 558-570, 2003."
"Ethinyl Estradiol";MM00119;C#CC1(O)CCC2C3CCc4cc(O)ccc4C3CCC21C;BFPYWIDHMRZLRN-UHFFFAOYSA-N;296.41;3.61;5991;DB00977;3WF;CHEMBL691;CACO;ECACO;37;0;;;;;;;;;;-3.42;;;;;;;;;;;;"Bergstrom C. A. S., Strafford M., Lazarova L., Avdeef A., Luthman  K., Artursson P.: Absorption Classification of Oral Drugs Based on Molecular Surface Properties. J. Med. Chem., 46(4), 558-570, 2003.";"Bergstrom C. A. S., Strafford M., Lazarova L., Avdeef A., Luthman  K., Artursson P.: Absorption Classification of Oral Drugs Based on Molecular Surface Properties. J. Med. Chem., 46(4), 558-570, 2003."
"Folinic acid";MM01370;Nc1nc2c(c(=O)[nH]1)N(C=O)C(CNc1ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc1)CN2;VVIAGPKUTFNRDU-ABLWVSNPSA-N;473.446;-0.73;135403648;DB00650;;CHEMBL1679;CACO;ECACO;37;-2;;;;;;;;;;-7.52;;;;;;;;;;;;"Bergstrom C. A. S., Strafford M., Lazarova L., Avdeef A., Luthman  K., Artursson P.: Absorption Classification of Oral Drugs Based on Molecular Surface Properties. J. Med. Chem., 46(4), 558-570, 2003.";"Bergstrom C. A. S., Strafford M., Lazarova L., Avdeef A., Luthman  K., Artursson P.: Absorption Classification of Oral Drugs Based on Molecular Surface Properties. J. Med. Chem., 46(4), 558-570, 2003."
"2-[1-(4-chlorobenzoyl)-5-methoxy-2-methylindol-3-yl]acetic acid";MM00656;COc1ccc2c(c1)c(CC(=O)O)c(C)n2C(=O)c1ccc(Cl)cc1;CGIGDMFJXJATDK-UHFFFAOYSA-N;357.79;3.93;3715;DB00328;IMN;CHEMBL6;CACO;ECACO;37;-1;;;;;;;;;;-3.96;;;;;;;;;;;;"Bergstrom C. A. S., Strafford M., Lazarova L., Avdeef A., Luthman  K., Artursson P.: Absorption Classification of Oral Drugs Based on Molecular Surface Properties. J. Med. Chem., 46(4), 558-570, 2003.";"Bergstrom C. A. S., Strafford M., Lazarova L., Avdeef A., Luthman  K., Artursson P.: Absorption Classification of Oral Drugs Based on Molecular Surface Properties. J. Med. Chem., 46(4), 558-570, 2003."
"(2S)-2-[[4-[(2,4-diaminopteridin-6-yl)methyl-methylamino]benzoyl]amino]pentanedioic acid";MM00270;CN(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(C(=O)NC(CCC(=O)O)C(=O)O)cc1;FBOZXECLQNJBKD-UHFFFAOYSA-N;454.447;0.27;126941;DB00563;MTX;CHEMBL34259;CACO;ECACO;37;-2;;;;;;;;;;-7.52;;;;;;;;;;;;"Bergstrom C. A. S., Strafford M., Lazarova L., Avdeef A., Luthman  K., Artursson P.: Absorption Classification of Oral Drugs Based on Molecular Surface Properties. J. Med. Chem., 46(4), 558-570, 2003.";"Bergstrom C. A. S., Strafford M., Lazarova L., Avdeef A., Luthman  K., Artursson P.: Absorption Classification of Oral Drugs Based on Molecular Surface Properties. J. Med. Chem., 46(4), 558-570, 2003."
3-phenyldiazenylpyridine-2,6-diamine;MM00540;Nc1ccc(N=Nc2ccccc2)c(N)n1;QPFYXYFORQJZEC-UHFFFAOYSA-N;213.244;2.66;4756;DB01438;;CHEMBL1242;CACO;ECACO;37;"1, 0";;;;;;;;;;-3.55;;;;;;;;;;;;"Bergstrom C. A. S., Strafford M., Lazarova L., Avdeef A., Luthman  K., Artursson P.: Absorption Classification of Oral Drugs Based on Molecular Surface Properties. J. Med. Chem., 46(4), 558-570, 2003.";"Bergstrom C. A. S., Strafford M., Lazarova L., Avdeef A., Luthman  K., Artursson P.: Absorption Classification of Oral Drugs Based on Molecular Surface Properties. J. Med. Chem., 46(4), 558-570, 2003."
4-N-(6-methoxyquinolin-8-yl)pentane-1,4-diamine;MM00548;COc1cc(NC(C)CCCN)c2ncccc2c1;INDBQLZJXZLFIT-UHFFFAOYSA-N;259.353;2.78;4908;DB01087;;CHEMBL506;CACO;ECACO;37;1;;;;;;;;;;-3.75;;;;;;;;;;;;"Bergstrom C. A. S., Strafford M., Lazarova L., Avdeef A., Luthman  K., Artursson P.: Absorption Classification of Oral Drugs Based on Molecular Surface Properties. J. Med. Chem., 46(4), 558-570, 2003.";"Bergstrom C. A. S., Strafford M., Lazarova L., Avdeef A., Luthman  K., Artursson P.: Absorption Classification of Oral Drugs Based on Molecular Surface Properties. J. Med. Chem., 46(4), 558-570, 2003."
N,N-dimethyl-1-phenothiazin-10-ylpropan-2-amine;MM00550;CC(CN1c2ccccc2Sc2ccccc21)N(C)C;PWWVAXIEGOYWEE-UHFFFAOYSA-N;284.421;4.24;4927;DB01069;;CHEMBL643;CACO;ECACO;37;1;;;;;;;;;;-3.78;;;;;;;;;;;;"Bergstrom C. A. S., Strafford M., Lazarova L., Avdeef A., Luthman  K., Artursson P.: Absorption Classification of Oral Drugs Based on Molecular Surface Properties. J. Med. Chem., 46(4), 558-570, 2003.";"Bergstrom C. A. S., Strafford M., Lazarova L., Avdeef A., Luthman  K., Artursson P.: Absorption Classification of Oral Drugs Based on Molecular Surface Properties. J. Med. Chem., 46(4), 558-570, 2003."
1,3-dimethyl-7H-purine-2,6-dione;MM00048;Cn1c(=O)c2nc[nH]c2n(C)c1=O;ZFXYFBGIUFBOJW-UHFFFAOYSA-N;180.167;-1.04;2153;DB00277;TEP;CHEMBL190;CACO;ECACO;37;0;;;;;;;;;;-4.17;;;;;;;;;;;;"Bergstrom C. A. S., Strafford M., Lazarova L., Avdeef A., Luthman  K., Artursson P.: Absorption Classification of Oral Drugs Based on Molecular Surface Properties. J. Med. Chem., 46(4), 558-570, 2003.";"Bergstrom C. A. S., Strafford M., Lazarova L., Avdeef A., Luthman  K., Artursson P.: Absorption Classification of Oral Drugs Based on Molecular Surface Properties. J. Med. Chem., 46(4), 558-570, 2003."
Verapamil;MM00585;COc1ccc(CCN(C)CCCC(C#N)(c2ccc(OC)c(OC)c2)C(C)C)cc1OC;SGTNSNPWRIOYBX-UHFFFAOYSA-N;454.611;5.09;2520;DB00661;;CHEMBL6966;CACO;ECACO;37;0;;;;;;;;;;-3.8;;;;;;;;;;;;"Bergstrom C. A. S., Strafford M., Lazarova L., Avdeef A., Luthman  K., Artursson P.: Absorption Classification of Oral Drugs Based on Molecular Surface Properties. J. Med. Chem., 46(4), 558-570, 2003.";"Bergstrom C. A. S., Strafford M., Lazarova L., Avdeef A., Luthman  K., Artursson P.: Absorption Classification of Oral Drugs Based on Molecular Surface Properties. J. Med. Chem., 46(4), 558-570, 2003."
4-hydroxy-3-(3-oxo-1-phenylbutyl)chromen-2-one;MM00095;CC(=O)CC(c1ccccc1)c1c(O)c2ccccc2oc1=O;PJVWKTKQMONHTI-UHFFFAOYSA-N;308.333;3.61;54678486;DB00682;;CHEMBL1464;CACO;ECACO;37;-1;;;;;;;;;;-4.23;;;;;;;;;;;;"Bergstrom C. A. S., Strafford M., Lazarova L., Avdeef A., Luthman  K., Artursson P.: Absorption Classification of Oral Drugs Based on Molecular Surface Properties. J. Med. Chem., 46(4), 558-570, 2003.";"Bergstrom C. A. S., Strafford M., Lazarova L., Avdeef A., Luthman  K., Artursson P.: Absorption Classification of Oral Drugs Based on Molecular Surface Properties. J. Med. Chem., 46(4), 558-570, 2003."
1-[(2R,4S,5S)-4-azido-5-(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione;MM00077;Cc1cn(C2CC(N=[N+]=[N-])C(CO)O2)c(=O)[nH]c1=O;HBOMLICNUCNMMY-UHFFFAOYSA-N;267.245;-0.2;35370;DB00495;AZZ;CHEMBL129;CACO;ECACO;37;0;;;;;;;;;;-5.21;;;;;;;;;;;;"Bergstrom C. A. S., Strafford M., Lazarova L., Avdeef A., Luthman  K., Artursson P.: Absorption Classification of Oral Drugs Based on Molecular Surface Properties. J. Med. Chem., 46(4), 558-570, 2003.";"Bergstrom C. A. S., Strafford M., Lazarova L., Avdeef A., Luthman  K., Artursson P.: Absorption Classification of Oral Drugs Based on Molecular Surface Properties. J. Med. Chem., 46(4), 558-570, 2003."
Chromen-2-one;MM00042;O=c1ccc2ccccc2o1;ZYGHJZDHTFUPRJ-UHFFFAOYSA-N;146.145;1.79;323;DB04665;COU;CHEMBL6466;CACO;ECACO;37;0;;;;;;;;;;-4.11;;;;;;;;;;;;"Camenisch, G., Alsenz, J., Van De Waterbeemd, H. & Folkers, G.: Estimation of permeability by passive diffusion through Caco-2 cell monolayers using the drugs’ lipophilicity and molecular weight. Eur. J. Pharm. Sci., 6, 313–319, 1998";"Camenisch, G., Alsenz, J., Van De Waterbeemd, H. & Folkers, G.: Estimation of permeability by passive diffusion through Caco-2 cell monolayers using the drugs’ lipophilicity and molecular weight. Eur. J. Pharm. Sci., 6, 313–319, 1998"
1,3-dimethyl-7H-purine-2,6-dione;MM00048;Cn1c(=O)c2nc[nH]c2n(C)c1=O;ZFXYFBGIUFBOJW-UHFFFAOYSA-N;180.167;-1.04;2153;DB00277;TEP;CHEMBL190;CACO;ECACO;37;-1,0;;;;;;;;;;-4.35;;;;;;;;;;;;"Camenisch, G., Alsenz, J., Van De Waterbeemd, H. & Folkers, G.: Estimation of permeability by passive diffusion through Caco-2 cell monolayers using the drugs’ lipophilicity and molecular weight. Eur. J. Pharm. Sci., 6, 313–319, 1998";"Camenisch, G., Alsenz, J., Van De Waterbeemd, H. & Folkers, G.: Estimation of permeability by passive diffusion through Caco-2 cell monolayers using the drugs’ lipophilicity and molecular weight. Eur. J. Pharm. Sci., 6, 313–319, 1998"
(2R,3R,4R,5R)-hexane-1,2,3,4,5,6-hexol;MM00386;OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO;FBPFZTCFMRRESA-KVTDHHQDSA-N;182.172;-3.59;6251;DB00742;MTL;CHEMBL689;CACO;ECACO;37;0;;;;;;;;;;-5.58;;;;;;;;;;;;"Camenisch, G., Alsenz, J., Van De Waterbeemd, H. & Folkers, G.: Estimation of permeability by passive diffusion through Caco-2 cell monolayers using the drugs’ lipophilicity and molecular weight. Eur. J. Pharm. Sci., 6, 313–319, 1998";"Camenisch, G., Alsenz, J., Van De Waterbeemd, H. & Folkers, G.: Estimation of permeability by passive diffusion through Caco-2 cell monolayers using the drugs’ lipophilicity and molecular weight. Eur. J. Pharm. Sci., 6, 313–319, 1998"
4-[(1R)-1-hydroxy-2-(methylamino)ethyl]benzene-1,2-diol;MM00644;CNCC(O)c1ccc(O)c(O)c1;UCTWMZQNUQWSLP-UHFFFAOYSA-N;183.207;0.35;5816;DB00668;ALE;CHEMBL679;CACO;ECACO;37;+1;;;;;;;;;;-6.02;;;;;;;;;;;;"Camenisch, G., Alsenz, J., Van De Waterbeemd, H. & Folkers, G.: Estimation of permeability by passive diffusion through Caco-2 cell monolayers using the drugs’ lipophilicity and molecular weight. Eur. J. Pharm. Sci., 6, 313–319, 1998";"Camenisch, G., Alsenz, J., Van De Waterbeemd, H. & Folkers, G.: Estimation of permeability by passive diffusion through Caco-2 cell monolayers using the drugs’ lipophilicity and molecular weight. Eur. J. Pharm. Sci., 6, 313–319, 1998"
2-(2,3-dihydro-1,4-benzodioxin-3-ylmethyl)guanidine;MM01430;N=C(N)NCC1COc2ccccc2O1;HIUVKVDQFXDZHU-UHFFFAOYSA-N;207.23;0.31;16564;" DB13211";;76725;CACO;ECACO;37;+1;;;;;;;;;;-4.71;;;;;;;;;;;;"Camenisch, G., Alsenz, J., Van De Waterbeemd, H. & Folkers, G.: Estimation of permeability by passive diffusion through Caco-2 cell monolayers using the drugs’ lipophilicity and molecular weight. Eur. J. Pharm. Sci., 6, 313–319, 1998";"Camenisch, G., Alsenz, J., Van De Waterbeemd, H. & Folkers, G.: Estimation of permeability by passive diffusion through Caco-2 cell monolayers using the drugs’ lipophilicity and molecular weight. Eur. J. Pharm. Sci., 6, 313–319, 1998"
2-[(E)-(2,6-dichlorophenyl)methylideneamino]guanidine;MM00497;N=C(N)NN=Cc1c(Cl)cccc1Cl;WDZVGELJXXEGPV-UHFFFAOYSA-N;231.08;1.81;5702063;DB00629;;CHEMBL420;CACO;ECACO;37;+1,0;;;;;;;;;;-4.14;;;;;;;;;;;;"Camenisch, G., Alsenz, J., Van De Waterbeemd, H. & Folkers, G.: Estimation of permeability by passive diffusion through Caco-2 cell monolayers using the drugs’ lipophilicity and molecular weight. Eur. J. Pharm. Sci., 6, 313–319, 1998";"Camenisch, G., Alsenz, J., Van De Waterbeemd, H. & Folkers, G.: Estimation of permeability by passive diffusion through Caco-2 cell monolayers using the drugs’ lipophilicity and molecular weight. Eur. J. Pharm. Sci., 6, 313–319, 1998"
2-(diethylamino)-N-(2,6-dimethylphenyl)acetamide;MM00092;CCN(CC)CC(=O)Nc1c(C)cccc1C;NNJVILVZKWQKPM-UHFFFAOYSA-N;234.343;2.58;3676;DB00281;LQZ;CHEMBL79;CACO;ECACO;37;+1,0;;;;;;;;;;-4.21;;;;;;;;;;;;"Camenisch, G., Alsenz, J., Van De Waterbeemd, H. & Folkers, G.: Estimation of permeability by passive diffusion through Caco-2 cell monolayers using the drugs’ lipophilicity and molecular weight. Eur. J. Pharm. Sci., 6, 313–319, 1998";"Camenisch, G., Alsenz, J., Van De Waterbeemd, H. & Folkers, G.: Estimation of permeability by passive diffusion through Caco-2 cell monolayers using the drugs’ lipophilicity and molecular weight. Eur. J. Pharm. Sci., 6, 313–319, 1998"
"(E)-3-(6-methylsulfanyl-4-oxoquinazolin-3-yl)prop-2-enoic acid";MM01431;CSc1ccc2ncn(C=CC(=O)O)c(=O)c2c1;VHFPVEGFRVEDBK-UHFFFAOYSA-N;262.29;1.67;6435375;;;337379;CACO;ECACO;37;-1;;;;;;;;;;-4.9;;;;;;;;;;;;"Camenisch, G., Alsenz, J., Van De Waterbeemd, H. & Folkers, G.: Estimation of permeability by passive diffusion through Caco-2 cell monolayers using the drugs’ lipophilicity and molecular weight. Eur. J. Pharm. Sci., 6, 313–319, 1998";"Camenisch, G., Alsenz, J., Van De Waterbeemd, H. & Folkers, G.: Estimation of permeability by passive diffusion through Caco-2 cell monolayers using the drugs’ lipophilicity and molecular weight. Eur. J. Pharm. Sci., 6, 313–319, 1998"
N-[4-[2-hydroxy-3-(propan-2-ylamino)propoxy]phenyl]acetamide;MM00544;CC(=O)Nc1ccc(OCC(O)CNC(C)C)cc1;DURULFYMVIFBIR-UHFFFAOYSA-N;266.341;1.38;4883;DB01297;;CHEMBL6995;CACO;ECACO;37;+1;;;;;;;;;;-5.86;;;;;;;;;;;;"Camenisch, G., Alsenz, J., Van De Waterbeemd, H. & Folkers, G.: Estimation of permeability by passive diffusion through Caco-2 cell monolayers using the drugs’ lipophilicity and molecular weight. Eur. J. Pharm. Sci., 6, 313–319, 1998";"Camenisch, G., Alsenz, J., Van De Waterbeemd, H. & Folkers, G.: Estimation of permeability by passive diffusion through Caco-2 cell monolayers using the drugs’ lipophilicity and molecular weight. Eur. J. Pharm. Sci., 6, 313–319, 1998"
2-[4-[2-hydroxy-3-(propan-2-ylamino)propoxy]phenyl]acetamide;MM00078;CC(C)NC[C@@H](O)COc1ccc(CC(N)=O)cc1;METKIMKYRPQLGS-UHFFFAOYSA-N;266.341;0.45;2249;DB00335;;CHEMBL24;CACO;ECACO;37;+1;;;;;;;;;;-6.63;;;;;;;;;;;;"Camenisch, G., Alsenz, J., Van De Waterbeemd, H. & Folkers, G.: Estimation of permeability by passive diffusion through Caco-2 cell monolayers using the drugs’ lipophilicity and molecular weight. Eur. J. Pharm. Sci., 6, 313–319, 1998";"Camenisch, G., Alsenz, J., Van De Waterbeemd, H. & Folkers, G.: Estimation of permeability by passive diffusion through Caco-2 cell monolayers using the drugs’ lipophilicity and molecular weight. Eur. J. Pharm. Sci., 6, 313–319, 1998"
3-(5,6-dihydrobenzo[b][1]benzazepin-11-yl)-N,N-dimethylpropan-1-amine;MM00504;CN(C)CCCN1c2ccccc2CCc2ccccc21;BCGWQEUPMDMJNV-UHFFFAOYSA-N;280.415;3.88;3696;DB00458;IXX;CHEMBL11;CACO;ECACO;37;+1;;;;;;;;;;-4.26;;;;;;;;;;;;"Camenisch, G., Alsenz, J., Van De Waterbeemd, H. & Folkers, G.: Estimation of permeability by passive diffusion through Caco-2 cell monolayers using the drugs’ lipophilicity and molecular weight. Eur. J. Pharm. Sci., 6, 313–319, 1998";"Camenisch, G., Alsenz, J., Van De Waterbeemd, H. & Folkers, G.: Estimation of permeability by passive diffusion through Caco-2 cell monolayers using the drugs’ lipophilicity and molecular weight. Eur. J. Pharm. Sci., 6, 313–319, 1998"
Testosterone;MM00423;CC12CCC(=O)C=C1CCC1C2CCC2(C)C(O)CCC12;MUMGGOZAMZWBJJ-UHFFFAOYSA-N;288.431;3.88;6013;DB00624;TES;CHEMBL386630;CACO;ECACO;37;0;;;;;;;;;;-4.23;;;;;;;;;;;;"Camenisch, G., Alsenz, J., Van De Waterbeemd, H. & Folkers, G.: Estimation of permeability by passive diffusion through Caco-2 cell monolayers using the drugs’ lipophilicity and molecular weight. Eur. J. Pharm. Sci., 6, 313–319, 1998";"Camenisch, G., Alsenz, J., Van De Waterbeemd, H. & Folkers, G.: Estimation of permeability by passive diffusion through Caco-2 cell monolayers using the drugs’ lipophilicity and molecular weight. Eur. J. Pharm. Sci., 6, 313–319, 1998"
4-hydroxy-3-(3-oxo-1-phenylbutyl)chromen-2-one;MM00095;CC(=O)CC(c1ccccc1)c1c(O)c2ccccc2oc1=O;PJVWKTKQMONHTI-UHFFFAOYSA-N;308.333;3.61;54678486;DB00682;;CHEMBL1464;CACO;ECACO;37;-1;;;;;;;;;;-4.27;;;;;;;;;;;;"Camenisch, G., Alsenz, J., Van De Waterbeemd, H. & Folkers, G.: Estimation of permeability by passive diffusion through Caco-2 cell monolayers using the drugs’ lipophilicity and molecular weight. Eur. J. Pharm. Sci., 6, 313–319, 1998";"Camenisch, G., Alsenz, J., Van De Waterbeemd, H. & Folkers, G.: Estimation of permeability by passive diffusion through Caco-2 cell monolayers using the drugs’ lipophilicity and molecular weight. Eur. J. Pharm. Sci., 6, 313–319, 1998"
"4-chloro-2-(furan-2-ylmethylamino)-5-sulfamoylbenzoic acid";MM00083;NS(=O)(=O)c1cc(C(=O)O)c(NCc2ccco2)cc1Cl;ZZUFCTLCJUWOSV-UHFFFAOYSA-N;330.739;1.89;3440;DB00695;FUN;CHEMBL35;CACO;ECACO;37;-1;;;;;;;;;;-6.09;;;;;;;;;;;;"Camenisch, G., Alsenz, J., Van De Waterbeemd, H. & Folkers, G.: Estimation of permeability by passive diffusion through Caco-2 cell monolayers using the drugs’ lipophilicity and molecular weight. Eur. J. Pharm. Sci., 6, 313–319, 1998";"Camenisch, G., Alsenz, J., Van De Waterbeemd, H. & Folkers, G.: Estimation of permeability by passive diffusion through Caco-2 cell monolayers using the drugs’ lipophilicity and molecular weight. Eur. J. Pharm. Sci., 6, 313–319, 1998"
N-[(1-ethylpyrrolidin-2-yl)methyl]-2-methoxy-5-sulfamoylbenzamide;MM00568;CCN1CCCC1CNC(=O)c1cc(S(N)(=O)=O)ccc1OC;BGRJTUBHPOOWDU-UHFFFAOYSA-N;341.426;0.56;5355;DB00391;;CHEMBL26;CACO;ECACO;37;+1;;;;;;;;;;-6.16;;;;;;;;;;;;"Camenisch, G., Alsenz, J., Van De Waterbeemd, H. & Folkers, G.: Estimation of permeability by passive diffusion through Caco-2 cell monolayers using the drugs’ lipophilicity and molecular weight. Eur. J. Pharm. Sci., 6, 313–319, 1998";"Camenisch, G., Alsenz, J., Van De Waterbeemd, H. & Folkers, G.: Estimation of permeability by passive diffusion through Caco-2 cell monolayers using the drugs’ lipophilicity and molecular weight. Eur. J. Pharm. Sci., 6, 313–319, 1998"
"5-O-ethyl 3-O-methyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate";MM00398;CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1c1cccc([N+](=O)[O-])c1;PVHUJELLJLJGLN-UHFFFAOYSA-N;360.366;2.57;4507;DB01054;;CHEMBL475534;CACO;ECACO;37;0;;;;;;;;;;-4.77;;;;;;;;;;;;"Camenisch, G., Alsenz, J., Van De Waterbeemd, H. & Folkers, G.: Estimation of permeability by passive diffusion through Caco-2 cell monolayers using the drugs’ lipophilicity and molecular weight. Eur. J. Pharm. Sci., 6, 313–319, 1998";"Camenisch, G., Alsenz, J., Van De Waterbeemd, H. & Folkers, G.: Estimation of permeability by passive diffusion through Caco-2 cell monolayers using the drugs’ lipophilicity and molecular weight. Eur. J. Pharm. Sci., 6, 313–319, 1998"
"6,8-difluoro-1-(2-fluoroethyl)-7-(4-methylpiperazin-1-yl)-4-oxoquinoline-3-carboxylic acid";MM00736;CN1CCN(c2c(F)cc3c(=O)c(C(=O)O)cn(CCF)c3c2F)CC1;XBJBPGROQZJDOJ-UHFFFAOYSA-N;369.344;1.7;3357;DB04576;;CHEMBL6273;CACO;ECACO;37;-1,0;;;;;;;;;;-4.81;;;;;;;;;;;;"Camenisch, G., Alsenz, J., Van De Waterbeemd, H. & Folkers, G.: Estimation of permeability by passive diffusion through Caco-2 cell monolayers using the drugs’ lipophilicity and molecular weight. Eur. J. Pharm. Sci., 6, 313–319, 1998";"Camenisch, G., Alsenz, J., Van De Waterbeemd, H. & Folkers, G.: Estimation of permeability by passive diffusion through Caco-2 cell monolayers using the drugs’ lipophilicity and molecular weight. Eur. J. Pharm. Sci., 6, 313–319, 1998"
Diltiazem;MM00477;COc1ccc(C2Sc3ccccc3N(CCN(C)C)C(=O)C2OC(C)=O)cc1;HSUGRBWQSSZJOP-UHFFFAOYSA-N;414.52;3.37;39186;DB00343;C9F;CHEMBL23;CACO;ECACO;37;0,+1;;;;;;;;;;-4.31;;;;;;;;;;;;"Camenisch, G., Alsenz, J., Van De Waterbeemd, H. & Folkers, G.: Estimation of permeability by passive diffusion through Caco-2 cell monolayers using the drugs’ lipophilicity and molecular weight. Eur. J. Pharm. Sci., 6, 313–319, 1998";"Camenisch, G., Alsenz, J., Van De Waterbeemd, H. & Folkers, G.: Estimation of permeability by passive diffusion through Caco-2 cell monolayers using the drugs’ lipophilicity and molecular weight. Eur. J. Pharm. Sci., 6, 313–319, 1998"
Verapamil;MM00585;COc1ccc(CCN(C)CCCC(C#N)(c2ccc(OC)c(OC)c2)C(C)C)cc1OC;SGTNSNPWRIOYBX-UHFFFAOYSA-N;454.611;5.09;2520;DB00661;;CHEMBL6966;CACO;ECACO;37;+1;;;;;;;;;;-4.58;;;;;;;;;;;;"Camenisch, G., Alsenz, J., Van De Waterbeemd, H. & Folkers, G.: Estimation of permeability by passive diffusion through Caco-2 cell monolayers using the drugs’ lipophilicity and molecular weight. Eur. J. Pharm. Sci., 6, 313–319, 1998";"Camenisch, G., Alsenz, J., Van De Waterbeemd, H. & Folkers, G.: Estimation of permeability by passive diffusion through Caco-2 cell monolayers using the drugs’ lipophilicity and molecular weight. Eur. J. Pharm. Sci., 6, 313–319, 1998"
Mibefradil;MM01432;COCC(=O)OC1(CCN(C)CCCc2nc3ccccc3[nH]2)CCc2cc(F)ccc2C1C(C)C;HBNPJJILLOYFJU-UHFFFAOYSA-N;495.64;5.27;60663;DB01388;MWV;45816;CACO;ECACO;37;+1,+2;;;;;;;;;;-4.87;;;;;;;;;;;;"Camenisch, G., Alsenz, J., Van De Waterbeemd, H. & Folkers, G.: Estimation of permeability by passive diffusion through Caco-2 cell monolayers using the drugs’ lipophilicity and molecular weight. Eur. J. Pharm. Sci., 6, 313–319, 1998";"Camenisch, G., Alsenz, J., Van De Waterbeemd, H. & Folkers, G.: Estimation of permeability by passive diffusion through Caco-2 cell monolayers using the drugs’ lipophilicity and molecular weight. Eur. J. Pharm. Sci., 6, 313–319, 1998"
Bosentan;MM01433;COc1ccccc1Oc1c(NS(=O)(=O)c2ccc(C(C)(C)C)cc2)nc(-c2ncccn2)nc1OCCO;GJPICJJJRGTNOD-UHFFFAOYSA-N;551.63;4.2;104865;DB00559;K86;957;CACO;ECACO;37;-1,0;;;;;;;;;;-5.89;;;;;;;;;;;;"Camenisch, G., Alsenz, J., Van De Waterbeemd, H. & Folkers, G.: Estimation of permeability by passive diffusion through Caco-2 cell monolayers using the drugs’ lipophilicity and molecular weight. Eur. J. Pharm. Sci., 6, 313–319, 1998";"Camenisch, G., Alsenz, J., Van De Waterbeemd, H. & Folkers, G.: Estimation of permeability by passive diffusion through Caco-2 cell monolayers using the drugs’ lipophilicity and molecular weight. Eur. J. Pharm. Sci., 6, 313–319, 1998"
Proscillaridin;MM01434;CC1OC(OC2C=C3CCC4C(CCC5(C)C(c6ccc(=O)oc6)CCC45O)C3(C)CC2)C(O)C(O)C1O;MYEJFUXQJGHEQK-UHFFFAOYSA-N;530.66;3.01;5284613;DB13307;;600325;CACO;ECACO;37;+1;;;;;;;;;;-6.2;;;;;;;;;;;;"Camenisch, G., Alsenz, J., Van De Waterbeemd, H. & Folkers, G.: Estimation of permeability by passive diffusion through Caco-2 cell monolayers using the drugs’ lipophilicity and molecular weight. Eur. J. Pharm. Sci., 6, 313–319, 1998";"Camenisch, G., Alsenz, J., Van De Waterbeemd, H. & Folkers, G.: Estimation of permeability by passive diffusion through Caco-2 cell monolayers using the drugs’ lipophilicity and molecular weight. Eur. J. Pharm. Sci., 6, 313–319, 1998"
Ceftriaxone;MM01435;CON=C(C(=O)NC1C(=O)N2C(C(=O)O)=C(CSc3nc(=O)c(O)nn3C)CSC12)c1csc(N)n1;VAAUVRVFOQPIGI-UHFFFAOYSA-N;554.59;-1.2;5479530;" DB01212";;161;CACO;ECACO;37;-2;;;;;;;;;;-6.88;;;;;;;;;;;;"Camenisch, G., Alsenz, J., Van De Waterbeemd, H. & Folkers, G.: Estimation of permeability by passive diffusion through Caco-2 cell monolayers using the drugs’ lipophilicity and molecular weight. Eur. J. Pharm. Sci., 6, 313–319, 1998";"Camenisch, G., Alsenz, J., Van De Waterbeemd, H. & Folkers, G.: Estimation of permeability by passive diffusion through Caco-2 cell monolayers using the drugs’ lipophilicity and molecular weight. Eur. J. Pharm. Sci., 6, 313–319, 1998"
Remikiren;MM01436;CC(C)(C)S(=O)(=O)C[C@@H](Cc1ccccc1)C(O)=N[C@@H](Cc1cnc[nH]1)C(O)=N[C@@H](CC1CCCCC1)[C@@H](O)[C@@H](O)C1CC1;UXIGZRQVLGFTOU-VQXQMPIVSA-N;630.85;4.78;6324659;DB00212;REM;31601;CACO;ECACO;37;0,+1;;;;;;;;;;-6.13;;;;;;;;;;;;"Camenisch, G., Alsenz, J., Van De Waterbeemd, H. & Folkers, G.: Estimation of permeability by passive diffusion through Caco-2 cell monolayers using the drugs’ lipophilicity and molecular weight. Eur. J. Pharm. Sci., 6, 313–319, 1998";"Camenisch, G., Alsenz, J., Van De Waterbeemd, H. & Folkers, G.: Estimation of permeability by passive diffusion through Caco-2 cell monolayers using the drugs’ lipophilicity and molecular weight. Eur. J. Pharm. Sci., 6, 313–319, 1998"
Saquinavir;MM00563;CC(C)(C)NC(=O)C1CC2CCCCC2CN1CC(O)C(Cc1ccccc1)NC(=O)C(CC(N)=O)NC(=O)c1ccc2ccccc2n1;QWAXKHKRTORLEM-UHFFFAOYSA-N;670.855;3.09;441243;DB01232;ROC;CHEMBL114;CACO;ECACO;37;0,+1;;;;;;;;;;-6.26;;;;;;;;;;;;"Camenisch, G., Alsenz, J., Van De Waterbeemd, H. & Folkers, G.: Estimation of permeability by passive diffusion through Caco-2 cell monolayers using the drugs’ lipophilicity and molecular weight. Eur. J. Pharm. Sci., 6, 313–319, 1998";"Camenisch, G., Alsenz, J., Van De Waterbeemd, H. & Folkers, G.: Estimation of permeability by passive diffusion through Caco-2 cell monolayers using the drugs’ lipophilicity and molecular weight. Eur. J. Pharm. Sci., 6, 313–319, 1998"
(2R,3R,4R,5R)-hexane-1,2,3,4,5,6-hexol;MM00386;OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO;FBPFZTCFMRRESA-KVTDHHQDSA-N;182.172;-3.59;6251;DB00742;MTL;CHEMBL689;CACO;ECACO;37;0;;;;;;;;;;-6.74;;;;;;;;;;;;"Artursson, P. & Karlsson, J.: Correlation between oral drug absorption in humans and apparent drug permeability coefficients in human intestinal epithelial (Caco-2) cells. Biochem. Biophys. Res. Commun., 175, 880–885, 1991.";"Artursson, P. & Karlsson, J.: Correlation between oral drug absorption in humans and apparent drug permeability coefficients in human intestinal epithelial (Caco-2) cells. Biochem. Biophys. Res. Commun., 175, 880–885, 1991."
5-[2-(tert-butylamino)-1-hydroxyethyl]benzene-1,3-diol;MM00306;CC(C)(C)NCC(O)c1cc(O)cc(O)c1;XWTYSIMOBUGWOL-UHFFFAOYSA-N;225.288;1.52;5403;DB00871;;CHEMBL1760;CACO;ECACO;37;+1;;;;;;;;;;-6.42;;;;;;;;;;;;"Artursson, P. & Karlsson, J.: Correlation between oral drug absorption in humans and apparent drug permeability coefficients in human intestinal epithelial (Caco-2) cells. Biochem. Biophys. Res. Commun., 175, 880–885, 1991.";"Artursson, P. & Karlsson, J.: Correlation between oral drug absorption in humans and apparent drug permeability coefficients in human intestinal epithelial (Caco-2) cells. Biochem. Biophys. Res. Commun., 175, 880–885, 1991."
1-(propan-2-ylamino)-3-(2-prop-2-enylphenoxy)propan-2-ol;MM00440;C=CCc1ccccc1OC[C@H](O)CNC(C)C;PAZJSJFMUHDSTF-UHFFFAOYSA-N;249.354;2.15;2119;DB00866;;CHEMBL266195;CACO;ECACO;37;+1;;;;;;;;;;-4.39;;;;;;;;;;;;"Artursson, P. & Karlsson, J.: Correlation between oral drug absorption in humans and apparent drug permeability coefficients in human intestinal epithelial (Caco-2) cells. Biochem. Biophys. Res. Commun., 175, 880–885, 1991.";"Artursson, P. & Karlsson, J.: Correlation between oral drug absorption in humans and apparent drug permeability coefficients in human intestinal epithelial (Caco-2) cells. Biochem. Biophys. Res. Commun., 175, 880–885, 1991."
1-naphthalen-1-yloxy-3-(propan-2-ylamino)propan-2-ol;MM00085;CC(C)NCC(O)COc1cccc2ccccc12;AQHHHDLHHXJYJD-UHFFFAOYSA-N;259.349;2.58;4946;DB00571;;CHEMBL27;CACO;ECACO;37;+1;;;;;;;;;;-4.38;;;;;;;;;;;;"Artursson, P. & Karlsson, J.: Correlation between oral drug absorption in humans and apparent drug permeability coefficients in human intestinal epithelial (Caco-2) cells. Biochem. Biophys. Res. Commun., 175, 880–885, 1991.";"Artursson, P. & Karlsson, J.: Correlation between oral drug absorption in humans and apparent drug permeability coefficients in human intestinal epithelial (Caco-2) cells. Biochem. Biophys. Res. Commun., 175, 880–885, 1991."
N-[4-[2-hydroxy-3-(propan-2-ylamino)propoxy]phenyl]acetamide;MM00544;CC(=O)Nc1ccc(OCC(O)CNC(C)C)cc1;DURULFYMVIFBIR-UHFFFAOYSA-N;266.341;1.38;4883;DB01297;;CHEMBL6995;CACO;ECACO;37;+1;;;;;;;;;;-6.05;;;;;;;;;;;;"Artursson, P. & Karlsson, J.: Correlation between oral drug absorption in humans and apparent drug permeability coefficients in human intestinal epithelial (Caco-2) cells. Biochem. Biophys. Res. Commun., 175, 880–885, 1991.";"Artursson, P. & Karlsson, J.: Correlation between oral drug absorption in humans and apparent drug permeability coefficients in human intestinal epithelial (Caco-2) cells. Biochem. Biophys. Res. Commun., 175, 880–885, 1991."
2-[4-[2-hydroxy-3-(propan-2-ylamino)propoxy]phenyl]acetamide;MM00078;CC(C)NC[C@@H](O)COc1ccc(CC(N)=O)cc1;METKIMKYRPQLGS-UHFFFAOYSA-N;266.341;0.45;2249;DB00335;;CHEMBL24;CACO;ECACO;37;+1;;;;;;;;;;-6.7;;;;;;;;;;;;"Artursson, P. & Karlsson, J.: Correlation between oral drug absorption in humans and apparent drug permeability coefficients in human intestinal epithelial (Caco-2) cells. Biochem. Biophys. Res. Commun., 175, 880–885, 1991.";"Artursson, P. & Karlsson, J.: Correlation between oral drug absorption in humans and apparent drug permeability coefficients in human intestinal epithelial (Caco-2) cells. Biochem. Biophys. Res. Commun., 175, 880–885, 1991."
1-[4-(2-methoxyethyl)phenoxy]-3-(propan-2-ylamino)propan-2-ol;MM00275;COCCc1ccc(OCC(O)CNC(C)C)cc1;IUBSYMUCCVWXPE-UHFFFAOYSA-N;267.369;1.61;4171;DB00264;;CHEMBL13;CACO;ECACO;37;+1;;;;;;;;;;-4.57;;;;;;;;;;;;"Artursson, P. & Karlsson, J.: Correlation between oral drug absorption in humans and apparent drug permeability coefficients in human intestinal epithelial (Caco-2) cells. Biochem. Biophys. Res. Commun., 175, 880–885, 1991.";"Artursson, P. & Karlsson, J.: Correlation between oral drug absorption in humans and apparent drug permeability coefficients in human intestinal epithelial (Caco-2) cells. Biochem. Biophys. Res. Commun., 175, 880–885, 1991."
Testosterone;MM00423;CC12CCC(=O)C=C1CCC1C2CCC2(C)C(O)CCC12;MUMGGOZAMZWBJJ-UHFFFAOYSA-N;288.431;3.88;6013;DB00624;TES;CHEMBL386630;CACO;ECACO;37;0;;;;;;;;;;-4.29;;;;;;;;;;;;"Artursson, P. & Karlsson, J.: Correlation between oral drug absorption in humans and apparent drug permeability coefficients in human intestinal epithelial (Caco-2) cells. Biochem. Biophys. Res. Commun., 175, 880–885, 1991.";"Artursson, P. & Karlsson, J.: Correlation between oral drug absorption in humans and apparent drug permeability coefficients in human intestinal epithelial (Caco-2) cells. Biochem. Biophys. Res. Commun., 175, 880–885, 1991."
"5-[(3-carboxy-4-hydroxyphenyl)diazenyl]-2-hydroxybenzoic acid";MM01437;O=C(O)c1cc(/N=N/c2ccc(O)c(C(=O)O)c2)ccc1O;QQBDLJCYGRGAKP-FOCLMDBBSA-N;302.24;2.91;22419;DB01250;;CHEMBL1201013;CACO;ECACO;37;-2;;;;;;;;;;-6.96;;;;;;;;;;;;"Artursson, P. & Karlsson, J.: Correlation between oral drug absorption in humans and apparent drug permeability coefficients in human intestinal epithelial (Caco-2) cells. Biochem. Biophys. Res. Commun., 175, 880–885, 1991.";"Artursson, P. & Karlsson, J.: Correlation between oral drug absorption in humans and apparent drug permeability coefficients in human intestinal epithelial (Caco-2) cells. Biochem. Biophys. Res. Commun., 175, 880–885, 1991."
4-hydroxy-3-(3-oxo-1-phenylbutyl)chromen-2-one;MM00095;CC(=O)CC(c1ccccc1)c1c(O)c2ccccc2oc1=O;PJVWKTKQMONHTI-UHFFFAOYSA-N;308.333;3.61;54678486;DB00682;;CHEMBL1464;CACO;ECACO;37;-1;;;;;;;;;;-4.42;;;;;;;;;;;;"Artursson, P. & Karlsson, J.: Correlation between oral drug absorption in humans and apparent drug permeability coefficients in human intestinal epithelial (Caco-2) cells. Biochem. Biophys. Res. Commun., 175, 880–885, 1991.";"Artursson, P. & Karlsson, J.: Correlation between oral drug absorption in humans and apparent drug permeability coefficients in human intestinal epithelial (Caco-2) cells. Biochem. Biophys. Res. Commun., 175, 880–885, 1991."
Corticosterone;MM00346;CC12CCC(=O)C=C1CCC1C2C(O)CC2(C)C(C(=O)CO)CCC12;OMFXVFTZEKFJBZ-UHFFFAOYSA-N;346.467;2.67;5753;DB04652;C0R;CHEMBL110739;CACO;ECACO;37;0;;;;;;;;;;-4.26;;;;;;;;;;;;"Artursson, P. & Karlsson, J.: Correlation between oral drug absorption in humans and apparent drug permeability coefficients in human intestinal epithelial (Caco-2) cells. Biochem. Biophys. Res. Commun., 175, 880–885, 1991.";"Artursson, P. & Karlsson, J.: Correlation between oral drug absorption in humans and apparent drug permeability coefficients in human intestinal epithelial (Caco-2) cells. Biochem. Biophys. Res. Commun., 175, 880–885, 1991."
Hydrocortisone;MM00044;CC12CCC(=O)C=C1CCC1C2C(O)CC2(C)C1CCC2(O)C(=O)CO;JYGXADMDTFJGBT-UHFFFAOYSA-N;362.466;1.78;5754;DB00741;HCY;CHEMBL389621;CACO;ECACO;37;0;;;;;;;;;;-4.67;;;;;;;;;;;;"Artursson, P. & Karlsson, J.: Correlation between oral drug absorption in humans and apparent drug permeability coefficients in human intestinal epithelial (Caco-2) cells. Biochem. Biophys. Res. Commun., 175, 880–885, 1991.";"Artursson, P. & Karlsson, J.: Correlation between oral drug absorption in humans and apparent drug permeability coefficients in human intestinal epithelial (Caco-2) cells. Biochem. Biophys. Res. Commun., 175, 880–885, 1991."
Felodipine;MM00363;CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1c1cccc(Cl)c1Cl;RZTAMFZIAATZDJ-UHFFFAOYSA-N;384.253;3.96;3333;DB01023;;CHEMBL1480;CACO;ECACO;37;0;;;;;;;;;;-4.64;;;;;;;;;;;;"Artursson, P. & Karlsson, J.: Correlation between oral drug absorption in humans and apparent drug permeability coefficients in human intestinal epithelial (Caco-2) cells. Biochem. Biophys. Res. Commun., 175, 880–885, 1991.";"Artursson, P. & Karlsson, J.: Correlation between oral drug absorption in humans and apparent drug permeability coefficients in human intestinal epithelial (Caco-2) cells. Biochem. Biophys. Res. Commun., 175, 880–885, 1991."
Dexamethasone;MM00355;C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO;UREBDLICKHMUKA-CXSFZGCWSA-N;392.467;1.9;5743;DB01234;DEX;CHEMBL384467;CACO;ECACO;37;0;;;;;;;;;;-4.9;;;;;;;;;;;;"Artursson, P. & Karlsson, J.: Correlation between oral drug absorption in humans and apparent drug permeability coefficients in human intestinal epithelial (Caco-2) cells. Biochem. Biophys. Res. Commun., 175, 880–885, 1991.";"Artursson, P. & Karlsson, J.: Correlation between oral drug absorption in humans and apparent drug permeability coefficients in human intestinal epithelial (Caco-2) cells. Biochem. Biophys. Res. Commun., 175, 880–885, 1991."
Sulfasalazine;MM00690;O=C(O)c1cc(N=Nc2ccc(S(=O)(=O)Nc3ccccn3)cc2)ccc1O;NCEXYHBECQHGNR-UHFFFAOYSA-N;398.393;3.7;5359476;DB00795;SAS;CHEMBL421;CACO;ECACO;37;"-2, -1";;;;;;;;;;-6.89;;;;;;;;;;;;"Artursson, P. & Karlsson, J.: Correlation between oral drug absorption in humans and apparent drug permeability coefficients in human intestinal epithelial (Caco-2) cells. Biochem. Biophys. Res. Commun., 175, 880–885, 1991.";"Artursson, P. & Karlsson, J.: Correlation between oral drug absorption in humans and apparent drug permeability coefficients in human intestinal epithelial (Caco-2) cells. Biochem. Biophys. Res. Commun., 175, 880–885, 1991."
Pr-norfloxacin;MM01438;;;;;;;;;CACO;ECACO;37;;;;;;;;;;;-4.47;;;;;;;;;;;;"Bermejo M., Avdeef A., Ruiz A., Nalda R., Ruell J.A., Tsinman O., González I., Fernández C., Sánchez G., Garrigues T.M, Merino V.: PAMPA - A drug absorption in vitro model: 7. Comparing rat in situ, Caco-2, and PAMPA permeability of fluoroquinolones. Eur. J. Pharm. Sci. 21, 429–441, 2004.";"Bermejo M., Avdeef A., Ruiz A., Nalda R., Ruell J.A., Tsinman O., González I., Fernández C., Sánchez G., Garrigues T.M, Merino V.: PAMPA - A drug absorption in vitro model: 7. Comparing rat in situ, Caco-2, and PAMPA permeability of fluoroquinolones. Eur. J. Pharm. Sci. 21, 429–441, 2004."
Me-ciprofloxacin;MM01307;CN1CCN(c2cc3c(cc2F)c(=O)c(C(=O)O)cn3C2CC2)CC1;TXJIOKSSHCOKKH-UHFFFAOYSA-N;345.374;1.93;465907;;;CHEMBL429961;CACO;ECACO;37;;;;;;;;;;;-4.59;;;;;;;;;;;;"Bermejo M., Avdeef A., Ruiz A., Nalda R., Ruell J.A., Tsinman O., González I., Fernández C., Sánchez G., Garrigues T.M, Merino V.: PAMPA - A drug absorption in vitro model: 7. Comparing rat in situ, Caco-2, and PAMPA permeability of fluoroquinolones. Eur. J. Pharm. Sci. 21, 429–441, 2004.";"Bermejo M., Avdeef A., Ruiz A., Nalda R., Ruell J.A., Tsinman O., González I., Fernández C., Sánchez G., Garrigues T.M, Merino V.: PAMPA - A drug absorption in vitro model: 7. Comparing rat in situ, Caco-2, and PAMPA permeability of fluoroquinolones. Eur. J. Pharm. Sci. 21, 429–441, 2004."
Pr-ciprofloxacin;MM01439;;;;;;;;;CACO;ECACO;37;;;;;;;;;;;-4.49;;;;;;;;;;;;"Bermejo M., Avdeef A., Ruiz A., Nalda R., Ruell J.A., Tsinman O., González I., Fernández C., Sánchez G., Garrigues T.M, Merino V.: PAMPA - A drug absorption in vitro model: 7. Comparing rat in situ, Caco-2, and PAMPA permeability of fluoroquinolones. Eur. J. Pharm. Sci. 21, 429–441, 2004.";"Bermejo M., Avdeef A., Ruiz A., Nalda R., Ruell J.A., Tsinman O., González I., Fernández C., Sánchez G., Garrigues T.M, Merino V.: PAMPA - A drug absorption in vitro model: 7. Comparing rat in situ, Caco-2, and PAMPA permeability of fluoroquinolones. Eur. J. Pharm. Sci. 21, 429–441, 2004."
Bu-ciprofloxacin;MM01440;;;;;;;;;CACO;ECACO;37;;;;;;;;;;;-4.52;;;;;;;;;;;;"Bermejo M., Avdeef A., Ruiz A., Nalda R., Ruell J.A., Tsinman O., González I., Fernández C., Sánchez G., Garrigues T.M, Merino V.: PAMPA - A drug absorption in vitro model: 7. Comparing rat in situ, Caco-2, and PAMPA permeability of fluoroquinolones. Eur. J. Pharm. Sci. 21, 429–441, 2004.";"Bermejo M., Avdeef A., Ruiz A., Nalda R., Ruell J.A., Tsinman O., González I., Fernández C., Sánchez G., Garrigues T.M, Merino V.: PAMPA - A drug absorption in vitro model: 7. Comparing rat in situ, Caco-2, and PAMPA permeability of fluoroquinolones. Eur. J. Pharm. Sci. 21, 429–441, 2004."
CNV97100;MM00727;CC1CN(c2cc3c(cc2F)c(=O)c(C(=O)O)cn3C2CC2)CCN1.O=C(O)C(F)(F)F;URJUNYOPXJPQGS-UHFFFAOYSA-N;459.398;2.61;46781144;;;;CACO;ECACO;37;;;;;;;;;;;-5.2;;;;;;;;;;;;"Bermejo M., Avdeef A., Ruiz A., Nalda R., Ruell J.A., Tsinman O., González I., Fernández C., Sánchez G., Garrigues T.M, Merino V.: PAMPA - A drug absorption in vitro model: 7. Comparing rat in situ, Caco-2, and PAMPA permeability of fluoroquinolones. Eur. J. Pharm. Sci. 21, 429–441, 2004.";"Bermejo M., Avdeef A., Ruiz A., Nalda R., Ruell J.A., Tsinman O., González I., Fernández C., Sánchez G., Garrigues T.M, Merino V.: PAMPA - A drug absorption in vitro model: 7. Comparing rat in situ, Caco-2, and PAMPA permeability of fluoroquinolones. Eur. J. Pharm. Sci. 21, 429–441, 2004."
CNV97101;MM01441;;;;;;;;;CACO;ECACO;37;;;;;;;;;;;-4.66;;;;;;;;;;;;"Bermejo M., Avdeef A., Ruiz A., Nalda R., Ruell J.A., Tsinman O., González I., Fernández C., Sánchez G., Garrigues T.M, Merino V.: PAMPA - A drug absorption in vitro model: 7. Comparing rat in situ, Caco-2, and PAMPA permeability of fluoroquinolones. Eur. J. Pharm. Sci. 21, 429–441, 2004.";"Bermejo M., Avdeef A., Ruiz A., Nalda R., Ruell J.A., Tsinman O., González I., Fernández C., Sánchez G., Garrigues T.M, Merino V.: PAMPA - A drug absorption in vitro model: 7. Comparing rat in situ, Caco-2, and PAMPA permeability of fluoroquinolones. Eur. J. Pharm. Sci. 21, 429–441, 2004."
"1-cyclopropyl-7-(4-ethyl-3-methylpiperazin-1-yl)-6-fluoro-4-oxoquinoline-3-carboxylic acid";MM00728;CCN1CCN(c2cc3c(cc2F)c(=O)c(C(=O)O)cn3C2CC2)CC1C;POMKZSJIYNWBRP-UHFFFAOYSA-N;373.428;2.7;10109876;;;;CACO;ECACO;37;;;;;;;;;;;-4.77;;;;;;;;;;;;"Bermejo M., Avdeef A., Ruiz A., Nalda R., Ruell J.A., Tsinman O., González I., Fernández C., Sánchez G., Garrigues T.M, Merino V.: PAMPA - A drug absorption in vitro model: 7. Comparing rat in situ, Caco-2, and PAMPA permeability of fluoroquinolones. Eur. J. Pharm. Sci. 21, 429–441, 2004.";"Bermejo M., Avdeef A., Ruiz A., Nalda R., Ruell J.A., Tsinman O., González I., Fernández C., Sánchez G., Garrigues T.M, Merino V.: PAMPA - A drug absorption in vitro model: 7. Comparing rat in situ, Caco-2, and PAMPA permeability of fluoroquinolones. Eur. J. Pharm. Sci. 21, 429–441, 2004."
CNV97103;MM00729;CCCN1CCN(c2cc3c(cc2F)c(=O)c(C(=O)O)cn3C2CC2)CC1C;WPGHZQMHNTXSAF-UHFFFAOYSA-N;387.455;3.09;13326823;;;;CACO;ECACO;37;;;;;;;;;;;-4.82;;;;;;;;;;;;"Bermejo M., Avdeef A., Ruiz A., Nalda R., Ruell J.A., Tsinman O., González I., Fernández C., Sánchez G., Garrigues T.M, Merino V.: PAMPA - A drug absorption in vitro model: 7. Comparing rat in situ, Caco-2, and PAMPA permeability of fluoroquinolones. Eur. J. Pharm. Sci. 21, 429–441, 2004.";"Bermejo M., Avdeef A., Ruiz A., Nalda R., Ruell J.A., Tsinman O., González I., Fernández C., Sánchez G., Garrigues T.M, Merino V.: PAMPA - A drug absorption in vitro model: 7. Comparing rat in situ, Caco-2, and PAMPA permeability of fluoroquinolones. Eur. J. Pharm. Sci. 21, 429–441, 2004."
"7-(4-butyl-3-methylpiperazin-1-yl)-1-cyclopropyl-6-fluoro-4-oxoquinoline-3-carboxylic acid";MM00730;CCCCN1CCN(c2cc3c(cc2F)c(=O)c(C(=O)O)cn3C2CC2)CC1C;QPVCGSGGZMAACV-UHFFFAOYSA-N;401.482;3.48;13385166;;;;CACO;ECACO;37;;;;;;;;;;;-4.86;;;;;;;;;;;;"Bermejo M., Avdeef A., Ruiz A., Nalda R., Ruell J.A., Tsinman O., González I., Fernández C., Sánchez G., Garrigues T.M, Merino V.: PAMPA - A drug absorption in vitro model: 7. Comparing rat in situ, Caco-2, and PAMPA permeability of fluoroquinolones. Eur. J. Pharm. Sci. 21, 429–441, 2004.";"Bermejo M., Avdeef A., Ruiz A., Nalda R., Ruell J.A., Tsinman O., González I., Fernández C., Sánchez G., Garrigues T.M, Merino V.: PAMPA - A drug absorption in vitro model: 7. Comparing rat in situ, Caco-2, and PAMPA permeability of fluoroquinolones. Eur. J. Pharm. Sci. 21, 429–441, 2004."
Ofloxacin;MM00769;CC1COc2c(N3CCN(C)CC3)c(F)cc3c(=O)c(C(=O)O)cn1c23;GSDSWSVVBLHKDQ-UHFFFAOYSA-N;361.373;1.54;4583;DB01165;;CHEMBL4;CACO;ECACO;37;;;;;;;;;;;-4.96;;;;;;;;;;;;"Bermejo M., Avdeef A., Ruiz A., Nalda R., Ruell J.A., Tsinman O., González I., Fernández C., Sánchez G., Garrigues T.M, Merino V.: PAMPA - A drug absorption in vitro model: 7. Comparing rat in situ, Caco-2, and PAMPA permeability of fluoroquinolones. Eur. J. Pharm. Sci. 21, 429–441, 2004.";"Bermejo M., Avdeef A., Ruiz A., Nalda R., Ruell J.A., Tsinman O., González I., Fernández C., Sánchez G., Garrigues T.M, Merino V.: PAMPA - A drug absorption in vitro model: 7. Comparing rat in situ, Caco-2, and PAMPA permeability of fluoroquinolones. Eur. J. Pharm. Sci. 21, 429–441, 2004."
"6-fluoro-1-(4-fluorophenyl)-4-oxo-7-piperazin-1-ylquinoline-3-carboxylic acid";MM00771;O=C(O)c1cn(-c2ccc(F)cc2)c2cc(N3CCNCC3)c(F)cc2c1=O;XBHBWNFJWIASRO-UHFFFAOYSA-N;385.371;2.38;56208;DB11491;;CHEMBL37858;CACO;ECACO;37;;;;;;;;;;;-5.35;;;;;;;;;;;;"Bermejo M., Avdeef A., Ruiz A., Nalda R., Ruell J.A., Tsinman O., González I., Fernández C., Sánchez G., Garrigues T.M, Merino V.: PAMPA - A drug absorption in vitro model: 7. Comparing rat in situ, Caco-2, and PAMPA permeability of fluoroquinolones. Eur. J. Pharm. Sci. 21, 429–441, 2004.";"Bermejo M., Avdeef A., Ruiz A., Nalda R., Ruell J.A., Tsinman O., González I., Fernández C., Sánchez G., Garrigues T.M, Merino V.: PAMPA - A drug absorption in vitro model: 7. Comparing rat in situ, Caco-2, and PAMPA permeability of fluoroquinolones. Eur. J. Pharm. Sci. 21, 429–441, 2004."
Flumequine;MM00646;CC1CCc2cc(F)cc3c(=O)c(C(=O)O)cn1c23;DPSPPJIUMHPXMA-UHFFFAOYSA-N;261.252;2.35;3374;DB08972;;CHEMBL370252;CACO;ECACO;37;;;;;;;;;;;-4.54;;;;;;;;;;;;"Bermejo M., Avdeef A., Ruiz A., Nalda R., Ruell J.A., Tsinman O., González I., Fernández C., Sánchez G., Garrigues T.M, Merino V.: PAMPA - A drug absorption in vitro model: 7. Comparing rat in situ, Caco-2, and PAMPA permeability of fluoroquinolones. Eur. J. Pharm. Sci. 21, 429–441, 2004.";"Bermejo M., Avdeef A., Ruiz A., Nalda R., Ruell J.A., Tsinman O., González I., Fernández C., Sánchez G., Garrigues T.M, Merino V.: PAMPA - A drug absorption in vitro model: 7. Comparing rat in situ, Caco-2, and PAMPA permeability of fluoroquinolones. Eur. J. Pharm. Sci. 21, 429–441, 2004."
Boc-Trp;MM01089;CC(C)(C)OC(=O)NC(Cc1cc2ccccc2[nH]1)C(=O)O;WXYGVKADAIJGHB-UHFFFAOYSA-N;304.346;2.69;44424848;;;;CACO;CVOLSURF;25;-1;;;;;;;;;;-5.81;;;;;;;;;;;;"Fujikawa M., Ano R., Nakao K., Shimizu R., Akamatsu M., Relationships between structure and high-throughput screening permeability of diverse drugs with artificial membranes: Application to prediction of Caco-2 cell permeability. Bioorg. Med. Chem. 13 (2005) 4721-4732";"Fujikawa M., Ano R., Nakao K., Shimizu R., Akamatsu M., Relationships between structure and high-throughput screening permeability of diverse drugs with artificial membranes: Application to prediction of Caco-2 cell permeability. Bioorg. Med. Chem. 13 (2005) 4721-4732"
Cbz-Trp;MM01090;O=C(NC(Cc1cc2ccccc2[nH]1)C(=O)O)OCc1ccccc1;DZJWNXSZBKGYKP-UHFFFAOYSA-N;338.363;3.09;44424857;;;;CACO;CVOLSURF;25;-1;;;;;;;;;;-5.67;;;;;;;;;;;;"Fujikawa M., Ano R., Nakao K., Shimizu R., Akamatsu M., Relationships between structure and high-throughput screening permeability of diverse drugs with artificial membranes: Application to prediction of Caco-2 cell permeability. Bioorg. Med. Chem. 13 (2005) 4721-4732";"Fujikawa M., Ano R., Nakao K., Shimizu R., Akamatsu M., Relationships between structure and high-throughput screening permeability of diverse drugs with artificial membranes: Application to prediction of Caco-2 cell permeability. Bioorg. Med. Chem. 13 (2005) 4721-4732"
Fmoc-Trp;MM01091;O=C(NC(Cc1cc2ccccc2[nH]1)C(=O)O)OCC1c2ccccc2-c2ccccc21;KUROROGTRLAIQQ-UHFFFAOYSA-N;426.472;4.7;44424858;;;;CACO;CVOLSURF;25;-1;;;;;;;;;;-4.96;;;;;;;;;;;;"Fujikawa M., Ano R., Nakao K., Shimizu R., Akamatsu M., Relationships between structure and high-throughput screening permeability of diverse drugs with artificial membranes: Application to prediction of Caco-2 cell permeability. Bioorg. Med. Chem. 13 (2005) 4721-4732";"Fujikawa M., Ano R., Nakao K., Shimizu R., Akamatsu M., Relationships between structure and high-throughput screening permeability of diverse drugs with artificial membranes: Application to prediction of Caco-2 cell permeability. Bioorg. Med. Chem. 13 (2005) 4721-4732"
L-Tryptophanamide;MM01079;NC(=O)C(N)Cc1c[nH]c2ccccc12;JLSKPBDKNIXMBS-UHFFFAOYSA-N;203.245;0.52;439356;;;CHEMBL1229086;CACO;CVOLSURF;25;0;;;;;;;;;;-5.88;;;;;;;;;;;;"Fujikawa M., Ano R., Nakao K., Shimizu R., Akamatsu M., Relationships between structure and high-throughput screening permeability of diverse drugs with artificial membranes: Application to prediction of Caco-2 cell permeability. Bioorg. Med. Chem. 13 (2005) 4721-4732";"Fujikawa M., Ano R., Nakao K., Shimizu R., Akamatsu M., Relationships between structure and high-throughput screening permeability of diverse drugs with artificial membranes: Application to prediction of Caco-2 cell permeability. Bioorg. Med. Chem. 13 (2005) 4721-4732"
(2S)-2-acetamido-3-(1H-indol-3-yl)propanamide;MM01076;CC(=O)NC(Cc1c[nH]c2ccccc12)C(N)=O;HNGIZKAMDMBRKJ-UHFFFAOYSA-N;245.282;0.7;94230;;;;CACO;CVOLSURF;25;-1;;;;;;;;;;-5.71;;;;;;;;;;;;"Fujikawa M., Ano R., Nakao K., Shimizu R., Akamatsu M., Relationships between structure and high-throughput screening permeability of diverse drugs with artificial membranes: Application to prediction of Caco-2 cell permeability. Bioorg. Med. Chem. 13 (2005) 4721-4732";"Fujikawa M., Ano R., Nakao K., Shimizu R., Akamatsu M., Relationships between structure and high-throughput screening permeability of diverse drugs with artificial membranes: Application to prediction of Caco-2 cell permeability. Bioorg. Med. Chem. 13 (2005) 4721-4732"
Gly-Trp-NH2;MM01081;NCC(=O)NC(Cc1c[nH]c2ccccc12)C(N)=O;YZMFLZVJQTUTKK-UHFFFAOYSA-N;260.297;-0.36;3081965;;;;CACO;CVOLSURF;25;0;;;;;;;;;;-6.56;;;;;;;;;;;;"Fujikawa M., Ano R., Nakao K., Shimizu R., Akamatsu M., Relationships between structure and high-throughput screening permeability of diverse drugs with artificial membranes: Application to prediction of Caco-2 cell permeability. Bioorg. Med. Chem. 13 (2005) 4721-4732";"Fujikawa M., Ano R., Nakao K., Shimizu R., Akamatsu M., Relationships between structure and high-throughput screening permeability of diverse drugs with artificial membranes: Application to prediction of Caco-2 cell permeability. Bioorg. Med. Chem. 13 (2005) 4721-4732"
Phe-Trp-NH2;MM01083;NC(=O)C(Cc1c[nH]c2ccccc12)NC(=O)C(N)Cc1ccccc1;GVIJYQOEFGLWKI-UHFFFAOYSA-N;350.422;1.25;7020143;;;;CACO;CVOLSURF;25;1;;;;;;;;;;-5.76;;;;;;;;;;;;"Fujikawa M., Ano R., Nakao K., Shimizu R., Akamatsu M., Relationships between structure and high-throughput screening permeability of diverse drugs with artificial membranes: Application to prediction of Caco-2 cell permeability. Bioorg. Med. Chem. 13 (2005) 4721-4732";"Fujikawa M., Ano R., Nakao K., Shimizu R., Akamatsu M., Relationships between structure and high-throughput screening permeability of diverse drugs with artificial membranes: Application to prediction of Caco-2 cell permeability. Bioorg. Med. Chem. 13 (2005) 4721-4732"
Trp-Ala-Val-NH2;MM01092;CC(NC(=O)C(N)Cc1c[nH]c2ccccc12)C(=O)NC(C(N)=O)C(C)C;FSIVAWBKYORDEB-UHFFFAOYSA-N;373.457;0.17;44424859;;;;CACO;CVOLSURF;25;1;;;;;;;;;;-6.44;;;;;;;;;;;;"Fujikawa M., Ano R., Nakao K., Shimizu R., Akamatsu M., Relationships between structure and high-throughput screening permeability of diverse drugs with artificial membranes: Application to prediction of Caco-2 cell permeability. Bioorg. Med. Chem. 13 (2005) 4721-4732";"Fujikawa M., Ano R., Nakao K., Shimizu R., Akamatsu M., Relationships between structure and high-throughput screening permeability of diverse drugs with artificial membranes: Application to prediction of Caco-2 cell permeability. Bioorg. Med. Chem. 13 (2005) 4721-4732"
N-Acetyl-L-tryptophyl-L-valinamide;MM01093;CC(=O)NC(Cc1c[nH]c2ccccc12)C(=O)NC(C(N)=O)C(C)C;ZFFQYIRICYOHAN-UHFFFAOYSA-N;344.415;0.84;44424860;;;;CACO;CVOLSURF;25;0;;;;;;;;;;-6.02;;;;;;;;;;;;"Fujikawa M., Ano R., Nakao K., Shimizu R., Akamatsu M., Relationships between structure and high-throughput screening permeability of diverse drugs with artificial membranes: Application to prediction of Caco-2 cell permeability. Bioorg. Med. Chem. 13 (2005) 4721-4732";"Fujikawa M., Ano R., Nakao K., Shimizu R., Akamatsu M., Relationships between structure and high-throughput screening permeability of diverse drugs with artificial membranes: Application to prediction of Caco-2 cell permeability. Bioorg. Med. Chem. 13 (2005) 4721-4732"
N-Acetyl-D-tryptophyl-L-valinamide;MM01094;CC(=O)NC(Cc1c[nH]c2ccccc12)C(=O)NC(C(N)=O)C(C)C;ZFFQYIRICYOHAN-UHFFFAOYSA-N;344.415;0.84;44424861;;;;CACO;CVOLSURF;25;0;;;;;;;;;;-5.91;;;;;;;;;;;;"Fujikawa M., Ano R., Nakao K., Shimizu R., Akamatsu M., Relationships between structure and high-throughput screening permeability of diverse drugs with artificial membranes: Application to prediction of Caco-2 cell permeability. Bioorg. Med. Chem. 13 (2005) 4721-4732";"Fujikawa M., Ano R., Nakao K., Shimizu R., Akamatsu M., Relationships between structure and high-throughput screening permeability of diverse drugs with artificial membranes: Application to prediction of Caco-2 cell permeability. Bioorg. Med. Chem. 13 (2005) 4721-4732"
Ac-Tyr-Leu-NH2;MM01088;CC(=O)NC(Cc1ccc(O)cc1)C(=O)NC(CC(C)C)C(N)=O;WGDDMZFVKNOORS-UHFFFAOYSA-N;335.404;0.46;14562813;;;;CACO;CVOLSURF;25;0;;;;;;;;;;-6.05;;;;;;;;;;;;"Fujikawa M., Ano R., Nakao K., Shimizu R., Akamatsu M., Relationships between structure and high-throughput screening permeability of diverse drugs with artificial membranes: Application to prediction of Caco-2 cell permeability. Bioorg. Med. Chem. 13 (2005) 4721-4732";"Fujikawa M., Ano R., Nakao K., Shimizu R., Akamatsu M., Relationships between structure and high-throughput screening permeability of diverse drugs with artificial membranes: Application to prediction of Caco-2 cell permeability. Bioorg. Med. Chem. 13 (2005) 4721-4732"
Ac-Tyr-Phe-NH2;MM01086;CC(=O)NC(Cc1ccc(O)cc1)C(=O)NC(Cc1ccccc1)C(N)=O;QJOFRQKWYZAXIZ-UHFFFAOYSA-N;369.421;0.65;11068626;;;;CACO;CVOLSURF;25;0;;;;;;;;;;-6.17;;;;;;;;;;;;"Fujikawa M., Ano R., Nakao K., Shimizu R., Akamatsu M., Relationships between structure and high-throughput screening permeability of diverse drugs with artificial membranes: Application to prediction of Caco-2 cell permeability. Bioorg. Med. Chem. 13 (2005) 4721-4732";"Fujikawa M., Ano R., Nakao K., Shimizu R., Akamatsu M., Relationships between structure and high-throughput screening permeability of diverse drugs with artificial membranes: Application to prediction of Caco-2 cell permeability. Bioorg. Med. Chem. 13 (2005) 4721-4732"
Cyclo(-Gly-Trp);MM01082;O=C1CNC(=O)C(Cc2c[nH]c3ccccc23)N1;IFQZEERDQXQTLJ-UHFFFAOYSA-N;243.266;0.33;6997508;;;;CACO;CVOLSURF;25;0;;;;;;;;;;-5.92;;;;;;;;;;;;"Fujikawa M., Ano R., Nakao K., Shimizu R., Akamatsu M., Relationships between structure and high-throughput screening permeability of diverse drugs with artificial membranes: Application to prediction of Caco-2 cell permeability. Bioorg. Med. Chem. 13 (2005) 4721-4732";"Fujikawa M., Ano R., Nakao K., Shimizu R., Akamatsu M., Relationships between structure and high-throughput screening permeability of diverse drugs with artificial membranes: Application to prediction of Caco-2 cell permeability. Bioorg. Med. Chem. 13 (2005) 4721-4732"
Cyclo(-Trp-Tyr);MM01087;O=C1N[C@@H](Cc2c[nH]c3ccccc23)C(=O)N[C@H]1Cc1ccc(O)cc1;ZJDMXAAEAVGGSK-ROUUACIJSA-N;349.39;1.64;7408259;;;;CACO;CVOLSURF;25;0;;;;;;;;;;-5.74;;;;;;;;;;;;"Fujikawa M., Ano R., Nakao K., Shimizu R., Akamatsu M., Relationships between structure and high-throughput screening permeability of diverse drugs with artificial membranes: Application to prediction of Caco-2 cell permeability. Bioorg. Med. Chem. 13 (2005) 4721-4732";"Fujikawa M., Ano R., Nakao K., Shimizu R., Akamatsu M., Relationships between structure and high-throughput screening permeability of diverse drugs with artificial membranes: Application to prediction of Caco-2 cell permeability. Bioorg. Med. Chem. 13 (2005) 4721-4732"
Cyclo(-Trp-Trp);MM01084;O=C1NC(Cc2c[nH]c3ccccc23)C(=O)NC1Cc1c[nH]c2ccccc12;DNHODRZUCGXYKU-UHFFFAOYSA-N;372.428;2.42;7091706;;;;CACO;CVOLSURF;25;0;;;;;;;;;;-5.25;;;;;;;;;;;;"Fujikawa M., Ano R., Nakao K., Shimizu R., Akamatsu M., Relationships between structure and high-throughput screening permeability of diverse drugs with artificial membranes: Application to prediction of Caco-2 cell permeability. Bioorg. Med. Chem. 13 (2005) 4721-4732";"Fujikawa M., Ano R., Nakao K., Shimizu R., Akamatsu M., Relationships between structure and high-throughput screening permeability of diverse drugs with artificial membranes: Application to prediction of Caco-2 cell permeability. Bioorg. Med. Chem. 13 (2005) 4721-4732"
1H-indole;MM01048;c1ccc2[nH]ccc2c1;SIKJAQJRHWYJAI-UHFFFAOYSA-N;117.151;2.17;798;DB04532;IND;CHEMBL15844;CACO;CVOLSURF;25;0;;;;;;;;;;-4.26;;;;;;;;;;;;"Fujikawa M., Ano R., Nakao K., Shimizu R., Akamatsu M., Relationships between structure and high-throughput screening permeability of diverse drugs with artificial membranes: Application to prediction of Caco-2 cell permeability. Bioorg. Med. Chem. 13 (2005) 4721-4732";"Fujikawa M., Ano R., Nakao K., Shimizu R., Akamatsu M., Relationships between structure and high-throughput screening permeability of diverse drugs with artificial membranes: Application to prediction of Caco-2 cell permeability. Bioorg. Med. Chem. 13 (2005) 4721-4732"
2-(1H-indol-3-yl)ethanol;MM01064;OCCc1c[nH]c2ccccc12;MBBOMCVGYCRMEA-UHFFFAOYSA-N;161.204;1.7;10685;;ZCW;CHEMBL226545;CACO;CVOLSURF;25;0;;;;;;;;;;-4.8;;;;;;;;;;;;"Fujikawa M., Ano R., Nakao K., Shimizu R., Akamatsu M., Relationships between structure and high-throughput screening permeability of diverse drugs with artificial membranes: Application to prediction of Caco-2 cell permeability. Bioorg. Med. Chem. 13 (2005) 4721-4732";"Fujikawa M., Ano R., Nakao K., Shimizu R., Akamatsu M., Relationships between structure and high-throughput screening permeability of diverse drugs with artificial membranes: Application to prediction of Caco-2 cell permeability. Bioorg. Med. Chem. 13 (2005) 4721-4732"
2-(1H-indol-3-yl)ethanamine;MM00582;NCCc1c[nH]c2ccccc12;APJYDQYYACXCRM-UHFFFAOYSA-N;160.22;1.67;1150;DB08653;TSS;CHEMBL6640;CACO;CVOLSURF;25;1;;;;;;;;;;-5.68;;;;;;;;;;;;"Fujikawa M., Ano R., Nakao K., Shimizu R., Akamatsu M., Relationships between structure and high-throughput screening permeability of diverse drugs with artificial membranes: Application to prediction of Caco-2 cell permeability. Bioorg. Med. Chem. 13 (2005) 4721-4732";"Fujikawa M., Ano R., Nakao K., Shimizu R., Akamatsu M., Relationships between structure and high-throughput screening permeability of diverse drugs with artificial membranes: Application to prediction of Caco-2 cell permeability. Bioorg. Med. Chem. 13 (2005) 4721-4732"
Indole-3-acetamide;MM11340;NC(=O)Cc1c[nH]c2ccccc12;ZOAMBXDOGPRZLP-UHFFFAOYSA-N;174.2;1.2;397;DB08652;TSR;;CACO;CVOLSURF;25;0;;;;;;;;;;-5.34;;;;;;;;;;;;"Fujikawa M., Ano R., Nakao K., Shimizu R., Akamatsu M., Relationships between structure and high-throughput screening permeability of diverse drugs with artificial membranes: Application to prediction of Caco-2 cell permeability. Bioorg. Med. Chem. 13 (2005) 4721-4732";"Fujikawa M., Ano R., Nakao K., Shimizu R., Akamatsu M., Relationships between structure and high-throughput screening permeability of diverse drugs with artificial membranes: Application to prediction of Caco-2 cell permeability. Bioorg. Med. Chem. 13 (2005) 4721-4732"
"Indole-3-carboxylic acid";MM01072;O=C(O)c1c[nH]c2ccccc12;KMAKOBLIOCQGJP-UHFFFAOYSA-N;161.16;1.87;69867;;ICO;CHEMBL387527;CACO;CVOLSURF;25;0;;;;;;;;;;-5.63;;;;;;;;;;;;"Fujikawa M., Ano R., Nakao K., Shimizu R., Akamatsu M., Relationships between structure and high-throughput screening permeability of diverse drugs with artificial membranes: Application to prediction of Caco-2 cell permeability. Bioorg. Med. Chem. 13 (2005) 4721-4732";"Fujikawa M., Ano R., Nakao K., Shimizu R., Akamatsu M., Relationships between structure and high-throughput screening permeability of diverse drugs with artificial membranes: Application to prediction of Caco-2 cell permeability. Bioorg. Med. Chem. 13 (2005) 4721-4732"
"Indole-3-acetic acid";MM01049;O=C(O)Cc1c[nH]c2ccccc12;SEOVTRFCIGRIMH-UHFFFAOYSA-N;175.187;1.8;802;DB07950;IAC;CHEMBL82411;CACO;CVOLSURF;25;-1;;;;;;;;;;-5.8;;;;;;;;;;;;"Fujikawa M., Ano R., Nakao K., Shimizu R., Akamatsu M., Relationships between structure and high-throughput screening permeability of diverse drugs with artificial membranes: Application to prediction of Caco-2 cell permeability. Bioorg. Med. Chem. 13 (2005) 4721-4732";"Fujikawa M., Ano R., Nakao K., Shimizu R., Akamatsu M., Relationships between structure and high-throughput screening permeability of diverse drugs with artificial membranes: Application to prediction of Caco-2 cell permeability. Bioorg. Med. Chem. 13 (2005) 4721-4732"
"3-Indolepropionic acid";MM01051;O=C(O)CCc1c[nH]c2ccccc12;GOLXRNDWAUTYKT-UHFFFAOYSA-N;189.214;2.19;3744;DB02758;IOP;CHEMBL207225;CACO;CVOLSURF;25;-1;;;;;;;;;;-5.57;;;;;;;;;;;;"Fujikawa M., Ano R., Nakao K., Shimizu R., Akamatsu M., Relationships between structure and high-throughput screening permeability of diverse drugs with artificial membranes: Application to prediction of Caco-2 cell permeability. Bioorg. Med. Chem. 13 (2005) 4721-4732";"Fujikawa M., Ano R., Nakao K., Shimizu R., Akamatsu M., Relationships between structure and high-throughput screening permeability of diverse drugs with artificial membranes: Application to prediction of Caco-2 cell permeability. Bioorg. Med. Chem. 13 (2005) 4721-4732"
N-[3-acetyl-4-[2-hydroxy-3-(propan-2-ylamino)propoxy]phenyl]butanamide;MM00437;CCCC(=O)Nc1ccc(OC[C@H](O)CNC(C)C)c(C(C)=O)c1;GOEMGAFJFRBGGG-UHFFFAOYSA-N;336.432;2.37;1978;DB01193;;CHEMBL642;CACO;CVOLSURF;25;1;;;;;;;;;;-5.83;;;;;;;;;;;;"Fujikawa M., Ano R., Nakao K., Shimizu R., Akamatsu M., Relationships between structure and high-throughput screening permeability of diverse drugs with artificial membranes: Application to prediction of Caco-2 cell permeability. Bioorg. Med. Chem. 13 (2005) 4721-4732";"Fujikawa M., Ano R., Nakao K., Shimizu R., Akamatsu M., Relationships between structure and high-throughput screening permeability of diverse drugs with artificial membranes: Application to prediction of Caco-2 cell permeability. Bioorg. Med. Chem. 13 (2005) 4721-4732"
N-(4-hydroxyphenyl)acetamide;MM00322;CC(=O)Nc1ccc(O)cc1;RZVAJINKPMORJF-UHFFFAOYSA-N;151.165;1.35;1983;DB00316;TYL;CHEMBL112;CACO;CVOLSURF;25;0;;;;;;;;;;-5.95;;;;;;;;;;;;"Fujikawa M., Ano R., Nakao K., Shimizu R., Akamatsu M., Relationships between structure and high-throughput screening permeability of diverse drugs with artificial membranes: Application to prediction of Caco-2 cell permeability. Bioorg. Med. Chem. 13 (2005) 4721-4732";"Fujikawa M., Ano R., Nakao K., Shimizu R., Akamatsu M., Relationships between structure and high-throughput screening permeability of diverse drugs with artificial membranes: Application to prediction of Caco-2 cell permeability. Bioorg. Med. Chem. 13 (2005) 4721-4732"
1-(propan-2-ylamino)-3-(2-prop-2-enylphenoxy)propan-2-ol;MM00440;C=CCc1ccccc1OC[C@H](O)CNC(C)C;PAZJSJFMUHDSTF-UHFFFAOYSA-N;249.354;2.15;2119;DB00866;;CHEMBL266195;CACO;CVOLSURF;25;0;;;;;;;;;;-4.83;;;;;;;;;;;;"Fujikawa M., Ano R., Nakao K., Shimizu R., Akamatsu M., Relationships between structure and high-throughput screening permeability of diverse drugs with artificial membranes: Application to prediction of Caco-2 cell permeability. Bioorg. Med. Chem. 13 (2005) 4721-4732";"Fujikawa M., Ano R., Nakao K., Shimizu R., Akamatsu M., Relationships between structure and high-throughput screening permeability of diverse drugs with artificial membranes: Application to prediction of Caco-2 cell permeability. Bioorg. Med. Chem. 13 (2005) 4721-4732"
1,5-dimethyl-2-phenylpyrazol-3-one;MM00333;Cc1cc(=O)n(-c2ccccc2)n1C;VEQOALNAAJBPNY-UHFFFAOYSA-N;188.23;1.48;2206;DB01435;;CHEMBL277474;CACO;CVOLSURF;25;0;;;;;;;;;;-5.14;;;;;;;;;;;;"Fujikawa M., Ano R., Nakao K., Shimizu R., Akamatsu M., Relationships between structure and high-throughput screening permeability of diverse drugs with artificial membranes: Application to prediction of Caco-2 cell permeability. Bioorg. Med. Chem. 13 (2005) 4721-4732";"Fujikawa M., Ano R., Nakao K., Shimizu R., Akamatsu M., Relationships between structure and high-throughput screening permeability of diverse drugs with artificial membranes: Application to prediction of Caco-2 cell permeability. Bioorg. Med. Chem. 13 (2005) 4721-4732"
Caffeine;MM00040;Cn1c(=O)c2c(ncn2C)n(C)c1=O;RYYVLZVUVIJVGH-UHFFFAOYSA-N;194.194;-1.03;2519;DB00201;CFF;CHEMBL113;CACO;CVOLSURF;25;0;;;;;;;;;;-5.73;;;;;;;;;;;;"Fujikawa M., Ano R., Nakao K., Shimizu R., Akamatsu M., Relationships between structure and high-throughput screening permeability of diverse drugs with artificial membranes: Application to prediction of Caco-2 cell permeability. Bioorg. Med. Chem. 13 (2005) 4721-4732";"Fujikawa M., Ano R., Nakao K., Shimizu R., Akamatsu M., Relationships between structure and high-throughput screening permeability of diverse drugs with artificial membranes: Application to prediction of Caco-2 cell permeability. Bioorg. Med. Chem. 13 (2005) 4721-4732"
2,2-dichloro-N-[(1R,2R)-1,3-dihydroxy-1-(4-nitrophenyl)propan-2-yl]acetamide;MM00342;O=C(NC(CO)C(O)c1ccc([N+](=O)[O-])cc1)C(Cl)Cl;WIIZWVCIJKGZOK-UHFFFAOYSA-N;323.126;0.91;5959;DB00446;CLM;CHEMBL130;CACO;CVOLSURF;25;0;;;;;;;;;;-5.72;;;;;;;;;;;;"Fujikawa M., Ano R., Nakao K., Shimizu R., Akamatsu M., Relationships between structure and high-throughput screening permeability of diverse drugs with artificial membranes: Application to prediction of Caco-2 cell permeability. Bioorg. Med. Chem. 13 (2005) 4721-4732";"Fujikawa M., Ano R., Nakao K., Shimizu R., Akamatsu M., Relationships between structure and high-throughput screening permeability of diverse drugs with artificial membranes: Application to prediction of Caco-2 cell permeability. Bioorg. Med. Chem. 13 (2005) 4721-4732"
N-(2,6-dichlorophenyl)-4,5-dihydro-1H-imidazol-2-amine;MM00344;Clc1cccc(Cl)c1N=C1NCCN1;GJSURZIOUXUGAL-UHFFFAOYSA-N;230.09;2.17;2803;DB00575;CLU;CHEMBL134;CACO;CVOLSURF;25;1;;;;;;;;;;-5.01;;;;;;;;;;;;"Fujikawa M., Ano R., Nakao K., Shimizu R., Akamatsu M., Relationships between structure and high-throughput screening permeability of diverse drugs with artificial membranes: Application to prediction of Caco-2 cell permeability. Bioorg. Med. Chem. 13 (2005) 4721-4732";"Fujikawa M., Ano R., Nakao K., Shimizu R., Akamatsu M., Relationships between structure and high-throughput screening permeability of diverse drugs with artificial membranes: Application to prediction of Caco-2 cell permeability. Bioorg. Med. Chem. 13 (2005) 4721-4732"
Corticosterone;MM00346;CC12CCC(=O)C=C1CCC1C2C(O)CC2(C)C(C(=O)CO)CCC12;OMFXVFTZEKFJBZ-UHFFFAOYSA-N;346.467;2.67;5753;DB04652;C0R;CHEMBL110739;CACO;CVOLSURF;25;0;;;;;;;;;;-4.95;;;;;;;;;;;;"Fujikawa M., Ano R., Nakao K., Shimizu R., Akamatsu M., Relationships between structure and high-throughput screening permeability of diverse drugs with artificial membranes: Application to prediction of Caco-2 cell permeability. Bioorg. Med. Chem. 13 (2005) 4721-4732";"Fujikawa M., Ano R., Nakao K., Shimizu R., Akamatsu M., Relationships between structure and high-throughput screening permeability of diverse drugs with artificial membranes: Application to prediction of Caco-2 cell permeability. Bioorg. Med. Chem. 13 (2005) 4721-4732"
Chromen-2-one;MM00042;O=c1ccc2ccccc2o1;ZYGHJZDHTFUPRJ-UHFFFAOYSA-N;146.145;1.79;323;DB04665;COU;CHEMBL6466;CACO;CVOLSURF;25;0;;;;;;;;;;-4.71;;;;;;;;;;;;"Fujikawa M., Ano R., Nakao K., Shimizu R., Akamatsu M., Relationships between structure and high-throughput screening permeability of diverse drugs with artificial membranes: Application to prediction of Caco-2 cell permeability. Bioorg. Med. Chem. 13 (2005) 4721-4732";"Fujikawa M., Ano R., Nakao K., Shimizu R., Akamatsu M., Relationships between structure and high-throughput screening permeability of diverse drugs with artificial membranes: Application to prediction of Caco-2 cell permeability. Bioorg. Med. Chem. 13 (2005) 4721-4732"
Dexamethasone;MM00355;C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO;UREBDLICKHMUKA-CXSFZGCWSA-N;392.467;1.9;5743;DB01234;DEX;CHEMBL384467;CACO;CVOLSURF;25;0;;;;;;;;;;-5.16;;;;;;;;;;;;"Fujikawa M., Ano R., Nakao K., Shimizu R., Akamatsu M., Relationships between structure and high-throughput screening permeability of diverse drugs with artificial membranes: Application to prediction of Caco-2 cell permeability. Bioorg. Med. Chem. 13 (2005) 4721-4732";"Fujikawa M., Ano R., Nakao K., Shimizu R., Akamatsu M., Relationships between structure and high-throughput screening permeability of diverse drugs with artificial membranes: Application to prediction of Caco-2 cell permeability. Bioorg. Med. Chem. 13 (2005) 4721-4732"
Dilthiazem;MM01511;;;;;;;;;CACO;CVOLSURF;25;0;;;;;;;;;;-4.64;;;;;;;;;;;;"Fujikawa M., Ano R., Nakao K., Shimizu R., Akamatsu M., Relationships between structure and high-throughput screening permeability of diverse drugs with artificial membranes: Application to prediction of Caco-2 cell permeability. Bioorg. Med. Chem. 13 (2005) 4721-4732";"Fujikawa M., Ano R., Nakao K., Shimizu R., Akamatsu M., Relationships between structure and high-throughput screening permeability of diverse drugs with artificial membranes: Application to prediction of Caco-2 cell permeability. Bioorg. Med. Chem. 13 (2005) 4721-4732"
"4-chloro-2-(furan-2-ylmethylamino)-5-sulfamoylbenzoic acid";MM00083;NS(=O)(=O)c1cc(C(=O)O)c(NCc2ccco2)cc1Cl;ZZUFCTLCJUWOSV-UHFFFAOYSA-N;330.739;1.89;3440;DB00695;FUN;CHEMBL35;CACO;CVOLSURF;25;1;;;;;;;;;;-6.65;;;;;;;;;;;;"Fujikawa M., Ano R., Nakao K., Shimizu R., Akamatsu M., Relationships between structure and high-throughput screening permeability of diverse drugs with artificial membranes: Application to prediction of Caco-2 cell permeability. Bioorg. Med. Chem. 13 (2005) 4721-4732";"Fujikawa M., Ano R., Nakao K., Shimizu R., Akamatsu M., Relationships between structure and high-throughput screening permeability of diverse drugs with artificial membranes: Application to prediction of Caco-2 cell permeability. Bioorg. Med. Chem. 13 (2005) 4721-4732"
6-chloro-1,1-dioxo-3,4-dihydro-2H-1lambda6,2,4-benzothiadiazine-7-sulfonamide;MM00373;NS(=O)(=O)c1cc2c(cc1Cl)NCNS2(=O)=O;JZUFKLXOESDKRF-UHFFFAOYSA-N;297.728;-0.35;3639;DB00999;HCZ;CHEMBL435;CACO;CVOLSURF;25;0;;;;;;;;;;-6.59;;;;;;;;;;;;"Fujikawa M., Ano R., Nakao K., Shimizu R., Akamatsu M., Relationships between structure and high-throughput screening permeability of diverse drugs with artificial membranes: Application to prediction of Caco-2 cell permeability. Bioorg. Med. Chem. 13 (2005) 4721-4732";"Fujikawa M., Ano R., Nakao K., Shimizu R., Akamatsu M., Relationships between structure and high-throughput screening permeability of diverse drugs with artificial membranes: Application to prediction of Caco-2 cell permeability. Bioorg. Med. Chem. 13 (2005) 4721-4732"
Hydrocortisone;MM00044;CC12CCC(=O)C=C1CCC1C2C(O)CC2(C)C1CCC2(O)C(=O)CO;JYGXADMDTFJGBT-UHFFFAOYSA-N;362.466;1.78;5754;DB00741;HCY;CHEMBL389621;CACO;CVOLSURF;25;0;;;;;;;;;;-5.27;;;;;;;;;;;;"Fujikawa M., Ano R., Nakao K., Shimizu R., Akamatsu M., Relationships between structure and high-throughput screening permeability of diverse drugs with artificial membranes: Application to prediction of Caco-2 cell permeability. Bioorg. Med. Chem. 13 (2005) 4721-4732";"Fujikawa M., Ano R., Nakao K., Shimizu R., Akamatsu M., Relationships between structure and high-throughput screening permeability of diverse drugs with artificial membranes: Application to prediction of Caco-2 cell permeability. Bioorg. Med. Chem. 13 (2005) 4721-4732"
Ibuprofen;MM00045;CC(C)Cc1ccc(C(C)C(=O)O)cc1;HEFNNWSXXWATRW-UHFFFAOYSA-N;206.285;3.07;3672;DB01050;;CHEMBL521;CACO;CVOLSURF;25;-1;;;;;;;;;;-4.68;;;;;;;;;;;;"Fujikawa M., Ano R., Nakao K., Shimizu R., Akamatsu M., Relationships between structure and high-throughput screening permeability of diverse drugs with artificial membranes: Application to prediction of Caco-2 cell permeability. Bioorg. Med. Chem. 13 (2005) 4721-4732";"Fujikawa M., Ano R., Nakao K., Shimizu R., Akamatsu M., Relationships between structure and high-throughput screening permeability of diverse drugs with artificial membranes: Application to prediction of Caco-2 cell permeability. Bioorg. Med. Chem. 13 (2005) 4721-4732"
"2-(3-benzoylphenyl)propanoic acid";MM00662;CC(C(=O)O)c1cccc(C(=O)c2ccccc2)c1;DKYWVDODHFEZIM-UHFFFAOYSA-N;254.285;3.11;3825;DB01009;;CHEMBL571;CACO;CVOLSURF;25;-1;;;;;;;;;;-5.07;;;;;;;;;;;;"Fujikawa M., Ano R., Nakao K., Shimizu R., Akamatsu M., Relationships between structure and high-throughput screening permeability of diverse drugs with artificial membranes: Application to prediction of Caco-2 cell permeability. Bioorg. Med. Chem. 13 (2005) 4721-4732";"Fujikawa M., Ano R., Nakao K., Shimizu R., Akamatsu M., Relationships between structure and high-throughput screening permeability of diverse drugs with artificial membranes: Application to prediction of Caco-2 cell permeability. Bioorg. Med. Chem. 13 (2005) 4721-4732"
2-hydroxy-5-[1-hydroxy-2-(4-phenylbutan-2-ylamino)ethyl]benzamide;MM00507;CC(CCc1ccccc1)NCC(O)c1ccc(O)c(C(N)=O)c1;SGUAFYQXFOLMHL-UHFFFAOYSA-N;328.412;2.14;3869;DB00598;;CHEMBL429;CACO;CVOLSURF;25;1;;;;;;;;;;-5.31;;;;;;;;;;;;"Fujikawa M., Ano R., Nakao K., Shimizu R., Akamatsu M., Relationships between structure and high-throughput screening permeability of diverse drugs with artificial membranes: Application to prediction of Caco-2 cell permeability. Bioorg. Med. Chem. 13 (2005) 4721-4732";"Fujikawa M., Ano R., Nakao K., Shimizu R., Akamatsu M., Relationships between structure and high-throughput screening permeability of diverse drugs with artificial membranes: Application to prediction of Caco-2 cell permeability. Bioorg. Med. Chem. 13 (2005) 4721-4732"
1-[4-(2-methoxyethyl)phenoxy]-3-(propan-2-ylamino)propan-2-ol;MM00275;COCCc1ccc(OCC(O)CNC(C)C)cc1;IUBSYMUCCVWXPE-UHFFFAOYSA-N;267.369;1.61;4171;DB00264;;CHEMBL13;CACO;CVOLSURF;25;0;;;;;;;;;;-5.44;;;;;;;;;;;;"Fujikawa M., Ano R., Nakao K., Shimizu R., Akamatsu M., Relationships between structure and high-throughput screening permeability of diverse drugs with artificial membranes: Application to prediction of Caco-2 cell permeability. Bioorg. Med. Chem. 13 (2005) 4721-4732";"Fujikawa M., Ano R., Nakao K., Shimizu R., Akamatsu M., Relationships between structure and high-throughput screening permeability of diverse drugs with artificial membranes: Application to prediction of Caco-2 cell permeability. Bioorg. Med. Chem. 13 (2005) 4721-4732"
(2R,3S)-5-[3-(tert-butylamino)-2-hydroxypropoxy]-1,2,3,4-tetrahydronaphthalene-2,3-diol;MM00525;CC(C)(C)NCC(O)COc1cccc2c1CC(O)C(O)C2;VWPOSFSPZNDTMJ-UHFFFAOYSA-N;309.406;0.63;39147;DB01203;;CHEMBL649;CACO;CVOLSURF;25;0;;;;;;;;;;-6.26;;;;;;;;;;;;"Fujikawa M., Ano R., Nakao K., Shimizu R., Akamatsu M., Relationships between structure and high-throughput screening permeability of diverse drugs with artificial membranes: Application to prediction of Caco-2 cell permeability. Bioorg. Med. Chem. 13 (2005) 4721-4732";"Fujikawa M., Ano R., Nakao K., Shimizu R., Akamatsu M., Relationships between structure and high-throughput screening permeability of diverse drugs with artificial membranes: Application to prediction of Caco-2 cell permeability. Bioorg. Med. Chem. 13 (2005) 4721-4732"
1-(1H-indol-4-yloxy)-3-(propan-2-ylamino)propan-2-ol;MM00542;CC(C)NCC(O)COc1cccc2[nH]ccc12;JZQKKSLKJUAGIC-UHFFFAOYSA-N;248.326;1.91;4828;DB00960;;CHEMBL500;CACO;CVOLSURF;25;0;;;;;;;;;;-4.78;;;;;;;;;;;;"Fujikawa M., Ano R., Nakao K., Shimizu R., Akamatsu M., Relationships between structure and high-throughput screening permeability of diverse drugs with artificial membranes: Application to prediction of Caco-2 cell permeability. Bioorg. Med. Chem. 13 (2005) 4721-4732";"Fujikawa M., Ano R., Nakao K., Shimizu R., Akamatsu M., Relationships between structure and high-throughput screening permeability of diverse drugs with artificial membranes: Application to prediction of Caco-2 cell permeability. Bioorg. Med. Chem. 13 (2005) 4721-4732"
1-naphthalen-1-yloxy-3-(propan-2-ylamino)propan-2-ol;MM00085;CC(C)NCC(O)COc1cccc2ccccc12;AQHHHDLHHXJYJD-UHFFFAOYSA-N;259.349;2.58;4946;DB00571;;CHEMBL27;CACO;CVOLSURF;25;0;;;;;;;;;;-4.66;;;;;;;;;;;;"Fujikawa M., Ano R., Nakao K., Shimizu R., Akamatsu M., Relationships between structure and high-throughput screening permeability of diverse drugs with artificial membranes: Application to prediction of Caco-2 cell permeability. Bioorg. Med. Chem. 13 (2005) 4721-4732";"Fujikawa M., Ano R., Nakao K., Shimizu R., Akamatsu M., Relationships between structure and high-throughput screening permeability of diverse drugs with artificial membranes: Application to prediction of Caco-2 cell permeability. Bioorg. Med. Chem. 13 (2005) 4721-4732"
Ranitidine;MM01053;CNC(=C[N+](=O)[O-])NCCSCc1ccc(CN(C)C)o1;VMXUWOKSQNHOCA-UHFFFAOYSA-N;314.404;1.46;5039;DB00863;;CHEMBL1790041;CACO;CVOLSURF;25;1;;;;;;;;;;-6.31;;;;;;;;;;;;"Fujikawa M., Ano R., Nakao K., Shimizu R., Akamatsu M., Relationships between structure and high-throughput screening permeability of diverse drugs with artificial membranes: Application to prediction of Caco-2 cell permeability. Bioorg. Med. Chem. 13 (2005) 4721-4732";"Fujikawa M., Ano R., Nakao K., Shimizu R., Akamatsu M., Relationships between structure and high-throughput screening permeability of diverse drugs with artificial membranes: Application to prediction of Caco-2 cell permeability. Bioorg. Med. Chem. 13 (2005) 4721-4732"
"Salicylic Acid";MM00093;O=C(O)c1ccccc1O;YGSDEFSMJLZEOE-UHFFFAOYSA-N;138.123;1.09;338;DB00936;SAL;CHEMBL424;CACO;CVOLSURF;25;-1;;;;;;;;;;-4.66;;;;;;;;;;;;"Fujikawa M., Ano R., Nakao K., Shimizu R., Akamatsu M., Relationships between structure and high-throughput screening permeability of diverse drugs with artificial membranes: Application to prediction of Caco-2 cell permeability. Bioorg. Med. Chem. 13 (2005) 4721-4732";"Fujikawa M., Ano R., Nakao K., Shimizu R., Akamatsu M., Relationships between structure and high-throughput screening permeability of diverse drugs with artificial membranes: Application to prediction of Caco-2 cell permeability. Bioorg. Med. Chem. 13 (2005) 4721-4732"
Testosterone;MM00423;CC12CCC(=O)C=C1CCC1C2CCC2(C)C(O)CCC12;MUMGGOZAMZWBJJ-UHFFFAOYSA-N;288.431;3.88;6013;DB00624;TES;CHEMBL386630;CACO;CVOLSURF;25;0;;;;;;;;;;-4.6;;;;;;;;;;;;"Fujikawa M., Ano R., Nakao K., Shimizu R., Akamatsu M., Relationships between structure and high-throughput screening permeability of diverse drugs with artificial membranes: Application to prediction of Caco-2 cell permeability. Bioorg. Med. Chem. 13 (2005) 4721-4732";"Fujikawa M., Ano R., Nakao K., Shimizu R., Akamatsu M., Relationships between structure and high-throughput screening permeability of diverse drugs with artificial membranes: Application to prediction of Caco-2 cell permeability. Bioorg. Med. Chem. 13 (2005) 4721-4732"
4-(dimethylamino)-1,5-dimethyl-2-phenylpyrazol-3-one;MM00331;Cc1c(N(C)C)c(=O)n(-c2ccccc2)n1C;RMMXTBMQSGEXHJ-UHFFFAOYSA-N;231.299;1.55;6009;DB01424;;CHEMBL288470;CACO;CVOLSURF;25;0;;;;;;;;;;-4.44;;;;;;;;;;;;"Fujikawa M., Ano R., Nakao K., Shimizu R., Akamatsu M., Relationships between structure and high-throughput screening permeability of diverse drugs with artificial membranes: Application to prediction of Caco-2 cell permeability. Bioorg. Med. Chem. 13 (2005) 4721-4732";"Fujikawa M., Ano R., Nakao K., Shimizu R., Akamatsu M., Relationships between structure and high-throughput screening permeability of diverse drugs with artificial membranes: Application to prediction of Caco-2 cell permeability. Bioorg. Med. Chem. 13 (2005) 4721-4732"
3-(5,6-dihydrobenzo[b][1]benzazepin-11-yl)-N-methylpropan-1-amine;MM00474;CNCCCN1c2ccccc2CCc2ccccc21;HCYAFALTSJYZDH-UHFFFAOYSA-N;266.388;3.53;2995;DB01151;DSM;CHEMBL72;CACO;CVOLSURF;25;1;;;;;;;;;;-4.61;;;;;;;;;;;;"Fujikawa M., Ano R., Nakao K., Shimizu R., Akamatsu M., Relationships between structure and high-throughput screening permeability of diverse drugs with artificial membranes: Application to prediction of Caco-2 cell permeability. Bioorg. Med. Chem. 13 (2005) 4721-4732";"Fujikawa M., Ano R., Nakao K., Shimizu R., Akamatsu M., Relationships between structure and high-throughput screening permeability of diverse drugs with artificial membranes: Application to prediction of Caco-2 cell permeability. Bioorg. Med. Chem. 13 (2005) 4721-4732"
5,5-diphenylimidazolidine-2,4-dione;MM00406;O=C1N=C(O)NC1(c1ccccc1)c1ccccc1;CXOFVDLJLONNDW-UHFFFAOYSA-N;252.273;1.97;1775;DB00252;;CHEMBL16;CACO;CVOLSURF;25;0;;;;;;;;;;-4.57;;;;;;;;;;;;"Fujikawa M., Ano R., Nakao K., Shimizu R., Akamatsu M., Relationships between structure and high-throughput screening permeability of diverse drugs with artificial membranes: Application to prediction of Caco-2 cell permeability. Bioorg. Med. Chem. 13 (2005) 4721-4732";"Fujikawa M., Ano R., Nakao K., Shimizu R., Akamatsu M., Relationships between structure and high-throughput screening permeability of diverse drugs with artificial membranes: Application to prediction of Caco-2 cell permeability. Bioorg. Med. Chem. 13 (2005) 4721-4732"
4-hydroxy-2-methyl-1,1-dioxo-N-pyridin-2-yl-1lambda6,2-benzothiazine-3-carboxamide;MM00682;CN1C(C(=O)Nc2ccccn2)=C(O)c2ccccc2S1(=O)=O;QYSPLQLAKJAUJT-UHFFFAOYSA-N;331.346;1.58;54676228;DB00554;;CHEMBL527;CACO;CVOLSURF;25;-1;;;;;;;;;;-4.45;;;;;;;;;;;;"Fujikawa M., Ano R., Nakao K., Shimizu R., Akamatsu M., Relationships between structure and high-throughput screening permeability of diverse drugs with artificial membranes: Application to prediction of Caco-2 cell permeability. Bioorg. Med. Chem. 13 (2005) 4721-4732";"Fujikawa M., Ano R., Nakao K., Shimizu R., Akamatsu M., Relationships between structure and high-throughput screening permeability of diverse drugs with artificial membranes: Application to prediction of Caco-2 cell permeability. Bioorg. Med. Chem. 13 (2005) 4721-4732"
11-[2-(4-methylpiperazin-1-yl)acetyl]-5H-pyrido[2,3-b][1,4]benzodiazepin-6-one;MM00543;CN1CCN(CC(=O)N2c3ccccc3C(=O)Nc3cccnc32)CC1;RMHMFHUVIITRHF-UHFFFAOYSA-N;351.41;1.56;4848;DB00670;;CHEMBL9967;CACO;CVOLSURF;25;1;;;;;;;;;;-6.36;;;;;;;;;;;;"Fujikawa M., Ano R., Nakao K., Shimizu R., Akamatsu M., Relationships between structure and high-throughput screening permeability of diverse drugs with artificial membranes: Application to prediction of Caco-2 cell permeability. Bioorg. Med. Chem. 13 (2005) 4721-4732";"Fujikawa M., Ano R., Nakao K., Shimizu R., Akamatsu M., Relationships between structure and high-throughput screening permeability of diverse drugs with artificial membranes: Application to prediction of Caco-2 cell permeability. Bioorg. Med. Chem. 13 (2005) 4721-4732"
Acebutalol;MM11344;;;;;;;;;CACO;ECACO;37;1;;;;;;;;;;-5.82;;;;;;;;;;;;"Marino A. M., Yardea M., Patela H., Chong S., Balimane P. V., Validation of the 96 well Caco-2 cell culture model for high throughput permeability assessment of discovery compounds. 2005. Int. J. Pharm. 297, 235-241";"Marino A. M., Yardea M., Patela H., Chong S., Balimane P. V., Validation of the 96 well Caco-2 cell culture model for high throughput permeability assessment of discovery compounds. 2005. Int. J. Pharm. 297, 235-241"
N-(4-hydroxyphenyl)acetamide;MM00322;CC(=O)Nc1ccc(O)cc1;RZVAJINKPMORJF-UHFFFAOYSA-N;151.165;1.35;1983;DB00316;TYL;CHEMBL112;CACO;ECACO;37;0;;;;;;;;;;-4.87;;;;;;;;;;;;"Marino A. M., Yardea M., Patela H., Chong S., Balimane P. V., Validation of the 96 well Caco-2 cell culture model for high throughput permeability assessment of discovery compounds. 2005. Int. J. Pharm. 297, 235-241";"Marino A. M., Yardea M., Patela H., Chong S., Balimane P. V., Validation of the 96 well Caco-2 cell culture model for high throughput permeability assessment of discovery compounds. 2005. Int. J. Pharm. 297, 235-241"
1,5-dimethyl-2-phenylpyrazol-3-one;MM00333;Cc1cc(=O)n(-c2ccccc2)n1C;VEQOALNAAJBPNY-UHFFFAOYSA-N;188.23;1.48;2206;DB01435;;CHEMBL277474;CACO;ECACO;37;0;;;;;;;;;;-4.37;;;;;;;;;;;;"Marino A. M., Yardea M., Patela H., Chong S., Balimane P. V., Validation of the 96 well Caco-2 cell culture model for high throughput permeability assessment of discovery compounds. 2005. Int. J. Pharm. 297, 235-241";"Marino A. M., Yardea M., Patela H., Chong S., Balimane P. V., Validation of the 96 well Caco-2 cell culture model for high throughput permeability assessment of discovery compounds. 2005. Int. J. Pharm. 297, 235-241"
2-[4-[2-hydroxy-3-(propan-2-ylamino)propoxy]phenyl]acetamide;MM00078;CC(C)NC[C@@H](O)COc1ccc(CC(N)=O)cc1;METKIMKYRPQLGS-UHFFFAOYSA-N;266.341;0.45;2249;DB00335;;CHEMBL24;CACO;ECACO;37;1;;;;;;;;;;-5.4;;;;;;;;;;;;"Marino A. M., Yardea M., Patela H., Chong S., Balimane P. V., Validation of the 96 well Caco-2 cell culture model for high throughput permeability assessment of discovery compounds. 2005. Int. J. Pharm. 297, 235-241";"Marino A. M., Yardea M., Patela H., Chong S., Balimane P. V., Validation of the 96 well Caco-2 cell culture model for high throughput permeability assessment of discovery compounds. 2005. Int. J. Pharm. 297, 235-241"
N-(Methylsulfonyl)-D-Phenylalanyl-N-[(1-Carbamimidoylpiperidin-4-Yl)methyl]-L-Prolinamide;MM11345;CS(=O)(=O)NC(Cc1ccccc1)C(=O)N1CCCC1C(=O)NCC1CCN(C(=N)N)CC1;UCVAQBJLJIKTFJ-UHFFFAOYSA-N;478.62;-0.14;9869699;;;;CACO;ECACO;37;;;;;;;;;;;-6.3;;;;;;;;;;;;"Marino A. M., Yardea M., Patela H., Chong S., Balimane P. V., Validation of the 96 well Caco-2 cell culture model for high throughput permeability assessment of discovery compounds. 2005. Int. J. Pharm. 297, 235-241";"Marino A. M., Yardea M., Patela H., Chong S., Balimane P. V., Validation of the 96 well Caco-2 cell culture model for high throughput permeability assessment of discovery compounds. 2005. Int. J. Pharm. 297, 235-241"
Ifetroban;MM11346;CCCCCNC(=O)c1coc(C2C3CCC(O3)C2Cc2ccccc2CCC(=O)O)n1;BBPRUNPUJIUXSE-UHFFFAOYSA-N;440.54;4.12;3037233;;;CHEMBL283100;CACO;ECACO;37;;;;;;;;;;;-4.67;;;;;;;;;;;;"Marino A. M., Yardea M., Patela H., Chong S., Balimane P. V., Validation of the 96 well Caco-2 cell culture model for high throughput permeability assessment of discovery compounds. 2005. Int. J. Pharm. 297, 235-241";"Marino A. M., Yardea M., Patela H., Chong S., Balimane P. V., Validation of the 96 well Caco-2 cell culture model for high throughput permeability assessment of discovery compounds. 2005. Int. J. Pharm. 297, 235-241"
Caffeine;MM00040;Cn1c(=O)c2c(ncn2C)n(C)c1=O;RYYVLZVUVIJVGH-UHFFFAOYSA-N;194.194;-1.03;2519;DB00201;CFF;CHEMBL113;CACO;ECACO;37;0;;;;;;;;;;-4.39;;;;;;;;;;;;"Marino A. M., Yardea M., Patela H., Chong S., Balimane P. V., Validation of the 96 well Caco-2 cell culture model for high throughput permeability assessment of discovery compounds. 2005. Int. J. Pharm. 297, 235-241";"Marino A. M., Yardea M., Patela H., Chong S., Balimane P. V., Validation of the 96 well Caco-2 cell culture model for high throughput permeability assessment of discovery compounds. 2005. Int. J. Pharm. 297, 235-241"
1-cyano-2-methyl-3-[2-[(5-methyl-1H-imidazol-4-yl)methylsulfanyl]ethyl]guanidine;MM00463;CNC(=NCCSCc1nc[nH]c1C)NC#N;AQIXAKUUQRKLND-UHFFFAOYSA-N;252.34;0.6;2756;DB00501;;CHEMBL30;CACO;ECACO;37;1;;;;;;;;;;-5.54;;;;;;;;;;;;"Marino A. M., Yardea M., Patela H., Chong S., Balimane P. V., Validation of the 96 well Caco-2 cell culture model for high throughput permeability assessment of discovery compounds. 2005. Int. J. Pharm. 297, 235-241";"Marino A. M., Yardea M., Patela H., Chong S., Balimane P. V., Validation of the 96 well Caco-2 cell culture model for high throughput permeability assessment of discovery compounds. 2005. Int. J. Pharm. 297, 235-241"
3-(5,6-dihydrobenzo[b][1]benzazepin-11-yl)-N-methylpropan-1-amine;MM00474;CNCCCN1c2ccccc2CCc2ccccc21;HCYAFALTSJYZDH-UHFFFAOYSA-N;266.388;3.53;2995;DB01151;DSM;CHEMBL72;CACO;ECACO;37;1;;;;;;;;;;-4.87;;;;;;;;;;;;"Marino A. M., Yardea M., Patela H., Chong S., Balimane P. V., Validation of the 96 well Caco-2 cell culture model for high throughput permeability assessment of discovery compounds. 2005. Int. J. Pharm. 297, 235-241";"Marino A. M., Yardea M., Patela H., Chong S., Balimane P. V., Validation of the 96 well Caco-2 cell culture model for high throughput permeability assessment of discovery compounds. 2005. Int. J. Pharm. 297, 235-241"
Dexamethasone;MM00355;C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO;UREBDLICKHMUKA-CXSFZGCWSA-N;392.467;1.9;5743;DB01234;DEX;CHEMBL384467;CACO;ECACO;37;0;;;;;;;;;;-4.94;;;;;;;;;;;;"Marino A. M., Yardea M., Patela H., Chong S., Balimane P. V., Validation of the 96 well Caco-2 cell culture model for high throughput permeability assessment of discovery compounds. 2005. Int. J. Pharm. 297, 235-241";"Marino A. M., Yardea M., Patela H., Chong S., Balimane P. V., Validation of the 96 well Caco-2 cell culture model for high throughput permeability assessment of discovery compounds. 2005. Int. J. Pharm. 297, 235-241"
2-[(E)-(2,6-dichlorophenyl)methylideneamino]guanidine;MM00497;N=C(N)NN=Cc1c(Cl)cccc1Cl;WDZVGELJXXEGPV-UHFFFAOYSA-N;231.08;1.81;5702063;DB00629;;CHEMBL420;CACO;ECACO;37;1;;;;;;;;;;-5.21;;;;;;;;;;;;"Marino A. M., Yardea M., Patela H., Chong S., Balimane P. V., Validation of the 96 well Caco-2 cell culture model for high throughput permeability assessment of discovery compounds. 2005. Int. J. Pharm. 297, 235-241";"Marino A. M., Yardea M., Patela H., Chong S., Balimane P. V., Validation of the 96 well Caco-2 cell culture model for high throughput permeability assessment of discovery compounds. 2005. Int. J. Pharm. 297, 235-241"
Phthalazin-1-ylhydrazine;MM00501;NNc1nncc2ccccc12;RPTUSVTUFVMDQK-UHFFFAOYSA-N;160.18;0.92;3637;DB01275;HLZ;CHEMBL276832;CACO;ECACO;37;1;;;;;;;;;;-4.82;;;;;;;;;;;;"Marino A. M., Yardea M., Patela H., Chong S., Balimane P. V., Validation of the 96 well Caco-2 cell culture model for high throughput permeability assessment of discovery compounds. 2005. Int. J. Pharm. 297, 235-241";"Marino A. M., Yardea M., Patela H., Chong S., Balimane P. V., Validation of the 96 well Caco-2 cell culture model for high throughput permeability assessment of discovery compounds. 2005. Int. J. Pharm. 297, 235-241"
Ibuprofen;MM00045;CC(C)Cc1ccc(C(C)C(=O)O)cc1;HEFNNWSXXWATRW-UHFFFAOYSA-N;206.285;3.07;3672;DB01050;;CHEMBL521;CACO;ECACO;37;-1;;;;;;;;;;-4.28;;;;;;;;;;;;"Marino A. M., Yardea M., Patela H., Chong S., Balimane P. V., Validation of the 96 well Caco-2 cell culture model for high throughput permeability assessment of discovery compounds. 2005. Int. J. Pharm. 297, 235-241";"Marino A. M., Yardea M., Patela H., Chong S., Balimane P. V., Validation of the 96 well Caco-2 cell culture model for high throughput permeability assessment of discovery compounds. 2005. Int. J. Pharm. 297, 235-241"
Inulin;MM01493;OCC1OC(OC2(COC3(COC4(COC5(COC6(COC7(COC8(COC9(COC%10(COC%11(COC%12(COC%13(COC%14(COC%15(COC%16(COC%17(COC%18(COC%19(COC%20(COC%21(COC%22(COC%23(COC%24(COC%25(COC%26(COC%27(COC%28(COC%29(COC%30(COC%31(COC%32(COC%33(COC%34(COC%35(COC%36(COC%37(COC%38(CO)OC(CO)C(O)C%38O)OC(CO)C(O)C%37O)OC(CO)C(O)C%36O)OC(CO)C(O)C%35O)OC(CO)C(O)C%34O)OC(CO)C(O)C%33O)OC(CO)C(O)C%32O)OC(CO)C(O)C%31O)OC(CO)C(O)C%30O)OC(CO)C(O)C%29O)OC(CO)C(O)C%28O)OC(CO)C(O)C%27O)OC(CO)C(O)C%26O)OC(CO)C(O)C%25O)OC(CO)C(O)C%24O)OC(CO)C(O)C%23O)OC(CO)C(O)C%22O)OC(CO)C(O)C%21O)OC(CO)C(O)C%20O)OC(CO)C(O)C%19O)OC(CO)C(O)C%18O)OC(CO)C(O)C%17O)OC(CO)C(O)C%16O)OC(CO)C(O)C%15O)OC(CO)C(O)C%14O)OC(CO)C(O)C%13O)OC(CO)C(O)C%12O)OC(CO)C(O)C%11O)OC(CO)C(O)C%10O)OC(CO)C(O)C9O)OC(CO)C(O)C8O)OC(CO)C(O)C7O)OC(CO)C(O)C6O)OC(CO)C(O)C5O)OC(CO)C(O)C4O)OC(CO)C(O)C3O)OC(CO)C(O)C2O)C(O)C(O)C1O;JYJIGFIDKWBXDU-UHFFFAOYSA-N;6179.37;-83.67;24763;DB00638;;;CACO;ECACO;37;;;;;;;;;;;-6;;;;;;;;;;;;"Marino A. M., Yardea M., Patela H., Chong S., Balimane P. V., Validation of the 96 well Caco-2 cell culture model for high throughput permeability assessment of discovery compounds. 2005. Int. J. Pharm. 297, 235-241";"Marino A. M., Yardea M., Patela H., Chong S., Balimane P. V., Validation of the 96 well Caco-2 cell culture model for high throughput permeability assessment of discovery compounds. 2005. Int. J. Pharm. 297, 235-241"
Ketoconazole;MM00506;CC(=O)N1CCN(c2ccc(OCC3COC(Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1;XMAYWYJOQHXEEK-UHFFFAOYSA-N;531.434;4.21;456201;DB01026;KTN;CHEMBL157101;CACO;ECACO;37;1;;;;;;;;;;-4.68;;;;;;;;;;;;"Marino A. M., Yardea M., Patela H., Chong S., Balimane P. V., Validation of the 96 well Caco-2 cell culture model for high throughput permeability assessment of discovery compounds. 2005. Int. J. Pharm. 297, 235-241";"Marino A. M., Yardea M., Patela H., Chong S., Balimane P. V., Validation of the 96 well Caco-2 cell culture model for high throughput permeability assessment of discovery compounds. 2005. Int. J. Pharm. 297, 235-241"
(2R,3R,4R,5R)-hexane-1,2,3,4,5,6-hexol;MM00386;OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO;FBPFZTCFMRRESA-KVTDHHQDSA-N;182.172;-3.59;6251;DB00742;MTL;CHEMBL689;CACO;ECACO;37;0;;;;;;;;;;-5.64;;;;;;;;;;;;"Marino A. M., Yardea M., Patela H., Chong S., Balimane P. V., Validation of the 96 well Caco-2 cell culture model for high throughput permeability assessment of discovery compounds. 2005. Int. J. Pharm. 297, 235-241";"Marino A. M., Yardea M., Patela H., Chong S., Balimane P. V., Validation of the 96 well Caco-2 cell culture model for high throughput permeability assessment of discovery compounds. 2005. Int. J. Pharm. 297, 235-241"
1-[4-(2-methoxyethyl)phenoxy]-3-(propan-2-ylamino)propan-2-ol;MM00275;COCCc1ccc(OCC(O)CNC(C)C)cc1;IUBSYMUCCVWXPE-UHFFFAOYSA-N;267.369;1.61;4171;DB00264;;CHEMBL13;CACO;ECACO;37;1;;;;;;;;;;-4.9;;;;;;;;;;;;"Marino A. M., Yardea M., Patela H., Chong S., Balimane P. V., Validation of the 96 well Caco-2 cell culture model for high throughput permeability assessment of discovery compounds. 2005. Int. J. Pharm. 297, 235-241";"Marino A. M., Yardea M., Patela H., Chong S., Balimane P. V., Validation of the 96 well Caco-2 cell culture model for high throughput permeability assessment of discovery compounds. 2005. Int. J. Pharm. 297, 235-241"
"Naproxen free A";MM11347;;;;;;;;;CACO;ECACO;37;0;;;;;;;;;;-4.34;;;;;;;;;;;;"Marino A. M., Yardea M., Patela H., Chong S., Balimane P. V., Validation of the 96 well Caco-2 cell culture model for high throughput permeability assessment of discovery compounds. 2005. Int. J. Pharm. 297, 235-241";"Marino A. M., Yardea M., Patela H., Chong S., Balimane P. V., Validation of the 96 well Caco-2 cell culture model for high throughput permeability assessment of discovery compounds. 2005. Int. J. Pharm. 297, 235-241"
"Naproxen sodium";MM11348;COc1ccc2cc(C(C)C(=O)[O-])ccc2c1.[Na+];CDBRNDSHEYLDJV-UHFFFAOYSA-M;252.25;-1.29;23681059;;;CHEMBL1903819;CACO;ECACO;37;-1;;;;;;;;;;-4.31;;;;;;;;;;;;"Marino A. M., Yardea M., Patela H., Chong S., Balimane P. V., Validation of the 96 well Caco-2 cell culture model for high throughput permeability assessment of discovery compounds. 2005. Int. J. Pharm. 297, 235-241";"Marino A. M., Yardea M., Patela H., Chong S., Balimane P. V., Validation of the 96 well Caco-2 cell culture model for high throughput permeability assessment of discovery compounds. 2005. Int. J. Pharm. 297, 235-241"
1-naphthalen-1-yloxy-3-(propan-2-ylamino)propan-2-ol;MM00085;CC(C)NCC(O)COc1cccc2ccccc12;AQHHHDLHHXJYJD-UHFFFAOYSA-N;259.349;2.58;4946;DB00571;;CHEMBL27;CACO;ECACO;37;1;;;;;;;;;;-4.56;;;;;;;;;;;;"Marino A. M., Yardea M., Patela H., Chong S., Balimane P. V., Validation of the 96 well Caco-2 cell culture model for high throughput permeability assessment of discovery compounds. 2005. Int. J. Pharm. 297, 235-241";"Marino A. M., Yardea M., Patela H., Chong S., Balimane P. V., Validation of the 96 well Caco-2 cell culture model for high throughput permeability assessment of discovery compounds. 2005. Int. J. Pharm. 297, 235-241"
Ranitidine;MM01053;CNC(=C[N+](=O)[O-])NCCSCc1ccc(CN(C)C)o1;VMXUWOKSQNHOCA-UHFFFAOYSA-N;314.404;1.46;5039;DB00863;;CHEMBL1790041;CACO;ECACO;37;1;;;;;;;;;;-5.24;;;;;;;;;;;;"Marino A. M., Yardea M., Patela H., Chong S., Balimane P. V., Validation of the 96 well Caco-2 cell culture model for high throughput permeability assessment of discovery compounds. 2005. Int. J. Pharm. 297, 235-241";"Marino A. M., Yardea M., Patela H., Chong S., Balimane P. V., Validation of the 96 well Caco-2 cell culture model for high throughput permeability assessment of discovery compounds. 2005. Int. J. Pharm. 297, 235-241"
"Salicylic Acid";MM00093;O=C(O)c1ccccc1O;YGSDEFSMJLZEOE-UHFFFAOYSA-N;138.123;1.09;338;DB00936;SAL;CHEMBL424;CACO;ECACO;37;-1;;;;;;;;;;-4.78;;;;;;;;;;;;"Marino A. M., Yardea M., Patela H., Chong S., Balimane P. V., Validation of the 96 well Caco-2 cell culture model for high throughput permeability assessment of discovery compounds. 2005. Int. J. Pharm. 297, 235-241";"Marino A. M., Yardea M., Patela H., Chong S., Balimane P. V., Validation of the 96 well Caco-2 cell culture model for high throughput permeability assessment of discovery compounds. 2005. Int. J. Pharm. 297, 235-241"
Nadalol;MM11349;;;;;12445656;;;;CACO;ECACO;37;1;;;;;;;;;;-5.77;;;;;;;;;;;;"Marino A. M., Yardea M., Patela H., Chong S., Balimane P. V., Validation of the 96 well Caco-2 cell culture model for high throughput permeability assessment of discovery compounds. 2005. Int. J. Pharm. 297, 235-241";"Marino A. M., Yardea M., Patela H., Chong S., Balimane P. V., Validation of the 96 well Caco-2 cell culture model for high throughput permeability assessment of discovery compounds. 2005. Int. J. Pharm. 297, 235-241"
Pravastatin;MM01522;CCC(C)C(=O)OC1CC(O)C=C2C=CC(C)C(CCC(O)CC(O)CC(=O)O)C21;TUZYXOIXSAXUGO-UHFFFAOYSA-N;424.53;2.44;54687;;;CHEMBL1617336;CACO;ECACO;37;-1;;;;;;;;;;-5.54;;;;;;;;;;;;"Marino A. M., Yardea M., Patela H., Chong S., Balimane P. V., Validation of the 96 well Caco-2 cell culture model for high throughput permeability assessment of discovery compounds. 2005. Int. J. Pharm. 297, 235-241";"Marino A. M., Yardea M., Patela H., Chong S., Balimane P. V., Validation of the 96 well Caco-2 cell culture model for high throughput permeability assessment of discovery compounds. 2005. Int. J. Pharm. 297, 235-241"
Sorivudine;MM11350;;;;;5282192;;;;CACO;ECACO;37;0;;;;;;;;;;-5.17;;;;;;;;;;;;"Marino A. M., Yardea M., Patela H., Chong S., Balimane P. V., Validation of the 96 well Caco-2 cell culture model for high throughput permeability assessment of discovery compounds. 2005. Int. J. Pharm. 297, 235-241";"Marino A. M., Yardea M., Patela H., Chong S., Balimane P. V., Validation of the 96 well Caco-2 cell culture model for high throughput permeability assessment of discovery compounds. 2005. Int. J. Pharm. 297, 235-241"
Sulfamethoxazole;MM11351;Cc1cc(NS(=O)(=O)c2ccc(N)cc2)no1;;;;5329;;;;CACO;ECACO;37;0;;;;;;;;;;-4.42;;;;;;;;;;;;"Marino A. M., Yardea M., Patela H., Chong S., Balimane P. V., Validation of the 96 well Caco-2 cell culture model for high throughput permeability assessment of discovery compounds. 2005. Int. J. Pharm. 297, 235-241";"Marino A. M., Yardea M., Patela H., Chong S., Balimane P. V., Validation of the 96 well Caco-2 cell culture model for high throughput permeability assessment of discovery compounds. 2005. Int. J. Pharm. 297, 235-241"
Sulfasalazine;MM00690;O=C(O)c1cc(N=Nc2ccc(S(=O)(=O)Nc3ccccn3)cc2)ccc1O;NCEXYHBECQHGNR-UHFFFAOYSA-N;398.393;3.7;5359476;DB00795;SAS;CHEMBL421;CACO;ECACO;37;-1;;;;;;;;;;-5.49;;;;;;;;;;;;"Marino A. M., Yardea M., Patela H., Chong S., Balimane P. V., Validation of the 96 well Caco-2 cell culture model for high throughput permeability assessment of discovery compounds. 2005. Int. J. Pharm. 297, 235-241";"Marino A. M., Yardea M., Patela H., Chong S., Balimane P. V., Validation of the 96 well Caco-2 cell culture model for high throughput permeability assessment of discovery compounds. 2005. Int. J. Pharm. 297, 235-241"
Sulfisoxazole;MM11352;Cc1noc(NS(=O)(=O)c2ccc(N)cc2)c1C;;;;5344;;;;CACO;ECACO;37;0;;;;;;;;;;-4.83;;;;;;;;;;;;"Marino A. M., Yardea M., Patela H., Chong S., Balimane P. V., Validation of the 96 well Caco-2 cell culture model for high throughput permeability assessment of discovery compounds. 2005. Int. J. Pharm. 297, 235-241";"Marino A. M., Yardea M., Patela H., Chong S., Balimane P. V., Validation of the 96 well Caco-2 cell culture model for high throughput permeability assessment of discovery compounds. 2005. Int. J. Pharm. 297, 235-241"
5-[2-(tert-butylamino)-1-hydroxyethyl]benzene-1,3-diol;MM00306;CC(C)(C)NCC(O)c1cc(O)cc(O)c1;XWTYSIMOBUGWOL-UHFFFAOYSA-N;225.288;1.52;5403;DB00871;;CHEMBL1760;CACO;ECACO;37;1;;;;;;;;;;-5.55;;;;;;;;;;;;"Marino A. M., Yardea M., Patela H., Chong S., Balimane P. V., Validation of the 96 well Caco-2 cell culture model for high throughput permeability assessment of discovery compounds. 2005. Int. J. Pharm. 297, 235-241";"Marino A. M., Yardea M., Patela H., Chong S., Balimane P. V., Validation of the 96 well Caco-2 cell culture model for high throughput permeability assessment of discovery compounds. 2005. Int. J. Pharm. 297, 235-241"
(2S)-1-(tert-butylamino)-3-[(4-morpholin-4-yl-1,2,5-thiadiazol-3-yl)oxy]propan-2-ol;MM00573;CC(C)(C)NCC(O)COc1nsnc1N1CCOCC1;BLJRIMJGRPQVNF-UHFFFAOYSA-N;316.42;0.5;33624;DB00373;TIM;CHEMBL499;CACO;ECACO;37;1;;;;;;;;;;-5.16;;;;;;;;;;;;"Marino A. M., Yardea M., Patela H., Chong S., Balimane P. V., Validation of the 96 well Caco-2 cell culture model for high throughput permeability assessment of discovery compounds. 2005. Int. J. Pharm. 297, 235-241";"Marino A. M., Yardea M., Patela H., Chong S., Balimane P. V., Validation of the 96 well Caco-2 cell culture model for high throughput permeability assessment of discovery compounds. 2005. Int. J. Pharm. 297, 235-241"
Sulfasalazine;MM00690;O=C(O)c1cc(N=Nc2ccc(S(=O)(=O)Nc3ccccn3)cc2)ccc1O;NCEXYHBECQHGNR-UHFFFAOYSA-N;398.393;3.7;5359476;DB00795;SAS;CHEMBL421;CACO;ECACO;37;-1;;;;;;;;;;-5.8;;;;;;;;;;;;"Balimane P. V., Pace E., Chong S., Zhu M., Jemal M., Van Pelt C. V. A novel high-throughput automated chip-based nanoelectrospray tandem mass spectrometric method for PAMPA sample analysis. (2005), 39, 8-16";"Balimane P. V., Pace E., Chong S., Zhu M., Jemal M., Van Pelt C. V. A novel high-throughput automated chip-based nanoelectrospray tandem mass spectrometric method for PAMPA sample analysis. (2005), 39, 8-16"
"1-ethyl-6-fluoro-4-oxo-7-piperazin-1-ylquinoline-3-carboxylic acid";MM00768;CCn1cc(C(=O)O)c(=O)c2cc(F)c(N3CCNCC3)cc21;OGJPXUAPXNRGGI-UHFFFAOYSA-N;319.336;1.27;4539;DB01059;;CHEMBL9;CACO;ECACO;37;+1-1;;;;;;;;;;-5.35;;;;;;;;;;;;"Balimane P. V., Pace E., Chong S., Zhu M., Jemal M., Van Pelt C. V. A novel high-throughput automated chip-based nanoelectrospray tandem mass spectrometric method for PAMPA sample analysis. (2005), 39, 8-16";"Balimane P. V., Pace E., Chong S., Zhu M., Jemal M., Van Pelt C. V. A novel high-throughput automated chip-based nanoelectrospray tandem mass spectrometric method for PAMPA sample analysis. (2005), 39, 8-16"
Ranitidine;MM01053;CNC(=C[N+](=O)[O-])NCCSCc1ccc(CN(C)C)o1;VMXUWOKSQNHOCA-UHFFFAOYSA-N;314.404;1.46;5039;DB00863;;CHEMBL1790041;CACO;ECACO;37;1;;;;;;;;;;-5.46;;;;;;;;;;;;"Balimane P. V., Pace E., Chong S., Zhu M., Jemal M., Van Pelt C. V. A novel high-throughput automated chip-based nanoelectrospray tandem mass spectrometric method for PAMPA sample analysis. (2005), 39, 8-16";"Balimane P. V., Pace E., Chong S., Zhu M., Jemal M., Van Pelt C. V. A novel high-throughput automated chip-based nanoelectrospray tandem mass spectrometric method for PAMPA sample analysis. (2005), 39, 8-16"
6-chloro-1,1-dioxo-3,4-dihydro-2H-1lambda6,2,4-benzothiadiazine-7-sulfonamide;MM00373;NS(=O)(=O)c1cc2c(cc1Cl)NCNS2(=O)=O;JZUFKLXOESDKRF-UHFFFAOYSA-N;297.728;-0.35;3639;DB00999;HCZ;CHEMBL435;CACO;ECACO;37;0;;;;;;;;;;-5.8;;;;;;;;;;;;"Balimane P. V., Pace E., Chong S., Zhu M., Jemal M., Van Pelt C. V. A novel high-throughput automated chip-based nanoelectrospray tandem mass spectrometric method for PAMPA sample analysis. (2005), 39, 8-16";"Balimane P. V., Pace E., Chong S., Zhu M., Jemal M., Van Pelt C. V. A novel high-throughput automated chip-based nanoelectrospray tandem mass spectrometric method for PAMPA sample analysis. (2005), 39, 8-16"
Benzo[b][1]benzazepine-11-carboxamide;MM00341;NC(=O)N1c2ccccc2C=Cc2ccccc21;FFGPTBGBLSHEPO-UHFFFAOYSA-N;236.274;3.39;2554;DB00564;N6W;CHEMBL108;CACO;ECACO;37;0;;;;;;;;;;-4.89;;;;;;;;;;;;"Balimane P. V., Pace E., Chong S., Zhu M., Jemal M., Van Pelt C. V. A novel high-throughput automated chip-based nanoelectrospray tandem mass spectrometric method for PAMPA sample analysis. (2005), 39, 8-16";"Balimane P. V., Pace E., Chong S., Zhu M., Jemal M., Van Pelt C. V. A novel high-throughput automated chip-based nanoelectrospray tandem mass spectrometric method for PAMPA sample analysis. (2005), 39, 8-16"
1-naphthalen-1-yloxy-3-(propan-2-ylamino)propan-2-ol;MM00085;CC(C)NCC(O)COc1cccc2ccccc12;AQHHHDLHHXJYJD-UHFFFAOYSA-N;259.349;2.58;4946;DB00571;;CHEMBL27;CACO;ECACO;37;1;;;;;;;;;;-4.88;;;;;;;;;;;;"Balimane P. V., Pace E., Chong S., Zhu M., Jemal M., Van Pelt C. V. A novel high-throughput automated chip-based nanoelectrospray tandem mass spectrometric method for PAMPA sample analysis. (2005), 39, 8-16";"Balimane P. V., Pace E., Chong S., Zhu M., Jemal M., Van Pelt C. V. A novel high-throughput automated chip-based nanoelectrospray tandem mass spectrometric method for PAMPA sample analysis. (2005), 39, 8-16"
1-[4-(2-methoxyethyl)phenoxy]-3-(propan-2-ylamino)propan-2-ol;MM00275;COCCc1ccc(OCC(O)CNC(C)C)cc1;IUBSYMUCCVWXPE-UHFFFAOYSA-N;267.369;1.61;4171;DB00264;;CHEMBL13;CACO;ECACO;37;1;;;;;;;;;;-4.92;;;;;;;;;;;;"Balimane P. V., Pace E., Chong S., Zhu M., Jemal M., Van Pelt C. V. A novel high-throughput automated chip-based nanoelectrospray tandem mass spectrometric method for PAMPA sample analysis. (2005), 39, 8-16";"Balimane P. V., Pace E., Chong S., Zhu M., Jemal M., Van Pelt C. V. A novel high-throughput automated chip-based nanoelectrospray tandem mass spectrometric method for PAMPA sample analysis. (2005), 39, 8-16"
Verapamil;MM00585;COc1ccc(CCN(C)CCCC(C#N)(c2ccc(OC)c(OC)c2)C(C)C)cc1OC;SGTNSNPWRIOYBX-UHFFFAOYSA-N;454.611;5.09;2520;DB00661;;CHEMBL6966;CACO;ECACO;37;1;;;;;;;;;;-4.83;;;;;;;;;;;;"Balimane P. V., Pace E., Chong S., Zhu M., Jemal M., Van Pelt C. V. A novel high-throughput automated chip-based nanoelectrospray tandem mass spectrometric method for PAMPA sample analysis. (2005), 39, 8-16";"Balimane P. V., Pace E., Chong S., Zhu M., Jemal M., Van Pelt C. V. A novel high-throughput automated chip-based nanoelectrospray tandem mass spectrometric method for PAMPA sample analysis. (2005), 39, 8-16"
1,5-dimethyl-2-phenylpyrazol-3-one;MM00333;Cc1cc(=O)n(-c2ccccc2)n1C;VEQOALNAAJBPNY-UHFFFAOYSA-N;188.23;1.48;2206;DB01435;;CHEMBL277474;CACO;ECACO;25;0;;;;;;;;;;-4.48;;;;;;;;;;;;;"Yamashita, S., Furubayashi, T., Kataoka, M., Sakane, T., Sezaki, H., Tokuda, H. Optimized conditions for prediction of intestinal drug permeability using Caco-2 cells. Europ. J. Pharm. Sci. 2000, 10(3) 195-204"
1,3-dimethyl-7H-purine-2,6-dione;MM00048;Cn1c(=O)c2nc[nH]c2n(C)c1=O;ZFXYFBGIUFBOJW-UHFFFAOYSA-N;180.167;-1.04;2153;DB00277;TEP;CHEMBL190;CACO;ECACO;25;0;;;;;;;;;;-4.6;;;;;;;;;;;;;"Yamashita, S., Furubayashi, T., Kataoka, M., Sakane, T., Sezaki, H., Tokuda, H. Optimized conditions for prediction of intestinal drug permeability using Caco-2 cells. Europ. J. Pharm. Sci. 2000, 10(3) 195-204"
Dexamethasone;MM00355;C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO;UREBDLICKHMUKA-CXSFZGCWSA-N;392.467;1.9;5743;DB01234;DEX;CHEMBL384467;CACO;ECACO;25;0;;;;;;;;;;-4.92;;;;;;;;;;;;;"Yamashita, S., Furubayashi, T., Kataoka, M., Sakane, T., Sezaki, H., Tokuda, H. Optimized conditions for prediction of intestinal drug permeability using Caco-2 cells. Europ. J. Pharm. Sci. 2000, 10(3) 195-204"
N-(4-hydroxyphenyl)acetamide;MM00322;CC(=O)Nc1ccc(O)cc1;RZVAJINKPMORJF-UHFFFAOYSA-N;151.165;1.35;1983;DB00316;TYL;CHEMBL112;CACO;ECACO;25;0;;;;;;;;;;-4.63;;;;;;;;;;;;;"Yamashita, S., Furubayashi, T., Kataoka, M., Sakane, T., Sezaki, H., Tokuda, H. Optimized conditions for prediction of intestinal drug permeability using Caco-2 cells. Europ. J. Pharm. Sci. 2000, 10(3) 195-204"
6-chloro-1,1-dioxo-3,4-dihydro-2H-1lambda6,2,4-benzothiadiazine-7-sulfonamide;MM00373;NS(=O)(=O)c1cc2c(cc1Cl)NCNS2(=O)=O;JZUFKLXOESDKRF-UHFFFAOYSA-N;297.728;-0.35;3639;DB00999;HCZ;CHEMBL435;CACO;ECACO;25;0;;;;;;;;;;-6.4;;;;;;;;;;;;;"Yamashita, S., Furubayashi, T., Kataoka, M., Sakane, T., Sezaki, H., Tokuda, H. Optimized conditions for prediction of intestinal drug permeability using Caco-2 cells. Europ. J. Pharm. Sci. 2000, 10(3) 195-204"
FITC–dextrane;MM15090;;;;;;;;;CACO;ECACO;25;0;;;;;;;;;;-8.52;;;;;;;;;;;;;"Yamashita, S., Furubayashi, T., Kataoka, M., Sakane, T., Sezaki, H., Tokuda, H. Optimized conditions for prediction of intestinal drug permeability using Caco-2 cells. Europ. J. Pharm. Sci. 2000, 10(3) 195-204"
1-(propan-2-ylamino)-3-(2-prop-2-enylphenoxy)propan-2-ol;MM00440;C=CCc1ccccc1OC[C@H](O)CNC(C)C;PAZJSJFMUHDSTF-UHFFFAOYSA-N;249.354;2.15;2119;DB00866;;CHEMBL266195;CACO;ECACO;25;1;;;;;;;;;;-4.52;;;;;;;;;;;;;"Yamashita, S., Furubayashi, T., Kataoka, M., Sakane, T., Sezaki, H., Tokuda, H. Optimized conditions for prediction of intestinal drug permeability using Caco-2 cells. Europ. J. Pharm. Sci. 2000, 10(3) 195-204"
5-[2-(tert-butylamino)-1-hydroxyethyl]benzene-1,3-diol;MM00306;CC(C)(C)NCC(O)c1cc(O)cc(O)c1;XWTYSIMOBUGWOL-UHFFFAOYSA-N;225.288;1.52;5403;DB00871;;CHEMBL1760;CACO;ECACO;25;1;;;;;;;;;;-6.92;;;;;;;;;;;;;"Yamashita, S., Furubayashi, T., Kataoka, M., Sakane, T., Sezaki, H., Tokuda, H. Optimized conditions for prediction of intestinal drug permeability using Caco-2 cells. Europ. J. Pharm. Sci. 2000, 10(3) 195-204"
2-[4-[2-hydroxy-3-(propan-2-ylamino)propoxy]phenyl]acetamide;MM00078;CC(C)NC[C@@H](O)COc1ccc(CC(N)=O)cc1;METKIMKYRPQLGS-UHFFFAOYSA-N;266.341;0.45;2249;DB00335;;CHEMBL24;CACO;ECACO;25;1;;;;;;;;;;-6.4;;;;;;;;;;;;;"Yamashita, S., Furubayashi, T., Kataoka, M., Sakane, T., Sezaki, H., Tokuda, H. Optimized conditions for prediction of intestinal drug permeability using Caco-2 cells. Europ. J. Pharm. Sci. 2000, 10(3) 195-204"
(2R,3S)-5-[3-(tert-butylamino)-2-hydroxypropoxy]-1,2,3,4-tetrahydronaphthalene-2,3-diol;MM00525;CC(C)(C)NCC(O)COc1cccc2c1CC(O)C(O)C2;VWPOSFSPZNDTMJ-UHFFFAOYSA-N;309.406;0.63;39147;DB01203;;CHEMBL649;CACO;ECACO;25;1;;;;;;;;;;-6.48;;;;;;;;;;;;;"Yamashita, S., Furubayashi, T., Kataoka, M., Sakane, T., Sezaki, H., Tokuda, H. Optimized conditions for prediction of intestinal drug permeability using Caco-2 cells. Europ. J. Pharm. Sci. 2000, 10(3) 195-204"
"Salicylic Acid";MM00093;O=C(O)c1ccccc1O;YGSDEFSMJLZEOE-UHFFFAOYSA-N;138.123;1.09;338;DB00936;SAL;CHEMBL424;CACO;ECACO;25;-1;;;;;;;;;;-5.47;;;;;;;;;;;;;"Yamashita, S., Furubayashi, T., Kataoka, M., Sakane, T., Sezaki, H., Tokuda, H. Optimized conditions for prediction of intestinal drug permeability using Caco-2 cells. Europ. J. Pharm. Sci. 2000, 10(3) 195-204"
4-hydroxy-3-(3-oxo-1-phenylbutyl)chromen-2-one;MM00095;CC(=O)CC(c1ccccc1)c1c(O)c2ccccc2oc1=O;PJVWKTKQMONHTI-UHFFFAOYSA-N;308.333;3.61;54678486;DB00682;;CHEMBL1464;CACO;ECACO;25;-1;;;;;;;;;;-4.81;;;;;;;;;;;;;"Yamashita, S., Furubayashi, T., Kataoka, M., Sakane, T., Sezaki, H., Tokuda, H. Optimized conditions for prediction of intestinal drug permeability using Caco-2 cells. Europ. J. Pharm. Sci. 2000, 10(3) 195-204"
"4-chloro-2-(furan-2-ylmethylamino)-5-sulfamoylbenzoic acid";MM00083;NS(=O)(=O)c1cc(C(=O)O)c(NCc2ccco2)cc1Cl;ZZUFCTLCJUWOSV-UHFFFAOYSA-N;330.739;1.89;3440;DB00695;FUN;CHEMBL35;CACO;ECACO;25;-1;;;;;;;;;;-7.35;;;;;;;;;;;;;"Yamashita, S., Furubayashi, T., Kataoka, M., Sakane, T., Sezaki, H., Tokuda, H. Optimized conditions for prediction of intestinal drug permeability using Caco-2 cells. Europ. J. Pharm. Sci. 2000, 10(3) 195-204"
Ampicillin;MM00627;CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccccc3)C(=O)N2[C@H]1C(=O)O;AVKUERGKIZMTKX-UHFFFAOYSA-N;403.45;0.32;6249;DB00415;AIC;CHEMBL174;CACO;ECACO;25;-1;;;;;;;;;;-7.09;;;;;;;;;;;;;"Yamashita, S., Furubayashi, T., Kataoka, M., Sakane, T., Sezaki, H., Tokuda, H. Optimized conditions for prediction of intestinal drug permeability using Caco-2 cells. Europ. J. Pharm. Sci. 2000, 10(3) 195-204"
Cephalexin;MM00721;CC1=C(C(=O)O)N2C(=O)C(NC(=O)C(N)c3ccccc3)C2SC1;ZAIPMKNFIOOWCQ-UHFFFAOYSA-N;347.389;0.44;27447;DB00567;;CHEMBL1727;CACO;ECACO;25;-1;;;;;;;;;;-6.82;;;;;;;;;;;;;"Yamashita, S., Furubayashi, T., Kataoka, M., Sakane, T., Sezaki, H., Tokuda, H. Optimized conditions for prediction of intestinal drug permeability using Caco-2 cells. Europ. J. Pharm. Sci. 2000, 10(3) 195-204"
Cefutibuten;MM15091;;;;;;;;;CACO;ECACO;25;-1;;;;;;;;;;-7.26;;;;;;;;;;;;;"Yamashita, S., Furubayashi, T., Kataoka, M., Sakane, T., Sezaki, H., Tokuda, H. Optimized conditions for prediction of intestinal drug permeability using Caco-2 cells. Europ. J. Pharm. Sci. 2000, 10(3) 195-204"
0311C90;MM15093;;;;;;;;;CACO;ECACO;25;;;;;;;;;;;-5.54;;;;;;;;;;;;;"Irvine JD, Takahashi L, Lockhart K, Cheong J, Tolan JW, Selick HE, Grove JR.: MDCK (Madin-Darby canine kidney) cells: A tool for membrane permeability screening. J Pharm Sci, Volume 88 (1), 28-33, 1999"
N-[3-acetyl-4-[2-hydroxy-3-(propan-2-ylamino)propoxy]phenyl]butanamide;MM00437;CCCC(=O)Nc1ccc(OC[C@H](O)CNC(C)C)c(C(C)=O)c1;GOEMGAFJFRBGGG-UHFFFAOYSA-N;336.432;2.37;1978;DB01193;;CHEMBL642;CACO;ECACO;25;;;;;;;;;;;-5.42;;;;;;;;;;;;;"Irvine JD, Takahashi L, Lockhart K, Cheong J, Tolan JW, Selick HE, Grove JR.: MDCK (Madin-Darby canine kidney) cells: A tool for membrane permeability screening. J Pharm Sci, Volume 88 (1), 28-33, 1999"
N-(4-hydroxyphenyl)acetamide;MM00322;CC(=O)Nc1ccc(O)cc1;RZVAJINKPMORJF-UHFFFAOYSA-N;151.165;1.35;1983;DB00316;TYL;CHEMBL112;CACO;ECACO;25;;;;;;;;;;;-4;;;;;;;;;;;;;"Irvine JD, Takahashi L, Lockhart K, Cheong J, Tolan JW, Selick HE, Grove JR.: MDCK (Madin-Darby canine kidney) cells: A tool for membrane permeability screening. J Pharm Sci, Volume 88 (1), 28-33, 1999"
"Acetylsalicylic acid";MM00080;CC(=O)Oc1ccccc1C(=O)O;BSYNRYMUTXBXSQ-UHFFFAOYSA-N;180.159;1.31;2244;DB00945;AIN;CHEMBL25;CACO;ECACO;25;;;;;;;;;;;-5.66;;;;;;;;;;;;;"Irvine JD, Takahashi L, Lockhart K, Cheong J, Tolan JW, Selick HE, Grove JR.: MDCK (Madin-Darby canine kidney) cells: A tool for membrane permeability screening. J Pharm Sci, Volume 88 (1), 28-33, 1999"
Acrivastine;MM00715;"Cc1ccc(/C(=C\CN2CCCC2)c2cccc(/C=C/C(=O)O)n2)cc1";PWACSDKDOHSSQD-IUTFFREVSA-N;348.446;4.02;5284514;DB09488;;CHEMBL1224;CACO;ECACO;25;;;;;;;;;;;-5.72;;;;;;;;;;;;;"Irvine JD, Takahashi L, Lockhart K, Cheong J, Tolan JW, Selick HE, Grove JR.: MDCK (Madin-Darby canine kidney) cells: A tool for membrane permeability screening. J Pharm Sci, Volume 88 (1), 28-33, 1999"
1-(propan-2-ylamino)-3-(2-prop-2-enylphenoxy)propan-2-ol;MM00440;C=CCc1ccccc1OC[C@H](O)CNC(C)C;PAZJSJFMUHDSTF-UHFFFAOYSA-N;249.354;2.15;2119;DB00866;;CHEMBL266195;CACO;ECACO;25;;;;;;;;;;;-3.77;;;;;;;;;;;;;"Irvine JD, Takahashi L, Lockhart K, Cheong J, Tolan JW, Selick HE, Grove JR.: MDCK (Madin-Darby canine kidney) cells: A tool for membrane permeability screening. J Pharm Sci, Volume 88 (1), 28-33, 1999"
Amoxicillin;MM00716;CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccc(O)cc3)C(=O)N2[C@H]1C(=O)O;LSQZJLSUYDQPKJ-UHFFFAOYSA-N;365.404;0.02;33613;DB01060;;CHEMBL1082;CACO;ECACO;25;;;;;;;;;;;-7.68;;;;;;;;;;;;;"Irvine JD, Takahashi L, Lockhart K, Cheong J, Tolan JW, Selick HE, Grove JR.: MDCK (Madin-Darby canine kidney) cells: A tool for membrane permeability screening. J Pharm Sci, Volume 88 (1), 28-33, 1999"
1,5-dimethyl-2-phenylpyrazol-3-one;MM00333;Cc1cc(=O)n(-c2ccccc2)n1C;VEQOALNAAJBPNY-UHFFFAOYSA-N;188.23;1.48;2206;DB01435;;CHEMBL277474;CACO;ECACO;25;;;;;;;;;;;-3.82;;;;;;;;;;;;;"Irvine JD, Takahashi L, Lockhart K, Cheong J, Tolan JW, Selick HE, Grove JR.: MDCK (Madin-Darby canine kidney) cells: A tool for membrane permeability screening. J Pharm Sci, Volume 88 (1), 28-33, 1999"
2-[4-[2-hydroxy-3-(propan-2-ylamino)propoxy]phenyl]acetamide;MM00078;CC(C)NC[C@@H](O)COc1ccc(CC(N)=O)cc1;METKIMKYRPQLGS-UHFFFAOYSA-N;266.341;0.45;2249;DB00335;;CHEMBL24;CACO;ECACO;25;;;;;;;;;;;-5.48;;;;;;;;;;;;;"Irvine JD, Takahashi L, Lockhart K, Cheong J, Tolan JW, Selick HE, Grove JR.: MDCK (Madin-Darby canine kidney) cells: A tool for membrane permeability screening. J Pharm Sci, Volume 88 (1), 28-33, 1999"
1-[(2R,4S,5S)-4-azido-5-(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione;MM00077;Cc1cn(C2CC(N=[N+]=[N-])C(CO)O2)c(=O)[nH]c1=O;HBOMLICNUCNMMY-UHFFFAOYSA-N;267.245;-0.2;35370;DB00495;AZZ;CHEMBL129;CACO;ECACO;25;;;;;;;;;;;-4.55;;;;;;;;;;;;;"Irvine JD, Takahashi L, Lockhart K, Cheong J, Tolan JW, Selick HE, Grove JR.: MDCK (Madin-Darby canine kidney) cells: A tool for membrane permeability screening. J Pharm Sci, Volume 88 (1), 28-33, 1999"
Bretylium;MM01548;;;;;2431;;;;CACO;ECACO;25;;;;;;;;;;;-5.96;;;;;;;;;;;;;"Irvine JD, Takahashi L, Lockhart K, Cheong J, Tolan JW, Selick HE, Grove JR.: MDCK (Madin-Darby canine kidney) cells: A tool for membrane permeability screening. J Pharm Sci, Volume 88 (1), 28-33, 1999"
2-(tert-butylamino)-1-(3-chlorophenyl)propan-1-one;MM00455;C[C@H](NC(C)(C)C)C(=O)c1cccc(Cl)c1;SNPPWIUOZRMYNY-UHFFFAOYSA-N;239.743;3.3;444;DB01156;;CHEMBL894;CACO;ECACO;25;;;;;;;;;;;-3.82;;;;;;;;;;;;;"Irvine JD, Takahashi L, Lockhart K, Cheong J, Tolan JW, Selick HE, Grove JR.: MDCK (Madin-Darby canine kidney) cells: A tool for membrane permeability screening. J Pharm Sci, Volume 88 (1), 28-33, 1999"
"Cefatrizine propylene glycol";MM15094;;;;;;;;;CACO;ECACO;25;;;;;;;;;;;-6.12;;;;;;;;;;;;;"Irvine JD, Takahashi L, Lockhart K, Cheong J, Tolan JW, Selick HE, Grove JR.: MDCK (Madin-Darby canine kidney) cells: A tool for membrane permeability screening. J Pharm Sci, Volume 88 (1), 28-33, 1999"
Cefuroxime;MM01507;CON=C(C(=O)NC1C(=O)N2C(C(=O)O)=C(COC(N)=O)CSC12)c1ccco1;JFPVXVDWJQMJEE-IZRZKJBUSA-N;424.39;-0.54;5479529;;;;CACO;ECACO;25;;;;;;;;;;;-6.42;;;;;;;;;;;;;"Irvine JD, Takahashi L, Lockhart K, Cheong J, Tolan JW, Selick HE, Grove JR.: MDCK (Madin-Darby canine kidney) cells: A tool for membrane permeability screening. J Pharm Sci, Volume 88 (1), 28-33, 1999"
Cephalexin;MM00721;CC1=C(C(=O)O)N2C(=O)C(NC(=O)C(N)c3ccccc3)C2SC1;ZAIPMKNFIOOWCQ-UHFFFAOYSA-N;347.389;0.44;27447;DB00567;;CHEMBL1727;CACO;ECACO;25;;;;;;;;;;;-6.57;;;;;;;;;;;;;"Irvine JD, Takahashi L, Lockhart K, Cheong J, Tolan JW, Selick HE, Grove JR.: MDCK (Madin-Darby canine kidney) cells: A tool for membrane permeability screening. J Pharm Sci, Volume 88 (1), 28-33, 1999"
6-chloro-1,1-dioxo-4H-1lambda6,2,4-benzothiadiazine-7-sulfonamide;MM00641;NS(=O)(=O)c1cc2c(cc1Cl)NC=NS2(=O)=O;JBMKAUGHUNFTOL-UHFFFAOYSA-N;295.712;0.13;2720;DB00880;;CHEMBL842;CACO;ECACO;25;;;;;;;;;;;-6.49;;;;;;;;;;;;;"Irvine JD, Takahashi L, Lockhart K, Cheong J, Tolan JW, Selick HE, Grove JR.: MDCK (Madin-Darby canine kidney) cells: A tool for membrane permeability screening. J Pharm Sci, Volume 88 (1), 28-33, 1999"
Corticosterone;MM00346;CC12CCC(=O)C=C1CCC1C2C(O)CC2(C)C(C(=O)CO)CCC12;OMFXVFTZEKFJBZ-UHFFFAOYSA-N;346.467;2.67;5753;DB04652;C0R;CHEMBL110739;CACO;ECACO;25;;;;;;;;;;;-3.92;;;;;;;;;;;;;"Irvine JD, Takahashi L, Lockhart K, Cheong J, Tolan JW, Selick HE, Grove JR.: MDCK (Madin-Darby canine kidney) cells: A tool for membrane permeability screening. J Pharm Sci, Volume 88 (1), 28-33, 1999"
Dexamethasone;MM00355;C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO;UREBDLICKHMUKA-CXSFZGCWSA-N;392.467;1.9;5743;DB01234;DEX;CHEMBL384467;CACO;ECACO;25;;;;;;;;;;;-4.4;;;;;;;;;;;;;"Irvine JD, Takahashi L, Lockhart K, Cheong J, Tolan JW, Selick HE, Grove JR.: MDCK (Madin-Darby canine kidney) cells: A tool for membrane permeability screening. J Pharm Sci, Volume 88 (1), 28-33, 1999"
Fluparoxan;MM01538;;;;;72036;;;;CACO;ECACO;25;;;;;;;;;;;-3.7;;;;;;;;;;;;;"Irvine JD, Takahashi L, Lockhart K, Cheong J, Tolan JW, Selick HE, Grove JR.: MDCK (Madin-Darby canine kidney) cells: A tool for membrane permeability screening. J Pharm Sci, Volume 88 (1), 28-33, 1999"
"4-chloro-2-(furan-2-ylmethylamino)-5-sulfamoylbenzoic acid";MM00083;NS(=O)(=O)c1cc(C(=O)O)c(NCc2ccco2)cc1Cl;ZZUFCTLCJUWOSV-UHFFFAOYSA-N;330.739;1.89;3440;DB00695;FUN;CHEMBL35;CACO;ECACO;25;;;;;;;;;;;-6.85;;;;;;;;;;;;;"Irvine JD, Takahashi L, Lockhart K, Cheong J, Tolan JW, Selick HE, Grove JR.: MDCK (Madin-Darby canine kidney) cells: A tool for membrane permeability screening. J Pharm Sci, Volume 88 (1), 28-33, 1999"
"2-[1-(aminomethyl)cyclohexyl]acetic acid";MM00737;NCC1(CC(=O)O)CCCCC1;UGJMXCAKCUNAIE-UHFFFAOYSA-N;171.24;1.37;3446;DB00996;GBN;CHEMBL940;CACO;ECACO;25;;;;;;;;;;;-8;;;;;;;;;;;;;"Irvine JD, Takahashi L, Lockhart K, Cheong J, Tolan JW, Selick HE, Grove JR.: MDCK (Madin-Darby canine kidney) cells: A tool for membrane permeability screening. J Pharm Sci, Volume 88 (1), 28-33, 1999"
2-[(E)-(2,6-dichlorophenyl)methylideneamino]guanidine;MM00497;N=C(N)NN=Cc1c(Cl)cccc1Cl;WDZVGELJXXEGPV-UHFFFAOYSA-N;231.08;1.81;5702063;DB00629;;CHEMBL420;CACO;ECACO;25;;;;;;;;;;;-4;;;;;;;;;;;;;"Irvine JD, Takahashi L, Lockhart K, Cheong J, Tolan JW, Selick HE, Grove JR.: MDCK (Madin-Darby canine kidney) cells: A tool for membrane permeability screening. J Pharm Sci, Volume 88 (1), 28-33, 1999"
6-chloro-1,1-dioxo-3,4-dihydro-2H-1lambda6,2,4-benzothiadiazine-7-sulfonamide;MM00373;NS(=O)(=O)c1cc2c(cc1Cl)NCNS2(=O)=O;JZUFKLXOESDKRF-UHFFFAOYSA-N;297.728;-0.35;3639;DB00999;HCZ;CHEMBL435;CACO;ECACO;25;;;;;;;;;;;-6.04;;;;;;;;;;;;;"Irvine JD, Takahashi L, Lockhart K, Cheong J, Tolan JW, Selick HE, Grove JR.: MDCK (Madin-Darby canine kidney) cells: A tool for membrane permeability screening. J Pharm Sci, Volume 88 (1), 28-33, 1999"
Hydrocortisone;MM00044;CC12CCC(=O)C=C1CCC1C2C(O)CC2(C)C1CCC2(O)C(=O)CO;JYGXADMDTFJGBT-UHFFFAOYSA-N;362.466;1.78;5754;DB00741;HCY;CHEMBL389621;CACO;ECACO;25;;;;;;;;;;;-4.25;;;;;;;;;;;;;"Irvine JD, Takahashi L, Lockhart K, Cheong J, Tolan JW, Selick HE, Grove JR.: MDCK (Madin-Darby canine kidney) cells: A tool for membrane permeability screening. J Pharm Sci, Volume 88 (1), 28-33, 1999"
"2-(3-benzoylphenyl)propanoic acid";MM00662;CC(C(=O)O)c1cccc(C(=O)c2ccccc2)c1;DKYWVDODHFEZIM-UHFFFAOYSA-N;254.285;3.11;3825;DB01009;;CHEMBL571;CACO;ECACO;25;;;;;;;;;;;-4.03;;;;;;;;;;;;;"Irvine JD, Takahashi L, Lockhart K, Cheong J, Tolan JW, Selick HE, Grove JR.: MDCK (Madin-Darby canine kidney) cells: A tool for membrane permeability screening. J Pharm Sci, Volume 88 (1), 28-33, 1999"
2-hydroxy-5-[1-hydroxy-2-(4-phenylbutan-2-ylamino)ethyl]benzamide;MM00507;CC(CCc1ccccc1)NCC(O)c1ccc(O)c(C(N)=O)c1;SGUAFYQXFOLMHL-UHFFFAOYSA-N;328.412;2.14;3869;DB00598;;CHEMBL429;CACO;ECACO;25;;;;;;;;;;;-4.11;;;;;;;;;;;;;"Irvine JD, Takahashi L, Lockhart K, Cheong J, Tolan JW, Selick HE, Grove JR.: MDCK (Madin-Darby canine kidney) cells: A tool for membrane permeability screening. J Pharm Sci, Volume 88 (1), 28-33, 1999"
6-(2,3-dichlorophenyl)-1,2,4-triazine-3,5-diamine;MM00383;Nc1nnc(-c2cccc(Cl)c2Cl)c(N)n1;PYZRQGJRPPTADH-UHFFFAOYSA-N;256.089;2.01;3878;DB00555;;CHEMBL741;CACO;ECACO;25;;;;;;;;;;;-3.96;;;;;;;;;;;;;"Irvine JD, Takahashi L, Lockhart K, Cheong J, Tolan JW, Selick HE, Grove JR.: MDCK (Madin-Darby canine kidney) cells: A tool for membrane permeability screening. J Pharm Sci, Volume 88 (1), 28-33, 1999"
Lisinopril;MM00763;NCCCCC(NC(CCc1ccccc1)C(=O)O)C(=O)N1CCCC1C(=O)O;RLAWWYSOJDYHDC-UHFFFAOYSA-N;405.495;1.24;5362119;DB00722;LPR;CHEMBL1237;CACO;ECACO;25;;;;;;;;;;;-6.66;;;;;;;;;;;;;"Irvine JD, Takahashi L, Lockhart K, Cheong J, Tolan JW, Selick HE, Grove JR.: MDCK (Madin-Darby canine kidney) cells: A tool for membrane permeability screening. J Pharm Sci, Volume 88 (1), 28-33, 1999"
Loracarbef;MM01552;NC(C(=O)NC1C(=O)N2C(C(=O)O)=C(Cl)CCC12)c1ccccc1;JAPHQRWPEGVNBT-UHFFFAOYSA-N;349.77;0.71;5284585;;;;CACO;ECACO;25;;;;;;;;;;;-6.62;;;;;;;;;;;;;"Irvine JD, Takahashi L, Lockhart K, Cheong J, Tolan JW, Selick HE, Grove JR.: MDCK (Madin-Darby canine kidney) cells: A tool for membrane permeability screening. J Pharm Sci, Volume 88 (1), 28-33, 1999"
(2R,3R,4R,5R)-hexane-1,2,3,4,5,6-hexol;MM00386;OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO;FBPFZTCFMRRESA-KVTDHHQDSA-N;182.172;-3.59;6251;DB00742;MTL;CHEMBL689;CACO;ECACO;25;;;;;;;;;;;-6.24;;;;;;;;;;;;;"Irvine JD, Takahashi L, Lockhart K, Cheong J, Tolan JW, Selick HE, Grove JR.: MDCK (Madin-Darby canine kidney) cells: A tool for membrane permeability screening. J Pharm Sci, Volume 88 (1), 28-33, 1999"
Methylprednisolone;MM00388;CC1CC2C(C(O)CC3(C)C2CCC3(O)C(=O)CO)C2(C)C=CC(=O)C=C12;VHRSUDSXCMQTMA-UHFFFAOYSA-N;374.477;1.8;6741;DB00959;;CHEMBL650;CACO;ECACO;25;;;;;;;;;;;-4.6;;;;;;;;;;;;;"Irvine JD, Takahashi L, Lockhart K, Cheong J, Tolan JW, Selick HE, Grove JR.: MDCK (Madin-Darby canine kidney) cells: A tool for membrane permeability screening. J Pharm Sci, Volume 88 (1), 28-33, 1999"
1-[4-(2-methoxyethyl)phenoxy]-3-(propan-2-ylamino)propan-2-ol;MM00275;COCCc1ccc(OCC(O)CNC(C)C)cc1;IUBSYMUCCVWXPE-UHFFFAOYSA-N;267.369;1.61;4171;DB00264;;CHEMBL13;CACO;ECACO;25;;;;;;;;;;;-3.85;;;;;;;;;;;;;"Irvine JD, Takahashi L, Lockhart K, Cheong J, Tolan JW, Selick HE, Grove JR.: MDCK (Madin-Darby canine kidney) cells: A tool for membrane permeability screening. J Pharm Sci, Volume 88 (1), 28-33, 1999"
(2R,3S)-5-[3-(tert-butylamino)-2-hydroxypropoxy]-1,2,3,4-tetrahydronaphthalene-2,3-diol;MM00525;CC(C)(C)NCC(O)COc1cccc2c1CC(O)C(O)C2;VWPOSFSPZNDTMJ-UHFFFAOYSA-N;309.406;0.63;39147;DB01203;;CHEMBL649;CACO;ECACO;25;;;;;;;;;;;-6.41;;;;;;;;;;;;;"Irvine JD, Takahashi L, Lockhart K, Cheong J, Tolan JW, Selick HE, Grove JR.: MDCK (Madin-Darby canine kidney) cells: A tool for membrane permeability screening. J Pharm Sci, Volume 88 (1), 28-33, 1999"
Netivudine;MM00395;CC#Cc1cn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)[nH]c1=O;QLOCVMVCRJOTTM-SDNRWEOFSA-N;282.252;-2.48;55281;DB12606;;CHEMBL1097615;CACO;ECACO;25;;;;;;;;;;;-6.17;;;;;;;;;;;;;"Irvine JD, Takahashi L, Lockhart K, Cheong J, Tolan JW, Selick HE, Grove JR.: MDCK (Madin-Darby canine kidney) cells: A tool for membrane permeability screening. J Pharm Sci, Volume 88 (1), 28-33, 1999"
"5-[(3-carboxy-4-hydroxyphenyl)diazenyl]-2-hydroxybenzoic acid";MM01437;O=C(O)c1cc(/N=N/c2ccc(O)c(C(=O)O)c2)ccc1O;QQBDLJCYGRGAKP-FOCLMDBBSA-N;302.24;2.91;22419;DB01250;;CHEMBL1201013;CACO;ECACO;25;;;;;;;;;;;-7.8;;;;;;;;;;;;;"Irvine JD, Takahashi L, Lockhart K, Cheong J, Tolan JW, Selick HE, Grove JR.: MDCK (Madin-Darby canine kidney) cells: A tool for membrane permeability screening. J Pharm Sci, Volume 88 (1), 28-33, 1999"
9-methyl-3-[(2-methylimidazol-1-yl)methyl]-2,3-dihydro-1H-carbazol-4-one;MM00531;Cc1nccn1CC1CCc2c(c3ccccc3n2C)C1=O;FELGMEQIXOGIFQ-UHFFFAOYSA-N;293.37;3.13;4595;DB00904;;CHEMBL46;CACO;ECACO;25;;;;;;;;;;;-3.96;;;;;;;;;;;;;"Irvine JD, Takahashi L, Lockhart K, Cheong J, Tolan JW, Selick HE, Grove JR.: MDCK (Madin-Darby canine kidney) cells: A tool for membrane permeability screening. J Pharm Sci, Volume 88 (1), 28-33, 1999"
Oxyprenolol;MM01539;;;;;94423;;;;CACO;ECACO;25;;;;;;;;;;;-3.8;;;;;;;;;;;;;"Irvine JD, Takahashi L, Lockhart K, Cheong J, Tolan JW, Selick HE, Grove JR.: MDCK (Madin-Darby canine kidney) cells: A tool for membrane permeability screening. J Pharm Sci, Volume 88 (1), 28-33, 1999"
"Penicillin v";MM01544;;;;;6869;;;;CACO;ECACO;25;;;;;;;;;;;-6.77;;;;;;;;;;;;;"Irvine JD, Takahashi L, Lockhart K, Cheong J, Tolan JW, Selick HE, Grove JR.: MDCK (Madin-Darby canine kidney) cells: A tool for membrane permeability screening. J Pharm Sci, Volume 88 (1), 28-33, 1999"
5,5-diphenylimidazolidine-2,4-dione;MM00406;O=C1N=C(O)NC1(c1ccccc1)c1ccccc1;CXOFVDLJLONNDW-UHFFFAOYSA-N;252.273;1.97;1775;DB00252;;CHEMBL16;CACO;ECACO;25;;;;;;;;;;;-3.8;;;;;;;;;;;;;"Irvine JD, Takahashi L, Lockhart K, Cheong J, Tolan JW, Selick HE, Grove JR.: MDCK (Madin-Darby canine kidney) cells: A tool for membrane permeability screening. J Pharm Sci, Volume 88 (1), 28-33, 1999"
1-(1H-indol-4-yloxy)-3-(propan-2-ylamino)propan-2-ol;MM00542;CC(C)NCC(O)COc1cccc2[nH]ccc12;JZQKKSLKJUAGIC-UHFFFAOYSA-N;248.326;1.91;4828;DB00960;;CHEMBL500;CACO;ECACO;25;;;;;;;;;;;-4.01;;;;;;;;;;;;;"Irvine JD, Takahashi L, Lockhart K, Cheong J, Tolan JW, Selick HE, Grove JR.: MDCK (Madin-Darby canine kidney) cells: A tool for membrane permeability screening. J Pharm Sci, Volume 88 (1), 28-33, 1999"
N-[4-[2-hydroxy-3-(propan-2-ylamino)propoxy]phenyl]acetamide;MM00544;CC(=O)Nc1ccc(OCC(O)CNC(C)C)cc1;DURULFYMVIFBIR-UHFFFAOYSA-N;266.341;1.38;4883;DB01297;;CHEMBL6995;CACO;ECACO;25;;;;;;;;;;;-5.21;;;;;;;;;;;;;"Irvine JD, Takahashi L, Lockhart K, Cheong J, Tolan JW, Selick HE, Grove JR.: MDCK (Madin-Darby canine kidney) cells: A tool for membrane permeability screening. J Pharm Sci, Volume 88 (1), 28-33, 1999"
Progesterone;MM00198;CC(=O)C1CCC2C3CCC4=CC(=O)CCC4(C)C3CCC12C;RJKFOVLPORLFTN-UHFFFAOYSA-N;314.469;4.72;5994;DB00396;STR;CHEMBL103;CACO;ECACO;25;;;;;;;;;;;-4.01;;;;;;;;;;;;;"Irvine JD, Takahashi L, Lockhart K, Cheong J, Tolan JW, Selick HE, Grove JR.: MDCK (Madin-Darby canine kidney) cells: A tool for membrane permeability screening. J Pharm Sci, Volume 88 (1), 28-33, 1999"
1-naphthalen-1-yloxy-3-(propan-2-ylamino)propan-2-ol;MM00085;CC(C)NCC(O)COc1cccc2ccccc12;AQHHHDLHHXJYJD-UHFFFAOYSA-N;259.349;2.58;4946;DB00571;;CHEMBL27;CACO;ECACO;25;;;;;;;;;;;-3.96;;;;;;;;;;;;;"Irvine JD, Takahashi L, Lockhart K, Cheong J, Tolan JW, Selick HE, Grove JR.: MDCK (Madin-Darby canine kidney) cells: A tool for membrane permeability screening. J Pharm Sci, Volume 88 (1), 28-33, 1999"
6-propyl-2-sulfanylidene-1H-pyrimidin-4-one;MM00415;CCCc1cc(=O)[nH]c(=S)[nH]1;KNAHARQHSZJURB-UHFFFAOYSA-N;170.23;1.38;657298;DB00550;3CJ;CHEMBL1518;CACO;ECACO;25;;;;;;;;;;;-4.02;;;;;;;;;;;;;"Irvine JD, Takahashi L, Lockhart K, Cheong J, Tolan JW, Selick HE, Grove JR.: MDCK (Madin-Darby canine kidney) cells: A tool for membrane permeability screening. J Pharm Sci, Volume 88 (1), 28-33, 1999"
"Salicylic Acid";MM00093;O=C(O)c1ccccc1O;YGSDEFSMJLZEOE-UHFFFAOYSA-N;138.123;1.09;338;DB00936;SAL;CHEMBL424;CACO;ECACO;25;;;;;;;;;;;-4.89;;;;;;;;;;;;;"Irvine JD, Takahashi L, Lockhart K, Cheong J, Tolan JW, Selick HE, Grove JR.: MDCK (Madin-Darby canine kidney) cells: A tool for membrane permeability screening. J Pharm Sci, Volume 88 (1), 28-33, 1999"
N-[4-[1-hydroxy-2-(propan-2-ylamino)ethyl]phenyl]methanesulfonamide;MM00567;CC(C)NCC(O)c1ccc(NS(C)(=O)=O)cc1;ZBMZVLHSJCTVON-UHFFFAOYSA-N;272.363;1.09;5253;DB00489;;CHEMBL471;CACO;ECACO;25;;;;;;;;;;;-5.3;;;;;;;;;;;;;"Irvine JD, Takahashi L, Lockhart K, Cheong J, Tolan JW, Selick HE, Grove JR.: MDCK (Madin-Darby canine kidney) cells: A tool for membrane permeability screening. J Pharm Sci, Volume 88 (1), 28-33, 1999"
Sulfasalazine;MM00690;O=C(O)c1cc(N=Nc2ccc(S(=O)(=O)Nc3ccccn3)cc2)ccc1O;NCEXYHBECQHGNR-UHFFFAOYSA-N;398.393;3.7;5359476;DB00795;SAS;CHEMBL421;CACO;ECACO;25;;;;;;;;;;;-6.22;;;;;;;;;;;;;"Irvine JD, Takahashi L, Lockhart K, Cheong J, Tolan JW, Selick HE, Grove JR.: MDCK (Madin-Darby canine kidney) cells: A tool for membrane permeability screening. J Pharm Sci, Volume 88 (1), 28-33, 1999"
5-[2-(tert-butylamino)-1-hydroxyethyl]benzene-1,3-diol;MM00306;CC(C)(C)NCC(O)c1cc(O)cc(O)c1;XWTYSIMOBUGWOL-UHFFFAOYSA-N;225.288;1.52;5403;DB00871;;CHEMBL1760;CACO;ECACO;25;;;;;;;;;;;-6.39;;;;;;;;;;;;;"Irvine JD, Takahashi L, Lockhart K, Cheong J, Tolan JW, Selick HE, Grove JR.: MDCK (Madin-Darby canine kidney) cells: A tool for membrane permeability screening. J Pharm Sci, Volume 88 (1), 28-33, 1999"
Testosterone;MM00423;CC12CCC(=O)C=C1CCC1C2CCC2(C)C(O)CCC12;MUMGGOZAMZWBJJ-UHFFFAOYSA-N;288.431;3.88;6013;DB00624;TES;CHEMBL386630;CACO;ECACO;25;;;;;;;;;;;-4;;;;;;;;;;;;;"Irvine JD, Takahashi L, Lockhart K, Cheong J, Tolan JW, Selick HE, Grove JR.: MDCK (Madin-Darby canine kidney) cells: A tool for membrane permeability screening. J Pharm Sci, Volume 88 (1), 28-33, 1999"
(2S)-1-(tert-butylamino)-3-[(4-morpholin-4-yl-1,2,5-thiadiazol-3-yl)oxy]propan-2-ol;MM00573;CC(C)(C)NCC(O)COc1nsnc1N1CCOCC1;BLJRIMJGRPQVNF-UHFFFAOYSA-N;316.42;0.5;33624;DB00373;TIM;CHEMBL499;CACO;ECACO;25;;;;;;;;;;;-4;;;;;;;;;;;;;"Irvine JD, Takahashi L, Lockhart K, Cheong J, Tolan JW, Selick HE, Grove JR.: MDCK (Madin-Darby canine kidney) cells: A tool for membrane permeability screening. J Pharm Sci, Volume 88 (1), 28-33, 1999"
5-[(3,4,5-trimethoxyphenyl)methyl]pyrimidine-2,4-diamine;MM00581;COc1cc(Cc2cnc(N)nc2N)cc(OC)c1OC;IEDVJHCEMCRBQM-UHFFFAOYSA-N;290.323;1.26;5578;DB00440;TOP;CHEMBL22;CACO;ECACO;25;;;;;;;;;;;-4.06;;;;;;;;;;;;;"Irvine JD, Takahashi L, Lockhart K, Cheong J, Tolan JW, Selick HE, Grove JR.: MDCK (Madin-Darby canine kidney) cells: A tool for membrane permeability screening. J Pharm Sci, Volume 88 (1), 28-33, 1999"
4-hydroxy-3-(3-oxo-1-phenylbutyl)chromen-2-one;MM00095;CC(=O)CC(c1ccccc1)c1c(O)c2ccccc2oc1=O;PJVWKTKQMONHTI-UHFFFAOYSA-N;308.333;3.61;54678486;DB00682;;CHEMBL1464;CACO;ECACO;25;;;;;;;;;;;-4.018;;;;;;;;;;;;;"Irvine JD, Takahashi L, Lockhart K, Cheong J, Tolan JW, Selick HE, Grove JR.: MDCK (Madin-Darby canine kidney) cells: A tool for membrane permeability screening. J Pharm Sci, Volume 88 (1), 28-33, 1999"
"(2S)-2-(6-methoxynaphthalen-2-yl)propanoic acid";MM00672;COc1ccc2cc(C(C)C(=O)O)ccc2c1;CMWTZPSULFXXJA-UHFFFAOYSA-N;230.263;3.04;156391;DB00788;NPS;CHEMBL154;CACO;ECACO;37;-1;;;;;;;;;;-4.4;;;;;;;;;;;;;"Pade V, Stavchansky S.: Link between drug absorption solubility and permeability measurements in Caco-2 cells. J Pharm Sci, Volume 87 (12), 1604-1607, 1998"
5,5-diphenylimidazolidine-2,4-dione;MM00406;O=C1N=C(O)NC1(c1ccccc1)c1ccccc1;CXOFVDLJLONNDW-UHFFFAOYSA-N;252.273;1.97;1775;DB00252;;CHEMBL16;CACO;ECACO;37;0;;;;;;;;;;-4.46;;;;;;;;;;;;;"Pade V, Stavchansky S.: Link between drug absorption solubility and permeability measurements in Caco-2 cells. J Pharm Sci, Volume 87 (12), 1604-1607, 1998"
"Salicylic Acid";MM00093;O=C(O)c1ccccc1O;YGSDEFSMJLZEOE-UHFFFAOYSA-N;138.123;1.09;338;DB00936;SAL;CHEMBL424;CACO;ECACO;37;-1;;;;;;;;;;-4.73;;;;;;;;;;;;;"Pade V, Stavchansky S.: Link between drug absorption solubility and permeability measurements in Caco-2 cells. J Pharm Sci, Volume 87 (12), 1604-1607, 1998"
6-chloro-1,1-dioxo-4H-1lambda6,2,4-benzothiadiazine-7-sulfonamide;MM00641;NS(=O)(=O)c1cc2c(cc1Cl)NC=NS2(=O)=O;JBMKAUGHUNFTOL-UHFFFAOYSA-N;295.712;0.13;2720;DB00880;;CHEMBL842;CACO;ECACO;37;1;;;;;;;;;;-6.82;;;;;;;;;;;;;"Pade V, Stavchansky S.: Link between drug absorption solubility and permeability measurements in Caco-2 cells. J Pharm Sci, Volume 87 (12), 1604-1607, 1998"
"4-chloro-2-(furan-2-ylmethylamino)-5-sulfamoylbenzoic acid";MM00083;NS(=O)(=O)c1cc(C(=O)O)c(NCc2ccco2)cc1Cl;ZZUFCTLCJUWOSV-UHFFFAOYSA-N;330.739;1.89;3440;DB00695;FUN;CHEMBL35;CACO;ECACO;37;-1;;;;;;;;;;-6.92;;;;;;;;;;;;;"Pade V, Stavchansky S.: Link between drug absorption solubility and permeability measurements in Caco-2 cells. J Pharm Sci, Volume 87 (12), 1604-1607, 1998"
1-naphthalen-1-yloxy-3-(propan-2-ylamino)propan-2-ol;MM00085;CC(C)NCC(O)COc1cccc2ccccc12;AQHHHDLHHXJYJD-UHFFFAOYSA-N;259.349;2.58;4946;DB00571;;CHEMBL27;CACO;ECACO;37;1;;;;;;;;;;-4.52;;;;;;;;;;;;;"Pade V, Stavchansky S.: Link between drug absorption solubility and permeability measurements in Caco-2 cells. J Pharm Sci, Volume 87 (12), 1604-1607, 1998"
Diltiazem;MM00477;COc1ccc(C2Sc3ccccc3N(CCN(C)C)C(=O)C2OC(C)=O)cc1;HSUGRBWQSSZJOP-UHFFFAOYSA-N;414.52;3.37;39186;DB00343;C9F;CHEMBL23;CACO;ECACO;37;1;;;;;;;;;;-4.53;;;;;;;;;;;;;"Pade V, Stavchansky S.: Link between drug absorption solubility and permeability measurements in Caco-2 cells. J Pharm Sci, Volume 87 (12), 1604-1607, 1998"
(1R,2S)-2-(methylamino)-1-phenylpropan-1-ol;MM00486;CN[C@@H](C)[C@H](O)c1ccccc1;KWGRBVOPPLSCSI-WPRPVWTQSA-N;165.236;1.33;9294;DB01364;;CHEMBL211456;CACO;ECACO;37;1;;;;;;;;;;-4.99;;;;;;;;;;;;;"Pade V, Stavchansky S.: Link between drug absorption solubility and permeability measurements in Caco-2 cells. J Pharm Sci, Volume 87 (12), 1604-1607, 1998"
1-cyano-2-methyl-3-[2-[(5-methyl-1H-imidazol-4-yl)methylsulfanyl]ethyl]guanidine;MM00463;CNC(=NCCSCc1nc[nH]c1C)NC#N;AQIXAKUUQRKLND-UHFFFAOYSA-N;252.34;0.6;2756;DB00501;;CHEMBL30;CACO;ECACO;37;1;;;;;;;;;;-6.13;;;;;;;;;;;;;"Pade V, Stavchansky S.: Link between drug absorption solubility and permeability measurements in Caco-2 cells. J Pharm Sci, Volume 87 (12), 1604-1607, 1998"
"4-chloro-2-(furan-2-ylmethylamino)-5-sulfamoylbenzoic acid";MM00083;NS(=O)(=O)c1cc(C(=O)O)c(NCc2ccco2)cc1Cl;ZZUFCTLCJUWOSV-UHFFFAOYSA-N;330.739;1.89;3440;DB00695;FUN;CHEMBL35;CACO;ECACO;37;;;;;;;;;;;-5.89;;;;;;;;;;;;;"Jin X, Luong TL, Reese N, Gaona H, Collazo-Velez V, Vuong C, Potter B, Sousa JC, Olmeda R, Li Q, Xie L, Zhang J, Zhang P, Reichard G, Melendez V, Marcsisin SR, Pybus BS.: Comparison of MDCK-MDR1 and Caco-2 cell based permeability assays for anti-malarial drug screening and drug investigations. J Pharmacol Toxicol Methods, Volume 70 (2), 188-194, 2014"
Vinblastine;MM00586;CCC1(O)CC2CN(CCc3c([nH]c4ccccc34)C(C(=O)OC)(c3cc4c(cc3OC)N(C)C3C(O)(C(=O)OC)C(OC(C)=O)C5(CC)C=CCN6CCC43C65)C2)C1;JXLYSJRDGCGARV-UHFFFAOYSA-N;810.989;3.99;13342;DB00570;VLB;CHEMBL159;CACO;ECACO;37;;;;;;;;;;;-5.94;;;;;;;;;;;;;"Jin X, Luong TL, Reese N, Gaona H, Collazo-Velez V, Vuong C, Potter B, Sousa JC, Olmeda R, Li Q, Xie L, Zhang J, Zhang P, Reichard G, Melendez V, Marcsisin SR, Pybus BS.: Comparison of MDCK-MDR1 and Caco-2 cell based permeability assays for anti-malarial drug screening and drug investigations. J Pharmacol Toxicol Methods, Volume 70 (2), 188-194, 2014"
"2-[1-(4-chlorobenzoyl)-5-methoxy-2-methylindol-3-yl]acetic acid";MM00656;COc1ccc2c(c1)c(CC(=O)O)c(C)n2C(=O)c1ccc(Cl)cc1;CGIGDMFJXJATDK-UHFFFAOYSA-N;357.79;3.93;3715;DB00328;IMN;CHEMBL6;CACO;ECACO;37;;;;;;;;;;;-5;;;;;;;;;;;;;"Jin X, Luong TL, Reese N, Gaona H, Collazo-Velez V, Vuong C, Potter B, Sousa JC, Olmeda R, Li Q, Xie L, Zhang J, Zhang P, Reichard G, Melendez V, Marcsisin SR, Pybus BS.: Comparison of MDCK-MDR1 and Caco-2 cell based permeability assays for anti-malarial drug screening and drug investigations. J Pharmacol Toxicol Methods, Volume 70 (2), 188-194, 2014"
[4-(4-amino-6,7-dimethoxyquinazolin-2-yl)piperazin-1-yl]-(furan-2-yl)methanone;MM00547;COc1cc2nc(N3CCN(C(=O)c4ccco4)CC3)nc(N)c2cc1OC;IENZQIKPVFGBNW-UHFFFAOYSA-N;383.408;1.78;4893;DB00457;XRA;CHEMBL2;CACO;ECACO;37;;;;;;;;;;;-4.76;;;;;;;;;;;;;"Jin X, Luong TL, Reese N, Gaona H, Collazo-Velez V, Vuong C, Potter B, Sousa JC, Olmeda R, Li Q, Xie L, Zhang J, Zhang P, Reichard G, Melendez V, Marcsisin SR, Pybus BS.: Comparison of MDCK-MDR1 and Caco-2 cell based permeability assays for anti-malarial drug screening and drug investigations. J Pharmacol Toxicol Methods, Volume 70 (2), 188-194, 2014"
1-naphthalen-1-yloxy-3-(propan-2-ylamino)propan-2-ol;MM00085;CC(C)NCC(O)COc1cccc2ccccc12;AQHHHDLHHXJYJD-UHFFFAOYSA-N;259.349;2.58;4946;DB00571;;CHEMBL27;CACO;ECACO;37;;;;;;;;;;;-4.56;;;;;;;;;;;;;"Jin X, Luong TL, Reese N, Gaona H, Collazo-Velez V, Vuong C, Potter B, Sousa JC, Olmeda R, Li Q, Xie L, Zhang J, Zhang P, Reichard G, Melendez V, Marcsisin SR, Pybus BS.: Comparison of MDCK-MDR1 and Caco-2 cell based permeability assays for anti-malarial drug screening and drug investigations. J Pharmacol Toxicol Methods, Volume 70 (2), 188-194, 2014"
(S)-[(2R,4S,5R)-5-ethenyl-1-azabicyclo[2.2.2]octan-2-yl]-(6-methoxyquinolin-4-yl)methanol;MM00558;C=C[C@H]1CN2CC[C@H]1C[C@@H]2[C@@H](O)c1ccnc2ccc(OC)cc12;LOUPRKONTZGTKE-LHHVKLHASA-N;324.424;3.17;441074;DB00908;QDN;CHEMBL1294;CACO;ECACO;37;;;;;;;;;;;-4.44;;;;;;;;;;;;;"Jin X, Luong TL, Reese N, Gaona H, Collazo-Velez V, Vuong C, Potter B, Sousa JC, Olmeda R, Li Q, Xie L, Zhang J, Zhang P, Reichard G, Melendez V, Marcsisin SR, Pybus BS.: Comparison of MDCK-MDR1 and Caco-2 cell based permeability assays for anti-malarial drug screening and drug investigations. J Pharmacol Toxicol Methods, Volume 70 (2), 188-194, 2014"
2-amino-9-(2-hydroxyethoxymethyl)-3H-purin-6-one;MM00074;Nc1nc(=O)c2ncn(COCCO)c2[nH]1;MKUXAQIIEYXACX-UHFFFAOYSA-N;225.208;-0.92;2022;DB00787;AC2;CHEMBL184;CACO;ECACO;25;;;;;;;;;;;-5.89;;;;;;;;;;;;;"Furubayashi T, Inoue D, Nishiyama N, Tanaka A, Yutani R, Kimura S, Katsumi H, Yamamoto A, Sakane T.: Comparison of Various Cell Lines and Three-Dimensional Mucociliary Tissue Model Systems to Estimate Drug Permeability Using an In Vitro Transport Study to Predict Nasal Drug Absorption in Rats. Pharmaceutics, Volume 12 (1), 2020"
"Sulfanilic acid";MM15136;;;;;8479;;;;CACO;ECACO;25;;;;;;;;;;;-6.23;;;;;;;;;;;;;"Furubayashi T, Inoue D, Nishiyama N, Tanaka A, Yutani R, Kimura S, Katsumi H, Yamamoto A, Sakane T.: Comparison of Various Cell Lines and Three-Dimensional Mucociliary Tissue Model Systems to Estimate Drug Permeability Using an In Vitro Transport Study to Predict Nasal Drug Absorption in Rats. Pharmaceutics, Volume 12 (1), 2020"
Inulin;MM01493;OCC1OC(OC2(COC3(COC4(COC5(COC6(COC7(COC8(COC9(COC%10(COC%11(COC%12(COC%13(COC%14(COC%15(COC%16(COC%17(COC%18(COC%19(COC%20(COC%21(COC%22(COC%23(COC%24(COC%25(COC%26(COC%27(COC%28(COC%29(COC%30(COC%31(COC%32(COC%33(COC%34(COC%35(COC%36(COC%37(COC%38(CO)OC(CO)C(O)C%38O)OC(CO)C(O)C%37O)OC(CO)C(O)C%36O)OC(CO)C(O)C%35O)OC(CO)C(O)C%34O)OC(CO)C(O)C%33O)OC(CO)C(O)C%32O)OC(CO)C(O)C%31O)OC(CO)C(O)C%30O)OC(CO)C(O)C%29O)OC(CO)C(O)C%28O)OC(CO)C(O)C%27O)OC(CO)C(O)C%26O)OC(CO)C(O)C%25O)OC(CO)C(O)C%24O)OC(CO)C(O)C%23O)OC(CO)C(O)C%22O)OC(CO)C(O)C%21O)OC(CO)C(O)C%20O)OC(CO)C(O)C%19O)OC(CO)C(O)C%18O)OC(CO)C(O)C%17O)OC(CO)C(O)C%16O)OC(CO)C(O)C%15O)OC(CO)C(O)C%14O)OC(CO)C(O)C%13O)OC(CO)C(O)C%12O)OC(CO)C(O)C%11O)OC(CO)C(O)C%10O)OC(CO)C(O)C9O)OC(CO)C(O)C8O)OC(CO)C(O)C7O)OC(CO)C(O)C6O)OC(CO)C(O)C5O)OC(CO)C(O)C4O)OC(CO)C(O)C3O)OC(CO)C(O)C2O)C(O)C(O)C1O;JYJIGFIDKWBXDU-UHFFFAOYSA-N;6179.37;-83.67;24763;DB00638;;;CACO;ECACO;25;;;;;;;;;;;-6.47;;;;;;;;;;;;;"Furubayashi T, Inoue D, Nishiyama N, Tanaka A, Yutani R, Kimura S, Katsumi H, Yamamoto A, Sakane T.: Comparison of Various Cell Lines and Three-Dimensional Mucociliary Tissue Model Systems to Estimate Drug Permeability Using an In Vitro Transport Study to Predict Nasal Drug Absorption in Rats. Pharmaceutics, Volume 12 (1), 2020"
(S)-[(2R,4S,5R)-5-ethenyl-1-azabicyclo[2.2.2]octan-2-yl]-(6-methoxyquinolin-4-yl)methanol;MM00558;C=C[C@H]1CN2CC[C@H]1C[C@@H]2[C@@H](O)c1ccnc2ccc(OC)cc12;LOUPRKONTZGTKE-LHHVKLHASA-N;324.424;3.17;441074;DB00908;QDN;CHEMBL1294;CACO;ECACO;25;;;;;;;;;;;-4.5;;;;;;;;;;;;;"Furubayashi T, Inoue D, Nishiyama N, Tanaka A, Yutani R, Kimura S, Katsumi H, Yamamoto A, Sakane T.: Comparison of Various Cell Lines and Three-Dimensional Mucociliary Tissue Model Systems to Estimate Drug Permeability Using an In Vitro Transport Study to Predict Nasal Drug Absorption in Rats. Pharmaceutics, Volume 12 (1), 2020"
"(2S)-2-[[4-[(2,4-diaminopteridin-6-yl)methyl-methylamino]benzoyl]amino]pentanedioic acid";MM00270;CN(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(C(=O)NC(CCC(=O)O)C(=O)O)cc1;FBOZXECLQNJBKD-UHFFFAOYSA-N;454.447;0.27;126941;DB00563;MTX;CHEMBL34259;CACO;ECACO;25;;;;;;;;;;;-6.54;;;;;;;;;;;;;"Furubayashi T, Inoue D, Nishiyama N, Tanaka A, Yutani R, Kimura S, Katsumi H, Yamamoto A, Sakane T.: Comparison of Various Cell Lines and Three-Dimensional Mucociliary Tissue Model Systems to Estimate Drug Permeability Using an In Vitro Transport Study to Predict Nasal Drug Absorption in Rats. Pharmaceutics, Volume 12 (1), 2020"
2-amino-9-(2-hydroxyethoxymethyl)-3H-purin-6-one;MM00074;Nc1nc(=O)c2ncn(COCCO)c2[nH]1;MKUXAQIIEYXACX-UHFFFAOYSA-N;225.208;-0.92;2022;DB00787;AC2;CHEMBL184;CACO;ECACO;37;;;;;;;;;;;-5.90658;0.084;;;;;;;;;;;"Teksin ZS, Seo PR, Polli JE.: Comparison of drug permeabilities and BCS classification: three lipid-component PAMPA system method versus Caco-2 monolayers. AAPS J, Volume 12 (2), 238-241, 2010";"Teksin ZS, Seo PR, Polli JE.: Comparison of drug permeabilities and BCS classification: three lipid-component PAMPA system method versus Caco-2 monolayers. AAPS J, Volume 12 (2), 238-241, 2010"
2-[4-[2-hydroxy-3-(propan-2-ylamino)propoxy]phenyl]acetamide;MM00078;CC(C)NC[C@@H](O)COc1ccc(CC(N)=O)cc1;METKIMKYRPQLGS-UHFFFAOYSA-N;266.341;0.45;2249;DB00335;;CHEMBL24;CACO;ECACO;37;;;;;;;;;;;-5.5817;0.0281603;;;;;;;;;;;"Teksin ZS, Seo PR, Polli JE.: Comparison of drug permeabilities and BCS classification: three lipid-component PAMPA system method versus Caco-2 monolayers. AAPS J, Volume 12 (2), 238-241, 2010";"Teksin ZS, Seo PR, Polli JE.: Comparison of drug permeabilities and BCS classification: three lipid-component PAMPA system method versus Caco-2 monolayers. AAPS J, Volume 12 (2), 238-241, 2010"
Buproprion;MM15131;;;;;;;;;CACO;ECACO;37;;;;;;;;;;;-4.17783;0.00392169;;;;;;;;;;;"Teksin ZS, Seo PR, Polli JE.: Comparison of drug permeabilities and BCS classification: three lipid-component PAMPA system method versus Caco-2 monolayers. AAPS J, Volume 12 (2), 238-241, 2010";"Teksin ZS, Seo PR, Polli JE.: Comparison of drug permeabilities and BCS classification: three lipid-component PAMPA system method versus Caco-2 monolayers. AAPS J, Volume 12 (2), 238-241, 2010"
Diethylcarbamazine;MM00854;CCN(CC)C(=O)N1CCN(C)CC1;RCKMWOKWVGPNJF-UHFFFAOYSA-N;199.298;0.7;3052;DB00711;;CHEMBL684;CACO;ECACO;37;;;;;;;;;;;-4.01909;0.0231285;;;;;;;;;;;"Teksin ZS, Seo PR, Polli JE.: Comparison of drug permeabilities and BCS classification: three lipid-component PAMPA system method versus Caco-2 monolayers. AAPS J, Volume 12 (2), 238-241, 2010";"Teksin ZS, Seo PR, Polli JE.: Comparison of drug permeabilities and BCS classification: three lipid-component PAMPA system method versus Caco-2 monolayers. AAPS J, Volume 12 (2), 238-241, 2010"
3-(4-chlorophenyl)-N,N-dimethyl-3-pyridin-2-ylpropan-1-amine;MM00460;CN(C)CCC(c1ccc(Cl)cc1)c1ccccn1;SOYKEARSMXGVTM-UHFFFAOYSA-N;274.792;3.82;2725;DB01114;;CHEMBL505;CACO;ECACO;37;;;;;;;;;;;-4.79588;0.0515375;;;;;;;;;;;"Teksin ZS, Seo PR, Polli JE.: Comparison of drug permeabilities and BCS classification: three lipid-component PAMPA system method versus Caco-2 monolayers. AAPS J, Volume 12 (2), 238-241, 2010";"Teksin ZS, Seo PR, Polli JE.: Comparison of drug permeabilities and BCS classification: three lipid-component PAMPA system method versus Caco-2 monolayers. AAPS J, Volume 12 (2), 238-241, 2010"
Chromen-2-one;MM00042;O=c1ccc2ccccc2o1;ZYGHJZDHTFUPRJ-UHFFFAOYSA-N;146.145;1.79;323;DB04665;COU;CHEMBL6466;CACO;ECACO;37;;;;;;;;;;;-3.85078;0.0184681;;;;;;;;;;;"Teksin ZS, Seo PR, Polli JE.: Comparison of drug permeabilities and BCS classification: three lipid-component PAMPA system method versus Caco-2 monolayers. AAPS J, Volume 12 (2), 238-241, 2010";"Teksin ZS, Seo PR, Polli JE.: Comparison of drug permeabilities and BCS classification: three lipid-component PAMPA system method versus Caco-2 monolayers. AAPS J, Volume 12 (2), 238-241, 2010"
4-[di(propan-2-yl)amino]-2-phenyl-2-pyridin-2-ylbutanamide;MM00480;CC(C)N(CCC(C(N)=O)(c1ccccc1)c1ccccn1)C(C)C;UVTNFZQICZKOEM-UHFFFAOYSA-N;339.483;3.36;3114;DB00280;;CHEMBL517;CACO;ECACO;37;;;;;;;;;;;-5.37263;0.00511792;;;;;;;;;;;"Teksin ZS, Seo PR, Polli JE.: Comparison of drug permeabilities and BCS classification: three lipid-component PAMPA system method versus Caco-2 monolayers. AAPS J, Volume 12 (2), 238-241, 2010";"Teksin ZS, Seo PR, Polli JE.: Comparison of drug permeabilities and BCS classification: three lipid-component PAMPA system method versus Caco-2 monolayers. AAPS J, Volume 12 (2), 238-241, 2010"
"4-chloro-2-(furan-2-ylmethylamino)-5-sulfamoylbenzoic acid";MM00083;NS(=O)(=O)c1cc(C(=O)O)c(NCc2ccco2)cc1Cl;ZZUFCTLCJUWOSV-UHFFFAOYSA-N;330.739;1.89;3440;DB00695;FUN;CHEMBL35;CACO;ECACO;37;;;;;;;;;;;-5.47756;0.00912312;;;;;;;;;;;"Teksin ZS, Seo PR, Polli JE.: Comparison of drug permeabilities and BCS classification: three lipid-component PAMPA system method versus Caco-2 monolayers. AAPS J, Volume 12 (2), 238-241, 2010";"Teksin ZS, Seo PR, Polli JE.: Comparison of drug permeabilities and BCS classification: three lipid-component PAMPA system method versus Caco-2 monolayers. AAPS J, Volume 12 (2), 238-241, 2010"
Hydrocholothiazide;MM15150;;;;;;;;;CACO;ECACO;37;;;;;;;;;;;-6.14874;0.0385099;;;;;;;;;;;"Teksin ZS, Seo PR, Polli JE.: Comparison of drug permeabilities and BCS classification: three lipid-component PAMPA system method versus Caco-2 monolayers. AAPS J, Volume 12 (2), 238-241, 2010";"Teksin ZS, Seo PR, Polli JE.: Comparison of drug permeabilities and BCS classification: three lipid-component PAMPA system method versus Caco-2 monolayers. AAPS J, Volume 12 (2), 238-241, 2010"
"2-[1-(4-chlorobenzoyl)-5-methoxy-2-methylindol-3-yl]acetic acid";MM00656;COc1ccc2c(c1)c(CC(=O)O)c(C)n2C(=O)c1ccc(Cl)cc1;CGIGDMFJXJATDK-UHFFFAOYSA-N;357.79;3.93;3715;DB00328;IMN;CHEMBL6;CACO;ECACO;37;;;;;;;;;;;-4.41567;0.0248646;;;;;;;;;;;"Teksin ZS, Seo PR, Polli JE.: Comparison of drug permeabilities and BCS classification: three lipid-component PAMPA system method versus Caco-2 monolayers. AAPS J, Volume 12 (2), 238-241, 2010";"Teksin ZS, Seo PR, Polli JE.: Comparison of drug permeabilities and BCS classification: three lipid-component PAMPA system method versus Caco-2 monolayers. AAPS J, Volume 12 (2), 238-241, 2010"
Inulin;MM01493;OCC1OC(OC2(COC3(COC4(COC5(COC6(COC7(COC8(COC9(COC%10(COC%11(COC%12(COC%13(COC%14(COC%15(COC%16(COC%17(COC%18(COC%19(COC%20(COC%21(COC%22(COC%23(COC%24(COC%25(COC%26(COC%27(COC%28(COC%29(COC%30(COC%31(COC%32(COC%33(COC%34(COC%35(COC%36(COC%37(COC%38(CO)OC(CO)C(O)C%38O)OC(CO)C(O)C%37O)OC(CO)C(O)C%36O)OC(CO)C(O)C%35O)OC(CO)C(O)C%34O)OC(CO)C(O)C%33O)OC(CO)C(O)C%32O)OC(CO)C(O)C%31O)OC(CO)C(O)C%30O)OC(CO)C(O)C%29O)OC(CO)C(O)C%28O)OC(CO)C(O)C%27O)OC(CO)C(O)C%26O)OC(CO)C(O)C%25O)OC(CO)C(O)C%24O)OC(CO)C(O)C%23O)OC(CO)C(O)C%22O)OC(CO)C(O)C%21O)OC(CO)C(O)C%20O)OC(CO)C(O)C%19O)OC(CO)C(O)C%18O)OC(CO)C(O)C%17O)OC(CO)C(O)C%16O)OC(CO)C(O)C%15O)OC(CO)C(O)C%14O)OC(CO)C(O)C%13O)OC(CO)C(O)C%12O)OC(CO)C(O)C%11O)OC(CO)C(O)C%10O)OC(CO)C(O)C9O)OC(CO)C(O)C8O)OC(CO)C(O)C7O)OC(CO)C(O)C6O)OC(CO)C(O)C5O)OC(CO)C(O)C4O)OC(CO)C(O)C3O)OC(CO)C(O)C2O)C(O)C(O)C1O;JYJIGFIDKWBXDU-UHFFFAOYSA-N;6179.37;-83.67;24763;DB00638;;;CACO;ECACO;37;;;;;;;;;;;-6.03574;0.0475939;;;;;;;;;;;"Teksin ZS, Seo PR, Polli JE.: Comparison of drug permeabilities and BCS classification: three lipid-component PAMPA system method versus Caco-2 monolayers. AAPS J, Volume 12 (2), 238-241, 2010";"Teksin ZS, Seo PR, Polli JE.: Comparison of drug permeabilities and BCS classification: three lipid-component PAMPA system method versus Caco-2 monolayers. AAPS J, Volume 12 (2), 238-241, 2010"
"2-(3-benzoylphenyl)propanoic acid";MM00662;CC(C(=O)O)c1cccc(C(=O)c2ccccc2)c1;DKYWVDODHFEZIM-UHFFFAOYSA-N;254.285;3.11;3825;DB01009;;CHEMBL571;CACO;ECACO;37;;;;;;;;;;;-4.29671;0.00429703;;;;;;;;;;;"Teksin ZS, Seo PR, Polli JE.: Comparison of drug permeabilities and BCS classification: three lipid-component PAMPA system method versus Caco-2 monolayers. AAPS J, Volume 12 (2), 238-241, 2010";"Teksin ZS, Seo PR, Polli JE.: Comparison of drug permeabilities and BCS classification: three lipid-component PAMPA system method versus Caco-2 monolayers. AAPS J, Volume 12 (2), 238-241, 2010"
(2R,3R,4R,5R)-hexane-1,2,3,4,5,6-hexol;MM00386;OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO;FBPFZTCFMRRESA-KVTDHHQDSA-N;182.172;-3.59;6251;DB00742;MTL;CHEMBL689;CACO;ECACO;37;;;;;;;;;;;-5.55129;0.0247117;;;;;;;;;;;"Teksin ZS, Seo PR, Polli JE.: Comparison of drug permeabilities and BCS classification: three lipid-component PAMPA system method versus Caco-2 monolayers. AAPS J, Volume 12 (2), 238-241, 2010";"Teksin ZS, Seo PR, Polli JE.: Comparison of drug permeabilities and BCS classification: three lipid-component PAMPA system method versus Caco-2 monolayers. AAPS J, Volume 12 (2), 238-241, 2010"
1-[4-(2-methoxyethyl)phenoxy]-3-(propan-2-ylamino)propan-2-ol;MM00275;COCCc1ccc(OCC(O)CNC(C)C)cc1;IUBSYMUCCVWXPE-UHFFFAOYSA-N;267.369;1.61;4171;DB00264;;CHEMBL13;CACO;ECACO;37;;;;;;;;;;;-4.39794;0.01519;;;;;;;;;;;"Teksin ZS, Seo PR, Polli JE.: Comparison of drug permeabilities and BCS classification: three lipid-component PAMPA system method versus Caco-2 monolayers. AAPS J, Volume 12 (2), 238-241, 2010";"Teksin ZS, Seo PR, Polli JE.: Comparison of drug permeabilities and BCS classification: three lipid-component PAMPA system method versus Caco-2 monolayers. AAPS J, Volume 12 (2), 238-241, 2010"
"(2S)-2-(6-methoxynaphthalen-2-yl)propanoic acid";MM00672;COc1ccc2cc(C(C)C(=O)O)ccc2c1;CMWTZPSULFXXJA-UHFFFAOYSA-N;230.263;3.04;156391;DB00788;NPS;CHEMBL154;CACO;ECACO;37;;;;;;;;;;;-3.89963;0.0137778;;;;;;;;;;;"Teksin ZS, Seo PR, Polli JE.: Comparison of drug permeabilities and BCS classification: three lipid-component PAMPA system method versus Caco-2 monolayers. AAPS J, Volume 12 (2), 238-241, 2010";"Teksin ZS, Seo PR, Polli JE.: Comparison of drug permeabilities and BCS classification: three lipid-component PAMPA system method versus Caco-2 monolayers. AAPS J, Volume 12 (2), 238-241, 2010"
Proxicam;MM15151;;;;;;;;;CACO;ECACO;37;;;;;;;;;;;-3.93554;0.00374138;;;;;;;;;;;"Teksin ZS, Seo PR, Polli JE.: Comparison of drug permeabilities and BCS classification: three lipid-component PAMPA system method versus Caco-2 monolayers. AAPS J, Volume 12 (2), 238-241, 2010";"Teksin ZS, Seo PR, Polli JE.: Comparison of drug permeabilities and BCS classification: three lipid-component PAMPA system method versus Caco-2 monolayers. AAPS J, Volume 12 (2), 238-241, 2010"
1-naphthalen-1-yloxy-3-(propan-2-ylamino)propan-2-ol;MM00085;CC(C)NCC(O)COc1cccc2ccccc12;AQHHHDLHHXJYJD-UHFFFAOYSA-N;259.349;2.58;4946;DB00571;;CHEMBL27;CACO;ECACO;37;;;;;;;;;;;-4.30539;0.0105212;;;;;;;;;;;"Teksin ZS, Seo PR, Polli JE.: Comparison of drug permeabilities and BCS classification: three lipid-component PAMPA system method versus Caco-2 monolayers. AAPS J, Volume 12 (2), 238-241, 2010";"Teksin ZS, Seo PR, Polli JE.: Comparison of drug permeabilities and BCS classification: three lipid-component PAMPA system method versus Caco-2 monolayers. AAPS J, Volume 12 (2), 238-241, 2010"
Ranitidine;MM01053;CNC(=C[N+](=O)[O-])NCCSCc1ccc(CN(C)C)o1;VMXUWOKSQNHOCA-UHFFFAOYSA-N;314.404;1.46;5039;DB00863;;CHEMBL1790041;CACO;ECACO;37;;;;;;;;;;;-6.39254;0.0332198;;;;;;;;;;;"Teksin ZS, Seo PR, Polli JE.: Comparison of drug permeabilities and BCS classification: three lipid-component PAMPA system method versus Caco-2 monolayers. AAPS J, Volume 12 (2), 238-241, 2010";"Teksin ZS, Seo PR, Polli JE.: Comparison of drug permeabilities and BCS classification: three lipid-component PAMPA system method versus Caco-2 monolayers. AAPS J, Volume 12 (2), 238-241, 2010"
1,3-dimethyl-7H-purine-2,6-dione;MM00048;Cn1c(=O)c2nc[nH]c2n(C)c1=O;ZFXYFBGIUFBOJW-UHFFFAOYSA-N;180.167;-1.04;2153;DB00277;TEP;CHEMBL190;CACO;ECACO;37;;;;;;;;;;;-4.21467;0.00640328;;;;;;;;;;;"Teksin ZS, Seo PR, Polli JE.: Comparison of drug permeabilities and BCS classification: three lipid-component PAMPA system method versus Caco-2 monolayers. AAPS J, Volume 12 (2), 238-241, 2010";"Teksin ZS, Seo PR, Polli JE.: Comparison of drug permeabilities and BCS classification: three lipid-component PAMPA system method versus Caco-2 monolayers. AAPS J, Volume 12 (2), 238-241, 2010"
Verapamil;MM00585;COc1ccc(CCN(C)CCCC(C#N)(c2ccc(OC)c(OC)c2)C(C)C)cc1OC;SGTNSNPWRIOYBX-UHFFFAOYSA-N;454.611;5.09;2520;DB00661;;CHEMBL6966;CACO;ECACO;37;;;;;;;;;;;-4.4828;0.0131915;;;;;;;;;;;"Teksin ZS, Seo PR, Polli JE.: Comparison of drug permeabilities and BCS classification: three lipid-component PAMPA system method versus Caco-2 monolayers. AAPS J, Volume 12 (2), 238-241, 2010";"Teksin ZS, Seo PR, Polli JE.: Comparison of drug permeabilities and BCS classification: three lipid-component PAMPA system method versus Caco-2 monolayers. AAPS J, Volume 12 (2), 238-241, 2010"
CNV97100;MM00727;CC1CN(c2cc3c(cc2F)c(=O)c(C(=O)O)cn3C2CC2)CCN1.O=C(O)C(F)(F)F;URJUNYOPXJPQGS-UHFFFAOYSA-N;459.398;2.61;46781144;;;;CACO;ECACO;37;;"apical to basolateral transport";;;;;;;;;-5.4437;0.168778;;;;;;;;;;;"Ruiz-García A, Lin H, Plá-Delfina JM, Hu M.: Kinetic characterization of secretory transport of a new ciprofloxacin derivative (CNV97100) across Caco-2 cell monolayers. J Pharm Sci, Volume 91 (12), 2511-2519, 2002";"Ruiz-García A, Lin H, Plá-Delfina JM, Hu M.: Kinetic characterization of secretory transport of a new ciprofloxacin derivative (CNV97100) across Caco-2 cell monolayers. J Pharm Sci, Volume 91 (12), 2511-2519, 2002"
CNV97101;MM01441;;;;;;;;;CACO;ECACO;37;;"apical to basolateral transport";;;;;;;;;-4.66154;0.0776422;;;;;;;;;;;"Ruiz-García A, Lin H, Plá-Delfina JM, Hu M.: Kinetic characterization of secretory transport of a new ciprofloxacin derivative (CNV97100) across Caco-2 cell monolayers. J Pharm Sci, Volume 91 (12), 2511-2519, 2002";"Ruiz-García A, Lin H, Plá-Delfina JM, Hu M.: Kinetic characterization of secretory transport of a new ciprofloxacin derivative (CNV97100) across Caco-2 cell monolayers. J Pharm Sci, Volume 91 (12), 2511-2519, 2002"
"1-cyclopropyl-7-(4-ethyl-3-methylpiperazin-1-yl)-6-fluoro-4-oxoquinoline-3-carboxylic acid";MM00728;CCN1CCN(c2cc3c(cc2F)c(=O)c(C(=O)O)cn3C2CC2)CC1C;POMKZSJIYNWBRP-UHFFFAOYSA-N;373.428;2.7;10109876;;;;CACO;ECACO;37;;"apical to basolateral transport";;;;;;;;;-4.77469;0.0800833;;;;;;;;;;;"Ruiz-García A, Lin H, Plá-Delfina JM, Hu M.: Kinetic characterization of secretory transport of a new ciprofloxacin derivative (CNV97100) across Caco-2 cell monolayers. J Pharm Sci, Volume 91 (12), 2511-2519, 2002";"Ruiz-García A, Lin H, Plá-Delfina JM, Hu M.: Kinetic characterization of secretory transport of a new ciprofloxacin derivative (CNV97100) across Caco-2 cell monolayers. J Pharm Sci, Volume 91 (12), 2511-2519, 2002"
CNV97103;MM00729;CCCN1CCN(c2cc3c(cc2F)c(=O)c(C(=O)O)cn3C2CC2)CC1C;WPGHZQMHNTXSAF-UHFFFAOYSA-N;387.455;3.09;13326823;;;;CACO;ECACO;37;;"apical to basolateral transport";;;;;;;;;-4.81816;0.0571053;;;;;;;;;;;"Ruiz-García A, Lin H, Plá-Delfina JM, Hu M.: Kinetic characterization of secretory transport of a new ciprofloxacin derivative (CNV97100) across Caco-2 cell monolayers. J Pharm Sci, Volume 91 (12), 2511-2519, 2002";"Ruiz-García A, Lin H, Plá-Delfina JM, Hu M.: Kinetic characterization of secretory transport of a new ciprofloxacin derivative (CNV97100) across Caco-2 cell monolayers. J Pharm Sci, Volume 91 (12), 2511-2519, 2002"
"7-(4-butyl-3-methylpiperazin-1-yl)-1-cyclopropyl-6-fluoro-4-oxoquinoline-3-carboxylic acid";MM00730;CCCCN1CCN(c2cc3c(cc2F)c(=O)c(C(=O)O)cn3C2CC2)CC1C;QPVCGSGGZMAACV-UHFFFAOYSA-N;401.482;3.48;13385166;;;;CACO;ECACO;37;;"apical to basolateral transport";;;;;;;;;-4.85699;0.124892;;;;;;;;;;;"Ruiz-García A, Lin H, Plá-Delfina JM, Hu M.: Kinetic characterization of secretory transport of a new ciprofloxacin derivative (CNV97100) across Caco-2 cell monolayers. J Pharm Sci, Volume 91 (12), 2511-2519, 2002";"Ruiz-García A, Lin H, Plá-Delfina JM, Hu M.: Kinetic characterization of secretory transport of a new ciprofloxacin derivative (CNV97100) across Caco-2 cell monolayers. J Pharm Sci, Volume 91 (12), 2511-2519, 2002"
"1-cyclopropyl-6-fluoro-4-oxo-7-piperazin-1-ylquinoline-3-carboxylic acid";MM00726;O=C(O)c1cn(C2CC2)c2cc(N3CCNCC3)c(F)cc2c1=O;MYSWGUAQZAJSOK-UHFFFAOYSA-N;331.347;1.58;2764;DB00537;CPF;CHEMBL8;CACO;ECACO;37;;"apical to basolateral transport";;;;;;;;;-5.67985;0.602201;;;;;;;;;;;"Ruiz-García A, Lin H, Plá-Delfina JM, Hu M.: Kinetic characterization of secretory transport of a new ciprofloxacin derivative (CNV97100) across Caco-2 cell monolayers. J Pharm Sci, Volume 91 (12), 2511-2519, 2002";"Ruiz-García A, Lin H, Plá-Delfina JM, Hu M.: Kinetic characterization of secretory transport of a new ciprofloxacin derivative (CNV97100) across Caco-2 cell monolayers. J Pharm Sci, Volume 91 (12), 2511-2519, 2002"
CNV97100;MM00727;CC1CN(c2cc3c(cc2F)c(=O)c(C(=O)O)cn3C2CC2)CCN1.O=C(O)C(F)(F)F;URJUNYOPXJPQGS-UHFFFAOYSA-N;459.398;2.61;46781144;;;;CACO;ECACO;37;;"basolateral to apical transport";;;;;;;;;-4.85387;0.1085;;;;;;;;;;;"Ruiz-García A, Lin H, Plá-Delfina JM, Hu M.: Kinetic characterization of secretory transport of a new ciprofloxacin derivative (CNV97100) across Caco-2 cell monolayers. J Pharm Sci, Volume 91 (12), 2511-2519, 2002";"Ruiz-García A, Lin H, Plá-Delfina JM, Hu M.: Kinetic characterization of secretory transport of a new ciprofloxacin derivative (CNV97100) across Caco-2 cell monolayers. J Pharm Sci, Volume 91 (12), 2511-2519, 2002"
CNV97101;MM01441;;;;;;;;;CACO;ECACO;37;;"basolateral to apical transport";;;;;;;;;-4.59517;0.217;;;;;;;;;;;"Ruiz-García A, Lin H, Plá-Delfina JM, Hu M.: Kinetic characterization of secretory transport of a new ciprofloxacin derivative (CNV97100) across Caco-2 cell monolayers. J Pharm Sci, Volume 91 (12), 2511-2519, 2002";"Ruiz-García A, Lin H, Plá-Delfina JM, Hu M.: Kinetic characterization of secretory transport of a new ciprofloxacin derivative (CNV97100) across Caco-2 cell monolayers. J Pharm Sci, Volume 91 (12), 2511-2519, 2002"
"1-cyclopropyl-7-(4-ethyl-3-methylpiperazin-1-yl)-6-fluoro-4-oxoquinoline-3-carboxylic acid";MM00728;CCN1CCN(c2cc3c(cc2F)c(=O)c(C(=O)O)cn3C2CC2)CC1C;POMKZSJIYNWBRP-UHFFFAOYSA-N;373.428;2.7;10109876;;;;CACO;ECACO;37;;"basolateral to apical transport";;;;;;;;;-4.67572;0.0555355;;;;;;;;;;;"Ruiz-García A, Lin H, Plá-Delfina JM, Hu M.: Kinetic characterization of secretory transport of a new ciprofloxacin derivative (CNV97100) across Caco-2 cell monolayers. J Pharm Sci, Volume 91 (12), 2511-2519, 2002";"Ruiz-García A, Lin H, Plá-Delfina JM, Hu M.: Kinetic characterization of secretory transport of a new ciprofloxacin derivative (CNV97100) across Caco-2 cell monolayers. J Pharm Sci, Volume 91 (12), 2511-2519, 2002"
CNV97103;MM00729;CCCN1CCN(c2cc3c(cc2F)c(=O)c(C(=O)O)cn3C2CC2)CC1C;WPGHZQMHNTXSAF-UHFFFAOYSA-N;387.455;3.09;13326823;;;;CACO;ECACO;37;;"basolateral to apical transport";;;;;;;;;-4.75696;0.434;;;;;;;;;;;"Ruiz-García A, Lin H, Plá-Delfina JM, Hu M.: Kinetic characterization of secretory transport of a new ciprofloxacin derivative (CNV97100) across Caco-2 cell monolayers. J Pharm Sci, Volume 91 (12), 2511-2519, 2002";"Ruiz-García A, Lin H, Plá-Delfina JM, Hu M.: Kinetic characterization of secretory transport of a new ciprofloxacin derivative (CNV97100) across Caco-2 cell monolayers. J Pharm Sci, Volume 91 (12), 2511-2519, 2002"
"7-(4-butyl-3-methylpiperazin-1-yl)-1-cyclopropyl-6-fluoro-4-oxoquinoline-3-carboxylic acid";MM00730;CCCCN1CCN(c2cc3c(cc2F)c(=O)c(C(=O)O)cn3C2CC2)CC1C;QPVCGSGGZMAACV-UHFFFAOYSA-N;401.482;3.48;13385166;;;;CACO;ECACO;37;;"basolateral to apical transport";;;;;;;;;-4.74958;0.109719;;;;;;;;;;;"Ruiz-García A, Lin H, Plá-Delfina JM, Hu M.: Kinetic characterization of secretory transport of a new ciprofloxacin derivative (CNV97100) across Caco-2 cell monolayers. J Pharm Sci, Volume 91 (12), 2511-2519, 2002";"Ruiz-García A, Lin H, Plá-Delfina JM, Hu M.: Kinetic characterization of secretory transport of a new ciprofloxacin derivative (CNV97100) across Caco-2 cell monolayers. J Pharm Sci, Volume 91 (12), 2511-2519, 2002"
"1-cyclopropyl-6-fluoro-4-oxo-7-piperazin-1-ylquinoline-3-carboxylic acid";MM00726;O=C(O)c1cn(C2CC2)c2cc(N3CCNCC3)c(F)cc2c1=O;MYSWGUAQZAJSOK-UHFFFAOYSA-N;331.347;1.58;2764;DB00537;CPF;CHEMBL8;CACO;ECACO;37;;"basolateral to apical transport";;;;;;;;;-5.11919;0.3255;;;;;;;;;;;"Ruiz-García A, Lin H, Plá-Delfina JM, Hu M.: Kinetic characterization of secretory transport of a new ciprofloxacin derivative (CNV97100) across Caco-2 cell monolayers. J Pharm Sci, Volume 91 (12), 2511-2519, 2002";"Ruiz-García A, Lin H, Plá-Delfina JM, Hu M.: Kinetic characterization of secretory transport of a new ciprofloxacin derivative (CNV97100) across Caco-2 cell monolayers. J Pharm Sci, Volume 91 (12), 2511-2519, 2002"
1-cyano-2-methyl-3-[2-[(5-methyl-1H-imidazol-4-yl)methylsulfanyl]ethyl]guanidine;MM00463;CNC(=NCCSCc1nc[nH]c1C)NC#N;AQIXAKUUQRKLND-UHFFFAOYSA-N;252.34;0.6;2756;DB00501;;CHEMBL30;CACO;ECACO;37;;;;;;;;;;;-5.79588;;;;;;;;;;;;"DOI: 10.1002/minf.201000118";"Pham The H, González-Álvarez I, Bermejo M, Mangas Sanjuan V, Mangas Sanjuan V, Centelles I, Garrigues TM, Cabrera-Pérez MÁ.: In Silico Prediction of Caco-2 Cell Permeability by a Classification QSAR Approach. Mol Inform, Volume 30 (4), 376-385, 2011"
1-naphthalen-1-yloxy-3-(propan-2-ylamino)propan-2-ol;MM00085;CC(C)NCC(O)COc1cccc2ccccc12;AQHHHDLHHXJYJD-UHFFFAOYSA-N;259.349;2.58;4946;DB00571;;CHEMBL27;CACO;ECACO;37;;;;;;;;;;;-4.64782;;;;;;;;;;;;"DOI: 10.1002/minf.201000118";"Pham The H, González-Álvarez I, Bermejo M, Mangas Sanjuan V, Mangas Sanjuan V, Centelles I, Garrigues TM, Cabrera-Pérez MÁ.: In Silico Prediction of Caco-2 Cell Permeability by a Classification QSAR Approach. Mol Inform, Volume 30 (4), 376-385, 2011"
"1-ethyl-6-fluoro-4-oxo-7-piperazin-1-ylquinoline-3-carboxylic acid";MM00768;CCn1cc(C(=O)O)c(=O)c2cc(F)c(N3CCNCC3)cc21;OGJPXUAPXNRGGI-UHFFFAOYSA-N;319.336;1.27;4539;DB01059;;CHEMBL9;CACO;ECACO;37;;;;;;;;;;;-5.72125;;;;;;;;;;;;"DOI: 10.1002/minf.201000118";"Pham The H, González-Álvarez I, Bermejo M, Mangas Sanjuan V, Mangas Sanjuan V, Centelles I, Garrigues TM, Cabrera-Pérez MÁ.: In Silico Prediction of Caco-2 Cell Permeability by a Classification QSAR Approach. Mol Inform, Volume 30 (4), 376-385, 2011"
Viblastine;MM15160;;;;;;;;;CACO;ECACO;37;;;;;;;;;;;-5.63827;;;;;;;;;;;;"DOI: 10.1002/minf.201000118";"Pham The H, González-Álvarez I, Bermejo M, Mangas Sanjuan V, Mangas Sanjuan V, Centelles I, Garrigues TM, Cabrera-Pérez MÁ.: In Silico Prediction of Caco-2 Cell Permeability by a Classification QSAR Approach. Mol Inform, Volume 30 (4), 376-385, 2011"
Fexofenadine;MM00735;CC(C)(C(=O)O)c1ccc(C(O)CCCN2CCC(C(O)(c3ccccc3)c3ccccc3)CC2)cc1;RWTNPBWLLIMQHL-UHFFFAOYSA-N;501.667;5.51;3348;DB00950;;CHEMBL914;CACO;ECACO;37;;;;;;;;;;;-7;;;;;;;;;;;;"DOI: 10.1002/minf.201000118";"Pham The H, González-Álvarez I, Bermejo M, Mangas Sanjuan V, Mangas Sanjuan V, Centelles I, Garrigues TM, Cabrera-Pérez MÁ.: In Silico Prediction of Caco-2 Cell Permeability by a Classification QSAR Approach. Mol Inform, Volume 30 (4), 376-385, 2011"
2-[4-[2-hydroxy-3-(propan-2-ylamino)propoxy]phenyl]acetamide;MM00078;CC(C)NC[C@@H](O)COc1ccc(CC(N)=O)cc1;METKIMKYRPQLGS-UHFFFAOYSA-N;266.341;0.45;2249;DB00335;;CHEMBL24;CACO;ECACO;37;;;;;;;;;;;-5.58503;;;;;;;;;;;;"DOI: 10.1002/minf.201000118";"Pham The H, González-Álvarez I, Bermejo M, Mangas Sanjuan V, Mangas Sanjuan V, Centelles I, Garrigues TM, Cabrera-Pérez MÁ.: In Silico Prediction of Caco-2 Cell Permeability by a Classification QSAR Approach. Mol Inform, Volume 30 (4), 376-385, 2011"
1,3-dimethyl-7H-purine-2,6-dione;MM00048;Cn1c(=O)c2nc[nH]c2n(C)c1=O;ZFXYFBGIUFBOJW-UHFFFAOYSA-N;180.167;-1.04;2153;DB00277;TEP;CHEMBL190;CACO;ECACO;37;;;;;;;;;;;-5.02687;;;;;;;;;;;;"DOI: 10.1002/minf.201000118";"Pham The H, González-Álvarez I, Bermejo M, Mangas Sanjuan V, Mangas Sanjuan V, Centelles I, Garrigues TM, Cabrera-Pérez MÁ.: In Silico Prediction of Caco-2 Cell Permeability by a Classification QSAR Approach. Mol Inform, Volume 30 (4), 376-385, 2011"
1-[4-(2-methoxyethyl)phenoxy]-3-(propan-2-ylamino)propan-2-ol;MM00275;COCCc1ccc(OCC(O)CNC(C)C)cc1;IUBSYMUCCVWXPE-UHFFFAOYSA-N;267.369;1.61;4171;DB00264;;CHEMBL13;CACO;ECACO;37;;;;;;;;;;;-4.67162;;;;;;;;;;;;"DOI: 10.1002/minf.201000118";"Pham The H, González-Álvarez I, Bermejo M, Mangas Sanjuan V, Mangas Sanjuan V, Centelles I, Garrigues TM, Cabrera-Pérez MÁ.: In Silico Prediction of Caco-2 Cell Permeability by a Classification QSAR Approach. Mol Inform, Volume 30 (4), 376-385, 2011"
Verapamil;MM00585;COc1ccc(CCN(C)CCCC(C#N)(c2ccc(OC)c(OC)c2)C(C)C)cc1OC;SGTNSNPWRIOYBX-UHFFFAOYSA-N;454.611;5.09;2520;DB00661;;CHEMBL6966;CACO;ECACO;37;;;;;;;;;;;-4.67778;;;;;;;;;;;;"DOI: 10.1002/minf.201000118";"Pham The H, González-Álvarez I, Bermejo M, Mangas Sanjuan V, Mangas Sanjuan V, Centelles I, Garrigues TM, Cabrera-Pérez MÁ.: In Silico Prediction of Caco-2 Cell Permeability by a Classification QSAR Approach. Mol Inform, Volume 30 (4), 376-385, 2011"
Sumatripan;MM15215;;;;;;;;;CACO;ECACO;37;;;;;;;;;;;-5.52288;;;;;;;;;;;;"Riedmaier AE, DeMent K, Huckle J, Bransford P, Stillhart C, Lloyd R, Alluri R, Basu S, Chen Y, Dhamankar V, Dodd S, Kulkarni P, Olivares-Morales A, Peng CC, Pepin X, Ren X, Tran T, Tistaert C, Heimbach T, Kesisoglou F, Wagner C, Parrott N.: Use of Physiologically Based Pharmacokinetic (PBPK) Modeling for Predicting Drug-Food Interactions: an Industry Perspective. AAPS J, Volume 22 (6), 2020";"Yee S. In Vitro Permeability Across Caco-2 Cells (Colonic) Can Predict In Vivo (Small Intestinal) Absorption in Man—Fact or Myth. Pharm Res. 1997, 14, 763-766"
PEG900;MM15216;;;;;;;;;CACO;ECACO;37;;"Polyethylene glycol MW 900";;;;;;;;;-6.08092;;;;;;;;;;;;"Riedmaier AE, DeMent K, Huckle J, Bransford P, Stillhart C, Lloyd R, Alluri R, Basu S, Chen Y, Dhamankar V, Dodd S, Kulkarni P, Olivares-Morales A, Peng CC, Pepin X, Ren X, Tran T, Tistaert C, Heimbach T, Kesisoglou F, Wagner C, Parrott N.: Use of Physiologically Based Pharmacokinetic (PBPK) Modeling for Predicting Drug-Food Interactions: an Industry Perspective. AAPS J, Volume 22 (6), 2020";"Yee S. In Vitro Permeability Across Caco-2 Cells (Colonic) Can Predict In Vivo (Small Intestinal) Absorption in Man—Fact or Myth. Pharm Res. 1997, 14, 763-766"
PEG4000;MM15217;;;;;8117;;;;CACO;ECACO;37;;"Polyethylene glycol MW 4000";;;;;;;;;-6.10791;;;;;;;;;;;;"Riedmaier AE, DeMent K, Huckle J, Bransford P, Stillhart C, Lloyd R, Alluri R, Basu S, Chen Y, Dhamankar V, Dodd S, Kulkarni P, Olivares-Morales A, Peng CC, Pepin X, Ren X, Tran T, Tistaert C, Heimbach T, Kesisoglou F, Wagner C, Parrott N.: Use of Physiologically Based Pharmacokinetic (PBPK) Modeling for Predicting Drug-Food Interactions: an Industry Perspective. AAPS J, Volume 22 (6), 2020";"Yee S. In Vitro Permeability Across Caco-2 Cells (Colonic) Can Predict In Vivo (Small Intestinal) Absorption in Man—Fact or Myth. Pharm Res. 1997, 14, 763-766"
2-amino-9-(2-hydroxyethoxymethyl)-3H-purin-6-one;MM00074;Nc1nc(=O)c2ncn(COCCO)c2[nH]1;MKUXAQIIEYXACX-UHFFFAOYSA-N;225.208;-0.92;2022;DB00787;AC2;CHEMBL184;CACO;ECACO;37;;;;;;;;;;;-5.69897;;;;;;;;;;;;"Riedmaier AE, DeMent K, Huckle J, Bransford P, Stillhart C, Lloyd R, Alluri R, Basu S, Chen Y, Dhamankar V, Dodd S, Kulkarni P, Olivares-Morales A, Peng CC, Pepin X, Ren X, Tran T, Tistaert C, Heimbach T, Kesisoglou F, Wagner C, Parrott N.: Use of Physiologically Based Pharmacokinetic (PBPK) Modeling for Predicting Drug-Food Interactions: an Industry Perspective. AAPS J, Volume 22 (6), 2020";"Yee S. In Vitro Permeability Across Caco-2 Cells (Colonic) Can Predict In Vivo (Small Intestinal) Absorption in Man—Fact or Myth. Pharm Res. 1997, 14, 763-766"
Erythromycin;MM00489;CCC1OC(=O)C(C)C(OC2CC(C)(OC)C(O)C(C)O2)C(C)C(OC2OC(C)CC(N(C)C)C2O)C(C)(O)CC(C)C(=O)C(C)C(O)C1(C)O;ULGZDMOVFRHVEP-UHFFFAOYSA-N;733.937;1.79;12560;DB00199;ERY;CHEMBL532;CACO;ECACO;37;;;;;;;;;;;-5.42829;;;;;;;;;;;;"Riedmaier AE, DeMent K, Huckle J, Bransford P, Stillhart C, Lloyd R, Alluri R, Basu S, Chen Y, Dhamankar V, Dodd S, Kulkarni P, Olivares-Morales A, Peng CC, Pepin X, Ren X, Tran T, Tistaert C, Heimbach T, Kesisoglou F, Wagner C, Parrott N.: Use of Physiologically Based Pharmacokinetic (PBPK) Modeling for Predicting Drug-Food Interactions: an Industry Perspective. AAPS J, Volume 22 (6), 2020";"Yee S. In Vitro Permeability Across Caco-2 Cells (Colonic) Can Predict In Vivo (Small Intestinal) Absorption in Man—Fact or Myth. Pharm Res. 1997, 14, 763-766"
Doxorubicin;MM00485;COc1cccc2c1C(=O)c1c(O)c3c(c(O)c1C2=O)C[C@@](O)(C(=O)CO)C[C@@H]3O[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1;AOJJSUZBOXZQNB-TZSSRYMLSA-N;543.525;;31703;DB00997;DM2;CHEMBL53463;CACO;ECACO;37;;;;;;;;;;;-6.79588;;;;;;;;;;;;"Riedmaier AE, DeMent K, Huckle J, Bransford P, Stillhart C, Lloyd R, Alluri R, Basu S, Chen Y, Dhamankar V, Dodd S, Kulkarni P, Olivares-Morales A, Peng CC, Pepin X, Ren X, Tran T, Tistaert C, Heimbach T, Kesisoglou F, Wagner C, Parrott N.: Use of Physiologically Based Pharmacokinetic (PBPK) Modeling for Predicting Drug-Food Interactions: an Industry Perspective. AAPS J, Volume 22 (6), 2020";"Yee S. In Vitro Permeability Across Caco-2 Cells (Colonic) Can Predict In Vivo (Small Intestinal) Absorption in Man—Fact or Myth. Pharm Res. 1997, 14, 763-766"
(2R,3R,4R,5R)-hexane-1,2,3,4,5,6-hexol;MM00386;OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO;FBPFZTCFMRRESA-KVTDHHQDSA-N;182.172;-3.59;6251;DB00742;MTL;CHEMBL689;CACO;ECACO;37;;;;;;;;;;;-6.18709;;;;;;;;;;;;"Riedmaier AE, DeMent K, Huckle J, Bransford P, Stillhart C, Lloyd R, Alluri R, Basu S, Chen Y, Dhamankar V, Dodd S, Kulkarni P, Olivares-Morales A, Peng CC, Pepin X, Ren X, Tran T, Tistaert C, Heimbach T, Kesisoglou F, Wagner C, Parrott N.: Use of Physiologically Based Pharmacokinetic (PBPK) Modeling for Predicting Drug-Food Interactions: an Industry Perspective. AAPS J, Volume 22 (6), 2020";"Yee S. In Vitro Permeability Across Caco-2 Cells (Colonic) Can Predict In Vivo (Small Intestinal) Absorption in Man—Fact or Myth. Pharm Res. 1997, 14, 763-766"
"2-aminoacetic acid";MM00741;NCC(=O)O;DHMQDGOQFOQNFH-UHFFFAOYSA-N;75.067;-0.97;750;DB00145;GLY;CHEMBL773;CACO;ECACO;37;;;;;;;;;;;-4.09691;;;;;;;;;;;;"Riedmaier AE, DeMent K, Huckle J, Bransford P, Stillhart C, Lloyd R, Alluri R, Basu S, Chen Y, Dhamankar V, Dodd S, Kulkarni P, Olivares-Morales A, Peng CC, Pepin X, Ren X, Tran T, Tistaert C, Heimbach T, Kesisoglou F, Wagner C, Parrott N.: Use of Physiologically Based Pharmacokinetic (PBPK) Modeling for Predicting Drug-Food Interactions: an Industry Perspective. AAPS J, Volume 22 (6), 2020";"Yee S. In Vitro Permeability Across Caco-2 Cells (Colonic) Can Predict In Vivo (Small Intestinal) Absorption in Man—Fact or Myth. Pharm Res. 1997, 14, 763-766"
Azithromycin;MM12580;CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(O)C[C@@H](C)CN(C)[C@H](C)[C@@H](O)[C@]1(C)O;MQTOSJVFKKJCRP-UHFFFAOYSA-N;749;1.9;2269;;;;CACO;ECACO;37;;;;;;;;;;;-5.98297;;;;;;;;;;;;"Riedmaier AE, DeMent K, Huckle J, Bransford P, Stillhart C, Lloyd R, Alluri R, Basu S, Chen Y, Dhamankar V, Dodd S, Kulkarni P, Olivares-Morales A, Peng CC, Pepin X, Ren X, Tran T, Tistaert C, Heimbach T, Kesisoglou F, Wagner C, Parrott N.: Use of Physiologically Based Pharmacokinetic (PBPK) Modeling for Predicting Drug-Food Interactions: an Industry Perspective. AAPS J, Volume 22 (6), 2020";"Yee S. In Vitro Permeability Across Caco-2 Cells (Colonic) Can Predict In Vivo (Small Intestinal) Absorption in Man—Fact or Myth. Pharm Res. 1997, 14, 763-766"
Caffeine;MM00040;Cn1c(=O)c2c(ncn2C)n(C)c1=O;RYYVLZVUVIJVGH-UHFFFAOYSA-N;194.194;-1.03;2519;DB00201;CFF;CHEMBL113;CACO;ECACO;37;;;;;;;;;;;-4.29671;;;;;;;;;;;;"Riedmaier AE, DeMent K, Huckle J, Bransford P, Stillhart C, Lloyd R, Alluri R, Basu S, Chen Y, Dhamankar V, Dodd S, Kulkarni P, Olivares-Morales A, Peng CC, Pepin X, Ren X, Tran T, Tistaert C, Heimbach T, Kesisoglou F, Wagner C, Parrott N.: Use of Physiologically Based Pharmacokinetic (PBPK) Modeling for Predicting Drug-Food Interactions: an Industry Perspective. AAPS J, Volume 22 (6), 2020";"Yee S. In Vitro Permeability Across Caco-2 Cells (Colonic) Can Predict In Vivo (Small Intestinal) Absorption in Man—Fact or Myth. Pharm Res. 1997, 14, 763-766"
1-cyano-2-methyl-3-[2-[(5-methyl-1H-imidazol-4-yl)methylsulfanyl]ethyl]guanidine;MM00463;CNC(=NCCSCc1nc[nH]c1C)NC#N;AQIXAKUUQRKLND-UHFFFAOYSA-N;252.34;0.6;2756;DB00501;;CHEMBL30;CACO;ECACO;37;;;;;;;;;;;-5.51428;;;;;;;;;;;;"Riedmaier AE, DeMent K, Huckle J, Bransford P, Stillhart C, Lloyd R, Alluri R, Basu S, Chen Y, Dhamankar V, Dodd S, Kulkarni P, Olivares-Morales A, Peng CC, Pepin X, Ren X, Tran T, Tistaert C, Heimbach T, Kesisoglou F, Wagner C, Parrott N.: Use of Physiologically Based Pharmacokinetic (PBPK) Modeling for Predicting Drug-Food Interactions: an Industry Perspective. AAPS J, Volume 22 (6), 2020";"Yee S. In Vitro Permeability Across Caco-2 Cells (Colonic) Can Predict In Vivo (Small Intestinal) Absorption in Man—Fact or Myth. Pharm Res. 1997, 14, 763-766"
CP-W;MM15218;;;;;;;;;CACO;ECACO;37;;;;;;;;;;;-5.50585;;;;;;;;;;;;"Riedmaier AE, DeMent K, Huckle J, Bransford P, Stillhart C, Lloyd R, Alluri R, Basu S, Chen Y, Dhamankar V, Dodd S, Kulkarni P, Olivares-Morales A, Peng CC, Pepin X, Ren X, Tran T, Tistaert C, Heimbach T, Kesisoglou F, Wagner C, Parrott N.: Use of Physiologically Based Pharmacokinetic (PBPK) Modeling for Predicting Drug-Food Interactions: an Industry Perspective. AAPS J, Volume 22 (6), 2020";"Yee S. In Vitro Permeability Across Caco-2 Cells (Colonic) Can Predict In Vivo (Small Intestinal) Absorption in Man—Fact or Myth. Pharm Res. 1997, 14, 763-766"
2,2-dichloro-N-[(1R,2R)-1,3-dihydroxy-1-(4-nitrophenyl)propan-2-yl]acetamide;MM00342;O=C(NC(CO)C(O)c1ccc([N+](=O)[O-])cc1)C(Cl)Cl;WIIZWVCIJKGZOK-UHFFFAOYSA-N;323.126;0.91;5959;DB00446;CLM;CHEMBL130;CACO;ECACO;37;;;;;;;;;;;-4.68613;;;;;;;;;;;;"Riedmaier AE, DeMent K, Huckle J, Bransford P, Stillhart C, Lloyd R, Alluri R, Basu S, Chen Y, Dhamankar V, Dodd S, Kulkarni P, Olivares-Morales A, Peng CC, Pepin X, Ren X, Tran T, Tistaert C, Heimbach T, Kesisoglou F, Wagner C, Parrott N.: Use of Physiologically Based Pharmacokinetic (PBPK) Modeling for Predicting Drug-Food Interactions: an Industry Perspective. AAPS J, Volume 22 (6), 2020";"Yee S. In Vitro Permeability Across Caco-2 Cells (Colonic) Can Predict In Vivo (Small Intestinal) Absorption in Man—Fact or Myth. Pharm Res. 1997, 14, 763-766"
Noloxone;MM15219;;;;;;;;;CACO;ECACO;37;;;;;;;;;;;-4.54975;;;;;;;;;;;;"Riedmaier AE, DeMent K, Huckle J, Bransford P, Stillhart C, Lloyd R, Alluri R, Basu S, Chen Y, Dhamankar V, Dodd S, Kulkarni P, Olivares-Morales A, Peng CC, Pepin X, Ren X, Tran T, Tistaert C, Heimbach T, Kesisoglou F, Wagner C, Parrott N.: Use of Physiologically Based Pharmacokinetic (PBPK) Modeling for Predicting Drug-Food Interactions: an Industry Perspective. AAPS J, Volume 22 (6), 2020";"Yee S. In Vitro Permeability Across Caco-2 Cells (Colonic) Can Predict In Vivo (Small Intestinal) Absorption in Man—Fact or Myth. Pharm Res. 1997, 14, 763-766"
"(2S)-2-[[4-[(2,4-diaminopteridin-6-yl)methyl-methylamino]benzoyl]amino]pentanedioic acid";MM00270;CN(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(C(=O)NC(CCC(=O)O)C(=O)O)cc1;FBOZXECLQNJBKD-UHFFFAOYSA-N;454.447;0.27;126941;DB00563;MTX;CHEMBL34259;CACO;ECACO;37;;;;;;;;;;;-5.92082;;;;;;;;;;;;"Riedmaier AE, DeMent K, Huckle J, Bransford P, Stillhart C, Lloyd R, Alluri R, Basu S, Chen Y, Dhamankar V, Dodd S, Kulkarni P, Olivares-Morales A, Peng CC, Pepin X, Ren X, Tran T, Tistaert C, Heimbach T, Kesisoglou F, Wagner C, Parrott N.: Use of Physiologically Based Pharmacokinetic (PBPK) Modeling for Predicting Drug-Food Interactions: an Industry Perspective. AAPS J, Volume 22 (6), 2020";"Yee S. In Vitro Permeability Across Caco-2 Cells (Colonic) Can Predict In Vivo (Small Intestinal) Absorption in Man—Fact or Myth. Pharm Res. 1997, 14, 763-766"
"Acetylsalycic acid";MM15220;;;;;;;;;CACO;ECACO;37;;;;;;;;;;;-4.51329;;;;;;;;;;;;"Riedmaier AE, DeMent K, Huckle J, Bransford P, Stillhart C, Lloyd R, Alluri R, Basu S, Chen Y, Dhamankar V, Dodd S, Kulkarni P, Olivares-Morales A, Peng CC, Pepin X, Ren X, Tran T, Tistaert C, Heimbach T, Kesisoglou F, Wagner C, Parrott N.: Use of Physiologically Based Pharmacokinetic (PBPK) Modeling for Predicting Drug-Food Interactions: an Industry Perspective. AAPS J, Volume 22 (6), 2020";"Yee S. In Vitro Permeability Across Caco-2 Cells (Colonic) Can Predict In Vivo (Small Intestinal) Absorption in Man—Fact or Myth. Pharm Res. 1997, 14, 763-766"
"Benzyl Penicillins";MM15221;;;;;;;;;CACO;ECACO;37;;;;;;;;;;;-5.70774;;;;;;;;;;;;"Riedmaier AE, DeMent K, Huckle J, Bransford P, Stillhart C, Lloyd R, Alluri R, Basu S, Chen Y, Dhamankar V, Dodd S, Kulkarni P, Olivares-Morales A, Peng CC, Pepin X, Ren X, Tran T, Tistaert C, Heimbach T, Kesisoglou F, Wagner C, Parrott N.: Use of Physiologically Based Pharmacokinetic (PBPK) Modeling for Predicting Drug-Food Interactions: an Industry Perspective. AAPS J, Volume 22 (6), 2020";"Yee S. In Vitro Permeability Across Caco-2 Cells (Colonic) Can Predict In Vivo (Small Intestinal) Absorption in Man—Fact or Myth. Pharm Res. 1997, 14, 763-766"
Dexamethasone;MM00355;C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO;UREBDLICKHMUKA-CXSFZGCWSA-N;392.467;1.9;5743;DB01234;DEX;CHEMBL384467;CACO;ECACO;37;;;;;;;;;;;-4.63078;;;;;;;;;;;;"Riedmaier AE, DeMent K, Huckle J, Bransford P, Stillhart C, Lloyd R, Alluri R, Basu S, Chen Y, Dhamankar V, Dodd S, Kulkarni P, Olivares-Morales A, Peng CC, Pepin X, Ren X, Tran T, Tistaert C, Heimbach T, Kesisoglou F, Wagner C, Parrott N.: Use of Physiologically Based Pharmacokinetic (PBPK) Modeling for Predicting Drug-Food Interactions: an Industry Perspective. AAPS J, Volume 22 (6), 2020";"Yee S. In Vitro Permeability Across Caco-2 Cells (Colonic) Can Predict In Vivo (Small Intestinal) Absorption in Man—Fact or Myth. Pharm Res. 1997, 14, 763-766"
Tenidap;MM15222;;;;;60712;;;;CACO;ECACO;37;;;;;;;;;;;-4.29073;;;;;;;;;;;;"Riedmaier AE, DeMent K, Huckle J, Bransford P, Stillhart C, Lloyd R, Alluri R, Basu S, Chen Y, Dhamankar V, Dodd S, Kulkarni P, Olivares-Morales A, Peng CC, Pepin X, Ren X, Tran T, Tistaert C, Heimbach T, Kesisoglou F, Wagner C, Parrott N.: Use of Physiologically Based Pharmacokinetic (PBPK) Modeling for Predicting Drug-Food Interactions: an Industry Perspective. AAPS J, Volume 22 (6), 2020";"Yee S. In Vitro Permeability Across Caco-2 Cells (Colonic) Can Predict In Vivo (Small Intestinal) Absorption in Man—Fact or Myth. Pharm Res. 1997, 14, 763-766"
Prasozin;MM15223;;;;;;;;;CACO;ECACO;37;;;;;;;;;;;-4.36051;;;;;;;;;;;;"Riedmaier AE, DeMent K, Huckle J, Bransford P, Stillhart C, Lloyd R, Alluri R, Basu S, Chen Y, Dhamankar V, Dodd S, Kulkarni P, Olivares-Morales A, Peng CC, Pepin X, Ren X, Tran T, Tistaert C, Heimbach T, Kesisoglou F, Wagner C, Parrott N.: Use of Physiologically Based Pharmacokinetic (PBPK) Modeling for Predicting Drug-Food Interactions: an Industry Perspective. AAPS J, Volume 22 (6), 2020";"Yee S. In Vitro Permeability Across Caco-2 Cells (Colonic) Can Predict In Vivo (Small Intestinal) Absorption in Man—Fact or Myth. Pharm Res. 1997, 14, 763-766"
"Valproic acid";MM00711;CCCC(CCC)C(=O)O;NIJJYAXOARWZEE-UHFFFAOYSA-N;144.214;2.29;3121;DB00313;2PP;CHEMBL109;CACO;ECACO;37;;;;;;;;;;;-4.31876;;;;;;;;;;;;"Riedmaier AE, DeMent K, Huckle J, Bransford P, Stillhart C, Lloyd R, Alluri R, Basu S, Chen Y, Dhamankar V, Dodd S, Kulkarni P, Olivares-Morales A, Peng CC, Pepin X, Ren X, Tran T, Tistaert C, Heimbach T, Kesisoglou F, Wagner C, Parrott N.: Use of Physiologically Based Pharmacokinetic (PBPK) Modeling for Predicting Drug-Food Interactions: an Industry Perspective. AAPS J, Volume 22 (6), 2020";"Yee S. In Vitro Permeability Across Caco-2 Cells (Colonic) Can Predict In Vivo (Small Intestinal) Absorption in Man—Fact or Myth. Pharm Res. 1997, 14, 763-766"
(S)-[(2R,4S,5R)-5-ethenyl-1-azabicyclo[2.2.2]octan-2-yl]-(6-methoxyquinolin-4-yl)methanol;MM00558;C=C[C@H]1CN2CC[C@H]1C[C@@H]2[C@@H](O)c1ccnc2ccc(OC)cc12;LOUPRKONTZGTKE-LHHVKLHASA-N;324.424;3.17;441074;DB00908;QDN;CHEMBL1294;CACO;ECACO;37;;;;;;;;;;;-4.69037;;;;;;;;;;;;"Riedmaier AE, DeMent K, Huckle J, Bransford P, Stillhart C, Lloyd R, Alluri R, Basu S, Chen Y, Dhamankar V, Dodd S, Kulkarni P, Olivares-Morales A, Peng CC, Pepin X, Ren X, Tran T, Tistaert C, Heimbach T, Kesisoglou F, Wagner C, Parrott N.: Use of Physiologically Based Pharmacokinetic (PBPK) Modeling for Predicting Drug-Food Interactions: an Industry Perspective. AAPS J, Volume 22 (6), 2020";"Yee S. In Vitro Permeability Across Caco-2 Cells (Colonic) Can Predict In Vivo (Small Intestinal) Absorption in Man—Fact or Myth. Pharm Res. 1997, 14, 763-766"
1-naphthalen-1-yloxy-3-(propan-2-ylamino)propan-2-ol;MM00085;CC(C)NCC(O)COc1cccc2ccccc12;AQHHHDLHHXJYJD-UHFFFAOYSA-N;259.349;2.58;4946;DB00571;;CHEMBL27;CACO;ECACO;37;;;;;;;;;;;-4.56067;;;;;;;;;;;;"Riedmaier AE, DeMent K, Huckle J, Bransford P, Stillhart C, Lloyd R, Alluri R, Basu S, Chen Y, Dhamankar V, Dodd S, Kulkarni P, Olivares-Morales A, Peng CC, Pepin X, Ren X, Tran T, Tistaert C, Heimbach T, Kesisoglou F, Wagner C, Parrott N.: Use of Physiologically Based Pharmacokinetic (PBPK) Modeling for Predicting Drug-Food Interactions: an Industry Perspective. AAPS J, Volume 22 (6), 2020";"Yee S. In Vitro Permeability Across Caco-2 Cells (Colonic) Can Predict In Vivo (Small Intestinal) Absorption in Man—Fact or Myth. Pharm Res. 1997, 14, 763-766"
Trovoflaxin;MM15224;;;;;;;;;CACO;ECACO;37;;;;;;;;;;;-4.51956;;;;;;;;;;;;"Riedmaier AE, DeMent K, Huckle J, Bransford P, Stillhart C, Lloyd R, Alluri R, Basu S, Chen Y, Dhamankar V, Dodd S, Kulkarni P, Olivares-Morales A, Peng CC, Pepin X, Ren X, Tran T, Tistaert C, Heimbach T, Kesisoglou F, Wagner C, Parrott N.: Use of Physiologically Based Pharmacokinetic (PBPK) Modeling for Predicting Drug-Food Interactions: an Industry Perspective. AAPS J, Volume 22 (6), 2020";"Yee S. In Vitro Permeability Across Caco-2 Cells (Colonic) Can Predict In Vivo (Small Intestinal) Absorption in Man—Fact or Myth. Pharm Res. 1997, 14, 763-766"
Ibuprofen;MM00045;CC(C)Cc1ccc(C(C)C(=O)O)cc1;HEFNNWSXXWATRW-UHFFFAOYSA-N;206.285;3.07;3672;DB01050;;CHEMBL521;CACO;ECACO;37;;;;;;;;;;;-4.27984;;;;;;;;;;;;"Riedmaier AE, DeMent K, Huckle J, Bransford P, Stillhart C, Lloyd R, Alluri R, Basu S, Chen Y, Dhamankar V, Dodd S, Kulkarni P, Olivares-Morales A, Peng CC, Pepin X, Ren X, Tran T, Tistaert C, Heimbach T, Kesisoglou F, Wagner C, Parrott N.: Use of Physiologically Based Pharmacokinetic (PBPK) Modeling for Predicting Drug-Food Interactions: an Industry Perspective. AAPS J, Volume 22 (6), 2020";"Yee S. In Vitro Permeability Across Caco-2 Cells (Colonic) Can Predict In Vivo (Small Intestinal) Absorption in Man—Fact or Myth. Pharm Res. 1997, 14, 763-766"
7-chloro-1-methyl-5-phenyl-3H-1,4-benzodiazepin-2-one;MM00094;CN1C(=O)CN=C(c2ccccc2)c2cc(Cl)ccc21;AAOVKJBEBIDNHE-UHFFFAOYSA-N;284.743;3.15;3016;DB00829;DZP;CHEMBL12;CACO;ECACO;37;;;;;;;;;;;-4.14893;;;;;;;;;;;;"Riedmaier AE, DeMent K, Huckle J, Bransford P, Stillhart C, Lloyd R, Alluri R, Basu S, Chen Y, Dhamankar V, Dodd S, Kulkarni P, Olivares-Morales A, Peng CC, Pepin X, Ren X, Tran T, Tistaert C, Heimbach T, Kesisoglou F, Wagner C, Parrott N.: Use of Physiologically Based Pharmacokinetic (PBPK) Modeling for Predicting Drug-Food Interactions: an Industry Perspective. AAPS J, Volume 22 (6), 2020";"Yee S. In Vitro Permeability Across Caco-2 Cells (Colonic) Can Predict In Vivo (Small Intestinal) Absorption in Man—Fact or Myth. Pharm Res. 1997, 14, 763-766"
N-(2,6-dichlorophenyl)-4,5-dihydro-1H-imidazol-2-amine;MM00344;Clc1cccc(Cl)c1N=C1NCCN1;GJSURZIOUXUGAL-UHFFFAOYSA-N;230.09;2.17;2803;DB00575;CLU;CHEMBL134;CACO;ECACO;37;;;;;;;;;;;-4.52143;;;;;;;;;;;;"Riedmaier AE, DeMent K, Huckle J, Bransford P, Stillhart C, Lloyd R, Alluri R, Basu S, Chen Y, Dhamankar V, Dodd S, Kulkarni P, Olivares-Morales A, Peng CC, Pepin X, Ren X, Tran T, Tistaert C, Heimbach T, Kesisoglou F, Wagner C, Parrott N.: Use of Physiologically Based Pharmacokinetic (PBPK) Modeling for Predicting Drug-Food Interactions: an Industry Perspective. AAPS J, Volume 22 (6), 2020";"Yee S. In Vitro Permeability Across Caco-2 Cells (Colonic) Can Predict In Vivo (Small Intestinal) Absorption in Man—Fact or Myth. Pharm Res. 1997, 14, 763-766"
Fluconazole;MM12535;OC(Cn1cncn1)(Cn1cncn1)c1ccc(F)cc1F;RFHAOTPXVQNOHP-UHFFFAOYSA-N;306.28;0.74;3365;;;;CACO;ECACO;37;;;;;;;;;;;-4.52578;;;;;;;;;;;;"Riedmaier AE, DeMent K, Huckle J, Bransford P, Stillhart C, Lloyd R, Alluri R, Basu S, Chen Y, Dhamankar V, Dodd S, Kulkarni P, Olivares-Morales A, Peng CC, Pepin X, Ren X, Tran T, Tistaert C, Heimbach T, Kesisoglou F, Wagner C, Parrott N.: Use of Physiologically Based Pharmacokinetic (PBPK) Modeling for Predicting Drug-Food Interactions: an Industry Perspective. AAPS J, Volume 22 (6), 2020";"Yee S. In Vitro Permeability Across Caco-2 Cells (Colonic) Can Predict In Vivo (Small Intestinal) Absorption in Man—Fact or Myth. Pharm Res. 1997, 14, 763-766"
3-(5,6-dihydrobenzo[b][1]benzazepin-11-yl)-N-methylpropan-1-amine;MM00474;CNCCCN1c2ccccc2CCc2ccccc21;HCYAFALTSJYZDH-UHFFFAOYSA-N;266.388;3.53;2995;DB01151;DSM;CHEMBL72;CACO;ECACO;37;;;;;;;;;;;-4.66555;;;;;;;;;;;;"Riedmaier AE, DeMent K, Huckle J, Bransford P, Stillhart C, Lloyd R, Alluri R, Basu S, Chen Y, Dhamankar V, Dodd S, Kulkarni P, Olivares-Morales A, Peng CC, Pepin X, Ren X, Tran T, Tistaert C, Heimbach T, Kesisoglou F, Wagner C, Parrott N.: Use of Physiologically Based Pharmacokinetic (PBPK) Modeling for Predicting Drug-Food Interactions: an Industry Perspective. AAPS J, Volume 22 (6), 2020";"Yee S. In Vitro Permeability Across Caco-2 Cells (Colonic) Can Predict In Vivo (Small Intestinal) Absorption in Man—Fact or Myth. Pharm Res. 1997, 14, 763-766"
Testosterone;MM00423;CC12CCC(=O)C=C1CCC1C2CCC2(C)C(O)CCC12;MUMGGOZAMZWBJJ-UHFFFAOYSA-N;288.431;3.88;6013;DB00624;TES;CHEMBL386630;CACO;ECACO;37;;;;;;;;;;;-4.14104;;;;;;;;;;;;"Riedmaier AE, DeMent K, Huckle J, Bransford P, Stillhart C, Lloyd R, Alluri R, Basu S, Chen Y, Dhamankar V, Dodd S, Kulkarni P, Olivares-Morales A, Peng CC, Pepin X, Ren X, Tran T, Tistaert C, Heimbach T, Kesisoglou F, Wagner C, Parrott N.: Use of Physiologically Based Pharmacokinetic (PBPK) Modeling for Predicting Drug-Food Interactions: an Industry Perspective. AAPS J, Volume 22 (6), 2020";"Yee S. In Vitro Permeability Across Caco-2 Cells (Colonic) Can Predict In Vivo (Small Intestinal) Absorption in Man—Fact or Myth. Pharm Res. 1997, 14, 763-766"
5-[2-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]ethyl]-6-chloro-1,3-dihydroindol-2-one;MM00589;O=C1Cc2cc(CCN3CCN(c4nsc5ccccc45)CC3)c(Cl)cc2N1;MVWVFYHBGMAFLY-UHFFFAOYSA-N;412.936;3.81;60854;DB00246;;CHEMBL708;CACO;ECACO;37;;;;;;;;;;;-4.91009;;;;;;;;;;;;"Riedmaier AE, DeMent K, Huckle J, Bransford P, Stillhart C, Lloyd R, Alluri R, Basu S, Chen Y, Dhamankar V, Dodd S, Kulkarni P, Olivares-Morales A, Peng CC, Pepin X, Ren X, Tran T, Tistaert C, Heimbach T, Kesisoglou F, Wagner C, Parrott N.: Use of Physiologically Based Pharmacokinetic (PBPK) Modeling for Predicting Drug-Food Interactions: an Industry Perspective. AAPS J, Volume 22 (6), 2020";"Yee S. In Vitro Permeability Across Caco-2 Cells (Colonic) Can Predict In Vivo (Small Intestinal) Absorption in Man—Fact or Myth. Pharm Res. 1997, 14, 763-766"
3-(5,6-dihydrobenzo[b][1]benzazepin-11-yl)-N,N-dimethylpropan-1-amine;MM00504;CN(C)CCCN1c2ccccc2CCc2ccccc21;BCGWQEUPMDMJNV-UHFFFAOYSA-N;280.415;3.88;3696;DB00458;IXX;CHEMBL11;CACO;ECACO;37;;;;;;;;;;;-4.85078;;;;;;;;;;;;"Riedmaier AE, DeMent K, Huckle J, Bransford P, Stillhart C, Lloyd R, Alluri R, Basu S, Chen Y, Dhamankar V, Dodd S, Kulkarni P, Olivares-Morales A, Peng CC, Pepin X, Ren X, Tran T, Tistaert C, Heimbach T, Kesisoglou F, Wagner C, Parrott N.: Use of Physiologically Based Pharmacokinetic (PBPK) Modeling for Predicting Drug-Food Interactions: an Industry Perspective. AAPS J, Volume 22 (6), 2020";"Yee S. In Vitro Permeability Across Caco-2 Cells (Colonic) Can Predict In Vivo (Small Intestinal) Absorption in Man—Fact or Myth. Pharm Res. 1997, 14, 763-766"
D-Phe-L-Pro;MM15225;;;;;12011797;;;;CACO;ECACO;37;;;;;;;;;;;-4.3536;;;;;;;;;;;;"Riedmaier AE, DeMent K, Huckle J, Bransford P, Stillhart C, Lloyd R, Alluri R, Basu S, Chen Y, Dhamankar V, Dodd S, Kulkarni P, Olivares-Morales A, Peng CC, Pepin X, Ren X, Tran T, Tistaert C, Heimbach T, Kesisoglou F, Wagner C, Parrott N.: Use of Physiologically Based Pharmacokinetic (PBPK) Modeling for Predicting Drug-Food Interactions: an Industry Perspective. AAPS J, Volume 22 (6), 2020";"Yee S. In Vitro Permeability Across Caco-2 Cells (Colonic) Can Predict In Vivo (Small Intestinal) Absorption in Man—Fact or Myth. Pharm Res. 1997, 14, 763-766"
"Taurocholic acid";MM00691;CC(CCC(=O)NCCS(=O)(=O)O)C1CCC2C3C(O)CC4CC(O)CCC4(C)C3CC(O)C12C;WBWWGRHZICKQGZ-UHFFFAOYSA-N;515.706;2.37;6675;DB04348;TCH;CHEMBL224867;CACO;ECACO;37;;;;;;;;;;;-4.46218;;;;;;;;;;;;"Riedmaier AE, DeMent K, Huckle J, Bransford P, Stillhart C, Lloyd R, Alluri R, Basu S, Chen Y, Dhamankar V, Dodd S, Kulkarni P, Olivares-Morales A, Peng CC, Pepin X, Ren X, Tran T, Tistaert C, Heimbach T, Kesisoglou F, Wagner C, Parrott N.: Use of Physiologically Based Pharmacokinetic (PBPK) Modeling for Predicting Drug-Food Interactions: an Industry Perspective. AAPS J, Volume 22 (6), 2020";"Yee S. In Vitro Permeability Across Caco-2 Cells (Colonic) Can Predict In Vivo (Small Intestinal) Absorption in Man—Fact or Myth. Pharm Res. 1997, 14, 763-766"
CP-X;MM15226;;;;;;;;;CACO;ECACO;37;;;;;;;;;;;-4.46661;;;;;;;;;;;;"Riedmaier AE, DeMent K, Huckle J, Bransford P, Stillhart C, Lloyd R, Alluri R, Basu S, Chen Y, Dhamankar V, Dodd S, Kulkarni P, Olivares-Morales A, Peng CC, Pepin X, Ren X, Tran T, Tistaert C, Heimbach T, Kesisoglou F, Wagner C, Parrott N.: Use of Physiologically Based Pharmacokinetic (PBPK) Modeling for Predicting Drug-Food Interactions: an Industry Perspective. AAPS J, Volume 22 (6), 2020";"Yee S. In Vitro Permeability Across Caco-2 Cells (Colonic) Can Predict In Vivo (Small Intestinal) Absorption in Man—Fact or Myth. Pharm Res. 1997, 14, 763-766"
Corticosterone;MM00346;CC12CCC(=O)C=C1CCC1C2C(O)CC2(C)C(C(=O)CO)CCC12;OMFXVFTZEKFJBZ-UHFFFAOYSA-N;346.467;2.67;5753;DB04652;C0R;CHEMBL110739;CACO;QSAR-PSA;25;;;;;;;;;;;-5.065;;;;;;;;;;;;"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006";"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006"
2-(diethylamino)-N-(2,6-dimethylphenyl)acetamide;MM00092;CCN(CC)CC(=O)Nc1c(C)cccc1C;NNJVILVZKWQKPM-UHFFFAOYSA-N;234.343;2.58;3676;DB00281;LQZ;CHEMBL79;CACO;QSAR-PSA;25;;;;;;;;;;;-4.184;;;;;;;;;;;;"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006";"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006"
7-chloro-1-methyl-5-phenyl-3H-1,4-benzodiazepin-2-one;MM00094;CN1C(=O)CN=C(c2ccccc2)c2cc(Cl)ccc21;AAOVKJBEBIDNHE-UHFFFAOYSA-N;284.743;3.15;3016;DB00829;DZP;CHEMBL12;CACO;QSAR-PSA;25;;;;;;;;;;;-4.31;;;;;;;;;;;;"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006";"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006"
2-[(E)-(2,6-dichlorophenyl)methylideneamino]guanidine;MM00497;N=C(N)NN=Cc1c(Cl)cccc1Cl;WDZVGELJXXEGPV-UHFFFAOYSA-N;231.08;1.81;5702063;DB00629;;CHEMBL420;CACO;QSAR-PSA;25;;;;;;;;;;;-4.879;;;;;;;;;;;;"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006";"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006"
Chromen-2-one;MM00042;O=c1ccc2ccccc2o1;ZYGHJZDHTFUPRJ-UHFFFAOYSA-N;146.145;1.79;323;DB04665;COU;CHEMBL6466;CACO;QSAR-PSA;25;;;;;;;;;;;-3.803;;;;;;;;;;;;"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006";"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006"
"Timolol ester";MM15244;;;;;;;;;CACO;QSAR-PSA;25;;;;;;;;;;;-5.331;;;;;;;;;;;;"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006";"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006"
1-[4-(2-methoxyethyl)phenoxy]-3-(propan-2-ylamino)propan-2-ol;MM00275;COCCc1ccc(OCC(O)CNC(C)C)cc1;IUBSYMUCCVWXPE-UHFFFAOYSA-N;267.369;1.61;4171;DB00264;;CHEMBL13;CACO;QSAR-PSA;25;;;;;;;;;;;-4.491;;;;;;;;;;;;"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006";"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006"
"Oxprenolol ester";MM15245;;;;;;;;;CACO;QSAR-PSA;25;;;;;;;;;;;-4.756;;;;;;;;;;;;"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006";"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006"
"Alprenolol ester";MM15246;;;;;;;;;CACO;QSAR-PSA;25;;;;;;;;;;;-4.61;;;;;;;;;;;;"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006";"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006"
"5-[(3-carboxy-4-hydroxyphenyl)diazenyl]-2-hydroxybenzoic acid";MM01437;O=C(O)c1cc(/N=N/c2ccc(O)c(C(=O)O)c2)ccc1O;QQBDLJCYGRGAKP-FOCLMDBBSA-N;302.24;2.91;22419;DB01250;;CHEMBL1201013;CACO;QSAR-PSA;25;;;;;;;;;;;-5.859;;;;;;;;;;;;"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006";"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006"
5-[2-(tert-butylamino)-1-hydroxyethyl]benzene-1,3-diol;MM00306;CC(C)(C)NCC(O)c1cc(O)cc(O)c1;XWTYSIMOBUGWOL-UHFFFAOYSA-N;225.288;1.52;5403;DB00871;;CHEMBL1760;CACO;QSAR-PSA;25;;;;;;;;;;;-4.728;;;;;;;;;;;;"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006";"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006"
4-[(1R)-1-hydroxy-2-(methylamino)ethyl]benzene-1,2-diol;MM00644;CNCC(O)c1ccc(O)c(O)c1;UCTWMZQNUQWSLP-UHFFFAOYSA-N;183.207;0.35;5816;DB00668;ALE;CHEMBL679;CACO;QSAR-PSA;25;;;;;;;;;;;-4.659;;;;;;;;;;;;"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006";"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006"
N-(4-hydroxyphenyl)acetamide;MM00322;CC(=O)Nc1ccc(O)cc1;RZVAJINKPMORJF-UHFFFAOYSA-N;151.165;1.35;1983;DB00316;TYL;CHEMBL112;CACO;QSAR-PSA;25;;;;;;;;;;;-4.203;;;;;;;;;;;;"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006";"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006"
Acrivastine;MM00715;"Cc1ccc(/C(=C\CN2CCCC2)c2cccc(/C=C/C(=O)O)n2)cc1";PWACSDKDOHSSQD-IUTFFREVSA-N;348.446;4.02;5284514;DB09488;;CHEMBL1224;CACO;QSAR-PSA;25;;;;;;;;;;;-4.696;;;;;;;;;;;;"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006";"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006"
2-(tert-butylamino)-1-(3-chlorophenyl)propan-1-one;MM00455;C[C@H](NC(C)(C)C)C(=O)c1cccc(Cl)c1;SNPPWIUOZRMYNY-UHFFFAOYSA-N;239.743;3.3;444;DB01156;;CHEMBL894;CACO;QSAR-PSA;25;;;;;;;;;;;-4.149;;;;;;;;;;;;"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006";"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006"
Cefuroxime;MM01507;CON=C(C(=O)NC1C(=O)N2C(C(=O)O)=C(COC(N)=O)CSC12)c1ccco1;JFPVXVDWJQMJEE-IZRZKJBUSA-N;424.39;-0.54;5479529;;;;CACO;QSAR-PSA;25;;;;;;;;;;;-6.647;;;;;;;;;;;;"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006";"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006"
6-chloro-1,1-dioxo-4H-1lambda6,2,4-benzothiadiazine-7-sulfonamide;MM00641;NS(=O)(=O)c1cc2c(cc1Cl)NC=NS2(=O)=O;JBMKAUGHUNFTOL-UHFFFAOYSA-N;295.712;0.13;2720;DB00880;;CHEMBL842;CACO;QSAR-PSA;25;;;;;;;;;;;-5.65;;;;;;;;;;;;"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006";"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006"
Fluparoxan;MM01538;;;;;72036;;;;CACO;QSAR-PSA;25;;;;;;;;;;;-4.132;;;;;;;;;;;;"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006";"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006"
6-chloro-1,1-dioxo-3,4-dihydro-2H-1lambda6,2,4-benzothiadiazine-7-sulfonamide;MM00373;NS(=O)(=O)c1cc2c(cc1Cl)NCNS2(=O)=O;JZUFKLXOESDKRF-UHFFFAOYSA-N;297.728;-0.35;3639;DB00999;HCZ;CHEMBL435;CACO;QSAR-PSA;25;;;;;;;;;;;-5.705;;;;;;;;;;;;"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006";"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006"
"2-(3-benzoylphenyl)propanoic acid";MM00662;CC(C(=O)O)c1cccc(C(=O)c2ccccc2)c1;DKYWVDODHFEZIM-UHFFFAOYSA-N;254.285;3.11;3825;DB01009;;CHEMBL571;CACO;QSAR-PSA;25;;;;;;;;;;;-4.515;;;;;;;;;;;;"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006";"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006"
2-hydroxy-5-[1-hydroxy-2-(4-phenylbutan-2-ylamino)ethyl]benzamide;MM00507;CC(CCc1ccccc1)NCC(O)c1ccc(O)c(C(N)=O)c1;SGUAFYQXFOLMHL-UHFFFAOYSA-N;328.412;2.14;3869;DB00598;;CHEMBL429;CACO;QSAR-PSA;25;;;;;;;;;;;-5.421;;;;;;;;;;;;"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006";"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006"
6-(2,3-dichlorophenyl)-1,2,4-triazine-3,5-diamine;MM00383;Nc1nnc(-c2cccc(Cl)c2Cl)c(N)n1;PYZRQGJRPPTADH-UHFFFAOYSA-N;256.089;2.01;3878;DB00555;;CHEMBL741;CACO;QSAR-PSA;25;;;;;;;;;;;-5.233;;;;;;;;;;;;"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006";"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006"
(2R,3S)-5-[3-(tert-butylamino)-2-hydroxypropoxy]-1,2,3,4-tetrahydronaphthalene-2,3-diol;MM00525;CC(C)(C)NCC(O)COc1cccc2c1CC(O)C(O)C2;VWPOSFSPZNDTMJ-UHFFFAOYSA-N;309.406;0.63;39147;DB01203;;CHEMBL649;CACO;QSAR-PSA;25;;;;;;;;;;;-5.109;;;;;;;;;;;;"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006";"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006"
Netivudine;MM00395;CC#Cc1cn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)[nH]c1=O;QLOCVMVCRJOTTM-SDNRWEOFSA-N;282.252;-2.48;55281;DB12606;;CHEMBL1097615;CACO;QSAR-PSA;25;;;;;;;;;;;-5.558;;;;;;;;;;;;"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006";"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006"
"Penicillin v";MM01544;;;;;6869;;;;CACO;QSAR-PSA;25;;;;;;;;;;;-5.436;;;;;;;;;;;;"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006";"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006"
5,5-diphenylimidazolidine-2,4-dione;MM00406;O=C1N=C(O)NC1(c1ccccc1)c1ccccc1;CXOFVDLJLONNDW-UHFFFAOYSA-N;252.273;1.97;1775;DB00252;;CHEMBL16;CACO;QSAR-PSA;25;;;;;;;;;;;-4.68;;;;;;;;;;;;"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006";"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006"
Progesterone;MM00198;CC(=O)C1CCC2C3CCC4=CC(=O)CCC4(C)C3CCC12C;RJKFOVLPORLFTN-UHFFFAOYSA-N;314.469;4.72;5994;DB00396;STR;CHEMBL103;CACO;QSAR-PSA;25;;;;;;;;;;;-4.398;;;;;;;;;;;;"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006";"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006"
6-propyl-2-sulfanylidene-1H-pyrimidin-4-one;MM00415;CCCc1cc(=O)[nH]c(=S)[nH]1;KNAHARQHSZJURB-UHFFFAOYSA-N;170.23;1.38;657298;DB00550;3CJ;CHEMBL1518;CACO;QSAR-PSA;25;;;;;;;;;;;-4.19;;;;;;;;;;;;"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006";"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006"
N-[4-[1-hydroxy-2-(propan-2-ylamino)ethyl]phenyl]methanesulfonamide;MM00567;CC(C)NCC(O)c1ccc(NS(C)(=O)=O)cc1;ZBMZVLHSJCTVON-UHFFFAOYSA-N;272.363;1.09;5253;DB00489;;CHEMBL471;CACO;QSAR-PSA;25;;;;;;;;;;;-4.999;;;;;;;;;;;;"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006";"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006"
5-[(3,4,5-trimethoxyphenyl)methyl]pyrimidine-2,4-diamine;MM00581;COc1cc(Cc2cnc(N)nc2N)cc(OC)c1OC;IEDVJHCEMCRBQM-UHFFFAOYSA-N;290.323;1.26;5578;DB00440;TOP;CHEMBL22;CACO;QSAR-PSA;25;;;;;;;;;;;-5.415;;;;;;;;;;;;"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006";"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006"
"4-chloro-2-(furan-2-ylmethylamino)-5-sulfamoylbenzoic acid";MM00083;NS(=O)(=O)c1cc(C(=O)O)c(NCc2ccco2)cc1Cl;ZZUFCTLCJUWOSV-UHFFFAOYSA-N;330.739;1.89;3440;DB00695;FUN;CHEMBL35;CACO;QSAR-PSA;25;;;;;;;;;;;-5.688;;;;;;;;;;;;"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006";"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006"
Lisinopril;MM00763;NCCCCC(NC(CCc1ccccc1)C(=O)O)C(=O)N1CCCC1C(=O)O;RLAWWYSOJDYHDC-UHFFFAOYSA-N;405.495;1.24;5362119;DB00722;LPR;CHEMBL1237;CACO;QSAR-PSA;25;;;;;;;;;;;-6.159;;;;;;;;;;;;"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006";"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006"
Loracarbef;MM01552;NC(C(=O)NC1C(=O)N2C(C(=O)O)=C(Cl)CCC12)c1ccccc1;JAPHQRWPEGVNBT-UHFFFAOYSA-N;349.77;0.71;5284585;;;;CACO;QSAR-PSA;25;;;;;;;;;;;-5.65;;;;;;;;;;;;"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006";"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006"
Cefatrizine;MM00719;N[C@@H](C(=O)N[C@@H]1C(=O)N2C(C(=O)O)=C(CSc3cn[nH]n3)CS[C@H]12)c1ccc(O)cc1;UOCJDOLVGGIYIQ-PBFPGSCMSA-N;462.499;0.04;6410758;DB13266;;CHEMBL1095284;CACO;QSAR-PSA;25;;;;;;;;;;;-7.055;;;;;;;;;;;;"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006";"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006"
Sulfasalazine;MM00690;O=C(O)c1cc(N=Nc2ccc(S(=O)(=O)Nc3ccccn3)cc2)ccc1O;NCEXYHBECQHGNR-UHFFFAOYSA-N;398.393;3.7;5359476;DB00795;SAS;CHEMBL421;CACO;QSAR-PSA;25;;;;;;;;;;;-6.204;;;;;;;;;;;;"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006";"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006"
Methylprednisolone;MM00388;CC1CC2C(C(O)CC3(C)C2CCC3(O)C(=O)CO)C2(C)C=CC(=O)C=C12;VHRSUDSXCMQTMA-UHFFFAOYSA-N;374.477;1.8;6741;DB00959;;CHEMBL650;CACO;QSAR-PSA;25;;;;;;;;;;;-5.375;;;;;;;;;;;;"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006";"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006"
1-[(2R,4S,5S)-4-azido-5-(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione;MM00077;Cc1cn(C2CC(N=[N+]=[N-])C(CO)O2)c(=O)[nH]c1=O;HBOMLICNUCNMMY-UHFFFAOYSA-N;267.245;-0.2;35370;DB00495;AZZ;CHEMBL129;CACO;QSAR-PSA;25;;;;;;;;;;;-5.727;;;;;;;;;;;;"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006";"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006"
Amoxicillin;MM00716;CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccc(O)cc3)C(=O)N2[C@H]1C(=O)O;LSQZJLSUYDQPKJ-UHFFFAOYSA-N;365.404;0.02;33613;DB01060;;CHEMBL1082;CACO;QSAR-PSA;25;;;;;;;;;;;-6.029;;;;;;;;;;;;"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006";"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006"
L-Leucine;MM00752;CC(C)C[C@H](N)C(=O)O;ROHFNLRQFUQHCH-YFKPBYRVSA-N;131.175;0.44;6106;DB00149;LEU;CHEMBL291962;CACO;QSAR-PSA;25;;;;;;;;;;;-4.32;;;;;;;;;;;;"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006";"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006"
(2R,3R,4R,5R)-hexane-1,2,3,4,5,6-hexol;MM00386;OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO;FBPFZTCFMRRESA-KVTDHHQDSA-N;182.172;-3.59;6251;DB00742;MTL;CHEMBL689;CACO;QSAR-PSA;25;;;;;;;;;;;-5.253;;;;;;;;;;;;"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006";"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006"
Sucrose;MM00421;OC[C@H]1O[C@H](O[C@]2(CO)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@H](O)[C@@H](O)[C@@H]1O;CZMRCDWAGMRECN-UGDNZRGBSA-N;342.297;-5.4;5988;DB02772;SUC;CHEMBL253582;CACO;QSAR-PSA;25;;;;;;;;;;;-6.412;;;;;;;;;;;;"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006";"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006"
L-Glutamine;MM00748;NC(=O)CC[C@H](N)C(=O)O;ZDXPYRJPNDTMRX-VKHMYHEASA-N;146.146;-1.34;5961;DB00130;GLN;CHEMBL930;CACO;QSAR-PSA;25;;;;;;;;;;;-5.065;;;;;;;;;;;;"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006";"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006"
L-Dopa;MM00746;NC(Cc1ccc(O)c(O)c1)C(=O)O;WTDRDQBEARUVNC-UHFFFAOYSA-N;197.19;0.05;6047;DB01235;DAH;CHEMBL1009;CACO;QSAR-PSA;25;;;;;;;;;;;-5.143;;;;;;;;;;;;"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006";"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006"
Azithromycin;MM12580;CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(O)C[C@@H](C)CN(C)[C@H](C)[C@@H](O)[C@]1(C)O;MQTOSJVFKKJCRP-UHFFFAOYSA-N;749;1.9;2269;;;;CACO;QSAR-PSA;25;;;;;;;;;;;-7.163;;;;;;;;;;;;"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006";"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006"
9-methyl-3-[(2-methylimidazol-1-yl)methyl]-2,3-dihydro-1H-carbazol-4-one;MM00531;Cc1nccn1CC1CCc2c(c3ccccc3n2C)C1=O;FELGMEQIXOGIFQ-UHFFFAOYSA-N;293.37;3.13;4595;DB00904;;CHEMBL46;CACO;QSAR-PSA;25;;;;;;;;;;;-4.41;;;;;;;;;;;;"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006";"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006"
"(2S)-2-[[4-[(2,4-diaminopteridin-6-yl)methyl-methylamino]benzoyl]amino]pentanedioic acid";MM00270;CN(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(C(=O)NC(CCC(=O)O)C(=O)O)cc1;FBOZXECLQNJBKD-UHFFFAOYSA-N;454.447;0.27;126941;DB00563;MTX;CHEMBL34259;CACO;QSAR-PSA;25;;;;;;;;;;;-7.552;;;;;;;;;;;;"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006";"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006"
"Acetylsalicylic acid";MM00080;CC(=O)Oc1ccccc1C(=O)O;BSYNRYMUTXBXSQ-UHFFFAOYSA-N;180.159;1.31;2244;DB00945;AIN;CHEMBL25;CACO;QSAR-PSA;25;;;;;;;;;;;-4.3;;;;;;;;;;;;"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006";"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006"
Cephalexin;MM00721;CC1=C(C(=O)O)N2C(=O)C(NC(=O)C(N)c3ccccc3)C2SC1;ZAIPMKNFIOOWCQ-UHFFFAOYSA-N;347.389;0.44;27447;DB00567;;CHEMBL1727;CACO;QSAR-PSA;25;;;;;;;;;;;-5.631;;;;;;;;;;;;"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006";"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006"
1-cyano-2-methyl-3-[2-[(5-methyl-1H-imidazol-4-yl)methylsulfanyl]ethyl]guanidine;MM00463;CNC(=NCCSCc1nc[nH]c1C)NC#N;AQIXAKUUQRKLND-UHFFFAOYSA-N;252.34;0.6;2756;DB00501;;CHEMBL30;CACO;QSAR-PSA;25;;;;;;;;;;;-5.284;;;;;;;;;;;;"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006";"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006"
Erythromycin;MM00489;CCC1OC(=O)C(C)C(OC2CC(C)(OC)C(O)C(C)O2)C(C)C(OC2OC(C)CC(N(C)C)C2O)C(C)(O)CC(C)C(=O)C(C)C(O)C1(C)O;ULGZDMOVFRHVEP-UHFFFAOYSA-N;733.937;1.79;12560;DB00199;ERY;CHEMBL532;CACO;QSAR-PSA;25;;;;;;;;;;;-7.357;;;;;;;;;;;;"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006";"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006"
"Taurocholic acid";MM00691;CC(CCC(=O)NCCS(=O)(=O)O)C1CCC2C3C(O)CC4CC(O)CCC4(C)C3CC(O)C12C;WBWWGRHZICKQGZ-UHFFFAOYSA-N;515.706;2.37;6675;DB04348;TCH;CHEMBL224867;CACO;QSAR-PSA;25;;;;;;;;;;;-6.5;;;;;;;;;;;;"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006";"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006"
H216;MM15248;;;;;169974;;;;CACO;QSAR-PSA;25;;;;;;;;;;;-5.929;;;;;;;;;;;;"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006";"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006"
Doxorubicin;MM00485;COc1cccc2c1C(=O)c1c(O)c3c(c(O)c1C2=O)C[C@@](O)(C(=O)CO)C[C@@H]3O[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1;AOJJSUZBOXZQNB-TZSSRYMLSA-N;543.525;;31703;DB00997;DM2;CHEMBL53463;CACO;QSAR-PSA;25;;;;;;;;;;;-7.182;;;;;;;;;;;;"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006";"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006"
Dnalaprilate;MM15249;;;;;;;;;CACO;QSAR-PSA;25;;;;;;;;;;;-5.507;;;;;;;;;;;;"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006";"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006"
"Penicillin G";MM01494;CC1(C)SC2C(NC(=O)Cc3ccccc3)C(=O)N2C1C(=O)O;JGSARLDLIJGVTE-UHFFFAOYSA-N;334.4;0.86;5904;" DB01053";PNN;29;CACO;QSAR-PSA;25;;;;;;;;;;;-5.264;;;;;;;;;;;;"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006";"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006"
N-[4-[2-hydroxy-3-(propan-2-ylamino)propoxy]phenyl]acetamide;MM00544;CC(=O)Nc1ccc(OCC(O)CNC(C)C)cc1;DURULFYMVIFBIR-UHFFFAOYSA-N;266.341;1.38;4883;DB01297;;CHEMBL6995;CACO;QSAR-PSA;25;;;;;;;;;;;-4.811;;;;;;;;;;;;"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006";"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006"
H95;MM15250;;;;;6950287;;;;CACO;QSAR-PSA;25;;;;;;;;;;;-4.807;;;;;;;;;;;;"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006";"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006"
Hydrocortisone;MM00044;CC12CCC(=O)C=C1CCC1C2C(O)CC2(C)C1CCC2(O)C(=O)CO;JYGXADMDTFJGBT-UHFFFAOYSA-N;362.466;1.78;5754;DB00741;HCY;CHEMBL389621;CACO;QSAR-PSA;25;;;;;;;;;;;-5.309;;;;;;;;;;;;"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006";"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006"
3-(5,6-dihydrobenzo[b][1]benzazepin-11-yl)-N,N-dimethylpropan-1-amine;MM00504;CN(C)CCCN1c2ccccc2CCc2ccccc21;BCGWQEUPMDMJNV-UHFFFAOYSA-N;280.415;3.88;3696;DB00458;IXX;CHEMBL11;CACO;QSAR-PSA;25;;;;;;;;;;;-3.978;;;;;;;;;;;;"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006";"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006"
3-(5,6-dihydrobenzo[b][1]benzazepin-11-yl)-N-methylpropan-1-amine;MM00474;CNCCCN1c2ccccc2CCc2ccccc21;HCYAFALTSJYZDH-UHFFFAOYSA-N;266.388;3.53;2995;DB01151;DSM;CHEMBL72;CACO;QSAR-PSA;25;;;;;;;;;;;-4.096;;;;;;;;;;;;"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006";"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006"
Naloxone;MM00277;C=CCN1CCC23c4c5ccc(O)c4OC2C(=O)CCC3(O)C1C5;UZHSEJADLWPNLE-UHFFFAOYSA-N;327.38;1.3;5284596;DB01183;;CHEMBL80;CACO;QSAR-PSA;25;;;;;;;;;;;-4.973;;;;;;;;;;;;"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006";"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006"
N-(2,6-dichlorophenyl)-4,5-dihydro-1H-imidazol-2-amine;MM00344;Clc1cccc(Cl)c1N=C1NCCN1;GJSURZIOUXUGAL-UHFFFAOYSA-N;230.09;2.17;2803;DB00575;CLU;CHEMBL134;CACO;QSAR-PSA;25;;;;;;;;;;;-4.345;;;;;;;;;;;;"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006";"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006"
1-(1H-indol-4-yloxy)-3-(propan-2-ylamino)propan-2-ol;MM00542;CC(C)NCC(O)COc1cccc2[nH]ccc12;JZQKKSLKJUAGIC-UHFFFAOYSA-N;248.326;1.91;4828;DB00960;;CHEMBL500;CACO;QSAR-PSA;25;;;;;;;;;;;-4.619;;;;;;;;;;;;"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006";"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006"
1-naphthalen-1-yloxy-3-(propan-2-ylamino)propan-2-ol;MM00085;CC(C)NCC(O)COc1cccc2ccccc12;AQHHHDLHHXJYJD-UHFFFAOYSA-N;259.349;2.58;4946;DB00571;;CHEMBL27;CACO;QSAR-PSA;25;;;;;;;;;;;-4.337;;;;;;;;;;;;"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006";"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006"
1-[4-[2-(cyclopropylmethoxy)ethyl]phenoxy]-3-(propan-2-ylamino)propan-2-ol;MM00922;CC(C)NCC(O)COc1ccc(CCOCC2CC2)cc1;NWIUTZDMDHAVTP-UHFFFAOYSA-N;307.434;2.39;2369;DB00195;;CHEMBL423;CACO;QSAR-PSA;25;;;;;;;;;;;-4.627;;;;;;;;;;;;"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006";"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006"
Tenidap;MM15222;;;;;60712;;;;CACO;QSAR-PSA;25;;;;;;;;;;;-5.073;;;;;;;;;;;;"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006";"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006"
Ibuprufen;MM15251;;;;;;;;;CACO;QSAR-PSA;25;;;;;;;;;;;-4.153;;;;;;;;;;;;"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006";"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006"
1-(propan-2-ylamino)-3-(2-prop-2-enoxyphenoxy)propan-2-ol;MM00289;C=CCOc1ccccc1OCC(O)CNC(C)C;CEMAWMOMDPGJMB-UHFFFAOYSA-N;265.353;1.99;4631;DB01580;;CHEMBL546;CACO;QSAR-PSA;25;;;;;;;;;;;-4.512;;;;;;;;;;;;"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006";"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006"
1-(propan-2-ylamino)-3-(2-prop-2-enylphenoxy)propan-2-ol;MM00440;C=CCc1ccccc1OC[C@H](O)CNC(C)C;PAZJSJFMUHDSTF-UHFFFAOYSA-N;249.354;2.15;2119;DB00866;;CHEMBL266195;CACO;QSAR-PSA;25;;;;;;;;;;;-4.353;;;;;;;;;;;;"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006";"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006"
Caffeine;MM00040;Cn1c(=O)c2c(ncn2C)n(C)c1=O;RYYVLZVUVIJVGH-UHFFFAOYSA-N;194.194;-1.03;2519;DB00201;CFF;CHEMBL113;CACO;QSAR-PSA;25;;;;;;;;;;;-4.375;;;;;;;;;;;;"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006";"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006"
"Betaxolol ester";MM15252;;;;;;;;;CACO;QSAR-PSA;25;;;;;;;;;;;-4.842;;;;;;;;;;;;"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006";"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006"
"Propranolol ester";MM15253;;;;;;;;;CACO;QSAR-PSA;25;;;;;;;;;;;-4.596;;;;;;;;;;;;"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006";"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006"
"(2S)-2-(6-methoxynaphthalen-2-yl)propanoic acid";MM00672;COc1ccc2cc(C(C)C(=O)O)ccc2c1;CMWTZPSULFXXJA-UHFFFAOYSA-N;230.263;3.04;156391;DB00788;NPS;CHEMBL154;CACO;QSAR-PSA;25;;;;;;;;;;;-4.329;;;;;;;;;;;;"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006";"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006"
Guanosine;MM15254;;;;;135398635;;;;CACO;QSAR-PSA;25;;;;;;;;;;;-6.194;;;;;;;;;;;;"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006";"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006"
G6700;MM15255;;;;;;;;;CACO;QSAR-PSA;25;;;;;;;;;;;-6.114;;;;;;;;;;;;"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006";"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006"
G6249;MM15256;;;;;;;;;CACO;QSAR-PSA;25;;;;;;;;;;;-6.058;;;;;;;;;;;;"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006";"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006"
G6191;MM15257;;;;;;;;;CACO;QSAR-PSA;25;;;;;;;;;;;-6.297;;;;;;;;;;;;"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006";"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006"
G6262;MM15258;;;;;;;;;CACO;QSAR-PSA;25;;;;;;;;;;;-6.092;;;;;;;;;;;;"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006";"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006"
G6703;MM15259;;;;;;;;;CACO;QSAR-PSA;25;;;;;;;;;;;-6.228;;;;;;;;;;;;"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006";"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006"
N-[(1-ethylpyrrolidin-2-yl)methyl]-2-methoxy-5-sulfamoylbenzamide;MM00568;CCN1CCCC1CNC(=O)c1cc(S(N)(=O)=O)ccc1OC;BGRJTUBHPOOWDU-UHFFFAOYSA-N;341.426;0.56;5355;DB00391;;CHEMBL26;CACO;QSAR-PSA;25;;;;;;;;;;;-5.527;;;;;;;;;;;;"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006";"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006"
2-[4-[2-hydroxy-3-(propan-2-ylamino)propoxy]phenyl]acetamide;MM00078;CC(C)NC[C@@H](O)COc1ccc(CC(N)=O)cc1;METKIMKYRPQLGS-UHFFFAOYSA-N;266.341;0.45;2249;DB00335;;CHEMBL24;CACO;QSAR-PSA;25;;;;;;;;;;;-5.092;;;;;;;;;;;;"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006";"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006"
2-amino-9-(2-hydroxyethoxymethyl)-3H-purin-6-one;MM00074;Nc1nc(=O)c2ncn(COCCO)c2[nH]1;MKUXAQIIEYXACX-UHFFFAOYSA-N;225.208;-0.92;2022;DB00787;AC2;CHEMBL184;CACO;QSAR-PSA;25;;;;;;;;;;;-5.486;;;;;;;;;;;;"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006";"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006"
1-[3-[2-(dimethylamino)ethyl]-1H-indol-5-yl]-N-methylmethanesulfonamide;MM00569;CNS(=O)(=O)Cc1ccc2[nH]cc(CCN(C)C)c2c1;KQKPFRSPSRPDEB-UHFFFAOYSA-N;295.401;1.32;5358;DB00669;;CHEMBL128;CACO;QSAR-PSA;25;;;;;;;;;;;-4.933;;;;;;;;;;;;"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006";"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006"
G6203;MM15260;;;;;;;;;CACO;QSAR-PSA;25;;;;;;;;;;;-6.186;;;;;;;;;;;;"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006";"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006"
H244;MM15261;;;;;21364;;;;CACO;QSAR-PSA;25;;;;;;;;;;;-4.881;;;;;;;;;;;;"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006";"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006"
5-[2-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]ethyl]-6-chloro-1,3-dihydroindol-2-one;MM00589;O=C1Cc2cc(CCN3CCN(c4nsc5ccccc45)CC3)c(Cl)cc2N1;MVWVFYHBGMAFLY-UHFFFAOYSA-N;412.936;3.81;60854;DB00246;;CHEMBL708;CACO;QSAR-PSA;25;;;;;;;;;;;-5.077;;;;;;;;;;;;"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006";"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006"
"(E)-3-(6-methylsulfanyl-4-oxoquinazolin-3-yl)prop-2-enoic acid";MM01431;CSc1ccc2ncn(C=CC(=O)O)c(=O)c2c1;VHFPVEGFRVEDBK-UHFFFAOYSA-N;262.29;1.67;6435375;;;337379;CACO;QSAR-PSA;25;;;;;;;;;;;-4.754;;;;;;;;;;;;"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006";"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006"
Mibefradil;MM01432;COCC(=O)OC1(CCN(C)CCCc2nc3ccccc3[nH]2)CCc2cc(F)ccc2C1C(C)C;HBNPJJILLOYFJU-UHFFFAOYSA-N;495.64;5.27;60663;DB01388;MWV;45816;CACO;QSAR-PSA;25;;;;;;;;;;;-5.382;;;;;;;;;;;;"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006";"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006"
"6,8-difluoro-1-(2-fluoroethyl)-7-(4-methylpiperazin-1-yl)-4-oxoquinoline-3-carboxylic acid";MM00736;CN1CCN(c2c(F)cc3c(=O)c(C(=O)O)cn(CCF)c3c2F)CC1;XBJBPGROQZJDOJ-UHFFFAOYSA-N;369.344;1.7;3357;DB04576;;CHEMBL6273;CACO;QSAR-PSA;25;;;;;;;;;;;-5.033;;;;;;;;;;;;"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006";"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006"
"5-O-ethyl 3-O-methyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate";MM00398;CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1c1cccc([N+](=O)[O-])c1;PVHUJELLJLJGLN-UHFFFAOYSA-N;360.366;2.57;4507;DB01054;;CHEMBL475534;CACO;QSAR-PSA;25;;;;;;;;;;;-5.502;;;;;;;;;;;;"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006";"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006"
2-(2,3-dihydro-1,4-benzodioxin-3-ylmethyl)guanidine;MM01430;N=C(N)NCC1COc2ccccc2O1;HIUVKVDQFXDZHU-UHFFFAOYSA-N;207.23;0.31;16564;" DB13211";;76725;CACO;QSAR-PSA;25;;;;;;;;;;;-4.9;;;;;;;;;;;;"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006";"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006"
2,2-dichloro-N-[(1R,2R)-1,3-dihydroxy-1-(4-nitrophenyl)propan-2-yl]acetamide;MM00342;O=C(NC(CO)C(O)c1ccc([N+](=O)[O-])cc1)C(Cl)Cl;WIIZWVCIJKGZOK-UHFFFAOYSA-N;323.126;0.91;5959;DB00446;CLM;CHEMBL130;CACO;QSAR-PSA;25;;;;;;;;;;;-5.559;;;;;;;;;;;;"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006";"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006"
Felodipine;MM00363;CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1c1cccc(Cl)c1Cl;RZTAMFZIAATZDJ-UHFFFAOYSA-N;384.253;3.96;3333;DB01023;;CHEMBL1480;CACO;QSAR-PSA;25;;;;;;;;;;;-4.914;;;;;;;;;;;;"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006";"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006"
Fluconazole;MM12535;OC(Cn1cncn1)(Cn1cncn1)c1ccc(F)cc1F;RFHAOTPXVQNOHP-UHFFFAOYSA-N;306.28;0.74;3365;;;;CACO;QSAR-PSA;25;;;;;;;;;;;-5.137;;;;;;;;;;;;"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006";"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006"
Trovaflaxicin;MM15262;;;;;;;;;CACO;QSAR-PSA;25;;;;;;;;;;;-5.646;;;;;;;;;;;;"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006";"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006"
4-hydroxy-3-(3-oxo-1-phenylbutyl)chromen-2-one;MM00095;CC(=O)CC(c1ccccc1)c1c(O)c2ccccc2oc1=O;PJVWKTKQMONHTI-UHFFFAOYSA-N;308.333;3.61;54678486;DB00682;;CHEMBL1464;CACO;QSAR-PSA;25;;;;;;;;;;;-4.694;;;;;;;;;;;;"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006";"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006"
(2S)-1-(tert-butylamino)-3-[(4-morpholin-4-yl-1,2,5-thiadiazol-3-yl)oxy]propan-2-ol;MM00573;CC(C)(C)NCC(O)COc1nsnc1N1CCOCC1;BLJRIMJGRPQVNF-UHFFFAOYSA-N;316.42;0.5;33624;DB00373;TIM;CHEMBL499;CACO;QSAR-PSA;25;;;;;;;;;;;-5.068;;;;;;;;;;;;"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006";"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006"
1,3-dimethyl-7H-purine-2,6-dione;MM00048;Cn1c(=O)c2nc[nH]c2n(C)c1=O;ZFXYFBGIUFBOJW-UHFFFAOYSA-N;180.167;-1.04;2153;DB00277;TEP;CHEMBL190;CACO;QSAR-PSA;25;;;;;;;;;;;-4.603;;;;;;;;;;;;"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006";"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006"
1,5-dimethyl-2-phenylpyrazol-3-one;MM00333;Cc1cc(=O)n(-c2ccccc2)n1C;VEQOALNAAJBPNY-UHFFFAOYSA-N;188.23;1.48;2206;DB01435;;CHEMBL277474;CACO;QSAR-PSA;25;;;;;;;;;;;-3.928;;;;;;;;;;;;"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006";"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006"
Diltiazem;MM00477;COc1ccc(C2Sc3ccccc3N(CCN(C)C)C(=O)C2OC(C)=O)cc1;HSUGRBWQSSZJOP-UHFFFAOYSA-N;414.52;3.37;39186;DB00343;C9F;CHEMBL23;CACO;QSAR-PSA;25;;;;;;;;;;;-4.945;;;;;;;;;;;;"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006";"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006"
Testosterone;MM00423;CC12CCC(=O)C=C1CCC1C2CCC2(C)C(O)CCC12;MUMGGOZAMZWBJJ-UHFFFAOYSA-N;288.431;3.88;6013;DB00624;TES;CHEMBL386630;CACO;QSAR-PSA;25;;;;;;;;;;;-4.382;;;;;;;;;;;;"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006";"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006"
N-[3-acetyl-4-[2-hydroxy-3-(propan-2-ylamino)propoxy]phenyl]butanamide;MM00437;CCCC(=O)Nc1ccc(OC[C@H](O)CNC(C)C)c(C(C)=O)c1;GOEMGAFJFRBGGG-UHFFFAOYSA-N;336.432;2.37;1978;DB01193;;CHEMBL642;CACO;QSAR-PSA;25;;;;;;;;;;;-5.206;;;;;;;;;;;;"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006";"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006"
L-Phenylalanine;MM00756;N[C@@H](Cc1ccccc1)C(=O)O;COLNVLDHVKWLRT-QMMMGPOBSA-N;165.192;0.64;6140;DB00120;PHE;CHEMBL301523;CACO;QSAR-PSA;25;;;;;;;;;;;-4.478;;;;;;;;;;;;"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006";"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006"
"Salicylic Acid";MM00093;O=C(O)c1ccccc1O;YGSDEFSMJLZEOE-UHFFFAOYSA-N;138.123;1.09;338;DB00936;SAL;CHEMBL424;CACO;QSAR-PSA;25;;;;;;;;;;;-4.228;;;;;;;;;;;;"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006";"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006"
(S)-[(2R,4S,5R)-5-ethenyl-1-azabicyclo[2.2.2]octan-2-yl]-(6-methoxyquinolin-4-yl)methanol;MM00558;C=C[C@H]1CN2CC[C@H]1C[C@@H]2[C@@H](O)c1ccnc2ccc(OC)cc12;LOUPRKONTZGTKE-LHHVKLHASA-N;324.424;3.17;441074;DB00908;QDN;CHEMBL1294;CACO;QSAR-PSA;25;;;;;;;;;;;-4.678;;;;;;;;;;;;"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006";"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006"
Dexamethasone;MM00355;C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO;UREBDLICKHMUKA-CXSFZGCWSA-N;392.467;1.9;5743;DB01234;DEX;CHEMBL384467;CACO;QSAR-PSA;25;;;;;;;;;;;-5.423;;;;;;;;;;;;"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006";"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006"
D-Glucose;MM00352;OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O;WQZGKKKJIJFFOK-GASJEMHNSA-N;180.156;-3.22;5793;;;CHEMBL1222250;CACO;QSAR-PSA;25;;;;;;;;;;;-5.094;;;;;;;;;;;;"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006";"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006"
Verapamil;MM00585;COc1ccc(CCN(C)CCCC(C#N)(c2ccc(OC)c(OC)c2)C(C)C)cc1OC;SGTNSNPWRIOYBX-UHFFFAOYSA-N;454.611;5.09;2520;DB00661;;CHEMBL6966;CACO;QSAR-PSA;25;;;;;;;;;;;-5.053;;;;;;;;;;;;"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006";"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006"
"Taurocholic acid";MM00691;CC(CCC(=O)NCCS(=O)(=O)O)C1CCC2C3C(O)CC4CC(O)CCC4(C)C3CC(O)C12C;WBWWGRHZICKQGZ-UHFFFAOYSA-N;515.706;2.37;6675;DB04348;TCH;CHEMBL224867;CACO;QSAR-PSA;25;;;;;;;;;;;-6.487;;;;;;;;;;;;"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006";"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006"
[4-(4-amino-6,7-dimethoxyquinazolin-2-yl)piperazin-1-yl]-(furan-2-yl)methanone;MM00547;COc1cc2nc(N3CCN(C(=O)c4ccco4)CC3)nc(N)c2cc1OC;IENZQIKPVFGBNW-UHFFFAOYSA-N;383.408;1.78;4893;DB00457;XRA;CHEMBL2;CACO;QSAR-PSA;25;;;;;;;;;;;-5.536;;;;;;;;;;;;"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006";"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006"
"Valproic acid";MM00711;CCCC(CCC)C(=O)O;NIJJYAXOARWZEE-UHFFFAOYSA-N;144.214;2.29;3121;DB00313;2PP;CHEMBL109;CACO;QSAR-PSA;25;;;;;;;;;;;-3.989;;;;;;;;;;;;"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006";"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006"
"2-aminoacetic acid";MM00741;NCC(=O)O;DHMQDGOQFOQNFH-UHFFFAOYSA-N;75.067;-0.97;750;DB00145;GLY;CHEMBL773;CACO;QSAR-PSA;25;;;;;;;;;;;-4.236;;;;;;;;;;;;"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006";"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006"
"2-[1-(aminomethyl)cyclohexyl]acetic acid";MM00737;NCC1(CC(=O)O)CCCCC1;UGJMXCAKCUNAIE-UHFFFAOYSA-N;171.24;1.37;3446;DB00996;GBN;CHEMBL940;CACO;QSAR-PSA;25;;;;;;;;;;;-4.468;;;;;;;;;;;;"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006";"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006"
Corticosterone;MM00346;CC12CCC(=O)C=C1CCC1C2C(O)CC2(C)C(C(=O)CO)CCC12;OMFXVFTZEKFJBZ-UHFFFAOYSA-N;346.467;2.67;5753;DB04652;C0R;CHEMBL110739;CACO;QSAR-HB;25;;;;;;;;;;;-4.273;;;;;;;;;;;;"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006";"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006"
2-(diethylamino)-N-(2,6-dimethylphenyl)acetamide;MM00092;CCN(CC)CC(=O)Nc1c(C)cccc1C;NNJVILVZKWQKPM-UHFFFAOYSA-N;234.343;2.58;3676;DB00281;LQZ;CHEMBL79;CACO;QSAR-HB;25;;;;;;;;;;;-5.512;;;;;;;;;;;;"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006";"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006"
7-chloro-1-methyl-5-phenyl-3H-1,4-benzodiazepin-2-one;MM00094;CN1C(=O)CN=C(c2ccccc2)c2cc(Cl)ccc21;AAOVKJBEBIDNHE-UHFFFAOYSA-N;284.743;3.15;3016;DB00829;DZP;CHEMBL12;CACO;QSAR-HB;25;;;;;;;;;;;-3.954;;;;;;;;;;;;"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006";"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006"
2-[(E)-(2,6-dichlorophenyl)methylideneamino]guanidine;MM00497;N=C(N)NN=Cc1c(Cl)cccc1Cl;WDZVGELJXXEGPV-UHFFFAOYSA-N;231.08;1.81;5702063;DB00629;;CHEMBL420;CACO;QSAR-HB;25;;;;;;;;;;;-3.908;;;;;;;;;;;;"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006";"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006"
Chromen-2-one;MM00042;O=c1ccc2ccccc2o1;ZYGHJZDHTFUPRJ-UHFFFAOYSA-N;146.145;1.79;323;DB04665;COU;CHEMBL6466;CACO;QSAR-HB;25;;;;;;;;;;;-1.792;;;;;;;;;;;;"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006";"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006"
"Timolol ester";MM15244;;;;;;;;;CACO;QSAR-HB;25;;;;;;;;;;;-3.712;;;;;;;;;;;;"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006";"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006"
1-[4-(2-methoxyethyl)phenoxy]-3-(propan-2-ylamino)propan-2-ol;MM00275;COCCc1ccc(OCC(O)CNC(C)C)cc1;IUBSYMUCCVWXPE-UHFFFAOYSA-N;267.369;1.61;4171;DB00264;;CHEMBL13;CACO;QSAR-HB;25;;;;;;;;;;;-4.978;;;;;;;;;;;;"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006";"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006"
"Oxprenolol ester";MM15245;;;;;;;;;CACO;QSAR-HB;25;;;;;;;;;;;-4.369;;;;;;;;;;;;"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006";"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006"
"Alprenolol ester";MM15246;;;;;;;;;CACO;QSAR-HB;25;;;;;;;;;;;-4.671;;;;;;;;;;;;"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006";"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006"
"5-[(3-carboxy-4-hydroxyphenyl)diazenyl]-2-hydroxybenzoic acid";MM01437;O=C(O)c1cc(/N=N/c2ccc(O)c(C(=O)O)c2)ccc1O;QQBDLJCYGRGAKP-FOCLMDBBSA-N;302.24;2.91;22419;DB01250;;CHEMBL1201013;CACO;QSAR-HB;25;;;;;;;;;;;-3.668;;;;;;;;;;;;"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006";"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006"
5-[2-(tert-butylamino)-1-hydroxyethyl]benzene-1,3-diol;MM00306;CC(C)(C)NCC(O)c1cc(O)cc(O)c1;XWTYSIMOBUGWOL-UHFFFAOYSA-N;225.288;1.52;5403;DB00871;;CHEMBL1760;CACO;QSAR-HB;25;;;;;;;;;;;-4.394;;;;;;;;;;;;"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006";"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006"
4-[(1R)-1-hydroxy-2-(methylamino)ethyl]benzene-1,2-diol;MM00644;CNCC(O)c1ccc(O)c(O)c1;UCTWMZQNUQWSLP-UHFFFAOYSA-N;183.207;0.35;5816;DB00668;ALE;CHEMBL679;CACO;QSAR-HB;25;;;;;;;;;;;-4.176;;;;;;;;;;;;"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006";"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006"
N-(4-hydroxyphenyl)acetamide;MM00322;CC(=O)Nc1ccc(O)cc1;RZVAJINKPMORJF-UHFFFAOYSA-N;151.165;1.35;1983;DB00316;TYL;CHEMBL112;CACO;QSAR-HB;25;;;;;;;;;;;-4.896;;;;;;;;;;;;"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006";"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006"
Acrivastine;MM00715;"Cc1ccc(/C(=C\CN2CCCC2)c2cccc(/C=C/C(=O)O)n2)cc1";PWACSDKDOHSSQD-IUTFFREVSA-N;348.446;4.02;5284514;DB09488;;CHEMBL1224;CACO;QSAR-HB;25;;;;;;;;;;;-4.39;;;;;;;;;;;;"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006";"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006"
2-(tert-butylamino)-1-(3-chlorophenyl)propan-1-one;MM00455;C[C@H](NC(C)(C)C)C(=O)c1cccc(Cl)c1;SNPPWIUOZRMYNY-UHFFFAOYSA-N;239.743;3.3;444;DB01156;;CHEMBL894;CACO;QSAR-HB;25;;;;;;;;;;;-4.572;;;;;;;;;;;;"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006";"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006"
Cefuroxime;MM01507;CON=C(C(=O)NC1C(=O)N2C(C(=O)O)=C(COC(N)=O)CSC12)c1ccco1;JFPVXVDWJQMJEE-IZRZKJBUSA-N;424.39;-0.54;5479529;;;;CACO;QSAR-HB;25;;;;;;;;;;;-5.477;;;;;;;;;;;;"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006";"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006"
6-chloro-1,1-dioxo-4H-1lambda6,2,4-benzothiadiazine-7-sulfonamide;MM00641;NS(=O)(=O)c1cc2c(cc1Cl)NC=NS2(=O)=O;JBMKAUGHUNFTOL-UHFFFAOYSA-N;295.712;0.13;2720;DB00880;;CHEMBL842;CACO;QSAR-HB;25;;;;;;;;;;;-4.691;;;;;;;;;;;;"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006";"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006"
Fluparoxan;MM01538;;;;;72036;;;;CACO;QSAR-HB;25;;;;;;;;;;;-3.476;;;;;;;;;;;;"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006";"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006"
6-chloro-1,1-dioxo-3,4-dihydro-2H-1lambda6,2,4-benzothiadiazine-7-sulfonamide;MM00373;NS(=O)(=O)c1cc2c(cc1Cl)NCNS2(=O)=O;JZUFKLXOESDKRF-UHFFFAOYSA-N;297.728;-0.35;3639;DB00999;HCZ;CHEMBL435;CACO;QSAR-HB;25;;;;;;;;;;;-4.238;;;;;;;;;;;;"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006";"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006"
"2-(3-benzoylphenyl)propanoic acid";MM00662;CC(C(=O)O)c1cccc(C(=O)c2ccccc2)c1;DKYWVDODHFEZIM-UHFFFAOYSA-N;254.285;3.11;3825;DB01009;;CHEMBL571;CACO;QSAR-HB;25;;;;;;;;;;;-4.242;;;;;;;;;;;;"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006";"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006"
2-hydroxy-5-[1-hydroxy-2-(4-phenylbutan-2-ylamino)ethyl]benzamide;MM00507;CC(CCc1ccccc1)NCC(O)c1ccc(O)c(C(N)=O)c1;SGUAFYQXFOLMHL-UHFFFAOYSA-N;328.412;2.14;3869;DB00598;;CHEMBL429;CACO;QSAR-HB;25;;;;;;;;;;;-6.599;;;;;;;;;;;;"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006";"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006"
6-(2,3-dichlorophenyl)-1,2,4-triazine-3,5-diamine;MM00383;Nc1nnc(-c2cccc(Cl)c2Cl)c(N)n1;PYZRQGJRPPTADH-UHFFFAOYSA-N;256.089;2.01;3878;DB00555;;CHEMBL741;CACO;QSAR-HB;25;;;;;;;;;;;-3.778;;;;;;;;;;;;"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006";"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006"
(2R,3S)-5-[3-(tert-butylamino)-2-hydroxypropoxy]-1,2,3,4-tetrahydronaphthalene-2,3-diol;MM00525;CC(C)(C)NCC(O)COc1cccc2c1CC(O)C(O)C2;VWPOSFSPZNDTMJ-UHFFFAOYSA-N;309.406;0.63;39147;DB01203;;CHEMBL649;CACO;QSAR-HB;25;;;;;;;;;;;-5.309;;;;;;;;;;;;"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006";"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006"
Netivudine;MM00395;CC#Cc1cn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)[nH]c1=O;QLOCVMVCRJOTTM-SDNRWEOFSA-N;282.252;-2.48;55281;DB12606;;CHEMBL1097615;CACO;QSAR-HB;25;;;;;;;;;;;-6.106;;;;;;;;;;;;"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006";"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006"
"Penicillin v";MM01544;;;;;6869;;;;CACO;QSAR-HB;25;;;;;;;;;;;-5.29;;;;;;;;;;;;"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006";"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006"
5,5-diphenylimidazolidine-2,4-dione;MM00406;O=C1N=C(O)NC1(c1ccccc1)c1ccccc1;CXOFVDLJLONNDW-UHFFFAOYSA-N;252.273;1.97;1775;DB00252;;CHEMBL16;CACO;QSAR-HB;25;;;;;;;;;;;-4.889;;;;;;;;;;;;"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006";"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006"
Progesterone;MM00198;CC(=O)C1CCC2C3CCC4=CC(=O)CCC4(C)C3CCC12C;RJKFOVLPORLFTN-UHFFFAOYSA-N;314.469;4.72;5994;DB00396;STR;CHEMBL103;CACO;QSAR-HB;25;;;;;;;;;;;-4.099;;;;;;;;;;;;"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006";"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006"
6-propyl-2-sulfanylidene-1H-pyrimidin-4-one;MM00415;CCCc1cc(=O)[nH]c(=S)[nH]1;KNAHARQHSZJURB-UHFFFAOYSA-N;170.23;1.38;657298;DB00550;3CJ;CHEMBL1518;CACO;QSAR-HB;25;;;;;;;;;;;-4.608;;;;;;;;;;;;"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006";"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006"
N-[4-[1-hydroxy-2-(propan-2-ylamino)ethyl]phenyl]methanesulfonamide;MM00567;CC(C)NCC(O)c1ccc(NS(C)(=O)=O)cc1;ZBMZVLHSJCTVON-UHFFFAOYSA-N;272.363;1.09;5253;DB00489;;CHEMBL471;CACO;QSAR-HB;25;;;;;;;;;;;-4.85;;;;;;;;;;;;"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006";"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006"
5-[(3,4,5-trimethoxyphenyl)methyl]pyrimidine-2,4-diamine;MM00581;COc1cc(Cc2cnc(N)nc2N)cc(OC)c1OC;IEDVJHCEMCRBQM-UHFFFAOYSA-N;290.323;1.26;5578;DB00440;TOP;CHEMBL22;CACO;QSAR-HB;25;;;;;;;;;;;-5.601;;;;;;;;;;;;"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006";"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006"
"4-chloro-2-(furan-2-ylmethylamino)-5-sulfamoylbenzoic acid";MM00083;NS(=O)(=O)c1cc(C(=O)O)c(NCc2ccco2)cc1Cl;ZZUFCTLCJUWOSV-UHFFFAOYSA-N;330.739;1.89;3440;DB00695;FUN;CHEMBL35;CACO;QSAR-HB;25;;;;;;;;;;;-5.124;;;;;;;;;;;;"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006";"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006"
Lisinopril;MM00763;NCCCCC(NC(CCc1ccccc1)C(=O)O)C(=O)N1CCCC1C(=O)O;RLAWWYSOJDYHDC-UHFFFAOYSA-N;405.495;1.24;5362119;DB00722;LPR;CHEMBL1237;CACO;QSAR-HB;25;;;;;;;;;;;-6.689;;;;;;;;;;;;"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006";"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006"
Loracarbef;MM01552;NC(C(=O)NC1C(=O)N2C(C(=O)O)=C(Cl)CCC12)c1ccccc1;JAPHQRWPEGVNBT-UHFFFAOYSA-N;349.77;0.71;5284585;;;;CACO;QSAR-HB;25;;;;;;;;;;;-6.579;;;;;;;;;;;;"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006";"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006"
Cefatrizine;MM00719;N[C@@H](C(=O)N[C@@H]1C(=O)N2C(C(=O)O)=C(CSc3cn[nH]n3)CS[C@H]12)c1ccc(O)cc1;UOCJDOLVGGIYIQ-PBFPGSCMSA-N;462.499;0.04;6410758;DB13266;;CHEMBL1095284;CACO;QSAR-HB;25;;;;;;;;;;;-6.552;;;;;;;;;;;;"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006";"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006"
Sulfasalazine;MM00690;O=C(O)c1cc(N=Nc2ccc(S(=O)(=O)Nc3ccccn3)cc2)ccc1O;NCEXYHBECQHGNR-UHFFFAOYSA-N;398.393;3.7;5359476;DB00795;SAS;CHEMBL421;CACO;QSAR-HB;25;;;;;;;;;;;-3.679;;;;;;;;;;;;"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006";"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006"
Methylprednisolone;MM00388;CC1CC2C(C(O)CC3(C)C2CCC3(O)C(=O)CO)C2(C)C=CC(=O)C=C12;VHRSUDSXCMQTMA-UHFFFAOYSA-N;374.477;1.8;6741;DB00959;;CHEMBL650;CACO;QSAR-HB;25;;;;;;;;;;;-5.34;;;;;;;;;;;;"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006";"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006"
1-[(2R,4S,5S)-4-azido-5-(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione;MM00077;Cc1cn(C2CC(N=[N+]=[N-])C(CO)O2)c(=O)[nH]c1=O;HBOMLICNUCNMMY-UHFFFAOYSA-N;267.245;-0.2;35370;DB00495;AZZ;CHEMBL129;CACO;QSAR-HB;25;;;;;;;;;;;-4;;;;;;;;;;;;"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006";"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006"
Amoxicillin;MM00716;CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccc(O)cc3)C(=O)N2[C@H]1C(=O)O;LSQZJLSUYDQPKJ-UHFFFAOYSA-N;365.404;0.02;33613;DB01060;;CHEMBL1082;CACO;QSAR-HB;25;;;;;;;;;;;-6.38;;;;;;;;;;;;"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006";"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006"
L-Leucine;MM00752;CC(C)C[C@H](N)C(=O)O;ROHFNLRQFUQHCH-YFKPBYRVSA-N;131.175;0.44;6106;DB00149;LEU;CHEMBL291962;CACO;QSAR-HB;25;;;;;;;;;;;-4.785;;;;;;;;;;;;"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006";"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006"
(2R,3R,4R,5R)-hexane-1,2,3,4,5,6-hexol;MM00386;OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO;FBPFZTCFMRRESA-KVTDHHQDSA-N;182.172;-3.59;6251;DB00742;MTL;CHEMBL689;CACO;QSAR-HB;25;;;;;;;;;;;-5.998;;;;;;;;;;;;"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006";"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006"
Sucrose;MM00421;OC[C@H]1O[C@H](O[C@]2(CO)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@H](O)[C@@H](O)[C@@H]1O;CZMRCDWAGMRECN-UGDNZRGBSA-N;342.297;-5.4;5988;DB02772;SUC;CHEMBL253582;CACO;QSAR-HB;25;;;;;;;;;;;-7.691;;;;;;;;;;;;"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006";"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006"
L-Glutamine;MM00748;NC(=O)CC[C@H](N)C(=O)O;ZDXPYRJPNDTMRX-VKHMYHEASA-N;146.146;-1.34;5961;DB00130;GLN;CHEMBL930;CACO;QSAR-HB;25;;;;;;;;;;;-6.409;;;;;;;;;;;;"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006";"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006"
L-Dopa;MM00746;NC(Cc1ccc(O)c(O)c1)C(=O)O;WTDRDQBEARUVNC-UHFFFAOYSA-N;197.19;0.05;6047;DB01235;DAH;CHEMBL1009;CACO;QSAR-HB;25;;;;;;;;;;;-5.474;;;;;;;;;;;;"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006";"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006"
Azithromycin;MM12580;CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(O)C[C@@H](C)CN(C)[C@H](C)[C@@H](O)[C@]1(C)O;MQTOSJVFKKJCRP-UHFFFAOYSA-N;749;1.9;2269;;;;CACO;QSAR-HB;25;;;;;;;;;;;-7.033;;;;;;;;;;;;"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006";"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006"
9-methyl-3-[(2-methylimidazol-1-yl)methyl]-2,3-dihydro-1H-carbazol-4-one;MM00531;Cc1nccn1CC1CCc2c(c3ccccc3n2C)C1=O;FELGMEQIXOGIFQ-UHFFFAOYSA-N;293.37;3.13;4595;DB00904;;CHEMBL46;CACO;QSAR-HB;25;;;;;;;;;;;-4.817;;;;;;;;;;;;"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006";"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006"
"(2S)-2-[[4-[(2,4-diaminopteridin-6-yl)methyl-methylamino]benzoyl]amino]pentanedioic acid";MM00270;CN(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(C(=O)NC(CCC(=O)O)C(=O)O)cc1;FBOZXECLQNJBKD-UHFFFAOYSA-N;454.447;0.27;126941;DB00563;MTX;CHEMBL34259;CACO;QSAR-HB;25;;;;;;;;;;;-7.272;;;;;;;;;;;;"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006";"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006"
"Acetylsalicylic acid";MM00080;CC(=O)Oc1ccccc1C(=O)O;BSYNRYMUTXBXSQ-UHFFFAOYSA-N;180.159;1.31;2244;DB00945;AIN;CHEMBL25;CACO;QSAR-HB;25;;;;;;;;;;;-1.296;;;;;;;;;;;;"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006";"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006"
Cephalexin;MM00721;CC1=C(C(=O)O)N2C(=O)C(NC(=O)C(N)c3ccccc3)C2SC1;ZAIPMKNFIOOWCQ-UHFFFAOYSA-N;347.389;0.44;27447;DB00567;;CHEMBL1727;CACO;QSAR-HB;25;;;;;;;;;;;-6.384;;;;;;;;;;;;"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006";"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006"
1-cyano-2-methyl-3-[2-[(5-methyl-1H-imidazol-4-yl)methylsulfanyl]ethyl]guanidine;MM00463;CNC(=NCCSCc1nc[nH]c1C)NC#N;AQIXAKUUQRKLND-UHFFFAOYSA-N;252.34;0.6;2756;DB00501;;CHEMBL30;CACO;QSAR-HB;25;;;;;;;;;;;-5.524;;;;;;;;;;;;"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006";"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006"
Erythromycin;MM00489;CCC1OC(=O)C(C)C(OC2CC(C)(OC)C(O)C(C)O2)C(C)C(OC2OC(C)CC(N(C)C)C2O)C(C)(O)CC(C)C(=O)C(C)C(O)C1(C)O;ULGZDMOVFRHVEP-UHFFFAOYSA-N;733.937;1.79;12560;DB00199;ERY;CHEMBL532;CACO;QSAR-HB;25;;;;;;;;;;;-6.789;;;;;;;;;;;;"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006";"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006"
"Taurocholic acid";MM00691;CC(CCC(=O)NCCS(=O)(=O)O)C1CCC2C3C(O)CC4CC(O)CCC4(C)C3CC(O)C12C;WBWWGRHZICKQGZ-UHFFFAOYSA-N;515.706;2.37;6675;DB04348;TCH;CHEMBL224867;CACO;QSAR-HB;25;;;;;;;;;;;-4.24;;;;;;;;;;;;"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006";"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006"
H216;MM15248;;;;;169974;;;;CACO;QSAR-HB;25;;;;;;;;;;;-6.973;;;;;;;;;;;;"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006";"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006"
Doxorubicin;MM00485;COc1cccc2c1C(=O)c1c(O)c3c(c(O)c1C2=O)C[C@@](O)(C(=O)CO)C[C@@H]3O[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1;AOJJSUZBOXZQNB-TZSSRYMLSA-N;543.525;;31703;DB00997;DM2;CHEMBL53463;CACO;QSAR-HB;25;;;;;;;;;;;-6.772;;;;;;;;;;;;"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006";"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006"
Dnalaprilate;MM15249;;;;;;;;;CACO;QSAR-HB;25;;;;;;;;;;;-5.661;;;;;;;;;;;;"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006";"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006"
"Penicillin G";MM01494;CC1(C)SC2C(NC(=O)Cc3ccccc3)C(=O)N2C1C(=O)O;JGSARLDLIJGVTE-UHFFFAOYSA-N;334.4;0.86;5904;" DB01053";PNN;29;CACO;QSAR-HB;25;;;;;;;;;;;-5.398;;;;;;;;;;;;"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006";"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006"
N-[4-[2-hydroxy-3-(propan-2-ylamino)propoxy]phenyl]acetamide;MM00544;CC(=O)Nc1ccc(OCC(O)CNC(C)C)cc1;DURULFYMVIFBIR-UHFFFAOYSA-N;266.341;1.38;4883;DB01297;;CHEMBL6995;CACO;QSAR-HB;25;;;;;;;;;;;-6.047;;;;;;;;;;;;"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006";"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006"
H95;MM15250;;;;;6950287;;;;CACO;QSAR-HB;25;;;;;;;;;;;-5.287;;;;;;;;;;;;"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006";"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006"
Hydrocortisone;MM00044;CC12CCC(=O)C=C1CCC1C2C(O)CC2(C)C1CCC2(O)C(=O)CO;JYGXADMDTFJGBT-UHFFFAOYSA-N;362.466;1.78;5754;DB00741;HCY;CHEMBL389621;CACO;QSAR-HB;25;;;;;;;;;;;-4.595;;;;;;;;;;;;"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006";"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006"
3-(5,6-dihydrobenzo[b][1]benzazepin-11-yl)-N,N-dimethylpropan-1-amine;MM00504;CN(C)CCCN1c2ccccc2CCc2ccccc21;BCGWQEUPMDMJNV-UHFFFAOYSA-N;280.415;3.88;3696;DB00458;IXX;CHEMBL11;CACO;QSAR-HB;25;;;;;;;;;;;-4.601;;;;;;;;;;;;"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006";"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006"
3-(5,6-dihydrobenzo[b][1]benzazepin-11-yl)-N-methylpropan-1-amine;MM00474;CNCCCN1c2ccccc2CCc2ccccc21;HCYAFALTSJYZDH-UHFFFAOYSA-N;266.388;3.53;2995;DB01151;DSM;CHEMBL72;CACO;QSAR-HB;25;;;;;;;;;;;-4.627;;;;;;;;;;;;"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006";"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006"
Naloxone;MM00277;C=CCN1CCC23c4c5ccc(O)c4OC2C(=O)CCC3(O)C1C5;UZHSEJADLWPNLE-UHFFFAOYSA-N;327.38;1.3;5284596;DB01183;;CHEMBL80;CACO;QSAR-HB;25;;;;;;;;;;;-4.885;;;;;;;;;;;;"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006";"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006"
N-(2,6-dichlorophenyl)-4,5-dihydro-1H-imidazol-2-amine;MM00344;Clc1cccc(Cl)c1N=C1NCCN1;GJSURZIOUXUGAL-UHFFFAOYSA-N;230.09;2.17;2803;DB00575;CLU;CHEMBL134;CACO;QSAR-HB;25;;;;;;;;;;;-4.094;;;;;;;;;;;;"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006";"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006"
1-(1H-indol-4-yloxy)-3-(propan-2-ylamino)propan-2-ol;MM00542;CC(C)NCC(O)COc1cccc2[nH]ccc12;JZQKKSLKJUAGIC-UHFFFAOYSA-N;248.326;1.91;4828;DB00960;;CHEMBL500;CACO;QSAR-HB;25;;;;;;;;;;;-4.752;;;;;;;;;;;;"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006";"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006"
1-naphthalen-1-yloxy-3-(propan-2-ylamino)propan-2-ol;MM00085;CC(C)NCC(O)COc1cccc2ccccc12;AQHHHDLHHXJYJD-UHFFFAOYSA-N;259.349;2.58;4946;DB00571;;CHEMBL27;CACO;QSAR-HB;25;;;;;;;;;;;-4.01;;;;;;;;;;;;"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006";"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006"
1-[4-[2-(cyclopropylmethoxy)ethyl]phenoxy]-3-(propan-2-ylamino)propan-2-ol;MM00922;CC(C)NCC(O)COc1ccc(CCOCC2CC2)cc1;NWIUTZDMDHAVTP-UHFFFAOYSA-N;307.434;2.39;2369;DB00195;;CHEMBL423;CACO;QSAR-HB;25;;;;;;;;;;;-4.546;;;;;;;;;;;;"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006";"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006"
Tenidap;MM15222;;;;;60712;;;;CACO;QSAR-HB;25;;;;;;;;;;;-4.584;;;;;;;;;;;;"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006";"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006"
Ibuprufen;MM15251;;;;;;;;;CACO;QSAR-HB;25;;;;;;;;;;;-3.969;;;;;;;;;;;;"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006";"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006"
1-(propan-2-ylamino)-3-(2-prop-2-enoxyphenoxy)propan-2-ol;MM00289;C=CCOc1ccccc1OCC(O)CNC(C)C;CEMAWMOMDPGJMB-UHFFFAOYSA-N;265.353;1.99;4631;DB01580;;CHEMBL546;CACO;QSAR-HB;25;;;;;;;;;;;-4.24;;;;;;;;;;;;"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006";"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006"
1-(propan-2-ylamino)-3-(2-prop-2-enylphenoxy)propan-2-ol;MM00440;C=CCc1ccccc1OC[C@H](O)CNC(C)C;PAZJSJFMUHDSTF-UHFFFAOYSA-N;249.354;2.15;2119;DB00866;;CHEMBL266195;CACO;QSAR-HB;25;;;;;;;;;;;-4.234;;;;;;;;;;;;"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006";"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006"
Caffeine;MM00040;Cn1c(=O)c2c(ncn2C)n(C)c1=O;RYYVLZVUVIJVGH-UHFFFAOYSA-N;194.194;-1.03;2519;DB00201;CFF;CHEMBL113;CACO;QSAR-HB;25;;;;;;;;;;;-4.035;;;;;;;;;;;;"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006";"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006"
"Betaxolol ester";MM15252;;;;;;;;;CACO;QSAR-HB;25;;;;;;;;;;;-4.27;;;;;;;;;;;;"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006";"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006"
"Propranolol ester";MM15253;;;;;;;;;CACO;QSAR-HB;25;;;;;;;;;;;-4.452;;;;;;;;;;;;"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006";"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006"
"(2S)-2-(6-methoxynaphthalen-2-yl)propanoic acid";MM00672;COc1ccc2cc(C(C)C(=O)O)ccc2c1;CMWTZPSULFXXJA-UHFFFAOYSA-N;230.263;3.04;156391;DB00788;NPS;CHEMBL154;CACO;QSAR-HB;25;;;;;;;;;;;-3.985;;;;;;;;;;;;"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006";"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006"
Guanosine;MM15254;;;;;135398635;;;;CACO;QSAR-HB;25;;;;;;;;;;;-7.53;;;;;;;;;;;;"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006";"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006"
G6700;MM15255;;;;;;;;;CACO;QSAR-HB;25;;;;;;;;;;;-6.678;;;;;;;;;;;;"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006";"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006"
G6249;MM15256;;;;;;;;;CACO;QSAR-HB;25;;;;;;;;;;;-6.681;;;;;;;;;;;;"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006";"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006"
G6191;MM15257;;;;;;;;;CACO;QSAR-HB;25;;;;;;;;;;;-7.557;;;;;;;;;;;;"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006";"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006"
G6262;MM15258;;;;;;;;;CACO;QSAR-HB;25;;;;;;;;;;;-6.848;;;;;;;;;;;;"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006";"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006"
G6703;MM15259;;;;;;;;;CACO;QSAR-HB;25;;;;;;;;;;;-6.805;;;;;;;;;;;;"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006";"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006"
N-[(1-ethylpyrrolidin-2-yl)methyl]-2-methoxy-5-sulfamoylbenzamide;MM00568;CCN1CCCC1CNC(=O)c1cc(S(N)(=O)=O)ccc1OC;BGRJTUBHPOOWDU-UHFFFAOYSA-N;341.426;0.56;5355;DB00391;;CHEMBL26;CACO;QSAR-HB;25;;;;;;;;;;;-5.356;;;;;;;;;;;;"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006";"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006"
2-[4-[2-hydroxy-3-(propan-2-ylamino)propoxy]phenyl]acetamide;MM00078;CC(C)NC[C@@H](O)COc1ccc(CC(N)=O)cc1;METKIMKYRPQLGS-UHFFFAOYSA-N;266.341;0.45;2249;DB00335;;CHEMBL24;CACO;QSAR-HB;25;;;;;;;;;;;-6.494;;;;;;;;;;;;"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006";"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006"
2-amino-9-(2-hydroxyethoxymethyl)-3H-purin-6-one;MM00074;Nc1nc(=O)c2ncn(COCCO)c2[nH]1;MKUXAQIIEYXACX-UHFFFAOYSA-N;225.208;-0.92;2022;DB00787;AC2;CHEMBL184;CACO;QSAR-HB;25;;;;;;;;;;;-5.353;;;;;;;;;;;;"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006";"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006"
1-[3-[2-(dimethylamino)ethyl]-1H-indol-5-yl]-N-methylmethanesulfonamide;MM00569;CNS(=O)(=O)Cc1ccc2[nH]cc(CCN(C)C)c2c1;KQKPFRSPSRPDEB-UHFFFAOYSA-N;295.401;1.32;5358;DB00669;;CHEMBL128;CACO;QSAR-HB;25;;;;;;;;;;;-6.193;;;;;;;;;;;;"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006";"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006"
G6203;MM15260;;;;;;;;;CACO;QSAR-HB;25;;;;;;;;;;;-6.072;;;;;;;;;;;;"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006";"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006"
H244;MM15261;;;;;21364;;;;CACO;QSAR-HB;25;;;;;;;;;;;-5.47;;;;;;;;;;;;"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006";"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006"
5-[2-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]ethyl]-6-chloro-1,3-dihydroindol-2-one;MM00589;O=C1Cc2cc(CCN3CCN(c4nsc5ccccc45)CC3)c(Cl)cc2N1;MVWVFYHBGMAFLY-UHFFFAOYSA-N;412.936;3.81;60854;DB00246;;CHEMBL708;CACO;QSAR-HB;25;;;;;;;;;;;-2.741;;;;;;;;;;;;"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006";"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006"
"(E)-3-(6-methylsulfanyl-4-oxoquinazolin-3-yl)prop-2-enoic acid";MM01431;CSc1ccc2ncn(C=CC(=O)O)c(=O)c2c1;VHFPVEGFRVEDBK-UHFFFAOYSA-N;262.29;1.67;6435375;;;337379;CACO;QSAR-HB;25;;;;;;;;;;;-3.245;;;;;;;;;;;;"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006";"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006"
Mibefradil;MM01432;COCC(=O)OC1(CCN(C)CCCc2nc3ccccc3[nH]2)CCc2cc(F)ccc2C1C(C)C;HBNPJJILLOYFJU-UHFFFAOYSA-N;495.64;5.27;60663;DB01388;MWV;45816;CACO;QSAR-HB;25;;;;;;;;;;;-4.316;;;;;;;;;;;;"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006";"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006"
"6,8-difluoro-1-(2-fluoroethyl)-7-(4-methylpiperazin-1-yl)-4-oxoquinoline-3-carboxylic acid";MM00736;CN1CCN(c2c(F)cc3c(=O)c(C(=O)O)cn(CCF)c3c2F)CC1;XBJBPGROQZJDOJ-UHFFFAOYSA-N;369.344;1.7;3357;DB04576;;CHEMBL6273;CACO;QSAR-HB;25;;;;;;;;;;;-3.928;;;;;;;;;;;;"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006";"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006"
"5-O-ethyl 3-O-methyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate";MM00398;CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1c1cccc([N+](=O)[O-])c1;PVHUJELLJLJGLN-UHFFFAOYSA-N;360.366;2.57;4507;DB01054;;CHEMBL475534;CACO;QSAR-HB;25;;;;;;;;;;;-5.443;;;;;;;;;;;;"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006";"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006"
2-(2,3-dihydro-1,4-benzodioxin-3-ylmethyl)guanidine;MM01430;N=C(N)NCC1COc2ccccc2O1;HIUVKVDQFXDZHU-UHFFFAOYSA-N;207.23;0.31;16564;" DB13211";;76725;CACO;QSAR-HB;25;;;;;;;;;;;-5.597;;;;;;;;;;;;"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006";"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006"
2,2-dichloro-N-[(1R,2R)-1,3-dihydroxy-1-(4-nitrophenyl)propan-2-yl]acetamide;MM00342;O=C(NC(CO)C(O)c1ccc([N+](=O)[O-])cc1)C(Cl)Cl;WIIZWVCIJKGZOK-UHFFFAOYSA-N;323.126;0.91;5959;DB00446;CLM;CHEMBL130;CACO;QSAR-HB;25;;;;;;;;;;;-4.831;;;;;;;;;;;;"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006";"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006"
Felodipine;MM00363;CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1c1cccc(Cl)c1Cl;RZTAMFZIAATZDJ-UHFFFAOYSA-N;384.253;3.96;3333;DB01023;;CHEMBL1480;CACO;QSAR-HB;25;;;;;;;;;;;-4.94;;;;;;;;;;;;"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006";"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006"
Fluconazole;MM12535;OC(Cn1cncn1)(Cn1cncn1)c1ccc(F)cc1F;RFHAOTPXVQNOHP-UHFFFAOYSA-N;306.28;0.74;3365;;;;CACO;QSAR-HB;25;;;;;;;;;;;-3.518;;;;;;;;;;;;"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006";"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006"
Trovaflaxicin;MM15262;;;;;;;;;CACO;QSAR-HB;25;;;;;;;;;;;-4.134;;;;;;;;;;;;"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006";"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006"
4-hydroxy-3-(3-oxo-1-phenylbutyl)chromen-2-one;MM00095;CC(=O)CC(c1ccccc1)c1c(O)c2ccccc2oc1=O;PJVWKTKQMONHTI-UHFFFAOYSA-N;308.333;3.61;54678486;DB00682;;CHEMBL1464;CACO;QSAR-HB;25;;;;;;;;;;;-3.98;;;;;;;;;;;;"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006";"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006"
(2S)-1-(tert-butylamino)-3-[(4-morpholin-4-yl-1,2,5-thiadiazol-3-yl)oxy]propan-2-ol;MM00573;CC(C)(C)NCC(O)COc1nsnc1N1CCOCC1;BLJRIMJGRPQVNF-UHFFFAOYSA-N;316.42;0.5;33624;DB00373;TIM;CHEMBL499;CACO;QSAR-HB;25;;;;;;;;;;;-4.37;;;;;;;;;;;;"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006";"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006"
1,3-dimethyl-7H-purine-2,6-dione;MM00048;Cn1c(=O)c2nc[nH]c2n(C)c1=O;ZFXYFBGIUFBOJW-UHFFFAOYSA-N;180.167;-1.04;2153;DB00277;TEP;CHEMBL190;CACO;QSAR-HB;25;;;;;;;;;;;-4.181;;;;;;;;;;;;"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006";"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006"
1,5-dimethyl-2-phenylpyrazol-3-one;MM00333;Cc1cc(=O)n(-c2ccccc2)n1C;VEQOALNAAJBPNY-UHFFFAOYSA-N;188.23;1.48;2206;DB01435;;CHEMBL277474;CACO;QSAR-HB;25;;;;;;;;;;;-3.745;;;;;;;;;;;;"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006";"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006"
Diltiazem;MM00477;COc1ccc(C2Sc3ccccc3N(CCN(C)C)C(=O)C2OC(C)=O)cc1;HSUGRBWQSSZJOP-UHFFFAOYSA-N;414.52;3.37;39186;DB00343;C9F;CHEMBL23;CACO;QSAR-HB;25;;;;;;;;;;;-4.625;;;;;;;;;;;;"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006";"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006"
Testosterone;MM00423;CC12CCC(=O)C=C1CCC1C2CCC2(C)C(O)CCC12;MUMGGOZAMZWBJJ-UHFFFAOYSA-N;288.431;3.88;6013;DB00624;TES;CHEMBL386630;CACO;QSAR-HB;25;;;;;;;;;;;-3.4;;;;;;;;;;;;"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006";"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006"
N-[3-acetyl-4-[2-hydroxy-3-(propan-2-ylamino)propoxy]phenyl]butanamide;MM00437;CCCC(=O)Nc1ccc(OC[C@H](O)CNC(C)C)c(C(C)=O)c1;GOEMGAFJFRBGGG-UHFFFAOYSA-N;336.432;2.37;1978;DB01193;;CHEMBL642;CACO;QSAR-HB;25;;;;;;;;;;;-6.635;;;;;;;;;;;;"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006";"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006"
L-Phenylalanine;MM00756;N[C@@H](Cc1ccccc1)C(=O)O;COLNVLDHVKWLRT-QMMMGPOBSA-N;165.192;0.64;6140;DB00120;PHE;CHEMBL301523;CACO;QSAR-HB;25;;;;;;;;;;;-4.822;;;;;;;;;;;;"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006";"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006"
"Salicylic Acid";MM00093;O=C(O)c1ccccc1O;YGSDEFSMJLZEOE-UHFFFAOYSA-N;138.123;1.09;338;DB00936;SAL;CHEMBL424;CACO;QSAR-HB;25;;;;;;;;;;;-3.39;;;;;;;;;;;;"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006";"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006"
(S)-[(2R,4S,5R)-5-ethenyl-1-azabicyclo[2.2.2]octan-2-yl]-(6-methoxyquinolin-4-yl)methanol;MM00558;C=C[C@H]1CN2CC[C@H]1C[C@@H]2[C@@H](O)c1ccnc2ccc(OC)cc12;LOUPRKONTZGTKE-LHHVKLHASA-N;324.424;3.17;441074;DB00908;QDN;CHEMBL1294;CACO;QSAR-HB;25;;;;;;;;;;;-3.669;;;;;;;;;;;;"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006";"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006"
Dexamethasone;MM00355;C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO;UREBDLICKHMUKA-CXSFZGCWSA-N;392.467;1.9;5743;DB01234;DEX;CHEMBL384467;CACO;QSAR-HB;25;;;;;;;;;;;-5.1;;;;;;;;;;;;"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006";"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006"
D-Glucose;MM00352;OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O;WQZGKKKJIJFFOK-GASJEMHNSA-N;180.156;-3.22;5793;;;CHEMBL1222250;CACO;QSAR-HB;25;;;;;;;;;;;-3.323;;;;;;;;;;;;"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006";"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006"
Verapamil;MM00585;COc1ccc(CCN(C)CCCC(C#N)(c2ccc(OC)c(OC)c2)C(C)C)cc1OC;SGTNSNPWRIOYBX-UHFFFAOYSA-N;454.611;5.09;2520;DB00661;;CHEMBL6966;CACO;QSAR-HB;25;;;;;;;;;;;-4.566;;;;;;;;;;;;"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006";"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006"
"Taurocholic acid";MM00691;CC(CCC(=O)NCCS(=O)(=O)O)C1CCC2C3C(O)CC4CC(O)CCC4(C)C3CC(O)C12C;WBWWGRHZICKQGZ-UHFFFAOYSA-N;515.706;2.37;6675;DB04348;TCH;CHEMBL224867;CACO;QSAR-HB;25;;;;;;;;;;;-6.922;;;;;;;;;;;;"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006";"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006"
[4-(4-amino-6,7-dimethoxyquinazolin-2-yl)piperazin-1-yl]-(furan-2-yl)methanone;MM00547;COc1cc2nc(N3CCN(C(=O)c4ccco4)CC3)nc(N)c2cc1OC;IENZQIKPVFGBNW-UHFFFAOYSA-N;383.408;1.78;4893;DB00457;XRA;CHEMBL2;CACO;QSAR-HB;25;;;;;;;;;;;-5.204;;;;;;;;;;;;"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006";"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006"
"Valproic acid";MM00711;CCCC(CCC)C(=O)O;NIJJYAXOARWZEE-UHFFFAOYSA-N;144.214;2.29;3121;DB00313;2PP;CHEMBL109;CACO;QSAR-HB;25;;;;;;;;;;;-4.595;;;;;;;;;;;;"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006";"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006"
"2-aminoacetic acid";MM00741;NCC(=O)O;DHMQDGOQFOQNFH-UHFFFAOYSA-N;75.067;-0.97;750;DB00145;GLY;CHEMBL773;CACO;QSAR-HB;25;;;;;;;;;;;-4.099;;;;;;;;;;;;"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006";"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006"
"2-[1-(aminomethyl)cyclohexyl]acetic acid";MM00737;NCC1(CC(=O)O)CCCCC1;UGJMXCAKCUNAIE-UHFFFAOYSA-N;171.24;1.37;3446;DB00996;GBN;CHEMBL940;CACO;QSAR-HB;25;;;;;;;;;;;-5.231;;;;;;;;;;;;"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006";"Subramanian G, Kitchen DB.: Computational approaches for modeling human intestinal absorption and permeability. J Mol Model, Volume 12 (5), 577-589, 2006"
